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ABSTRACT
Barbituric acids have been historically classified as compounds that act on the
central nervous system, and as such provide therapeutic uses as anxiolytics, sedatives,
hypnotics, and anti-convulsants. Recent investigations of barbituric acid derivatives have
provided scientists with information that barbituric acids may have applications in
antibacterial, anti-chlamydial, anti-viral, as well as anti-cancer treatments. Additionally,
recent literature accounts have indicated that barbituric acid derivatives may also act as
immune modulators.
The recent explorations of barbiturates and their potential anti-cancer and immune
modulating properties are the subject of this work. Novel synthetic approaches to the
development of new barbituric acid derivatives were explored thoroughly, and the
mechanisms of these novel syntheses were detailed by experiment and spectroscopic
characterizations. In many cases the reaction procedures were designed for large scale,
efficient syntheses, that are directly applicable to pharmaceutical production of these
potentially valuable therapeutic compounds.
Several new products unique to barbituric acid reactions were characterized
spectroscopically. Barbituric acid derivatives were the subject of biological evaluation,
and the results are reported in this work. Overall, unique synthetic approaches to the
production of novel barbituric acid derivatives were accomplished to create several new
classes of barbiturates with potential applications in cancer treatment.

xvi

1

INTRODUCTION
Ia. History of Barbituric Acid
In 1864, German chemist Adolph von Bayer, future founder of Bayer
Pharmaceuticals, discovered one of the most notorious therapeutics known to chemists,
malonylurea, more commonly known as barbituric acid (1).1 During the scientific era of
Bayer, chemists had none of the tools available to modern day scientists, and analyses of
compounds thought to possess biological activity were routinely characterized by taste,
giving chemists first hand knowledge of the physiological effects of potential
therapeutics. Curiously, after this routine analysis was performed, barbituric acid in itself
was determined to be without therapeutic significance.1 However, the discovery of
barbituric acid subsequently led to the introduction of many other barbiturate derivatives,
fueling the discoveries of a broad new class of therapeutics that would quickly dominate
both the medical and social circles in the early 20th century.1

O

NH2

EtO

NH2

EtO

O

O

base

O
urea

H
N

O

malonic ester

Figure I.1: Synthesis of barbituric acid (1).

H

N
O

barbituric acid (1)
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Ia.1 Modifications to original barbituric acid
Among the early derivatives of barbituric acid was 5,5’-diethylbarbituric acid. In
1903 Fischer and von Mering synthesized the first therapeutically active derivative of
barbituric acid, done by replacing the C-5 hydrogens of the barbituric acid ring with ethyl
substituents.1 Upon administration of this new barbiturate derivative, human subjects fell
into a state of hypnosis, or deep sleep. This new diethyl barbiturate, commonly called
Veronal (3) (Figure I.2), is the first known active derivative of hypnotics derived from
barbituric acid.1,2

EtO
EtO
O

O

1. NaOMe
2. CH3CH2Cl

EtO
EtO

O

O

O
H2N

NH2

base

O

H
N

H

O

N
O

2
Veronal (3)
Figure I.2: Original synthesis of Veronal (5,5’-diethylbarbituric acid) (3).

Even in the early 20th Century, chemists realized that there was a serious problem
with the metabolic degradation of Veronal. The hypnotic drug was slow to take effect,
and very slowly metabolized. According to early scientific accounts, human subjects
administered this compound would sleep for several days, unable to be roused from the
coma-like state induced by the drug.1,2 From this point on, medicinal chemists have been
exploring the therapeutic effects of barbituric acids, barbituric acid derivatives and new
substitutions and derivations of barbituric acids as compounds with therapeutic value.
Since the synthesis of Veronal, improvements have been made to this class of

3

therapeutics, which in turn elicited new structures belonging to perhaps one of the most
valuable medicinal classes of compounds known to date.1
Early advances in the structure-activity relationship of barbiturates and their
therapeutic effects produced, in 1912, the active drug Phenobarbital 1 (4) (Figure I.3).
Phenobarbital has been classically described as a medicinal compound possessing
hypnotic and anticonvulsant activity, and given twice daily, keeps epileptic seizures
under control.2

O
H

O
N

N

H

O
phenobarbital (4)

Figure I.3: Structure of the active anti-epileptic Phenobarbital (4).

Subsequent research pertaining to the structure-activity relationship of
barbiturates produced further understanding that the lack of drug activity and subsequent
metabolism of the earlier derivatives, such as original barbituric acid (1) and Veronal (3),
existed due to the same physical property, namely negligent passage across tissues lining
the gastrointestinal tract (GI) of the human body. This negligent passage inhibited the
drugs’ passage into the circulatory system. These early scientific discoveries led to the
production of barbiturates that contained larger hydrocarbon groups, similar to those in
the fatty tissue of the gastrointestinal tract.1,2

4

Ia.2 Effects of subsequent barbituric acid modification
The modifications of barbiturates led to the yield of lipophilic compounds able to
quickly pass through both the GI tract and the blood-brain barrier (BBB), enabling the
transformation of barbiturates into widely used anesthetics, anxiolytics, and sedatives.
Functional substitutions of the original barbituric acid stem from either C-5 substitutions
or C-2 substitutions, each producing compounds with varying activities. For example,
manipulations of the C-5 position have resulted in the production of amobarbital (5),
pentobarbital (6), secobarbital (7) and hexobarbital (8). Substitutions at C-2 have
resulted in the production of the short acting barbiturates, thiopental (9), and thiamylal
(10) (Figure I.4).1,2

*
O
C-5 substituted

H

N

N

O

O

H

H

N

N

*
O

O

H

H

O

O

amobarbital (5)

pentobarbital (6)

N

N

C-2 substituted
H

N

N

O

H

H

O
N

N

secobarbital (7)

hexobarbital (8)

*
O

O

H

H

S
thiopental (9)

O
N

H

O

O

*
O

O

N

H

S
thiamylal (10)

Figure I.4: Substitutions of the original barbituric acid at either C-5 or C-2.
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Ib. Classifications of Barbiturates
Barbituric acids and their subsequent derivatives are broken down into four
classes, and are classified according to their metabolic degradation and tissue deposition.2
The duration of the effects of barbiturates as well as the protein binding affinity of
barbiturates are directly proportional to the chain length of the hydrocarbon attached to
the C-5 position of the barbituric acid ring.2 For example, the classes include the
following:
1) Ultra short-acting barbiturates. Include compounds that are metabolized rapidly
and are highly lipid soluble. These are typically used as intravenous anesthetics.
Examples include hexobarbital (8), thiopental (9), thiamylal (10), all of which
have C-5 substituents that are hydrocarbons of four or more carbon units.2
2) Short-acting barbiturates. Include compounds that are lipid soluble and bind to
proteins. Renal clearance of these derivatives is very low and they are generally
used as hypnotics for patients who need help falling asleep. These compounds
typically have a half life of about three hours, and are advantageous because they
do not cause next-day drowsiness. While these are compounds with similar
structures of ultra-short acting counterparts, they lack the additional C-2
substitution. Several examples of short acting barbiturates include pentobarbital
(6) and secobarbital (7). 2
3) Intermediate-acting barbiturates. These derivatives are typically used as
hypnotics for persons waking in the middle of the night. They generally have a
half life of three to six hours, and cause next-day drowsiness. Several examples
in this class include butabarbital and amobarbital (5). 2

6

4) Long acting barbiturates. These compounds exert a hypnotic effect for longer
than six hours, causing sedation and subsequent drowsiness. They are
traditionally used for anti-convulsant effects rather than hypnotic effects, due to
the side effects. Examples include Phenobarbital (4) and veronal (3). 2

Ic. Physical Properties of barbituric acids
Barbituric acids and the active derivatives of barbituric acid are considered both
hydrophilic, due to the 2,4,6-pyrimidinetrione ring system, and lipophilic, depending on
the nature of the 5,5’-substituents. Barbituric acid in itself is a strong acid, having a pKa
of 4.01 in water.3a It is partially soluble in polar solvents, such as methanol and water,
and in these solvents retains its acidic properties, as well as be converted into the
corresponding salt when treated with a base.3b Generally speaking, barbiturate
derivatives having at least one unsubstituted NH hydrogen retain their acidic properties,
but the relative acidity of barbituric acid derivatives depends not only on the Nsubstitution, but the C-5 substitution as well (Figure I.5).3b

O
H
O

N

H
H

N
H

O

barbituric acid
pKa = 4.01

O
H
O

N

R

O
H

R'
N
H

O

5,5'-disubstituted
barbituric acid pKa = 6.5-8

Figure I.5: Acidic properties of barbituric acids.3

O

N

R
R'

N
O
CH3

3,5,5'-trisubstituted
barbituric acid pKa = >8
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The barbituric acid ring itself contains one sp3 hybridized carbon atom, and is treated as
an achiral ring system unless the 5,5’-substituents differ from one another and one of the
NH moieties is substituted.3b

Id. Pharmacological effects of barbiturates and barbituric acids as building blocks
for large heterocycles with pharmaceutical value
Historical literature accounts describe barbituric acids as exhibiting a primary
mode of action on the central nervous system. The primary binding site of barbiturates is
the GABAa-ion receptor complex, which will be described in further detail. Once bound
to this ion-receptor complex, barbiturates elicit effects that can be manifested in several
ways:2,3
1) hypnosis and anesthesia.
2) Anti-convulsant
3) Miscellaneous, including analgesic, autonomic nervous system actions,
respiratory effects etc.

While traditional roles of barbiturates in medicinal chemistry have been identified as
GABAa-ion receptor complex, 3 there have been more recent literature documentation
that barbiturates can exhibit biological activities in other areas, such as anti-bacterial,
anti-fungal, possess anti-cancer activity, anti-osteoporosis activity to name just a few.4

8

Id.1 The traditional barbiturate target: the GABAa-ion Receptor Complex
The human nervous system is composed of specialized cells known as neurons.
Communication between neurons via chemical synapses is vital to the normal function of
both the central and peripheral nervous systems.5 Neurons are separated from one
another by a space called the synaptic cleft, which effectively prohibits direct
communication between adjacent neurons. Instead, neurotransmitters that bind to
specific receptors present in post-synaptic terminals are used as a means of
communication between two neurons.5 Neurotransmitters can be of two types; excitatory
or inhibitory. Excitatory neurotransmitters act by depolarizing the next cell, which
increases the probability that an action potential will be fired. Inhibitory
neurotransmitters act by causing the next cell to hyperpolarize, which decreases the
probability that an action potential will be fired.5,6
The main inhibitory neurotransmitter in the central nervous system (CNS) is
gamma-aminobutyric acid (GABA). Release of this neurotransmitter into the synaptic
cleft allows the interaction with the corresponding post-synaptic ligand gated GABAa
receptor.5,6 Chloride channels are then activated and the rapid influx of chloride ions into
the neuron makes the intracellular charge negative, and in turn depresses the excitatory
depolarization of that neuron, making it less likely to fire an action potential.5,6 The
release of GABA and its subsequent post-synaptic recognition by the corresponding
GABAa receptor essentially inhibits the excitatory responses that result from fear or
anxiety and ensures a tranquilizing effect. In this respect, GABA can be deemed one of
the most important neurotransmitters in the CNS, ensuring a level of homeostasis of
neuron firing in the CNS.5,6
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The GABAa receptor has a structure common to most ligand-gated receptors.
The receptor is made up of five protein subunits of approximately 50 kD, arranged in a
circle, labeled α, β, or γ, which forms a channel that traverses the cell membrane (Figure
I.6).5-7
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Figure I.6: Cartoon of the GABAa receptor.7

This channel remains closed until GABA binds to the site of recognition of the receptor
and causes several conformational changes, including the rotation of the five subunits
until the diameter of the channel is widened. This widening of the channel allows for the
passage of the chloride ion into the neuron. Each protein subunit is a string of amino
acids that pass both in and out of the cell membrane as a trans-membrane 4 helix bundle.
The extracellular end, the N-terminus, is traditionally described as the mediator of the
interaction between GABA and the GABAa receptor (Figure I.7).5-7
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Figure I.7: Cartoon of protein subunits of GABAa that traverse the cell membrane.

GABAa receptors are common targets for many therapeutic drugs, including antiepileptic drugs, general anesthetics, barbituric acids and benzodiazepines. When certain
chemical structures, such as barbituric acid, bind to the GABAa-ion receptor complex
associated with the neuron, the chloride current, activated by GABA, is enhanced.5,6
Barbituric acids bind to the β-subunit of the GABAa-ion receptor complex and cause a
conformation in the ion channel which allows more chlorine ions into the intracellular
matrix of the cell. The mediating factor of barbituric acid activity within the human body
is the ability of the compound to pass through the blood brain barrier.5,6 Therefore, most
barbiturate derivatives that are lipophilic enough to pass the blood brain barrier do
enhance the chloride ion influx into the cell, and inhibit the firing of the action potential
to the next cell.
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Id.2 Discovery of Benzodiazepines
The vast research surrounding barbiturates has indirectly led to the discovery of
another potent class of anxiolytic compounds known and benzodiazepines. The
benzodiazepine family consists of a large class of compounds that have a variety of
substitutions on a basic tricyclic ring structure. Among these are clinically used
chlorodiazepoxide (11), flurazepam (12), triazolam (13), diazepam (valium) (14),
lorazepam (15), and nitrazepam (16) (Figure I.7a).5,6
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Figure I.7a: Benzodiazepines commonly used today.

The structural changes on the tricyclic ring are responsible for the widely variant halflives of each compound.8 Benzodiazepines act as sedatives, anxiolytic, muscle relaxants,
and anti-convulsants, and do so with a moderate degree of selectivity.5 However, each of
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the physiological characteristics elicited by benzodiazepines typically are a result of the
same action. Benzodiazepines tend to enhance the inhibitory activity of GABA at the
GABAa receptors.5,6 Once bound to the GABAa receptor-ion complex, benzodiazepines
cause an allosteric change in the receptor, which ultimately increases the number of
chloride channels opened at once.5-7 One other advantage to using benzodiazepines as
therapeutics is that they exhibit a much lesser degree of toxicity than do their barbiturate
counterparts.5 While accidental overdoses of persons using barbiturates became a serious
problem for the medical community, this problem is almost non-existent with the use of
benzodiazepines. To this end, benzodiazepines have largely replaced barbiturates in the
pharmaceutical marketplace.5

Id.3 Other possible physiological targets for barbiturates: Histone
deacetylase enzymes
Chromatin is classically defined as a complex of protein/DNA material within a
given cell. Nucleosomes are the basic units of chromatin within the cell, and they consist
of an octamer of core histones. These histones, labeled H2A, H2B, H3, and H4 wrap 1.8
turns of DNA and form a compact structure within the cell. Localized changes within the
chromatin structure are one of the main components of transcriptional gene regulation.8
Several of the localized changes in the chromatin structure are a consequence of
post-translational modifications of the histone tails. These modifications include
acetylation, methylation, phosphorylation, ubiquitination and poly-ADP-ribosylation, all
playing important roles in gene regulation (Figure I.8).9 Perhaps one of the best studied
post-translational histone modifications is histone acetylation and deacetylation.
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Acetylation of histones generally occurs at lysine residues, and there are two classes of
enzymes involved in determining the degree of acetylation of histones. These enzymes
are histone acetylases (HATs) and histone deacetylases (HDACs).12 Generally,
hyperacetylated histones are associated with transcriptional permissiveness, and
hypoacetylated histones mediate gene repression.10 Histone deacetylases (HDAC) are
enzymes found in association with large protein complexes that are involved in gene
expression.12 HDACs both regulate gene expression by deacetylating transcription
factors and participate in cell cycle regulation.12 Compounds that inhibit HDAC increase
histone acetylation by preventing deacetylation, and regulating a small subset of genes
(approximately 2%).10

H3 N-ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKP
H4

Ac-SGRGKGGKGLGKGGAKRHRKV

H2B N-PEPSKSAPAPKKGSKKAITKA
H2A

Ac-SGRGKQGGKA

Figure I.8: Cartoon of targets for post-translational histone modification via acetylation
of lysine residues (K).11

There are several known compounds that act as histone deacetylase inhibitors
(HDACIs). Among these are sodium butyrate, phenylbutyrate, PhthalimidoCaproyl
Hydroxamic Acid (PCHA) (17), trichostatin A (18), SuberoylAnilide Hydroxamic Acid
(SAHA) (19), apicidin (20), and trapoxin (21) (Figure I.9).10,12
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Figure I.9: Several known histone deacetylase inhibitors.
In cellular cultures, the physiological effects of each of these compounds include cell
growth inhibition, cell differentiation, apoptosis (programmed cell-death), as well as
inhibition of cancer cell growth in animal models.12 Development through the cell cycle
requires that gene expression be synchronized to the activities of proteins.10,13 Several
small polar hydroxamic acids act as HDAC inhibitors and mediate cell growth, arrest
and/or differentiation. SAHA (19) and PCHA (17) are in fact two of those compounds.
SAHA (19), perhaps one of the most widely studied hydroxamic acid HDACI’s, has been
shown both in vitro and in vivo to increase the accumulation of acetylated histones in
both tumor tissue and normal tissue, however, the growth suppression and apoptotic
activity of SAHA appears to be limited to only transformed (cancerous) cells.12,14
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Treatment of normal cells with these small polar compounds causes no growth inhibition
or apoptosis, even though the increases of histone acetylation are detected in both normal
and transformed cells.14a
Recent advances have been made with respect to the active site of the HDAC.
For instance, scientists have been able to analyze the enzyme active site of an HDAC-like
protein (HDLP) isolated from a species of anaerobic bacteria. Through these studies, it
was shown that the catalytic site of the enzyme has a tubular pocket with a zinc binding
site at the base of the pocket and two Asp-Histadine charge relay systems.12 The
hydroxamic acid part of SAHA was shown to bind with the zinc atom (Figure I.10).12
Furthermore, these hydroxamic acid HDACI’s have been shown to bind directly to the
enzyme active site, thereby blocking the substrate access, and causing an accumulation of
acetylated proteins.14b
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Figure I.10: HDLP Enzyme catalytic site with suberylanilido hydroxamic acid (19)
bound.14b
The ensuing pharmacophore developed using this model consists of a metal
binding domain that actively interacts with the catalytic binding site, a linker domain that
occupies the tubular channel of the protein, and a surface recognition domain that
interacts with the residues on the rim of the active site (Figure I.11).14b Since HDACI’s
have been shown to cause growth arrest, differentiation, and apoptosis in a wide variety
of in vitro cell cultures, including neuroblastoma, melanoma, leukemia, breast, prostate,
lung, ovarian, and colon cancers,12 we felt that exploration of the potential HDAC
inhibition effects of novel barbiturates structured to resemble in many ways both SAHA
and PCHA, were ideal starting points for the discovery of novel compounds that could
mediate cell differentiation, or arrest tumor cell division by acting as HDACI’s, while
maintaining some structural resemblance of the previously described pharmacophore.
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For instance, that can be accomplished by replacing the aromatic moiety of SAHA or
PCHA with the barbituric acid moiety. In doing so, we would effectively increase the
number of hydrogen bonding interactions between the new inhibitor and the targeted
enzyme. Based on this logic, our hypothesis was that barbituric acid analogs could be
designed to retain the pharmacophore of potent HDACIs by either utilizing barbituric
acid as the metal binding moiety of the pharmacophore or the surface recognition moiety
of the pharmacophore and in turn create a new class of HDACIs with ideally the same
biological activity as observed in SAHA and PCHA.
linker

metal binding

O

H
N
O

N
H

O H

surface recognition

Figure I.11: Pharmacophore of potential histone deacetylase inhibitors.

Id.4 Barbiturates as Potential Immuno-Modulating Compounds
From an immunological point of view, cancer cells can be defined as cells that
have somehow escaped the normal cell growth regulatory mechanisms, producing nonfunctional cells.15 These non-functioning cells then give rise to clone cells which are
constantly replicating, leading to the development of a tumor.15 While the human
immune system has genes and cells that have many functions, including maintaining
homeostasis of normal tissue by regulating cellular proliferation and cell death, it is
clearly indicated by the number of annual cancer deaths worldwide that the level of
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effectiveness of the immune response to tumor cells is often inadequate or poorly
expressed. Because of this, scientists have been increasing focus on the exploration of
the immune system response to the regulation and destruction of cancer cells, designing
vaccines as well as molecular systems that enable the reactivation of human immune
responses to cancer cells.15

Overview of the Immune System
An effective immune response involves two cellular groups. These groups are
known as lymphocytes and antigen-presenting cells. There are many types of
lymphocytes, and these cells are produced as white blood cells from bone marrow. Once
the lymphocyte leaves the bone marrow, it circulates in the blood and the lymphatic
systems, and finally resides in lymphoid organs in the body. Lymphocytes have antigen
(foreign body) binding cell surface receptors that mediate immunological responses, such
as specificity, diversity, memory, and self-nonself recognition.15
T lymphocytes leave the bone marrow and travel to the thymus to mature. Here,
these cells differentiate to express a unique antigen binding molecule, the T-cell receptor,
on its membrane. These T-cell receptors can only recognize antigens bound to cell
membrane proteins, known as major histocompatibility complex (MHC) molecules.
MHCs function in recognition, termed “antigen presentation” in which the recognition
occurs between the molecule and glycoproteins found on cell membranes.15
Dendritic cells (DC) are antigen-presenting cells of the human immune system
that are involved in the initiation of the immune response.16a DCs are responsible for the
acquisition of antigens or cancer cells, and their subsequent transport to T-lymphocyte
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rich areas. They are present in lymphatic tissues and lymphoid organs. Once the DCs
interact with antigens and become activated, they are able to derive specific immune
responses. Secondary lymphoid organs, such as the skin, recruit both naive Tlymphocytes and antigen-stimulated DCs into T-cell rich lymphoid areas, and the colocalization of these early immune response constituents is representative of T-cell
activation. 16a Effective anti-tumor responses elicited from the immune system require
the presence of both antigen presenting cells and T lymphocytes.16b
In order for a T-cell to become activated, which in turn initiates the immune
response of antigen destruction, a T-cell activation signal is required. This signal is
triggered by the recognition of the peptide-MHC molecular complex by the T-cell
receptor as well as by a co-stimulatory signal. The co-stimulatory signal is usually
triggered by an interaction between cell surface glycoproteins of the antigen presenting
cell and the T-cell (Figure I.12).15 Because tumor cells express low levels of MHCs and
lack necessary co-stimulatory molecules, both necessary to initiate the proliferation of Tcells, they are not effective modulators of antigen presenting cells.15, 16c Without
sufficient antigen presenting cells in the vicinity of a tumor, T-cells receive only partial
activating signals, and tumors are allowed to proliferate.15
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Figure I.12: Antigen initiated human immune response.

Immunotherapy is an approach in cancer treatment that attempts to supplement
the natural immune defenses of the human body.15 To that end, one compound that has
been clinically shown to demonstrate significant anticancer activities is 4,4’dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007 (22) Figure I.13).17 X-ray
crystallography data revealed that A-007 (as monoclinic crystals) exists as two unique
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Figure I.13: Structural crystallography characteristics of A-007 (22). 18
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rotamers. These rotamers differ only in the orientation of the bis-diphenylmethane group,
where the rings are approximately perpendicular to each other and rotated approximately
90o from the orientation of the rings in each rotamer (Figure I.13).18a Both rotamers
show strong intramolecular hydrogen bonds between the -NH of the -HN-N=C- moiety
and an oxygen of the o-nitro group. Examining the structure of A-007, one can see that
there are three unique functional moieties present in A-007 that may contribute to its
overall biological activity. These three moieties are the dihydroxy-bis-diphenylmethane
rings, the hydrazone moiety and the dinitrophenyl moiety. However, despite A-007's
high electrophilicity, it has no chemical reactivity with cell surface glycoproteins, making
this compound and analogs of this compound promising new anti-cancer treatments.18b
A-007 and its structural analogs appear to act as T-cell activators via CD45+
surface receptors on lymphoendothelial cells, and in particular with dendritic cells. Thus
far, thirty-three people have been treated with topical A-007 (22) (as a 0.25% gel) in the
Phase I study, and of these subjects, 31% objective remissions have been observed with
two complete responses.17 During the Phase I study, it was discovered that A-007 was
not acting through a cytotoxic mechanism. There was no local or systemic toxicity noted,
and histochemical reviews of biopsies of human skin topically treated with A-007
revealed that increased infiltrates of T-lymphocytes containing the membrane
glycoproteins CD4+ (T-helper cells), CD3+(T-cytotoxic cells), CD8+(T-cytotoxic cells),
and CD45+ had occurred after treatment.17 Increased skin infiltrates of CD11c+
dendritic cells (function as antigen presenters to T-helper cells) were also observed in
treated areas.19 Further immunohistochemical studies suggested that immune modulation
had occurred in vitro and in vivo following exposure to A-007.17,19
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A-007 is a simple organic molecule that appears to act as an antigen, possibly due
to the unique electronic properties associated with this molecule. It has been
hypothesized by Morgan, et al. that up-regulation of the CD45+ receptor is an initiation
site for the A-007-induced immune modulations that are being observed in patients with
cancer.19 Our hypothesis is that if this is in fact the initiation site for up-regulation of
receptor glycoproteins involved in immune modulation, then other structural analogs of
A-007 should be able to elicit the same, or greater responses.
CD45+ is expressed on dendritic cells, lymphocytes, monocytes, and leukocytes,
as well as some neoplastic cells, as a protein tyrosine phosphatase (PTP), which together
with other members of the PTPs, are responsible for phosphorylating tyrosine residues.16d
Blocking the CD45+ sites with anti-CD45 antibodies has been shown to inhibit T-cell
activation and prevent mitogen (lectin) activation of naïve T-cells.20a CD45+ receptor
surfaces contain the amino acid residues of arginine, serine/threonine, and cysteine, and
these residues can bind to or transfer natural ligands to the surface of antigen presenting
cells and hydrolyze tyrosyl phosphates.20b Morgan et al. hypothesized that A-007 does
not inhibit or block CD45+, but up-regulates lymphocytes and dendritic cells (to antigen
presenting cells) via electrostatic and/or non-covalent binding with the Arg, Cys, Ser/
Threo residues, as depicted in Figure I.14.19 Furthermore, A-007-activated DCs are
capable of initiating mitotic events with naïve human blood peripheral mononuclear cells
(PBMC) and up-regulating both CD45+ and CD11c+ receptors in human peripheral
dendritic cells,20c all exemplifying the fact that A-007 is not an inhibitor of CD45+, but
rather an up-regulator or modulator of the molecular sites (Figure I.14). The influence
that functional group substitutions may have on A-007's intra-/inter-molecular hydrogen
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bonding and electrostatic interactions is presented below (This figure illustrates several
possible interactions, and is not meant to illustrate the fact that all interactions occur).
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Figure I.14: Postulated possible interactions of A-007 with the CD45 receptor (modified
from Ref. 16d).

Considering this, we felt that one possibility of a moiety that would elicit the
same up-regulation of CD receptors was the barbituric acid moiety. Since the possibility
exists for barbituric acid to make the same types of non-covalent interactions as A-007
with the active site of the CD45 receptor, and was a versatile functional group in itself,
we chose barbituric acid as the starting point for our explorations into the possibility of
designing new and more potent immune modulating compounds. Outlined through the
remaining portion of this thesis are our synthetic and spectroscopic studies outlining the
designed barbituric acid derivatives. While several classes of compounds were selected
and designed for future in vitro studies as HDACI’s, (namely those compounds
designated in chapters IIa-d of this dissertation) several other classes were outlined as
potential immune modulating compounds (chapters IId-i). In both cases, the
explorations of the reaction procedures, spectroscopic characterizations of the intended
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products, and explorations of the reaction mechanisms are thoroughly outlined. All
obtained in vitro results are also included in the subsequent chapters of this dissertation.
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RESULTS AND DISCUSSION
IIa. Condensation Products
IIa.1 Preamble
Because barbituric acid has an active methylene group located at the C-5 position
the molecule is easily involved in condensation reactions with aldehydes or ketones that
do not contain an α-hydrogen. This general type of reaction is known as the
Knoevenagel condensation reaction.21 The reaction of barbituric acid with carbonyl
compounds was studied as early as 1864, traditionally using urea and derivatives of
malonate, and the isolated products obtained from these reactions were typically the
mono C-5 or C-5,5’-disubstituted products (Figure I.4).22 However, to perform such
reactions, the acid chloride of the alkyl substituent was necessary and due to the nature of
the reaction, this procedure was applicable to a limited variety of reagents.
Benzylidene barbituric acids are generally considered important biologically
active compounds. Benzylidene barbituric acids are useful as potential organic
oxidizers,23 as building blocks in the preparation of oxadeazaflavines,24 and for the
unsymmetrical synthesis of disulfides.25 Other applications have been reported, such as
several studies indicating that benzylidene barbiturates could be used as nonlinear optical
materials.26 Considering the discussed uses of benzylidene barbiturates, we felt that a
straightforward and simple synthesis of a large variety of these compounds was virtually
essential for both the scientific and pharmaceutical marketplaces.
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To achieve the formation of the mono condensation product between aromatic
aldehydes and barbituric acid, various methods utilizing acid or base catalyzed reactions
have been previously employed such as clay mediated catalysis, radiation, and reactions
without solvents just to name a few.27-33 There are some drawbacks to using previously
described literature procedures. For example, in basic conditions, the product of the
reactions between barbituric acids and alkyl or aryl halides is not only the C-5 substituted
alkyl or aryl product, but the N, N’-disubstituted alkyl or aryl products as well. Even so,
literature accounts dictate several very interesting approaches utilized for obtaining high
yields of benzylidene barbituric acids as a product of condensation. For instance,
Villemin and Labiad microwaved a mixture of barbituric acid, aromatic aldehydes, and
clay (Montmorillonite KSF) without solvent.29 The product of the condensation was
obtained in high yield after extraction from the solid reaction residue using the solvent
DMF (Figure IIa.1).
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Figure IIa.1: Villemin et.al. preparation of Knoevenagel condensation products.29
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Another interesting approach to the preparation of Knoevenagel condensation
products utilized a solid state reaction using clay and infrared radiation to obtain
relatively high yields of the desired product (Figure IIa.2).34-35
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Figure IIa.2: Formation of Knoevenagel products from solid state reactions.35

While both of these methods provided the mono-condensation products of
benzaldehydes and barbituric acid in adequate yields, the cost and availability of the
necessary instruments and acidic clay catalysts provided a limitation for the production of
large quantities of these compounds, therefore there was still a need for the development
of a better synthetic procedure for our future studies utilizing these derivatives.

IIa.2 Results and Discussion
The synthetic procedure that we subsequently developed proved to be
exceptionally simple and allowed the Knoevenagel condensation between aromatic and
α,β-conjugated aromatic aldehydes with both N,N’-disubstituted and unsubstituted
barbituric acids in methanol solution. The reaction was performed utilizing the barbituric
acids ability for self-catalysis in the case of unsubstituted barbituric acid to ensure the
formation of the product. In the case of N,N’-disubstituted barbituric acids, such as 1,3-
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dimethylbarbituric acid, a catalytic amount of either sulfuric acid or formic acid was used
to ensure reactant conversion. The general procedure involved mixing aldehydes with
barbituric acid in a sufficient amount of alcohol to dissolve both reactants. Based on the
reactivity of the aldehydes used as reactants, the reaction was allowed to stir at room
temperature for several hours to one full day (Figure IIa.3). While typically, the
reactions were performed at room temperature, we determined that in some cases, namely
in the case of reactive aromatic aldehydes, the reaction mixtures could also be refluxed in
methanol to give quantitative yields of the respective products in shorter time periods
(~1-2 h). However, when refluxing conditions are used, care must be taken with the
length of the reaction time. After extended refluxing time (12 h), we observed
spectroscopically the products of decomposition in the reaction mixture solution, the
formation of which hinders the isolation and purity of the desired product.
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Figure IIa.3: General procedure for obtaining Knoevenagel condensation products.

Our experiments indicated that aldehydes possessing electron-donating
substituents, such as OH, and N(CH3)2 react much faster, and the condensation product,
visually observable by the change in color (darker) of the reaction mixture due to
extended conjugation of the product, was detected as early as one minute after the
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reaction progression. Similarly, trans-cinnamaldehyde and its counterparts reacted with
similar reaction rates as did the electron-donating aldehydes. For example, the α,βconjugated aromatic aldehydes such as trans-cinnamaldehyde and trans-3-(2furyl)acrolein produced a dark solid precipitate after a few minutes in methanol at room
temperature, and was subsequently characterized spectroscopically as the condensation
product.
The products generally had a very low solubility in methanol, and the separation
of the product from the reactants was done by simple filtration and ensuing washes with
cold methanol, which provided highly pure condensation products. The products of
condensation were thermally sensitive and decomposed rapidly at temperatures
exceeding 260º C in the solid state. In solution, the products of condensation were even
more thermally sensitive, and purification by hot crystallization was deemed not a
preferred method of purification for these products.
To obtain a 90% conversion in the less reactive aldehydes such as unsubstituted
benzaldehydes, a longer reaction time was typically required. Generally, the reaction
could be performed in 1-2 days in methanol at room temperature. Careful monitoring of
the reaction was needed, because once the volume of alcohol decreased, starting materials
as well as our condensation products precipitated from the methanol solution, determined
through 1H-NMR spectroscopy in DMSO-d6 of the solid precipitate present after
evaporation of methanol occurred. In our spectral analyses, there were clear differences
in the chemical shift for the NH signals of the Knoevenagel condensation product
(~11.25 and 11.35 ppm) and the starting barbituric acid (11.11 ppm). The ratios of these
signals were used to determine the percentage of reaction conversion, which, depending
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on the time elapsed varied from 50%-80% conversion. To prevent obtaining impure
products, the reactions with less reactive aldehydes were subsequently performed in
closed flasks as opposed to open beakers.
As previously mentioned, crystallization using hot liquid was not a preferable
method of purification, due to low thermal stability of the products in solution, for any of
the desired products. Purification of the product from the starting material using solvents
such as ethyl acetate or petroleum ether slightly improved the isolated yield, but
elimination of unreacted barbituric acid was not accomplished. It was also necessary to
perform the purification procedures several times, which ultimately lowered the yields of
the condensation products. Our best purification procedure involved the evaporation of
methanol at reduced pressure and room temperature to a solid residue. Elimination of
barbituric acid was accomplished by adding water to the resulting solid residue and after
stirring at room temperature for 30 minutes, the solid was separated by filtration. To
eliminate any starting aldehydes and to remove traces of water, the solid was washed
with ether, providing highly pure (> 98%) products of condensation obtained in high
yields.
Our reaction procedure was only applicable to aromatic and α,β−conjugated
aromatic aldehydes (Table IIa.1). All attempts to isolate the Knoevenagel condensation
product of aliphatic aldehydes, such as hexanal, and barbituric acid were unsuccessful.
Following the reaction by 1H-NMR spectroscopy in methanol-d4 (CD3OD) as a solvent,
we observed the formation of 5-10% of the condensation product (23, Figure IIa.4).
This was done by monitoring the intensity of the olefinic (CH=C) proton in the spectra
(typically appearing around 8 ppm). The reaction conversion ratio remained the same
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after several days at room temperature. One can assume that the preparation of the
aliphatic C-5 substituted compounds could have been facilitated by using different
solvents or elevated temperatures. However, the formed products were exceptionally
sensitive to both high temperatures and acidic solvents, and decomposed rapidly. If the
reaction was carried out for several days in a closed flask at room temperature, then
traces of other products, including the Aldol condensation product (24) were detected by
spectroscopy (Figure IIa.4). This was also the case when the reaction was attempted
using aliphatic or aromatic ketones. For instance, when acetophenone was used as the
carbonyl source we were unable to detect even a trace of the condensation product in the
reaction mixture.
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Figure IIa.4: Spectroscopically detected products in reaction between barbituric acid and
aliphatic aldehydes.

Likewise, performing the reaction with aromatic aldehydes containing electronwithdrawing substituents, such as NO2, COOH, or pyridinium moieties was unsuccessful
in producing the desired Knoevenagel products of condensation. While literature reports
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indicated that it would be possible to form the Knoevenagel condensation product using
5-nitro-2-furaldehyde and barbituric acid,35 our own results suggested that the nature of
the condensation product was not the single addition, but the products of double
condensation, and the products obtained from these reactions will be discussed in further
detail in IIe of this dissertation.
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Figure IIa.5: Products of described reactions in Table IIa.1.
Table IIa.1: Description of Knoevenagel condensations.
Product

Y

R

n

Procedure

Yield (%)

A1

4-Me2N

H

0

A

98

A2#

H

H

2

A

95

A3#

4-Me2N

H

2

A

99

A4#

4-OH

H

0

A

95

A5*,#

C5H4O2

H

0

B

81

A6#

H

H

0

B

85

A7

3,4-(CH)4

H

0

B

83

A8

2,4-OH

H

0

B

85

A9**,#

C9H7NO

H

0

B

96

A10

2-OH

H

0

B

80

A11

2,4,6-OCH3

CH3

0

C

81

A12

2,3,4-OCH3

CH3

0

C

79

A13

4-OH

CH3

0

C

80

A14

2,4-OH

CH3

0

C

79

A15

H

CH3

2

C

81

*2-furaldehyde used for this relation; **2-indoylaldehyde used for this reaction. Procedure A: reactions stirred at room
temperature overnight. Procedure B: stirred at room temperature in closed reaction vessels over several days. Procedure C:
additional acid catalyst used. # Indicate compounds synthesized by Jursic.
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IIb. Reductive C-5 alkylation and C-5 benzylation of barbituric acids
IIb.1 Preamble
The majority of barbituric acid derivatives available for pharmaceutical use
consist of compounds that are C-5 mono or C-5 dialkylated or benzylated barbituric
acids. Several examples of these include common sedatives such as veronal (3),
pentobarbital (6), and phenobarbital (4). Considering the availability and use of these
compounds by the pharmaceutical industry, it seems logical that there would be a simple
general procedure for the production of derivatives of such widely used compounds.
Surprisingly, there is no simple synthetic procedure for preparing many derivatives of
these compounds in the literature, and the methodology used to prepare mono and di-C-5
substituted barbiturates has changed little from the century old method that uses malonic
esters and urea as starting materials.36-38
Also noteworthy, mono C-alkylated and benzylated barbiturates are highly
important intermediate compounds necessary for the production of assymmetrical
barbiturates of pharmacological importance. Typically, chiral barbiturates can be
classified in one of two categories, one in which chirality is associated with the
heterocyclic ring system making C-5 a prochiral center if R1 is not equal to R2 (Type I,
Figure IIb.1), and the other in which chirality exits outside the ring system, wherein R3
or R4 have optical activity (Type II, Figure IIb.1).
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chiral if R3 or R4 have a chiral center
Type II

Figure IIb.1: Examples of asymmetric barbiturates

All chiral barbiturates currently marketed are in the racemic form, even though it has
been classically shown that different enantiomers of chiral barbiturates exhibit different
physiological effects.39 In 2000, Trost et al. described experimental work performed
toward the palladium catalyzed asymmetric allylic alkylation reaction (AAA) as an
advancement toward the production of enantioenriched barbituric acid derivatives, a feat
not yet accomplished by literature accounts. In these experiments the mono C-5
alkylated intermediate (25), Pd2dba3-CHCl3 and a chiral ligand (26) were utilized in
producing several chiral barbiturates (e.g. 27) of pharmaceutical value obtained as
enantioenriched products (Figure IIb.2).39
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H
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PPh2

Ph2P

84% ee
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NH HN
O
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(S,S)-ligand
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Figure IIb.2: Trost utilization of mono C-5 alkylated barbiturates.39

While the isolated yields of Trost’s experiments are less than desirable (39%),39 the initial
results of enantioenriched products prepared open an avenue of barbituric acid chemistry
that has been under explored to date. Given these current advancements, we felt it clearly
relevant explore reaction conditions necessary to develop new methodology that would
enable the mono C-5 alkylated and benzylated products to be produced by a synthetically
simple method in large scale quantities.

IIb.2 Results and Discussion
IIb.2.1 Alkylation
The preparation of both mono and di-C-5-alkylated barbituric acids was done
using catalytic reductive alkylation procedures. While our developed procedures remain
general and almost all 5-alkyl and 5,5’-dialkyl products were prepared easily, some of the
analog preparations required different solvents, catalysts, and order of reactant mixing.
Through our experimentation, we determined that the best catalysts for these reactions
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was 5 wt% (dry basis) Pd or Pt on active carbon with the water content normally 50%.
Combining the catalyst with a specific order of addition of reactants as well as
monitoring solvent selection, the selective mono and di-C-5-alkylation and benzylation of
three classes of barbituric acids were achieved, utilizing unsubstituted (barbituric acid),
N-substituted (1-phenylbarbituric acid), and N,N’-disubstituted (1,3-dimethylbarbituric
acid) derivatives.
Based on our previous experiments described in section IIa of this dissertation,
we hypothesized that the first step of the reductive alkylation process between aliphatic
aldehydes and ketones would be the formation of the Knoevenagel condensation product
(~5% conversion), which would immediately yield upon catalytic hydrogenation of the
newly formed C=C bond our desired mono C-5 substituted barbiturate. Through
experimentation, our initial hypothesis appeared correct, and we were able to perform the
selective mono C-alkylation of barbituric acids with aliphatic aldehydes and ketones
under described catalytic reductive alkylation conditions. The initial condensation
reactions were catalyzed by acid, either by auto-catalysis of barbituric acid (R1 or R2 =
H), or by the addition of an acid catalyst such as concentrated HCl (several drops to 1
mL). The reactions were carried out as one pot syntheses in either methanol or ethanol as
a reaction media (Figure IIb.3). In cases where the carbonyl reagent in the reaction was
used in high excess as a solvent and a reactant, such as in the case of acetone, the mono
C-5 alkylated product was the only detectable product. Despite our previous
experiments’ indications of only a small conversion of reactants to the Knoevenagel
condensation products, both aliphatic aldehydes and ketones were excellent alkylating
agents. Additionally, there were no apparent structural restrictions on the aldehydes or
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ketones, with the exception being that there can be no reductive hydrogenation sensitive
functionalities on any reactant (Table IIb.1).

R1
N

O

O

R3

solvent

O
R3

O

R4

N
R2

R1
N

O

N
O

R2

O

H2/5% Pd/C

R4

R1
N

O
R3

O
N
O

R2

B1-4

R4

Knoevenagel Condensation

R1=H, Ph, CH3

R2=H, CH3

R3=H, n-C11H23, CH3, n-C6H7, n-C6H13, -(CH2)5-

R4=H, CH3, C6H5, n-C6H13

Figure IIb.3: General reaction for synthesis of mono C-5 alkylated barbiturates.

Table IIb.1: Selected representative mono C-alkylated products (General Procedure D)
Product R1

R2

R3

R4

Solvent

Yield (%)

B1

H

C6H5

CH3

H

Acetic Acid

96

B2

CH3

CH3

CH3

CH3

Acetic Acid

97

B3

H

H

-(CH2)5-

Methanol

95

B4

H

H

n-C6H13

Methanol

97

H

If R1 or R2 of the barbituric acid was not hydrogen, then acidic conditions were
required to perform the reaction. In such cases, the solvent for the reaction was acetic
acid, and a few drops of sulfuric acid were sufficient to catalyze the initial condensation
reaction.
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IIb.2.2 Benzylation
We determined through experiment that it was not possible to utilize the one-pot
synthesis for the monobenzylated products due to the fact that even when one equivalent
of the aldehyde was used, we obtained the di-C-5 benzylated product. We hypothesized
that this was due to the additional stability provided by the aromatic ring to the
intermediate formed in situ, which subsequently facilitated the second aldehyde addition.
Nevertheless, the mono C-benzylation of barbituric acid with aromatic aldehydes seemed
to be a particularly straightforward process that afforded the mono C-benzylated products
in high yields. The first step consisted of the synthesis of the Knoevenagel condensation
product between the barbiturate and corresponding aromatic aldehyde. The second step
was the catalytic reduction of the condensation product using catalytic amounts of Pd/C
(50% water content). Extended conjugation on the aromatic aldehydes or electron
donating groups, such as methoxy and dimethylamino, substantially decreased the
reaction time. For instance, the condensation reaction between 4(dimethylamino)benzaldehyde and barbituric acid was complete in several seconds in hot
methanol (60º C). The catalytic reduction of this compound was carried out in the same
reaction mixture without isolation of the condensation product.
Our initial experiments determined that the conjugated double bonds of the
condensation product hydrogenated first, as determined by 1H-NMR of the reaction
mixture after 20 minutes hydrogenation at 15 psi. However, both Pt and Pd catalysts
produced total aromatic hydrogenation when the benzaldehydes used possessed an
electron donating substituent, such as -OCH3, -OH, or –N(CH3)2,. For example, while
reduction of the double conjugated bond of these derivatives was complete after 2 hours
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at relatively low hydrogen pressure (15 psi), stopping the reaction this time provided a
reaction mixture containing both the desired reduced product (B10) and the
corresponding product of aromatic hydrogenation (28, Figure IIb.4).

H3C
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N
H3C

O
O
H

N(CH3)2

H3C
N
O
N
H3C

O

H3C
N
O
N
H3C

O

O
N(CH3)2
H3C
N
O
N
H3C

B10
O
N(CH3)2
N(CH3)2

O

O

O

28

Figure IIb.4: Products of mono C-5 benzylation after hydrogenation

Searching the literature for ideas to overcome this problem, we came across one reference
that indicated that one method utilized to eliminate the reduction of the aromatic ring of a
molecule was to use benzylic alcohols as a solvent.40 We utilized this method to avoid
obtaining the mixture of products, using 4-methoxybenzyl alcohol as the reaction media.
However, several of our condensation products were not sufficiently soluble in 4methoxybenzyl alcohol, and through further experiments we determined that using
benzene as a co-solvent eliminated the aromatic ring reduction upon catalytic
hydrogenation, even at higher pressures. Therefore, all electron-rich aromatic aldehydes
were subjected to reductive benzylation conditions using benzene as a co-solvent (Figure
IIb.5). In such cases the only isolated products were the mono-C-benzylation products
(Table IIb.2).
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Figure IIb.5: General synthesis of mono C-5-benzylated products.

Table IIb.2: Representative mono C-5-benzylated products (General Procedure E)
Compound

R1

R2

R3

Yield (%)

B5

H

H

85

B6

H

H

90

B7

H

H

92

B8

H

H

B10

CH3

CH3

B11

CH3

CH3

B12

CH3

CH3

B13

CH3

CH3

N

89
97

N

91

N

94
95

N

B14

CH3

CH3

OH

91

B15

H

H

OH

94

B16

H

H

OH

75
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IIb.2.3 C-5 dibenzylation of barbituric acid
We experimentally determined that by using an excess of reactive aromatic or
conjugated aldehydes and varying the reaction conditions slightly, it was possible to
obtain the double benzylation product of barbituric acid C-5 benzylation in quantitative
yields (Figure IIb.6). In these cases, it seemed that the addition the excess of the
reactive aldehydes served as an inhibitor to aromatic reduction, thereby replacing the role
of benzene as a co-solvent. Isolation procedures for the C-5 di-benzylated products were
very simple, and produced the desired compounds in high yields. As determined
previously, auto-catalysis by barbituric acid was a sufficient acid catalyst for the initial
condensation reaction, and no additional acid was needed for the reaction to proceed.
Likewise, catalytic amounts of sulfuric acid were needed to produce the Knoevenagel
condensation products when N,N’-disubstituted barbituric acids were used as reactants.

Y
Y
H
N

H2/5% Pd/C

N

CH3OH or
CH3COOH

O
H

H

O
O
O

H
2 equiv.

O
N

O
N
H

O

Y
B17: Y=H, 86% yield
B18: Y=Me2N, 95% yield

Figure IIb.6: Two representative structures of barbituric acid C-5 dibenzylation
(General Procedure F).
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IIb.2.4 Unsymmetrical C-5 alkylation of barbituric acid
Finally, we explored the possibility of producing the unsymmetrical C-5
dibenzylation of barbituric acids. We experimentally determined that C-5 -benzylation
can also be performed on mono C-5 alkylated or benzylated barbituric acids through
reductive alkylation with aromatic aldehydes. Utilizing the products of mono Calkylation, which were described above, we successfully benzylated the mono Calkylated barbiturates to yield the desired unsymmetrical alkylated barbituric acid
derivative (B19, Figure IIb.7). When R1 and R2 of the barbituric acid were not equal,
then the racemate was obtained. However, we were unsuccessful in producing the
second alkylation when aliphatic aldehydes or ketones were used as the second alkylating
agent. Therefore, in the cases where unsymmetrical double alkylation products having
one C-5 substituent of aliphatic nature are necessary, aliphatic alkylation must be the first
step of the reaction.

O
H
O

N

H2/5% Pt/C(67% water)

N
H

methanol

O
O
H

H
N

O

O

B19
N
H

O

N(CH3)2
N(CH3)2

barbituric acids=barbituric acid, 1-phenylbarbituric acid, 1,3-dimethylbarbituric acid
C5-monosubstitutions=CH(CH3)2, C6H5(CH2)3
aromatic aldehydes=C6H5, p-CH3C6H4, p-CH3OC6H4, p-(CH3)2NC6H4, p-(CH3)2NC6H4CH=CH

Figure IIb.7: Representative synthesis of unsymmetrical double alkylation products.
(General Procedure G).
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IIc. Development of 5-cyclohexylmethyl barbituric acids-Precursors for Asymmetric
Synthesis
IIc.1 Preamble
In our literature searches for the preparation of new barbituric acid derivatives, it
also came as a surprise that there were no available methods for the preparation of other
simple mono C-5 substituted barbituric acid derivatives, such as 5-cyclohexylmethyl
barbiturates. This came as a surprise because C-5-monoalkylated barbiturates could
potentially be very important intermediates in the preparation of asymmetric biologically
active barbituric acid derivatives. Given the fact that generally barbiturates containing
lipophilic substituents tend have biological activity associated with them,1,2 we focused
our attention on the development of a model reaction to produce new types of derivatives,
namely those with a cyclohexylmethyl substituent in the C-5 position of the barbituric
acid ring.

IIc.2 Results and Discussion
Our previous research led to the synthetic procedures developed to produce not
only mono C-alkylated products, but mono C-benzylated products as well, both
potentially valuable precursors for asymmetric synthesis of barbiturates if the barbituric
acid in itself is prochiral.39, 41-44 However, while during the course of these studies we
were able to selectively hydrogenate the activated aromatic rings of compounds such as
B10 and B14 (Table IIb.1), we were unsuccessful in producing the corresponding
derivative with unactivated aromatics, such as benzaldehyde and naphthaldehyde.
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To be able to thoroughly explore the area of asymmetric synthesis with respect to
barbiturates, we reasoned that it would be pertinent to begin not only with our previously
synthesized mono C-5 alkylated products, but cyclohexylmethyl barbiturates as well. To
perform our future studies, various derivatives of 5-cyclohexylmethyl barbiturates must
be readily synthesized in order to utilize this potentially important moiety for later
generations of new and more potent chiral barbiturates. Based on the previously
discussed successful results with reductive C-alkylation of barbituric acids, we tailored
our synthesis for the desired cyclohexylmethyl derivatives.
Electron-donating substituents increased the reactivity of the aldehydes and due to
the ease of the preparation of the mono C-5 benzylated products, one would assume that
the synthesis of 5-cyclohexylmethyl derivatives would be a straightforward process under
the optimal reaction conditions. We predicted that -OH and –OCH3 substituted
benzaldehydes would be the ideal precursors for the preparation of our targeted
compounds. Our assumption was based on the fact that in either water or methanol the
OH or OCH3 substituent would be easy to remove from the cyclohexane ring after ring
reduction, utilizing the reactivity of the substituent to be protonated.
Depicted in Figure IIc.1 is our methodological development for the synthesis of
C-5 cyclohexylmethyl barbiturates. Condensation of both para hydroxybenzaldehyde
and para methoxybenzaldehyde with barbituric acids in methanol requires only several
minutes in refluxing methanol to produce compounds 2a. The product precipitates from
the methanol solution and the isolated yields for each of the reactions should be almost
quantitative (> 90%). Reduction of these condensation products, either with 5% wt (dry
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basis) Pd-C or Pt-C with 50% water content, in methanol and benzene as a co-solvent
generate product 2b with reduction of only the double bond, and not the aromatic ring.
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Figure IIc.1: Reaction methodology for 5-cyclohexylmethyl barbiturates.

Using this method, product 2b can be isolated in quantitative yields. If the reduction is
performed in a 0.01 M methanol suspension with PtO2 as a catalyst at 80 psi hydrogen
pressure at 70º C for several days, then the product of hydrogenation, product 2c is
generated. In our experimental studies, we were able to isolate product 2c when both R1
and R2 of the barbituric acid ring were CH3 and Y was OH. To confirm the product
identity, we crystallized a small amount of 2c, which was subjected to X-ray analysis.
The ratio of the cis to trans isomer was 4:1, as determined through 1H-NMR
spectroscopy. From this point we hypothesized that in acidic media, compound 2c
should be transformed to compound 2d, which would be further reduced under catalytic
reduction to our targeted product, compound 2e.
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To avoid having to isolate and characterize each of these intermediates and to
increase the overall isolated yield of the respective reactions producing cyclohexylmethyl
derivatives of barbiturates, we thoroughly explored the possibility of performing the
reactions as a one-pot synthesis. Reactions were performed in various acidic solvents,
such as acetic acid, methanol-dilute sulfuric acid, methanol-trichloroacetic acid, aqueous
hydrochloric acid, and methanol-hydrochloric acid. The combination of methanolhydrochloric acid as a solvent system gave the best results, and was subsequently chosen
as the media. In retrospect, the solvent system was logical, considering the low solubility
of condensation product 2a in many solvents could potentially hinder the reaction
progression. The optimal solvent ratios were determined experimentally to be 1:1. While
the methanol-HCl solvent mixture was determined to be the optimal media for
performing this reaction, it should also be noted that in several other solvent mixtures,
some amount of the desired product 2e could be detected in the reaction mixture if 5%
Pd-C with 50% water was used. Limited reactant conversion and subsequent product
isolation hampered the outcome of the reaction in these cases. Our best results were
obtained when 5% Pt-C 50% water with methanol-HCl (1:1) were used as a catalyst and
reaction media (Figure IIc.2), in which case the product of the reaction was obtained
almost quantitatively in a one-pot synthesis (Table IIc.1).
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Figure IIc.2: One pot synthesis of 5-cyclohexylmethyl barbiturates.
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Table IIc.1: Aromatic hydrogenation of selected barbituric acid benzylidenes.
Product

R1

R2

Y

Yield (%)

C1

H

H

OCH3

89

C2

H

CH3

OH

84

C3

H

C6H5

OCH3

93

C4

CH3

CH3

OH

88

To fully confirm the structure of our compounds, one compound C4 was the
subject of X-ray structural analysis. The monoclinic P21/c crystals were grown from a
methanol solution by allowing methanol to slowly evaporate at room temperature. The
X-ray determined structure of 5-(cyclohexylmethyl)-1,3-dimethylbarbiturate is presented
in Figure IIc.3. Both amide nitrogens of the barbituric acid ring are blocked with methyl
groups, therefore the strong hydrogen bonding generally present in crystalline barbituric
acid derivates cannot be observed in this instance. The barbituric acid ring is almost
planar, and almost perpendicular to the cyclohexane ring, which is in the chair
conformation.
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Figure IIc.3: Ortep drawing of compound C4 (courtesy of Prof.s E. D. Stevens and K. L.
Martin).
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IId. Preparation of 5-Formyl and 5-Acetyl Barbiturates and Corresponding Schiff
Base Products
IId.1 Preamble
Many new drugs can be envisioned using the small 5-formyl or 5-acetyl
barbiturates as a primary building block. Synthetic procedures for the preparation of 5acetylbarbiturates with acyl groups containing phenyl as well as long alkyl groups are
well documented in literature.45-46 Direct pharmaceutical and other industrial
applications for the uses of these derivatives have also been documented in the literature,
and while the applications exist,46-47 unfortunately, there are no good synthetic
procedures for the preparation of simple acylbarbiturates, such as formyl and acetyl
barbiturates.
There are several very efficient ways of introducing the formyl group to organic
molecules.48-49 The general methods for the introduction of a masked formyl group can
be divided into three classes, according to the nature of the reactant (C, -C, or +C). The
first group, C, belong to the Inanaga SmI2-induced masked formylation of carbonyl
compounds.50 This reaction has a limited synthetic scope because strong oxidants or SmI2
must be used (Figure IId.1).

O
R1

O
R2

SmI2

O

O

OH
R1

O

R2

Figure IId.1: Inanaga method for introduction of a masked formyl group.50
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On the other hand, using a masked nucleophile (-C) to introduce the formyl group is
probably the most widely developed method today (see 31, Figure IId.2), but not
applicable to our system due to the fact that the C-5 of barbituric acid is a (-C)
nucleophile.51-54
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Figure IId.2: Example of (–C) masked nucleophile to introduce formyl group.54

Other classical examples of the formylation include using cation (+C) equivalents in
reactions of alkyl orthoformates with organometallics.55-57 Direct formylation of organic
compounds is also well established in organic chemistry. The Vilsmeier or VilsmeierHaack reaction is the most common method for the direct formylation of reactive
aromatic rings, such as anilines or phenols (Figure IId.3).58-60
CHO
POCl3

N
H

MeO2C

DMF

N
H

MeO2C

Figure IId.3: Example of direct formylation via Vilsmeier-Haack reaction.60b
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Another direct formylation that can be applied to phenols and certain heterocyclic
compounds, such as pyrroles and indoles, is the Reimer-Tiemann reaction.61-63 This
reaction is performed in basic solution and the yields are generally low, seldom
overcoming 50%.64 This methodology was employed previously by Panteleimonov and
Madrik in their preparation of 5-formylbarbituric acid in 30% yield.65

IId.2 Results and Discussion
By modifying the Reimer-Tiemann reaction procedure, we simplified the reaction
procedure and obtained a higher purity and higher yield of 5-formylbarbiturates (Figure
IId.4). By following the course of the reaction through 1H-NMR spectroscopy, it was
apparent that 80% of the barbituric acid was converted to the corresponding formyl
compound. Unfortunately, the solubility of barbituric acid and 5-formylbarbituric acid in
both water and methanol are very similar, and a large quantity of product was lost during
the purification process. When phenyl or methyl substituted barbituric acids were used
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Figure IId.4: Synthesis of 5-formyl and 5-acetyl barbiturates (General procedures I and
J).
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the isolated yields obtained were much higher (Table IId.1). To our surprise we were
unable to find in the literature a reliable procedure for the preparation of 5acetylbarbiturates as well, although the preparation of some N-substituted 5acetlybarbiturates is known.66 If 5-acetylbarbiturates are to be used as precursors in the
preparation of valuable pharmaceuticals, they should be inexpensive and available in high
yields. To meet these requirements, a simple, preferably one-pot synthesis should be
prepared using readily available starting materials. Our resulting developed procedure
adheres to these requirements, utilizing acetic anhydride as a reagent for introducing the
acetyl substitution in the 5-position of barbituric acids (Table IId.1).

Table IId.1: 5-Formyl and 5-acetyl barbiturates.
Product

R1

R2

R3

Yield (%)

D1

CH3

CH3

H

75

D2

H

H

H

45

D3

C6H5

H

H

67

D4

H

H

CH3

95

D5

C6H5

H

CH3

65

D6

CH3

CH3

CH3

92

IId.3 Preparations of ω-aminoalkanoic acid Schiff Base Products
Schiff-base products of 5-formyl and 5-acetylbarbituric acids have been reported
as showing some interesting biological properties, therefore, the need for the preparation
of these compounds in larger quantities using simple and effective synthetic procedures
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was evident.67-70 Based on our previous experience, we felt especially valuable
biologically active compounds could come as a result of a Schiff base reaction between
formylated or acetylated barbituric acids and ω-aminoalkanoic acids. Based on
previously performed structure-activity relationship studies with already known histone
deacetylase inhibitors as anticancer compounds, such as PCHA (17) and SAHA (19), we
hypothesized that our Schiff base products of barbituric acid derivatives and ωaminoalkanoic acids , designed to structurally resemble these inhibitors, might also be
active anticancer compounds (Figure IId.5).71-73
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Figure IId.5: Formyl barbiturates designed as potential histone deacetylase inhibitors.

Our ensuing procedure used to develop these potentially valuable compounds
involved the one-pot synthesis of the condensation of the two reactants (barbiturate and
ω-aminoalkanoic acid) in methanol (Figure IId.6). The products had physical properties
that easily set them apart from both starting materials, as well as made them an easy
O
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Figure IId.6: Synthesis of ω-aminoalkanoic acid Schiff bases (General Procedure K).
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subject of biological evaluation, being highly water soluble, and having similar structures
as zwitterionic amino acids. Furthermore, considering the nature of the physical
properties of the products, our isolated yields were very high (Table IId.2).

Table IId.2: ω-aminoalkanoic acid and barbituric acid Schiff base products.
Product

R1

R2

R3

n

Yield (%)

D7

CH3

CH3

H

5

90

D8

H

H

H

3

95

D9

H

H

H

5

91

D10

C6H5

H

H

3

80

D11

H

H

CH3

3

89

D12

H

H

CH3

5

87

D13

H

H

CH3

2

90

IId.3.1 Physical properties of Schiff base products with ω-aminoalkanoic acid
The positions of the double bonds in the Schiff base product strongly varied with
the nature of the solvent and temperature applied. It is commonly interpreted that Schiff
bases are compounds that have a carbon-nitrogen double bond,74 which can move
throughout the molecule to produce the more thermally stable isomer. This double bond
isomerization occurs via either proton exchange in solvent, or proton exchange with
another molecule of the Schiff base product. Our barbituric acid Schiff bases were
perfect examples of this type of equilibrium. The equilibrium was temperature sensitive
and the two isomers, one containing a C-N double bond, and the other containing a C-C
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double bond had substantially different proton 1H-NMR chemical shifts, as demonstrated
in the 1H-NMR spectrum of D13 (Figure IId.7). D13 was highly soluble in water and
dimethyl sulfoxide (DMSO), but only slightly soluble in methanol. At room temperature,
more than 90% of compound D13 had a C-C double bond (Figure IId.7 A). This
structural assignment was based on the chemical shift for β-alanine as a standard in
DMSO-d6. β-alanine is slightly soluble in DMSO, and all hydrogens on the nitrogens are
exchanged with deuterium from the solvent, therefore two triplets, one at 2.789 ppm (J=
4.5 Hz) for –NCH2- of β-alanine and the other at 2.060 ppm (J= 4.5 Hz) for –CH2CO- of
β-alanine were observed. With the assumption that the chemical shift for –NCH2- of
D13 in the C-C double bond isomer is similar to the chemical shift of our standard, βalanine, we assigned the 2.973 ppm peak to the –NCH2- of the D13 C-C double bond
isomer (Figure IId.7 A). The chemical shifts at 3.632 and 3.616 ppm were assigned to –
NHCH2 in the D13 C-N double bond isomer (Figure IId.7 A). By refluxing a methanolwater solution for 5 minutes, the ratio of the isomers does not change to a discernable
degree, as determined by 1H-NMR spectroscopy.
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Figure IId.7: Spectroscopic following by 1H-NMR (DMSO-d6) of the change in the
ratios of the two structural isomers of D13. (A) two isomers isolated from the methanol
reaction mixture; (B) ratio of isomers after heating DMSO-d6 solution for 1 min; (C) 3
min heating; (D) 5 min heating then standing at room temperature for 8 h.

It seemed obvious that due to the low boiling point of each of these solvents, the
temperature necessary to induce the isomerization of D13 could not be reached using
methanol and water. On the other hand, DMSO has a boiling point of 189º C, and its heat
capacity is much higher than that of methanol and water, thus a higher temperature can be
reached in this refluxing solvent. By heating the DMSO solution and allowing the
solvent to reflux for one minute, the amount of the C=N isomer in solution increased
from 18% to 61% (Figure IId.7 B). With prolonged heating the C=N isomer ratio
increased to 89% (Figure IId.7, C), and after 5 minutes, the C=N isomer was practically
the only observed isomer spectroscopically. Upon standing at room temperature for
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several hours, the C=C isomer begins to re-establish, however not to the ratio previously
observed in spectrum A (Figure IId.7 D). From this study, it can be stated that the C=C
isomer is probably the kinetic product of the reaction, while the C=N isomer is probably
the thermodynamically favored product. When the Schiff base product D13 was purified
by crystallization, only the C=C isomer was present in the isolated material.

IId.4 Preparations of Phenylhydrazones of 5-Formyl and 5-Acetyl
barbiturates
It was demonstrated that simple nitrophenylhydrazones of 4hydroxybenzophenone have strong anticancer properties.75 With respect to the binding
capabilities to biomolecules, the barbituric acid moiety should be superior to phenols, due
to the larger number of hydrogen bonds that can be formed during non-bonding
interactions. Because of this rationale, we felt it of interest to develop the
phenylhydrazones of the simple 5-formyl and 5-acetyl barbiturates previously described
with the intent to do biological evaluation of these derivatives. Several methods for this
synthesis were explored. The simplest and most effective methods were the direct
condensation of the corresponding phenylhydrazine with the 5-formyl or 5-acetyl
barbiturates in methanol at elevated temperatures (Figure IId.8).
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Figure IId.8: Synthesis of traditional Schiff bases of phenylhydrazines and barbituric
acids (General Reaction L).

After the reaction was completed, the isolation of the product was dependent on the
physical properties of the compound; however the products generally tended to be only
slightly soluble in reduced volumes of methanol. The optimized isolated yields of several
derivatives are presented in Table IId.3.
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Table IId.3: Schiff base products of phenylhydrazines and barbiturates.
Product

R1

R2

R3

R4

R5

Yield (%)

D14

H

H

H

H

NO2

80

D15

H

H

H

NO2

NO2

88

D16

Ph

H

H

H

NO2

92

D17

Ph

H

H

H

COOH

93

D18

CH3

CH3

H

H

NO2

95

D19

CH3

CH3

H

H

COOH

91

D20

H

H

CH3

H

NO2

73

D21

H

H

CH3

NO2

NO2

86

D22

Ph

H

CH3

H

NO2

84

D23

Ph

H

CH3

NO2

NO2

81

D24

CH3

CH3

CH3

H

NO2

63

D25

CH3

CH3

CH3

NO2

NO2

84

61

IIe. Aromatic-dibarbiturates- Pyridine and Quinoline Derivatives
IIe.1 Preamble
There are some molecular systems that are capable of modulating immune
responses, effectively opening an avenue for new and innovative treatments that combat
terrible diseases such as AIDS and cancer.76-78 Until recently, barbiturates were mostly
used as sedative and anesthetic drugs.79-81 However, there are a few recent literature
reports that suggest that some aromatic-dibarbiturates may also possess modulating
activity, and initiate the human immune response.82-83 One could argue that the reason
that aromatic dibarbiturates have not yet been thoroughly explored is due to the lack of
availability of these derivatives. Additionally, even in the few cases reported, once the
derivatives were prepared, the low water solubility of these synthetic compounds
hampered further the biological evaluation of their immune modulating activities. One
can propose that both of these problems can be eliminated if the aromatic moieties of the
dibarbiturates are substituted with either a pyridine or quinoline moiety, thereby
providing aromatic heterocycles that are more water soluble than corresponding benzene
or naphthalene derivatives. Unfortunately, procedures for the preparation of aromatic
and heterocyclic dibarbiturates were not available at the time of our initial literature
searches, indicating that we would need to devise our own synthetic design to produce
these analogs in sufficient quantities for future testing.
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IIe.2 Results and Discussion
We hypothesized that the ideal starting materials for the preparation of these types
of barbiturate analogs would be aromatic and heteroaromatic aldehydes and nitrogen
substituted barbituric acids (Figure IIe.1). In general, barbituric acid condenses
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Figure IIe.1: Possible starting materials for the preparation of heterocyclic
dibarbiturates.

with aromatic aldehydes to form Knoevenagel condensation products.84 However, the
outcome of these types of condensations is not always the simple arylidenebarbiturate.
Some very interesting condensation products can be formed by simply varying either the
nature of the aldehydes or the position of the heterocyclic atom of the aldehyde. In
general, the nature of the condensation product is determined by the arylcarboxaldehyde.
For instance, when 1,3-dimethylbarbituric acid is condensed with 2pyridinecarboxaldehyde, regardless of the reaction solvent used (DMSO, methanol, acetic
acid, etc.) the final product is the unique dipyridine-dibarbituric acid ylide (Figure IIe.2),
which will be discussed at length in subsequent chapters of this manuscript. When
barbituric acid is used instead of 1,3-dimethylbarbituric acid the reaction outcome is
different. For example, in trifluoroacetic acid (TFA) the condensation product between
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2-pyridinecarboxaldehyde and barbituric acid is 2-pyridinemethylenedibarbiturate i rather
than the corresponding dipyridine-dibarbituric acid ylide ii (Figure IIe.2). This is not
true for all reaction conditions. Even with barbituric acid as a starting material (R=H) the
reaction conditions can be optimized in such way that ylide ii (R=H) becomes the major
product of the condensation. This finding suggests that through careful exploration of
the reaction conditions, a variety of aromatic-dibarbiturates can be prepared from the
same starting materials, and specific reaction conditions required to produce the desired
bis barbiturate must be thoroughly explored.
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Figure IIe.2: Two different products of barbituric acid (R=H) and 1,3-dimethylbarbituric
acid (R=CH3) condensation with 2-pyridinecarbaldehyde.

Therefore, we outlined and performed a systematic study of aromatic and
heteroaromatic aldehydes in condensation with barbituric acids, with the target being to
prepare both aromatic and heteroaromatic-dibarbiturates. The fact that the major product
of the Knoevenagel condensation between aromatic aldehydes and barbituric acid is the
5-arylidenebarbituric acid was perfectly demonstrated in our 1H-NMR spectra, recorded
throughout the course of the reaction of the condensation between 1-naphthaldehyde and
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barbituric acid (Figure IIe.3). Regardless of the nature of the reaction media (neutral,
acidic, or basic) only one product of the reaction was detected and isolated, and that
product was 5-naphthalen-1-ylmethylenebarbituric acid (A7). This reaction could be
performed in many different solvents (methanol, dioxane, tetrahydrofuran, and dimethyl
sulfoxide to name some of them) in a period of 20-40 hours at room temperature, each
giving the respective Knoevenagel condensation product. In acidic solvents, such as
trifluoroacetic acid, the reaction was practically over in two hours at room temperature.
Even when the reaction was conducted using a ten-fold molar excess of barbituric acid
and higher temperatures (~70-120º C) overnight, we were not able to obtain the double
barbituric acid addition product with 1-naphthaldehyde. Furthermore, the same reaction
outcome was obtained when the reaction was carried out with benzaldehyde instead of
naphthaldehyde, indicating that the nature of the formation of the bis-barbiturate required
some other stabilization, not found in the unsubstituted aromatic aldehydes.

Figure IIe.3: 1H-NMR (500 MHz) reaction following for 1-naphthaldehyde (1 mM)
condensation with barbituric acid (5 mM) in CF3COOH to produce A7.
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Through the course of our experiments, we were also able to demonstrate the
influence of both the solvent and the nature of the substituents attached to benzaldehyde
on the outcome of the condensation reaction. For instance, in our previous studies,
outlined in Chapter IIa, we demonstrated that benzaldehydes with electron donating
substituents, such as the dimethylamino or hydroxyl groups, form the Knoevenagel
condensation product easily. The reaction was completed and the product isolated as
quickly as one hour after refluxing in methanol, or several hours stirring at room
temperature. The same product can be detected if the condensation reaction is performed
in dimethyl sulfoxide as a reaction media, therefore, we chose to use dimethyl sulfoxide
as the reaction media for our 1H-NMR spectroscopic studies of the reaction progression
for several reasons. In both methanol and DMSO, the initial reaction mixture is a
solution, but when methanol is used as a reaction media the condensation product
precipitates from the reaction mixture. Due to this precipitation, we were unable to
determine through 1H-NMR the existence of any product in solution. In DMSO the
Knoevenagel condensation reaction was completed after fourteen hours at room
temperature (Figure IIe.4). In our 1H-NMR spectra following the reaction, we could not
detect traces of the double barbituric acid addition product E1. One can argue that this is
due to the fact that the addition of the second barbituric acid to the condensation product
A1 is a slow process. The second addition of barbituric acid in many ways resembles the
Michael-type of nucleophilic addition to α,β-unsaturated carbonyl compounds, and85 to
be able to perform this reaction it would be necessary to utilize a strong nucleophile.
Consequently, the second addition of barbituric acid could only be accomplished with the
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Figure IIe.4: The 1H-NMR (500 MHz) reaction following of 4dimethylaminobenzaldehyde condensation with barbituric acid in DMSO (a, b, and c) to
yield A1 and CF3COOH (d, e, and f) to yield E1.

enol form of barbituric acid. In such a case, we hypothesized that strong acidic media
would be the required reaction media in order to perform the double addition reaction
with barbituric acid acting as a nucleophile.
Through our 1H-NMR spectroscopic monitoring of the reaction progression using
acidic media, such as D2O-HCl, CH3CO2H, H2SO4, CF3CO2H, CF3SO3H, and H2SO4, we
noted that we obtained the best results for the formation of the double addition products
using CF3CO2H as our strong acid. The reaction was practically complete in one hour,
and the formation of the Knoevenagel condensation product A1 was observed
spectroscopically (Figure IIe.4-spectrum e) during the course of the reaction. This
intermediate was a very good α,β-unsaturated carbonyl compound that facilitated the
second barbituric acid addition in CF3CO2H, which resulted in the dibarbituric acid
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adduct E1 (Figure IIe.4 spectra e and f). We were able to fully convert 4dimethylaminobenzaldehyde into the double barbituric acid adduct E1. At this point, and
based on our experimental evidence, one argument could be made. In order for the
double barbituric acid addition to aromatic aldehydes to occur, a strong electronwithdrawing group attached to the aldehyde’s aromatic ring is required. This argument
can be validated examining the following facts. In DMSO-d6 as a reaction media the
electron-donating (CH3)2N group attached to the aromatic ring is not protonated,
therefore only the Knoevenagel condensation product A1 is detected and isolated.
However, in CF3CO2H media (pKa=0.0) the dimethylamino group is protonated,
(CH3)2HN+, and the substituent becomes electron-withdrawing. The pKa of anilines (1012) is considerably higher than the pKa of trifluoroacetic acid, therefore the aniline
should be protonated in TFA. On the other hand, the pKa for protonated phenols and
anisoles is between -6 and -8, and in TFA would exist primarily in the OH and OCH3
forms.86
The 1H-NMR barbituric acid condensation with both 4-methoxy and 4hydroxybenzaldehyde (Figure IIe.5) in trifluoroacetic acid further validates this
argument. Aromatic aldehydes with strong electron-donating groups, such as hydroxy
and methoxy, react selectively with barbituric acid derivatives to produce only the
Knoevenagel condensation product in quantitative yield, regardless of the applied
reaction media (methanol, H2O-HCl, H2SO4, CH3CO2H, CF3CO2H).86 This is clearly
demonstrated in the 1H-NMR reaction following experiment for the 4hydroxybenzaldehyde condensation with barbituric acid in trifluoroacetic acid. Only the
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condensation product A4 was detected in the NMR spectra of the reaction mixture
(Figure IIe.5).

Figure IIe.5: 1H-NMR reaction following of 4-hydroxybenzaldehyde condensation with
barbituric acid in CF3CO2H yielding A4.

We hypothesized that if it was in fact true that strong electron-withdrawing
substituents on the aromatic ring facilitate the second barbituric acid addition to
benzaldehyde, then the preparation of aromatic-dibarbiturates from nitrobenzaldehyde
should occur in protic as well as aprotic solvents. This hypothesis was confirmed, and
was demonstrated by the H-NMR spectroscopic study following the progression of the
reaction for the barbituric acid addition to benzaldehyde in both dimethyl sulfoxide and
trifluoroacetic acid as reaction media (Figure IIe.6). The same double addition product
E2 was obtained regardless of the nature of the solvent, the difference being only the time
required for the reaction completion. For example, the reaction was completed in 40
minutes in trifluoroacetic acid media and in 24 hours in dimethyl sulfoxide media, both at
room temperature.
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Figure IIe.6: 1H-NMR reaction following in DMSO-d6 -300 MHz Varian Unity and
CF3COOH with electron-deficient aromatic aldehydes to yield E2.

Regarding reactivity, nitrogen heterocycles are similar to corresponding
nitroaromates.87 Heterocyclic compounds similar to substituted benzenes have
preferences for nucleophilic and electrophilic reactions. In the case of pyridine87 it is not
the free base that is involved in the electrophilic reaction, rather the conjugate acid of
pyridine. This is also true if a neutral nucleophile such as barbituric acid, malonic ester,
phenylacetonitrile, etc. is added to the heterocyclic carboxaldehyde N-oxide.88
A similar parallel can be drawn between the reactivity of nitronaphthaldehydes
and quinolinecarboxaldehydes. If this assumption is true then the addition of barbituric
acid to quinolinecarboxaldehyde in any solvent should afford the double addition product
and the required reaction time should be relatively short. This was completely
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demonstrated in the H-NMR spectra following the reaction between barbituric acid and
4-quinolinecarboxaldehyde E3 (Figure IIe.7). The reaction was complete after one hour
at room temperature. It appeared that the second addition of barbituric acid to the
Knoevenagel intermediate was a faster reaction than the first addition of barbituric acid to
4-quinolinecarboxaldehyde, we were not able to detect even a trace of the condensation
intermediate by NMR spectroscopy.

Figure IIe.7: The 1H-NMR (DMSO-d6 -300 MHz Varian Unity, 500 MHz) reaction
following for 4-quinolinecarboxaldehyde condensation with barbituric acid to yield E3.

Given the previously described results, it is also logical to assume that larger
barbituric acid adducts can be formed if two or more heterocyclic carboxaldehydes are
covalently bound together. With respect to biological activity, we had a curiosity to
prepare these compounds in order to determine whether the doubles of the structural
moieties necessary for activity would have additive effects on the biological activity.
Synthetically, this could be a daunting task because increasing the size and the number of
the heterocycles makes the new target molecule harder to handle with respect to the
formation of various reaction intermediates, their solubility in the course of the reaction,
and the solubility of the final compound. These problems are perfectly demonstrated on

71

the example for the tetra barbituric acid addition to the dipyridinedicarboxaldehyde
(Figure IIe.8). Although the reaction can occur in any given solvent that can dissolve
both barbituric acid and dipyridinedicarboxaldehyde, the solubility of various reaction
intermediates as well as tetra-adduct E4 limits us to using only dimethyl sulfoxide as a
solvent and the reaction concentration must not be higher than 0.1 mM. In the course of
the NMR reaction, signals for every intermediate of the barbituric acid adducts can be
detected (the first Knoevenagel adduct, the second Knoevenagel adduct, the first
Michael-type of adduct and the second Michael-type of adduct (compound E4, Figure
IIe.8). There are many more intermediates involved in the barbituric acid tetra-addition
to dipyridinedialdehyde DPDA. With close evaluation of the NMR spectra five minutes
after the reagents are mixed (Figure IIe.9) two new aldehyde hydrogen signals around
9.9 ppm and a signal for α-CHOH at 6.7 ppm (besides the signals for the starting
aldehyde DPDA) indicate the formation of iii. Signals at 10.15 ppm and 8.2 ppm are
assigned to the aldehyde and the vinyl hydrogen of intermediate iv and v, respectively.
A small singlet at 8.25 ppm belongs to intermediate vi, and the singlet at 6.08 ppm
belongs to the α-CH(Ba)2 of intermediate vii, while the singlet at 6.15 ppm belongs to the
same hydrogen (α-CH(Ba)2 ) of the tetra-adduct E4 (Figures IIe.8 and IIe.9). This
analysis is performed with the assumption that the barbituric acid addition to the C=O is
faster than the addition to the C=C double bond, and that elimination of water is faster
from intermediates iii and v than both the barbituric acid additions. Further spectroscopic
study of the mechanism of the tetra-addition of barbituric acid is currently underway
using positive electro spray studies and NMR studies.
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Figure IIe.9: 1H-NMR (500 MHz) following of barbituric acid (10 mM) condensation
with 2,2’-bipyridine-4,4’-carboxaldehyde (2.5 mM) in TFA-DMSO (3:1) at room
temperature yielding E4.
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Additionally, we carefully explored the double addition reaction through NMR
experiments in various organic solvents, as well as various acid-base conditions, and
simple and very efficient reaction conditions were developed for the preparation of these
valuable compounds (Figure IIe.10). Isolated yields are almost quantitative and in many
cases isolation and purification of the product simply involve filtration and washing the
precipitate with solvent (Table IIe.1). In these cases, the previously described NMR
experiments utilizing both aromatic and heteroaromatic carboxaldehydes in both protic
and aprotic solvents provided optimal reaction conditions for the preparation of double
barbituric acid addition adducts to aromatic aldehydes. Our preparation procedures
developed are applicable to multi-gram as well as multi kilogram scales and considering
the simplicity of the preparation and isolation of these compounds, the procedures are
directly applicable to the industrial scale preparation with little or no modification.
Crystals of E3 were obtained by slow evaporation of methanol at room temperature. The
structure of compound E3 was confirmed by X-ray structural analysis (Figure IIe.11).
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Table IIe.1: Barbituric acid condensation with aromatic aldehydes
Product

R1

R2

Aldehyde

Yield (%)

CHO

E5

CH3

CH3

N

92

N

E7

H

H

97
N

E8

CH3

CH3

92
N

E9

H

CH3

97
N

E10

H

C4H9

81
N

E11

H

C6H5

93
N

E12

H

H

97
N

E13

H

CH3

98
N

E14

H

C4H9

92
N

E15

H

C6H5

92
N

E16

CH3

CH3

86
N
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Table IIe.1 continued…
E17

H
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93
N

E18

CH3

CH3

84
N

E19

H

CH3

78
N

E20

H

C6H5

95
N

Figure IIe.11: ORTEP drawing of compound E3 (courtesy of E. D. Stevens).
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IIf. Unique Molecules: Charge Separated Pyridinium-Barbiturate Zwitterions
IIf.1 Preamble
Pyridinium zwitterions are widely used in organic synthesis, either as nucleophilic
agents or as reagents in dipolar cycloaddition reactions. The latter are used to synthesize
fused heterocyclic systems that are otherwise very difficult to synthesize. Figure IIf.1 is
an example of the dipolar nature of pyridinium zwitterions and how they can be involved
in dipolar cycloaddition reactions.89-92
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Figure IIf.1: Dipolar nature of pyridinium zwitterions.91

Usually, pyridinium zwitterions are compounds that are very reactive toward activated
olefins and alkynes, and should be kept at low temperatures and in an inert atmosphere
(Figure IIf.1). The majority of pyridinium zwitterions were synthesized by first
preparing the pyridinium salt, followed by the elimination of an acid in reaction with a
base. However, there are some other routes that are one-step syntheses which utilize the
capability of pyridine derivatives to add to reactive double bonds or to trap carbenes
(Figure IIf.2).93
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Figure IIf.2: Formation of pyridinium zwitterions.93b

Another application is the 1,4-dihydropyridine addition to alkoxycarbene complexes of
transition metals, which has been shown to produce pyridinium zwitterions whose
negative charge resides on the transition metal (Figure IIf.3, viii). These reactive
zwitterions have been shown to be successful in a number of reactions, one of which is
selective cyclopropanation (Figure IIf.3, ix).94-96
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Figure IIf.3: Pyridinium zwitterions used in cyclopropanation reactions.95

However, in the majority of cases, the negative charge resides on the carbon attached to
the pyridinium nitrogen and is delocalized by the presence of electron-withdrawing
substituents.89-92 For example, pyridinium-cyclopentadienylide (Figure IIf.4, x) is
probably the most theoretically explored pyridinium zwitterion with aromatic
stabilization of a negative charge.97 Yet, even in this case, the molecule has low stability
and little is known about its reactivity.98-99 To make pyridinium cyclopentadienylide
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sufficiently stable for structure determination in order to evaluate its reactivity, the
cyclopentadienide moiety must have strong electron-withdrawing groups, as in the case
of pyridiniotetrabromocyclopentadienides (Figure IIf.4, xi).100
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4-CO2Me, 3-CO2Me, 4-CN, 4-N(Me)2

Br

xi

Figure IIf.4: Pyridinium zwitterions with aromatic stabilization of a negative charge

IIf.2 Results and Discussion
In our previous attempts to outline reaction procedures for the double addition of
substituted barbituric acid to electron withdrawing aromatic aldehydes described in the
previous chapter, we were surprised to find that under comparable reaction conditions,
the 2-pyridine and 2-quinolinecarboxaldehydes did not give our desired Michael type
adduct. Instead, through these reaction conditions, we obtained a unique compound that
we were unable to immediately assign a structure to, based on our spectroscopic data.
Later, we characterized the compound through X-Ray structural analysis (Figure IIf.5),
as a unique, stable pyridinium zwitterion, and therefore set out to design and explore the
reaction requirements more thoroughly to form our unique molecule.
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Figure IIf.5: ORTEP drawing of X-ray determined structure of F1 (courtesy of E. D.
Stevens).

We subsequently developed an efficient synthetic procedure for the preparation of a
unique pyridinium zwitterion (F1), synthesized through the controlled condensation
between 1,3-dimethyl barbituric acid and 2-pyridinecarbaldehyde, with an aromatic
stabilization of the negative charge. In the case of barbituric acids, amide resonance
dominates over aromaticity. With a negative charge localized on the barbituric acid ring,
it is reasonable to assume that π−π atomic orbital overlap between the atoms in the ring
should increase, thereby stabilizing the negative charge, which is indicated by the
planarity of one of the barbituric acid rings of F1.
Previous literature data suggests that if the reaction between a barbituric acid and
an electron-rich aromatic aldehyde is performed, then the Knoevenagel condensation101-
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product (F4) must be the major product isolated (Figure IIf.8).29, 84, 103-104 However,

this application does not apply to electron poor aldehydes, such as nitrobenzaldehyde, in
which there are unexpected products and the double addition product (Michael Addition,
F2) is obtained (Figure IIf.6).105-107
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Figure IIf.6: Typical reaction product of barbituric acids and electron-deficient aromatic
aldehydes.
Considering the similarities in the electronic properties of 2-nitrobenzaldehyde and 2pyridinecarbaldehyde, one would expect that the isolated product of the condensation
between 2-pyridinecarbaldehyde and substituted barbituric acids should be of the Michael
Type adduct. This is not the case and the isolated product of this condensation is (F1) in
almost quantitative yield (Figure IIf.7).
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Figure IIf.7: Reaction outcome when 2-pyridinecarboxaldehyde is used as electrondeficient aromatic aldehydes.
To explain the formation of our unique compound, we hypothesized that two
intermediates must exist. The first intermediate, and one that we have had previous
spectroscopic evidence that lends to its formation during the course of double addition
reactions, is the intermediate Knoevenagel product (F4). The second intermediate would
be an unstable pyridinium barbiturate zwitterion (F5) (Figure IIf.8), which should
undergo rearrangement to produce the more stable compound F1.
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Figure IIf.8: Two proposed reactive intermediates in formation of F1.
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Our attempt to actually isolate the Knoevenagel condensation product (F4) in the reaction
between 1,3-dimethyl barbituric acid and 2-pyridinecarbaldehyde was not successful,
regardless of the nature of solvent or base and acid used in this reaction. From NMR
spectra taken during the reaction, we know that intermediate (F4) is formed and almost
instantly consumed in nucleophilic addition of the barbituric acid (leading to product F1).
We hypothesized that when a better nucleophile was not present in the reaction mixture,
then the nitrogen of the pyridine moiety of F4 acted as a nucleophile to another molecule
of F4, producing the pyridinium zwitterion F5. This zwitterion subsequently rearranged
into the more stable pyridinium zwitterion F1. Both of these zwitterions contain
negatively charged barbituric acid rings. Although we do not have direct evidence for the
formation of pyridinium zwitterion F5, we have indirect experimental information that
strongly supports our hypothesis of its existence. For instance, if the reaction is
performed in a strong acid, such as sulfuric acid, then the only isolated product is the
sulfonate salt of the 2-pyridinium Knoevenagel condensation product. If the reaction is
done in acetic acid, then a virtually insoluble polymeric product is obtained. While we
were unable to spectroscopically determine the structure of this compound, due to its
insolubility in solvents such as DMSO, methanol, water, acetic acid, chloroform,
nitromethane, benzene and pyridine, we hypothesized that the insoluble material could be
the polymer formed between two molecules of the reactive intermediate F5. This
assumption was based on the fact that acetic acid should be strong enough to protonate
the carbon of the negative barbituric acid ring of F5, facilitating the nucleophilic addition
of the pyridine-N of one molecule of F5 to the double bond of a second molecule of F5
(Figure IIf.9).
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Figure IIf.9: Possible polymeric material of F5 in acetic acid.
Another indication of the existence of F5 as a reactive intermediate comes from the fact
that we were unable to prepare type F1 zwitterions if 1-methyl, 1-phenyl, or
unsubstituted barbituric acid was used as a starting reagent instead of the disubstituted
1,3-dimethyl barbituric acid in the condensation reaction with 2-pyridinecarbaldehyde.
Performing the reaction with these barbiturates in methanol also gave an insoluble
material, appearing to be the same as the polymer like material obtained from the
previous reaction in acetic acid. We hypothesized that the insoluble material was indeed
the polymeric material obtained from reactions of F5, catalyzed by the free NH of the
barbituric acids used. From this point, we ceased exploration of the characterization of
the insoluble material obtained through these reactions, due to solubility problems with
further characterization. In the absence of solvents strong enough to either protonate the
N of the pyridine ring, resulting in the Knoevenagel condensation product, or protonate
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the barbituric acid ring, resulting in the polymer, the zwitterion F5 would readily
rearrange to the more stable isomer, F1.
IIf.3 Physical properties of Pyridinium-barbituric acid Zwitterion F1
Pyridinium zwitterion F1 shows some interesting chemical properties. One
would expect that due to the negative charge localized on the barbituric acid ring,
zwitterion F1 would be very sensitive to protic solvents. However, it is stable in water,
alcohol, and acetic acid. In fact, the compound is stable in hot acetic acid, which was
determined by the lack of formation of decomposition products upon heating. The
formation of decomposition products was monitored by (1) spectroscopic
characterization by VT 1H-NMR (80º C over 24 hours) and (2) by Thin Layer
Chromatography of F1 before extensive heating and periodic examination of the reaction
mixture following several days of heating in acetic acid. In a more extensive, long-term
NMR experiment using acetic acid and following the possible decomposition at room
temperature over a period of 30 days, the only observable changes in the spectra were
proton-deuterium exchange products. This proton exchange in a modest acid such as
acetic acid is characteristic of an aromatic ring.108
Another surprise comes from the stability of the pyridinium zwitterion skeleton in
basic solution. It was expected that in aqueous sodium hydroxide, the five-membered
ring of F1 would open. Instead, the second barbituric acid ring, the ring not part of the
pyridinium zwitterion substructure, opens and the decarbonylation product F6 is isolated
(Figure IIf.10), again indicating the stability of zwitterion F1.
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Figure IIf.10: The decarbonylation of F1.

This decarbonylation is a typical reaction for highly substituted barbituric acids,
the reaction previously developed by Jursic.109 Given this information, we hypothesized
that if the reaction were performed in polar solvents such as DMSO or methanol, the
formation of pyridinium zwitterions F1 and F6 should be favored, and we were able to
confirm this by spectroscopic characterization by NMR of the subsequent products. On
the other hand, less polar solvents, such as chloroform or dichloromethane, should inhibit
the formation of pyridinium zwitterions F5, subsequently inhibiting the formation of the
more stable F1 zwitterion, and the less polar product (F3, Figure IIf.11) should be
favored. In our NMR experiment using chloroform as the solvent and reaction media, we
detected the formation of both F3 and F1 in an approximate ratio of 7:3. If even less
polar solvents such as carbon tetrachloride were used, then completion of the reaction
was prolonged but the ratio of F3 to F1 became ~9:1.
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Figure IIf.11: Formation of F3 in non-polar solvents.
What is the source of this unique stability of pyridinium-barbituric acid
zwitterion? The unique structure of zwitterion F1 allows direct comparison of the X-ray
structural parameters. Jursic previously postulated that uniformity of the ring bond order
is directly related to high stability.110 This postulate can be supported through X-ray data
obtained for zwitterion F1. The negative charge that resides mostly on the barbituric acid
ring makes that ring more aromatic and adds to the bond order-bond distance uniformity.
The barbituric acid ring with the negative charge becomes almost planar. The
experimental dihedral angles are almost zero and the dihedral angles for C(16)-N(17)C(18)-N(19) and C(20)-C(15)-C(16)-N(17) are -0.22 and -3.90º, respectively. Even the
carbonyl oxygen and methyl carbon reside close to the plane of the negatively charged
barbituric acid. For instance, the dihedral angle for C(27)-N(17)-C(18)-O(28) is -0.89º
and the dihedral angle for O(26)-C(16)-N(17)-C(27) are 2.61º. Given this data, it is quite
obvious that the second barbituric acid ring is out of the plane. The dihedral angle for
C(10)-C(9)-C(14)-N(13) is -40.64º. Comparison of bond distances between two of the
barbituric rings further indicates the aromatic character of the ring that bears the negative
charge. For instance, bond distances in the nonaromatic barbituric acid ring for C(9)-
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C(10), C(10)-N(11), and N(11)-C(12) are 1.5128, 1.3934, and 1.3996 Å, respectively,
while for the same kind of bonds in the aromatic barbituric acid moiety these distances
for C(15)-C(16), C(16)-N(17), and N(17)-C(18) are 1.4138, 1.4220, and 1.3769 Å. On
the other hand, structural changes regarding pyridine and pyridinium rings are not
substantial.
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IIg. Syntheses of Heteroaromatic, Electron Rich, and Aliphatic Bis-barbiturate
Ammonium Salts.
IIg.1 Preamble
In previous chapters, we reported our successful synthesis of pyrilidene and
quinolidine bis-barbiturates via the Michael-type addition of barbituric acid to
intermediate Knoevenagel condensation products.84 While this methodology proved
successful for the synthesis of a wide variety of bis-barbiturates containing heterocyclic
or electron poor aromatics, it was equally unsuccessful in producing bis-barbiturates with
either electron rich aromatic or aliphatic substituents. During the course of our
exploration of barbituric acid double addition of heteroaromatic aldehydes we discovered
that it was necessary for the aldehydes to be electron deficient in order for the reaction to
occur. Thus, in order to obtain the Michael type adducts rather than the Knoevenagel
product with aldehydes such as 4-(dimethylamino)benzaldehyde, it was necessary to do
the reaction in highly acidic media, such as TFA. This effectively transformed the
electron rich N(CH3)2 group into the electron deficient N(CH3)2H+ group, and the
reaction was facilitated.
While we were able to use certain electron rich aromatic aldehydes in reaction
with barbituric acids to form the double adducts, as mentioned above, this method was
not comprehensive. Many electron rich derivatives, such as aldehydes with OH
substitutions, as well as unsubstituted aldehydes were not successfully transformed into
the double adduct. Additionally, the dimethylamino derivatives and nitro derivatives
were unstable compounds prone to decomposition. Therefore, we began exploring new,
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comprehensive methods that would be applicable to all types of aldehydes, inherently
necessary for our through exploration of bis-barbiturate adducts.
We did find sporadic literature reports describing the condensations of aromatic
electron deficient aldehydes, such as nitrobenzaldehyde, with barbituric acids in pyridine
as a reaction media, where the formation of the mono and di pyridinium salts were
formed.111 While this method seemed to produce the corresponding double adduct in
relatively high yields (65-95%), the synthesis was again only applicable to electron
deficient aromatic aldehydes.

IIg.2 Results and Discussion
Based on our previous studies, we hypothesized that transformation of the
electron rich substituent to the electron poor substituents was not the only barrier
necessary to overcome to produce our desired products. We hypothesized that during the
course of the reaction between barbiturates and aldehydes to form the double addition
adduct, it may also be necessary to stabilize the charge formed on the barbituric acid ring,
yet still maintain the acidic conditions required to produce the enolate needed
(nucleophile) for the second addition of barbituric acid to the intermediate Knoevenagel
product. To this end, we began exploring the use of ammonium compounds, such as
triethylamine, N-methylmorpholine, morpholine, and piperidine, as both a hydrogen
acceptor and conjugate acid to form our bis-barbiturates with electron donating and
aliphatic aldehydes. We experimentally determined that the best ammonium bases were
morpholine, ethanolamine, and piperidine, and when used in a 0.1 molar excess, we were
able to generate corresponding bis-barbiturate ammonium salts using electron-donating,
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electron-withdrawing, and aliphatic aldehydes in a one-pot synthesis (Figure IIg.1).
Table IIg.1 gives a description of the electron-withdrawing aldehydes used to produce
the bis-barbiturate ammonium salts.
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Figure IIg.1: Reaction scheme for the synthesis of bisbarbiturate ammonium salts
(General Procedure N).
Table IIg.1: Bis-barbiturate ammonium salts of electron-withdrawing aldehydes
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Our main objectives in preparing bis-barbiturates having the electron donating
substituents centered on the novelty of these types of barbiturates. To the best of our
knowledge, there were no experimental reports indicating the existence of these types of
compounds. Furthermore, the ammonium salts of these compounds were highly water
soluble, making possible biological evaluation of these types of compounds relatively
easy. Table IIg.2 lists a description of the electron-donating aldehydes used, and the bisbarbiturate ammonium salts synthesized as a one-pot synthesis (Figure IIg.1). The
reaction proceeded to completion and the isolated yields were quantitative, regardless of
the electron-donating benzaldehyde used during the course of the reaction. Additionally,
substitutions of the benzaldehydes could be in ortho, meta, or para positions without
altering the outcome of the reaction. N-methylmorpholine was used in several of the
reaction mixtures as the source of the ammonium counterion, however, in each of these
cases, we isolated the Knoevenagel condensation products in quantitative yields and from
this point on, the only ammonium compounds used were bases with at least one free NH
moiety.
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Table IIg.2: Bis-barbiturate ammonium salts of electron-donating aldehydes
Compound R1
G18

H

R2

XH+

R3

H

O

H

CH3

G19

H

H

H

H

H

H
H

H

H3C

H

N

H

H

H

N

95
H

N

96
H

O

H

N

95
H

O

90

OH

H

G24

H

CH3

H

G23

N

90

O

H

G22

H

O

OCH3

G21

95

O

CH3

G20

N

Yield(%)

H

N

H

O

H

N

H

OH

G25

H

H

O

96

OCH3
OCH3

H

N

H

OCH3

G26

CH3

CH3

O

93

OCH3
H

N

H

94

Table IIg.2 contiued…
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Considering that the most biologically potent barbituric acid derivatives are
usually those with an aliphatic C-5 moiety, we decided to develop the synthetic procedure
for the preparation of aliphatic bisbarbiturate salts. In such cases, we were able to
condense simple aliphatic aldehydes, barbituric acids, and amines, and the appropriate
ammonium salts are listed in Table IIg.3.
While there seemed no apparent restriction on the aliphatic aldehydes used in the
course of this reaction, we were unable to isolate pure products of higher aldehydes, such
as dodecanal using the method outlined in Figure IIg.1. In the reactions between
aldehydes containing more than 12 carbons and barbituric acids, the outcomes of the
reactions were a viscous oily material that we were unable to re-crystallize. The H-NMR
spectra of these products provided evidence of both the unreacted starting material, and
the bis barbiturate ammonium salt. Re-crystallization in solvents such as ether,
dichloromethane, chloroform, and petroleum ether resulted in the re-precipitation of the
oily material, and re-crystallization in solvents such as ethyl acetate, methanol, ethanol,
and THF provided the precipitation only of the unreacted barbituric acid. While we did
not attempt further methods of purification for these compounds, but expect that
separation by column chromatography would provide the pure products of aliphatic
aldehydes greater than 12 carbons in reaction with barbituric acids.
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To avoid using column chromatography as a method of purification, we attempted
to change the reaction conditions to encompass aliphatic aldehydes greater than 12
carbons. Unfortunately, while the aldehydes are soluble in virtually all reaction media
attempted, such as THF, ether, ethanol, propanol, and ethyl acetate, the respective
barbituric acids were insufficiently soluble to perform these reactions.

Table IIg.3: Bis-barbiturate ammonium salts of aliphatic aldehydes
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Because there are different biological properties elicited when a substitution is
made on the C-2 atom of barbituric acids (Figure IIg.2), such as shorter retention times,
or changes of potency, we employed the use of thiobarbituric acids to synthesize novel C2 substituted bis barbiturates using electron withdrawing, electron donating, and aliphatic
aldehydes using the general method outline in Figure IIg.1. The products were insoluble
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in methanol and immediately precipitated out, regardless of the nature of the aldehydes
used (Table IIg.4).
C-2 substitution

H
N

S

O

HN
O

Figure IIg.2: Example of C-2 substitution of barbituric acids.

Table IIg.4: Thiobisbarbiturate ammonium salts of electron-poor, electron-rich and
aliphatic aldehydes.
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The H-NMR spectra of bis-barbiturate ammonium salts are very similar to the
spectra of the corresponding bis-barbiturates described in Chapter IIe of this manuscript.
The singlet for –CH- of the bis-barbiturate structure, located between 5.5 and 6.5 ppm, is
indicative of double barbituric acid addition. In the ammonium salts, this singlet remains
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between 5.5 and 6.5 ppm (Figure IIg.4). The signals for the corresponding ammonium
base integrate to show a ratio of one molecule of the cation per one molecule of the
corresponding bis-barbiturate.

Figure IIg.4: A portion of the typical H-NMR spectra of morpholinium aromatic
bisbarbiturates.

Aliphatic bis barbiturates give a triplet (J= 8.1 Hz) between 4.5 and 5.5 ppm, indicative
of the addition of the aliphatic moiety to the barbiturate. To confirm the structure of the
bis-barbiturate ammonium salts, compound G37 was crystallized from DMSO at room
temperature (Figure IIg.5).
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Figure IIg.5: ORTEP drawing of G37 (courtesy of E. D. Stevens).
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IIh. Syntheses of Substituted and Unsubstituted 5-benzoylbarbituric acids and
Corresponding Phenylhydrazones
IIh.1 Preamble
There have been recent reports that indicate that some aromatic substituted
barbiturates, aromatic substituted barbituric acid phenylhydrazones, and other Schiff
bases containing barbituric acid moieties may actually possess immuno-modulating
properties.83, 111-114 Compounds, such as A-007 (22) (Figure IIh.1), have been shown to
possess these immuno-modulating properties, yet little is known about the mechanism(s)
underlying this biological activity. To thoroughly explore the possibility of immunemodulation within aromatic substituted barbiturate Schiff bases, structural variants of the
A-007 molecule, as well as to explore the structural requirements necessary for immune
modulating activity, a large variety of both substituted and unsubstituted 5benzoylbarbiturates were necessary precursors for the synthesis of the targeted
phenylhydrozone Schiff bases.
HO

Electron-poor moiety

Electron-rich moiety
N

O
N

N

H

O

O N
HO

O

Figure IIh.1: 4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007).

There are literature reports indicating that some substituted and unsubstituted 5benzoyl barbiturates have been previously synthesized and are used as herbicides and
insecticides.47, 115-116 However, the typical synthetic procedure for the preparation of
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these compounds involves several steps. In one of the preparation procedures, Zn(CN)2
in acetonitrile was used as a catalyst for the acylation and benzoylation of barbituric acid
with corresponding acid chlorides. Isolated yields are ~80%. Nevertheless, this synthetic
approach is not applicable for the preparation of a wide variety of substituents attached to
both aryl and barbituric moieties of 5-benzoylbarbituric acids. Therefore, there is a need
for developing new synthetic methods for the preparation of these compounds.

IIh.2 Synthesis of benzoyl barbiturates
Through our experimental exploration, we determined that the simplest way to
prepare benzoyl substituted barbituric acids was to condense N-substituted barbituric
acids (R1, R2=H, alkyl, or aryl, Figure IIh.2) with the corresponding acid chloride.
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Figure IIh.2: Syntheses of 5-benzoyl and 5-(methoxybenzoyl)barbiturates H1-7.

Many of these starting materials are commercially available, however if the desirable
starting materials are not available they can be readily prepared.117 Pyridine seems to be
an ideal solvent for this reaction. It was not necessary to fully dissolve the reactants for
the reaction to be completed; therefore a relatively small amount of pyridine is sufficient
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for the reactant conversion (~25 mL). In many instances the reaction is completed after
30 minutes. Isolation involves pouring the pyridine reaction mixture into hydrochloric
acid (conc. HCl:H2O 3:1). The formed crystalline product is of sufficient purity (~98%)
that further purification is not necessary (Table IIh.1).

Table IIh.1: Isolated yields of 5-benzoylbarbiturates.
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These preparation procedures were not applicable to the preparation of 5benzoylbarbiturates with strong electron-withdrawing groups, such as nitro groups, and a
separate synthetic procedure was developed to produce these derivatives of our Schiff
base precursors. The nitro compounds could also be prepared in pyridine as reaction
media, but the isolation and separation from both pyridine and the resulting pyridinium
chloride was very difficult. Therefore, another synthetic route utilizing N-methyl
morpholine as a base and dioxane or tetrahydrofuran as the reaction solvent was
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developed (Figure IIh.3). In such cases, the desired product was isolated in higher than
90% yield (Table IIh.2).
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Figure IIh.3: General route for preparation of 5-(nitrobenzoyl)barbiturates H8-13.

Table IIh.2: 5-(nitrobenzoyl)barbiturates
Product

R1

R2

R3

R4

Yield(%)

H8

H

H

H

NO2

93

H9

CH3

H

H

NO2

91

H10

H

H

NO2

H

93

H11

CH3

H

NO2

H

95

H12

H

NO2

H

NO2

90

H13

CH3

NO2

H

NO2

93

IIh.2.1 Physical properties
All of the 5-benzoylbarbiturates are relatively strong carbon acids due to the
mobility of the hydrogen atom attached at the C-5 position of the barbituric acid ring.
This acidity is responsible for the keto-enol equilibrium that is present in solution. The
equilibrium is relatively slow and it is possible follow the change in the equilibrium
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constant by 1H-NMR. Depending on the method of purification and crystallization of the
5-benzoylbarbiturate, one can isolate either the keto only or enol only product. This was
perfectly demonstrated on the example of 5-(3-nitrobenzoyl)-1,3-dimethylbarbituric acid
(H9, Figure IIh.4). The precipitated product formed by the condensation reaction
between 3-nitrobenzoyl chloride and barbituric acid in THF and N-methylmorpholine as
a base was exclusively in the keto form. If the product is purified by crystallization from
large quantities of water, then the enol form was present in crystalline form. It is also
obvious that the enol form was the thermally more stable species as demonstrated by
NMR following thermal distribution of keto-enol forms in DMSO at 80º C (Figure
IIh.4).

Figure IIh.4: The NMR following of thermal induced transformation of keto form of
H9 into it enol form in DMSO-d6 at 80º C.

There are couple of very interesting points that can be concluded from the NMR
following of the keto-enol equilibrium presented in Figure IIh.4. The presence of the
enol form of H9 is determined by the nature of the solvent as well as the temperature. In
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solvents that cannot form strong hydrogen bonding with N, N’-disubstituted barbiturates,
such as H9, the keto form is dominant or the only present tautomer. In solvents such as
DMSO and water, which can form strong hydrogen bonding with the enol alcohol group,
the enol tautomer is dominant. Our AM1 computational studies agree that the enol form
is thermally more stable (by 0.8 kcal/mol). Structural properties for these two tautomers
are considerably different. The carbonyl group of the p-nitrobenzoyl moiety of the keto
form of H9 is almost perpendicular to the barbituric ring (the O16-C10-C9-C14 dihedral
is 79.4º) while in its enol form, it is almost coplanar with the barbituric acid ring (O16C10-C9-C14 dihedral ring is 5.7º) (Figure IIh.5). The structural orientation of carbonyl
group toward the p-nitrophenyl moiety is exactly opposite (almost coplanar in its ketoform) and perpendicular in its enol-form, Figure IIh.5). There is also very short distance
between H27 and O15 of the enol-form (1.914 A), indicating strong hydrogen bonding in
the gas phase. This might not be the case with such polar solvents as DMSO because the
DMSO oxygen is a much better proton acceptor than the amide carbonyl of barbituric
acid. This is also evident by the fact that the barbituric acid hydrogen was not observed
in the NMR spectra of the DMSO-d6 solution of H9 due to the H-D exchange.

O16

C4
O15

C5
C14
C10
C9
H27
O16

keto-form

C10
C9

C4

H9

H27
O15
C14

C5

enol-form

Figure IIh.5:The AM1 semi-empirical computed structures of keto and enol forms of H9
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NMR spectroscopic studies of H9 in chloroform is much closer to our AM1 gasphase computational studies, therefore one can assume that the enol form with
intramolecular hydrogen bonding is present. Furthermore, the existence of C9-C10
double bond in the enol-form makes the two methyl barbituric acid groups
spectroscopically nonequivalent. In other words, the aromatic portion of the NMR
spectra in chloroform at room temperature is very similar to the NMR in DMSO-d6 at
elevated temperatures. The methyl range is different from the previous spectrum (Figure
IIh.4) because at 80º C in DMSO, due to low rotational barrier, the two methyl groups
are equivalent and in chloroform at room temperature they are not (Figure IIh.6). The
strongest evidence for the enol-form of H9 comes from the fact that at 17.8 ppm there is a
broad singlet with an integral of 1H, corresponding to the enol hydrogen involved in
internal hydrogen bonding interactions with one of carbonyl oxygens of the barbituric
acid moiety (Figure IIh.6).

Figure IIh.6: The NMR (500 MHz) spectra of chloroform solution of H9 at room
temperature
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IIh.3 Hydroxy-benzoyl barbiturate precursors
None of the discussed procedures applied for the preparation of methyl, methoxy,
and nitrobenzoyl barbiturates could be used for the preparation of hydroxybenzoyl
barbiturates. Furthermore, our exhaustive literature searches provided no evidence that
there is a method of preparation for hydroxybenzoyl barbiturates. Naturally, the hydroxyl
group attached to the benzoyl moiety must be protected during the course of the
preparation of hydroxybenzoyl barbiturates. Because we already developed the
preparation procedures for methoxybenzoyl barbiturates, we attempted to use these
compounds as starting materials for the preparation of the corresponding hydroxybenzoyl
barbiturates. Unfortunately, using various methods of deprotection, during the course of
the methoxy group transformation into the unprotected hydroxyl group, the barbituric
acid part of the molecule decomposed.118 After exploring several routes for the
preparation of these compounds, we developed a simple and high yield preparation
(Figure IIh.7). The preparation starts with acetyloxybenzoic acid, which is converted
into the corresponding acid chloride. Then, by following the previously described
procedure for the benzoyl chloride condensation with barbituric acid in pyridine, the
hydroxyl-protected product was produced. The final step involved hydrolysis of the
acetic acid ester protecting group, followed by the isolation of pure product upon
acidification (Table IIh.3).
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Figure IIh.7: Synthetic partway for preparation hydroxybenzoylbarbiturates H14-18

Table IIh.3: Isolated yields of hydroxybenzoylbarbiturates
Compound

R1

R2

Acid chloride

Yield(%)

H14

H

H

m-OCOCH3

91

H15

C4H9

H

p-OCOCH3

77

H16

CH3

CH3

p-OCOCH3

85

H17

H

H

p-OCOCH3

80

H18

H

Ph

p-OCOCH3

83

With our successful developments of synthetic procedures for the preparation of
aryl substituted 5-benzoylbarbiturates we turned our attention to the preparation of the
corresponding phenylhydrazones. As mentioned above, the preparation of various Schiff
bases between amines and amino acids with acylbarbiturates was previously described
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and some of these derivatives were used as herbicides.47 None of the patented work
focused on 5-benzoylbarbituric phenylhydrazones. Our attempt to apply the patented
synthetic procedures for the preparation of our phenylhydrazones of benzoylbarbiturates
was not successful. From these experiments it was obvious that our benzoylbarbiturates
were substantially less reactive toward hydrazine condensation reactions. In some
instances, products were formed but isolation and purification from the reaction mixture
was very difficult. Furthermore, our experiments suggested that both the reactants and
the products of the reaction were very sensitive to reaction solvent and the pH of the
reaction media. Therefore, we carefully explored reaction conditions with the target
being to select the optimal reaction conditions for the preparation of these valuable
compounds. Wanting to find and optimize appropriate reaction conditions for the
preparation of phenylhydrazones of benzoylbarbiturates, we performed several NMR
experiments following these types of reactions. A typical 1H-NMR experiment for these
compounds was demonstrated by the transformation of p-nitrophenylhydrazine and 5-(4methoxybenzoyl)-1,3-dimethyl pyrimidine-2,4,6-trione (H7) into 5-{(4-Methoxyphenyl)[N'-(4-nitrophenyl)hydrazino]methylene}-1,3-dimethyl-pyrimidine-2,4,6-trione (H25)
(Figure IIh.8). The reaction was followed by taking a sample of the reaction mixture
(one drop), evaporating the solvent under a nitrogen stream at room temperature and
preparing the sample in a DMSO-d6 solution. p-Nitrophenylhydrazine was used in slight
excess in the reaction mixture. After the reaction mixture was refluxed for fifteen
minutes all benzoylbarbiturate H7 was consumed. It was obvious that there are two
major products of the condensation reaction. When sulfuric acid was added, one of the
products was transformed into the other. Prolonged refluxing of the reaction mixture
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Figure IIh.8: The 1H-NMR (DMSO-d6, 500 MHz) reactions following for condensation
reaction in 1-propanol without and with sulfuric acid as catalyst to yield H25.

does not noticeably change the composition of the product. After cooling down the
reaction mixture, a solid precipitate containing only one molecular species, compound
H25 (Figure IIh.8) was isolated. Following this synthetic procedure, or by slight
modification of this procedure, the phenylhydrazones of benzoylbarbiturates (Figure
IIh.9) were prepared. It is important to mention that for the preparation of these
compounds, precipitation of the product from the reaction mixture during the reaction is
crucial for obtaining both high yield of the product, as well as high product purity. In
some cases, solvents such as methanol and ethanol can be used, but 1-propanol seems to
be applicable to almost all reactions performed, and the yields and purities of the
products prepared in 1-propanol are high. To obtain better isolated yields for some
specific cases of the phenylhydrazones, specific reaction conditions were developed and
are mentioned in the experimental section of this paper. The designed phenylhydrazones
were necessary to explore the structural requirements necessary to elicit the immune
modulation, as in the case of A-007 (Table IIh.4).
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Figure IIh.9: Preparation path for phenylhydrazones of benzoylbarbiturates
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Table IIh.4: Phenylhydrazones of benzoylbarbiturates
Product

R1

R2

R3

R4

R5

R6

Yield(%)

H19

H

H

H

H

H

NO2

73

H20

H

H

H

H

H

COOH

79

H21

CH3

CH3

H

H

NO2

NO2

83

H22

H

Ph

H

H

NO2

NO2

88

H23

H

H

H

H

NO2

NO2

84

H24

CH3

CH3

H

H

H

COOH

79

H25

CH3

CH3

OCH3

H

H

NO2

82

H26

CH3

CH3

OCH3

H

NO2

NO2

81

H27

H

H

OCH3

H

NO2

NO2

81

H28

H

H

H

OH

NO2

NO2

88

H29

H

CH3

OH

H

NO2

NO2

88

H30

H

C4H9

OH

H

NO2

NO2

80

H31

H

H

OH

H

NO2

NO2

91

H32

H

Ph

OH

H

NO2

NO2

83

H33

H

CH3

OH

H

NO2

NO2

84

H34

CH3

CH3

OH

H

NO2

NO2

91

H35

CH3

CH3

NO2

H

NO2

NO2

89

H36

H

H

NO2

H

NO2

NO2

91

As in the cases of 5-benzoylbarbiturates, phenylhydrazones of 5benzoylbarbiturates have several tautomeric forms. In solution, equilibrium can be
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reached where several tautomeric forms are present. It is often the case that one
tautomeric form can crystallize from nonpolar aprotic solvents where the other form
crystallizes from polar aprotic solvents. For instance, phenylhydrazone H23 crystallizes
from the 1-propanol reaction mixture as the hydrazone with a double bond between
nitrogen and carbon (H23-CN). In pure DMSO solution 1H-NMR shows that the
solution actually contains this isomer as a major isomer (Figure IIh.10). After the
addition of trifluoroacetic acid, the nitrogen of the C=N is protonated and equilibrium is
shifted toward the enamine form H23-CC (Figure IIh.10). In the DMSO-CF3CO2H
solution after one hour H23-CC is the only detectable isomer. Similar behavior was
observed with other prepared hydrazones.

Figure IIh.10: 1H-NMR (500 MHz) isomerization following of H23-CN transformation
into H23-CC in CF3CO2H.

A major problem in the evaluation of biological properties for 5benzoylbarbiturates comes from the low solubility of these compounds in aqueous media
and most common organic solvents. This is even more evident for aryl substituted
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derivatives. Considering that by increasing the size of the aliphatic or aromatic moieties
of 5-benzoylbarbiturates makes these compounds even less water soluble, in order to
evaluate the potential activities it is important to make them water soluble. Both acyl and
benzoylbarbiturates have acidic hydrogens in the 5 position of the barbituric acid moiety,
therefore preparation of their ammonium salts with secondary amines is straightforward.
Preparation procedures included mixing benzoylbarbituric acid derivatives with the
amine in a solvent, such as tetrahydrofuran or dioxane or even propanol, evaporating the
solvent, and finally purification of the product (Figure IIh.11, Table IIh.5).
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Figure IIh.11: Preparation of substituted ammonium salts of substituted
benzoylbarbiturates
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Table IIh.5: Ammonium salts of substituted benzoylbarbiturates
Product

R1

R2

R3

X

Yield(%)

H37

H

H

H

HN(CH2)5

80

H38

CH3

H

H

HN(CH2)5

95

H39

H

H

OCH3

HN(CH2)5

88

H40

CH3

CH3

OCH3

HN(CH2)5

93

H41

H

H

NO2

HN(CH2)5

95

H42

H

H

NO2

HN(CH2CH2)2O

90

H43

H

H

NO2

CH3N(CH2CH2)2O

91

H44

H

H

NO2

NH2CH2CH2OH

98

H45

H

H

NO2

4-(CH3)2NPy

97

H46

CH3

CH3

NO2

HN(CH2)5

92

H47

CH3

CH3

NO2

HN(CH2CH2)2O

94

H48

CH3

CH3

NO2

CH3N(CH2CH2)2O

89

H49

CH3

CH3

NO2

NH2CH2CH2OH

92

H50

CH3

CH3

NO2

4-(CH3)2NPy

93

Similar to benzoylbarbiturates, phenylhydrazones also have low solubility in
aqueous media. These compounds are strong carbon acids due to the mobility of
hydrogen attached to C-5 of the barbituric acid moiety of compounds H19-36.
Preparation of the corresponding salts with almost any amine was a straightforward
process. Reaction components were dissolved in methanol, ethanol, or 1-propanol,
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stirred at room temperature for a few hours and the resulting salt was isolated from the
reaction mixture (see experimental procedures G and H) (Figure IIh.12).
O
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H52:R1=R2=CH3, R3=H,R4=OH
H53:R1=R3=H,R2=C6H5,R4=OH

Figure IIh.12: Preparation of piperidinium salts of phenylhydrazones (General
Procedure O).

It is very important to emphasize again that both 5-benzoylbarbiturates and their
phenylhydrazones can exist in several different tautomeric forms. Therefore, the NMR
spectra of the same compound in different solvents can show different ratios of two
tautomeric forms, as it was demonstrated in Figure IIh.13. To confirm these findings, xray structural analysis of H25 obtained from a 1-propanol solution with a few drops of
sulfuric acid was performed (Figure IIh.14). According to our NMR spectroscopic
studies, hydrazones in acidic polar media should be in an enamine form (CC) while in
neutral polar media, the Schiff base form (CN) should be present, as it was demonstrated
on the NMR equilibrium experiment with hydrazone H25. Considering this finding, even
if hydrazone H25 is present in its Schiff base H25-CN form in neutral solution, in the
acidic polar media the enamine isomer H25-CC (Figure IIh.13) should be a dominate
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species. This isomer should also be present in the crystalline state if H25 is crystallized
from 1-propanol with sulfuric acid present.
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H3CO

CH3
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H
N
N
H

NO2

H25-CC

Figure IIh.13: Schiff base H25-CN and enamine H25-CC tautomeric forms present in
solutions.

The x ray structure of H25 (Figure IIh.14) fully confirms our structural
assignment based on the NMR spectroscopy. Compound H25 is in its enamine form
(double bonds are C6C7 and C56C57) with strong hydrogen bonding between the
hydrazine hydrogen and the barbituric acid carbonyl (N8-H----O20 and N58-H----O70).
Two of the molecular units of H25 are combined through stacking the nitrophenyl and
methoxyphenyl moieties of two hydrazones of H25, as well as hydrogen bonding
between two of these units N9-H-----O66.
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Figure IIh.14: The ORTEP drawing x-ray determined structure of H25

The x-ray structure of piperidinium salt H52 was obtained from a single crystal
grown from acetonitrile as a solvent. The structure is in full agreement with our
spectroscopic characterization of this compound. The hydrogen from C6, rather than
from O33 of the phenol moiety, is removed by the base to form perfect conjugation
throughout entire molecule (Figure IIh.15). Hydrogen bonding no longer exists between
the nitrogen of the hydrazone moiety and barbituric acid moiety, as in H25 due to fact
that the acidic α-hydrogen of the barbituric acid moiety is removed with piperidene as a
base. Negative charge is mostly located on O22 and O26 of the barbituric acid moiety.
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Figure IIh.15: The ORTEP drawing of x-ray determined structure of H52.

At this point it is very interesting to compare structural features of H52 obtained from
x-ray experimental data and ones obtained by AM1 semi-empirical modeling of the anion
portion of H52 in the gas phase (Table IIh.6). Both experiment and theory agree that the
barbituric acid moiety is almost planar (the bond angles dihedral ring for O22-C1-C6-C5
is close to 180º, Table IIh.6). There is relatively good agreement between experimental
and computed structural properties. The biggest discrepancy comes from estimating
dihedral angels and hydrogen bond distances. For instance, from x-ray structural studies
it is obvious that there is very strong hydrogen bonding between N9H and the nitro O17
oxygen (the O17-H9 bond distance is 1.937 Å, Table 1), while there is a little bonding
interaction with the barbituric acid carbonyl O26 that bears the partial negative charge.
The AM1 estimates fairly well the first hydrogen bond distances, while substantially
overestimates the latter one (Table IIh.6). It is obvious that both experimental (x-ray)
and computational (AM1) data agree that the hydrogen in the barbituric acid ring is more
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acidic than the phenolic hydrogen, therefore it is removed by piperidene. Negative
charge is localized on two oxygens (O22 and O27) and one carbon (C6) atom of
barbituric acid moiety (the AM1 computational studies estimates 1/3 of negative charge
being on each of these three atoms). Strong hydrogen bonding between the NH hydrogen
and the oxygen of the nitro group of the dinitrophenylhydrazine moiety of H52 keeps this
portion of the molecule in one plane.

Table IIh.6: The X-ray determined and AM1 computed properties for anionic part of
H52 salt
X-Ray

AM1

X-Ray

AM1

Atoms

Bond distance in Å Atoms

Bond angles in (º)

C1-C6

1.417

1.439

C1-C6-C5

121.5

121.6

C5-C6

1.411

1.433

C1-C6-C7

119.3

118.9

C6-C7

1.483

1.448

C6-C7-N8

123.8

128.7

C7-N8

1.303

1.323

Atoms

Dihedral angles in (º)

N8-N9

1.373

1.354

O22-C1-C6-C5

-171.2

175.6

O22-C1 1.231

1.253

C1-C6-C7-N8

123.7

131.0

O26-H9 2.740

2.098

C6-C7-N8-N9

-5.7

0.0

O17-H9 1.936

2.116

C32-C27-C7-N8 156.2

130.4
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IIi. A Barbituric Acid Initiated Rearrangement Reaction: Formation of 5-5’-(2pyrilidine)bis barbituric acids
IIi.1 Preamble
While we were able to perform the preparation of a wide variety of 5,5’-(3pyrilidene) and 5,5’-(4-pyrilidene)bisbarbituric acids and their ammonium salts through
the condensation of pyridine carboxaldehydes and the corresponding barbituric acid, the
similar condensation between 2-pyridinecarboxaldehyde and 1,3-dimethylbarbituric acid
yields a unique pyridinium barbiturate ylide F1. Moreover, the desired 5,5’-(2pyrilidine)bisbarbituric acid analogs were not obtained when either N,N’-unsubstituted or
N-substituted barbiturates were used as the starting reagents. We were able to obtain the
desired bisbarbiturate when dimethylbarbituric acid was used, and the reaction was
performed in carbon tetrachloride, but this procedure was not applicable to other
barbiturates, nor was it a very practical synthesis for obtaining the desired material in
large quantities.
Considering that the 5,5’-(2-pyrilidine)bisbarbiturates could not be prepared by
our previously developed methods, we searched for a 2-pyridinecarboxaldehyde synthetic
equivalent in order to pursue the preparation of this compound type. In searching the
literature, we discovered that in many chemical reactions the phenyl moiety of a molecule
can be substituted with pyridine without altering the side chain reaction. We
hypothesized that if this is in fact true for benzil (PhCOCOPh), then the corresponding
pyridine synthetic equivalent of benzil (PyCOCOPy) could be of use in the preparation of
our targeted compounds. There is an abundance of literature reports that indicate that it is
possible to transform benzyl benzoates or even benzaldehydes into benzil derivatives.
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One example, reported by Zheng et.al, demonstrated this with the discovery that OBenzoylbenzaldehyde cyanohydrin was found to form benzil in a base-catalyzed
reversible reaction in DMF.119-120 Examining these reports, we hypothesized that if it is
possible to enforce the reverse benzyl reaction of the pyridine synthetic equivalent, then
2,2’-bipyridil should be the logical starting point for this preparation, used as the
equivalent of 2-pyridinecarboxaldehyde. It was interesting to note, however, that there
was a lack of benzyl-benzylic acid rearrangements in the literature. We believed that this
was due to the fact that the base present was too weak to promote the desired
rearrangement, but with the addition of a strong base, the desired rearrangement may be
possible to enforce.

IIi.2 Results and Discussion
Based on the information provided for the benzil model, the acid catalyzed
rearrangement mechanism proposed for the conversion of 2,2’-pyridil into our desired
5,5’-(2-pyrilidene)bisbarbituric acid is presented in Figure IIi.1.
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Figure IIi.1: Proposed mechanism for preparation of I-1.

It was expected that the most energy demanding transformation would be the
rearrangement of keto alcohol I-a into ester I-d. The third step of the transformation (I-d
to I-1) would be the nucleophilic substitution by barbituric acid on ester I-d. One can
envision at least two pathways in the preparation of 5,5’-(2-pyrilidene)bisbarbituric acid;
one through the addition of the first barbituric acid, followed by the elimination of
picolinic acid and finally the addition of the second barbituric acid; and the other by
simple nucleophilic substitution of the picolinic acid moiety of ester I-d with barbituric
acid. We experimentally determined that depending on the solvent and temperature, both
of these reactions can occur. For instance, if the reaction is performed in refluxing
methanol, the only product is the product of condensation I-1 in more than 80% isolated
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yield. In our extended time experiment at room temperature, it seemed that the reaction
proceeded through either elimination-addition, or the elimination-addition and
nucleophilic substitution reactions compete. This determination was based on the fact
that from a closed-bottle mixture of 2,2’-pyridil (2mg) and 1,3-dimethylbarbituric acid (5
mg) in 1 mL of methanol, a single crystal was grown after 30 days at room temperature
and present in the crystal are both products F-1 (pyridinium zwitterions) and I-1 in a ratio
of 32:68.
To determine the validity of the mechanism, we followed the reaction through HNMR spectra recorded at room temperature in various solvents, including methanol,
tetrahydrofuran, acetic acid, chloroform, and dimethyl sulfoxide. In DMSO the reaction
mixture was solution. In all other solvents a precipitate formed. From this experiment it
was obvious that the formation of ester I-d was required for a high yield transformation
of 2,2’pyridil and barbituric acid into pyrilidene I-1 and picolinic acid (Figure IIi.3). In
prolonged DMSO experiments a low field NMR aromatic compound was formed, which
was not detected when the preparation of I-1 was performed in methanol.
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Figure IIi.3: H-NMR (DMSO-d6 -300 MHz Varian Unity) spectra over the course of
the reaction time to yield I-1.

Finally, to confirm the general applicability of this reaction method in the
preparation of a wide variety of 2-pyrilidenes, we used the barbituric acid derivatives 1phenyl, 1-methyl, 1-butyl, and barbituric acid in itself. In every case, the corresponding
I-1 pyrilidene was isolated in almost quantitative yields. Additionally, we were not able
to detect the presence of any other byproducts of the reactions performed through
subsequent spectroscopic analysis. Structural properties of I-1 when R1 and R2= CH3
were determined using x-ray analysis. The single crystal of the I-1 analog was obtained
from slow crystallization in acetic acid, and the structure shows interesting
characteristics. In solution, we were unable to determine the location of the 5 and 5’
hydrogens. We determined that this was due to the fact that in solution one hydrogen is
on the pyridine ring and the other is involved in hydrogen bonding interactions between
both barbituric acid rings. In the crystalline state I-1 has a zwitterionic structure with a
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positive charge located on the pyridinium molecule and a negative charge located almost
equally on both barbituric acid rings (Figure IIi.4). The plane with the pyridinium ring
is almost perpendicular to the plane that separates the two barbituric acid rings. The
C(1)-C(4) bond distance is 1.365 Å in comparison with the C(1)-C(2) distance of 1.4275
Å, and the C(1)-C(7) distance of 1.5201 Å, indicating a strong double bond character of
the first two bonds, and delocalization of the negative charge. All atoms in the ring and
the ones attached to the ring are basically in the ring plane, indicating aromaticity.

Figure IIi.4: ORTEP drawing of X-ray determined structure of I-1 (courtesy of E. D.
Stevens and K. L. Martin).
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BIOLOGICAL EVALUATIONS OF NOVEL BARBITURATES
IIIa. Introduction
In order to gather preliminary information on the concept that A-007 and analogs
of A-007 may be binding to a CD45+ surface receptor, or other CD surface receptors, and
upgrading dendritic cells and /or T- lymphocytes, we have successfully synthesized and
tested a number of phenylhydrazones, all structural analogs of our lead compound, A007. To date, the synthesized compounds were tested in vitro on various cell lines to
determine if they have the ability to bind to (or up-regulate) surface CD receptors, with
cytotoxicity or apoptosis. Structural changes made to A-007 include changes to the a)
bis-diphenyl methane and b) the phenylhydrazone moieties.

IIIb. Biology Methods
The T-leukemia cell line, HH (CRL-2105), available from ATCC, Manassas, VA
,having the receptors, CD45+, CD3+, CD4+ and CD11C+, all dendritic cell surface CD
receptors, was used to screen A-007 and analogs for up-regulation of CD surface receptor
expression, loss of agglutination properties and cell death (Tables III.1-III.5).
Multicolor immunofluorescence staining and analysis were performed by standard
procedures.20b Primary and secondary antibodies were conjugated to biotin, fluorescin
isothiocyanate (FITC), phyco-erythrin (PE), peridinin-chlorophyl protein or allophycocyanin. Antibodies and conjugates for CD3, CD4, CD8, CD11C, CD19, and
CD30, were obtained from Becton-Dickinson; CD45 was obtained from PharMingen.
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Cells were analyzed using a FACSscan flow cytometer (Becton-Dickinson). HH Tlymphocytic leukemia cells were cultured in RPMI 1640 media (BioCell) supplemented
with activated 10% fetal calf serum, 10 mcg/mL streptomycin and 100 U/mL penicillin
(Sigma) in a CO2 incubator at 36º C. All analogs were prepared in DMSO and stored in a
1:15 ratio of DMSO/RPMI1640 media. CD marker assays and standard
cytotoxicity/apoptosis studies were conducted in Corning Cell WellsTM. Assys involved
105 HH-cells incubated with the analogs for 24 hours, cells were removed, washed with
RPMI media and analyzed by a BD fluorescent-activated cell sorter. Agglutination was
documented using scanning density assays.20c Cytotoxicity analysis was conducted using
the MTT assay. 20c Apoptosis was followed with - Annexin V – FITC and fluorescein
Fragel DNA kits (Oncogene, Inc, San Diego, CA) and DNA fragmentation/cell death
analyzed with a FACScanner.

IIIc. Results and Discussion
Table III.1 reviews toxicity and binding intensity values for the A-007 molecule.
A-007 prevented HH cells from agglutination, resulting in well-differentiated cells with
up-regulation of CD45+ and CD11C+ binding affinities. Apoptosis, or programmed cell
death, occurred 12-24 hours post A-007 exposure, as determined by the DNA fragments
detected. The up-regulation of CD receptors varied depending on the structural analogs
tested, and are indicated in the data provided in the tables. All biological evaluations
were performed by Dr. Lee Roy Morgan and Dekk-Tec, Inc.
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Table III.1: Toxicity and binding intensity values for the A-007, our lead compound*.
Compound

A-007

Structure

HO

Cytotoxicity

Binding

Binding

IC50 µg/mL)

Intensity

Intensity Intensity

@5

@5

@5

µg/mL

µg/mL

µg/mL

for CD4+

CD11C+ CD45+

a

30%

3.2
N

NC

Binding

100%

O
N

N

H

O
O N

HO

O

a

Vs HH leukemia cells. *All in vitro evaluations were performed by Lee Roy Morgan
through Dekk-Tec, Inc.
Subsequent modification of the bis-diphenyl and the phenylhydrazone moieties, such as
replacement of this structural motif with the corresponding bis-barbiturate moiety
resulted in loss of activity. The compounds of this type tested and the results obtained
are indicated in Table III.2.
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Table III.2: Anticancer and up-regulation for quinoline and pyridine bis-barbituric acid
analogs.a,*
Compound

E3

Structure

H
N

O
H

H
N

O O

N

Binding

Binding

Binding

IC50 µg/mL)

Intensity

Intensity Intensity

@5

@5

@5

µg/mL

µg/mL

µg/mL

CD4+

CD11C+ CD45+

>10

b

NC

NC

↑25%

>10

c

NA

NA

NA

>10

NA

NA

NA

O
N

O

Cytotoxicity

H

O
N

H3C
N
O

E18

H3C

CH3
N
O

O O

N

N
O

O

CH3

N

E7

O

H
N

O O

H
N

HN

O
NH

O

O
N

a

Vs HH leukemia cells; bNC – no change in CD; cNA – not available. *All in vitro
evaluations were performed by Lee Roy Morgan through Dekk-Tec, Inc.
The replacements of A-007's bis-diphenyl rings with a barbituric acid moiety with retention of
nitrophenylhydrazone moiety resulted in some retention of activity, but no surface CD upregulation was noted. The compounds belonging to this class of analogs tested are presented in
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the following table (Table III.3). These analogs utilized the 5-formyl and acetyl barbiturate
analogs as well as some benzoyl analogs.

Table III.3: Anticancer and up-regulation for formyl and acetylbarbituric
phenylhydrazone analogs.a,*
Compound Structure

D25

O

H3C

H3C N

O 2N
N
NH
O

H
O
H3C N

O

D14

Binding

IC50 µg/mL)

Intensity

Intensity Intensity

@5

@5

@5

µg/mL

µg/mL

µg/mL

CD4+

CD11C+ CD45+

>10

b

NC

NA

>8

NA

NA

NA

3.5

c

NC

NC

NA

Binding

NO2

NO2

N

O

CH3

H3C

O2N
N
NH
O

H N
O

Binding

N
CH3

O

D21

O 2N
N
NH
O

Cytotoxicity

NC

NO2

N
H

H
O

N
NH
O

H N

>6

NC

NC

NC

>10

NC

NC

NC

NO2

N
O

D20

O

H

H3C

H N
O

N
H

N
NH
O

NO2
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Table III.3 continued…
H23
O2N
N
NH
O

O
H N

>10

NC

NC

NC

>10

NC

NC

NC

NO2

N
O

H28

H

HO

O2N
N
NH
O

O
H N
O

NO2

N
H

a

Vs HH leukemia cells; bNC – no change in CD; cNA – not available. *All in vitro
evaluations were performed by Lee Roy Morgan through Dekk-Tec, Inc.

Further modifications that consisted of the elimination of the phenylhydrazone moiety
(Table III.4) provided at least one analog with equivalent properties to A-007. Table
III.4 reviews Schiff base analogs of barbituric acids that have been prepared and
screened. Analog D8 is a very encouraging lead that also has slight (~25%) binding with
CD45+. Similarly, effects on cell agglutination, but with less apoptosis (25% vs 100% for
A-007) were noted.
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Table III.4: Anticancer and up-regulation for formylbarbituric acid Schiff base
analogs.a,*
Compound Structure

D13

H
N

O

O

H

N

Cytotoxicity

Binding

Binding

IC50 µg/mL)

Intensity

Intensity Intensity

@5

@5

@5

µg/mL

µg/mL

µg/mL

CD4+

CD11C+ CD45+

>12

b

Binding

NC

NC

NC

3.5

NC

NC

↑25%

>10

NC

NC

NC

>10

NC

NC

NC

H

N
O
(CH2)2
CO2H

D8

O

H
N

O

H

N

H

N
O
(CH2)3
CO2H

D9

H
N

O

O

H

N

H

N
O
(CH2)5
CO2H

O

H
N

O
N

H

N
O
(CH2)3
CO2H

a

Vs HH leukemia cells; bNC – no change in CD. *All in vitro evaluations were performed
by Lee Roy Morgan through Dekk-Tec, Inc.
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To date, no analog with improved immune modulating activity over A-007, which
includes apoptosis without direct cytotoxicity, has been identified. In designing these
potential cell surface modulators, the new products cannot be cytotoxic to the point of
the therapeutic index being surpassed.121, 122 Based on our initial screenings of these
compounds, the biological properties for some of the described simple analogs appeared
to be associated with modulation which resulted in programmed cell death. This is in
contrast to previously described analogs containing fused ring systems, such as
anthracenes, xanthenes, thioxanthenes, fluorenes and phthalazenes. In these cases, only
intracellular changes occurred with immediate cancer cell death, as well as toxicity to
normal tissues.121 A-007’s –NH moiety could be involved in intramolecular –H---O=
bonding, which would cause it to have little reactivity with any cell surface receptors.18
As a result, A-007 and its active analogs may be initiating the CD4+/8+ T-cell cascade
via up-regulation of the CD45+ receptor at the level of antigen presenting cells (APC).1617

The potential use of the immune modulating properties of these compounds in

malignant, as well as infectious disease processes, is encouraging.
It appears that in order for the CD45+ up-regulation to occur, several structural
features must be present within the phenylhydrazones molecule. At least one NO2
moiety, or an isostere of this moiety, such as a pyridine ring, appears necessary for upregulation. In the absence of these groups, compounds containing the COOH moiety,
also elicit CD45+ up-regulation, lending to the fact that at least one strong electrondeficient moiety is necessary for activity.
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CONCLUSIONS
Through the synthetic explorations described in the previous chapters, we have
made available a new class of compounds containing the barbituric acid moiety as a
functional moiety that could potentially elicit histone deacetylase inhibition, immune
modulation, apoptotic effects on various cancer cell lines. Our hypothesis that barbituric
acids could replace the hydroxamic acid moieties of potent HDACI’s is currently being
investigated. While the in vitro biological evaluations are still underway for a large
number of these derivatives, we have successfully synthesized several novel barbituric
acid derivatives that do act as CD45+ up-regulators, or as compounds with a therapeutic
index within the range of several other potent drugs, such as A-007, which are currently
undergoing clinical trials.
Through the course of our synthetic preparations, several new and interesting
molecular systems were designed, studied, and explained. These systems include the
5,5’-barbituric acid initiated rearrangement reactions, as well as the preparation of the
novel pyridinium-barbituric acid zwitterions. Spectroscopic studies evaluating the
physical properties, as well as reaction mechanisms were performed to enable us to
outline synthetic procedures that could be performed in the multi-gram quantities, or that
could be easily adapted to industrial applications should our target molecules show
promise after subsequent in vitro evaluation.
Our target molecules were identified as either histone deacetylase inhibitors,
modeled after the successful HDACIs SAHA and PCHA, or as immune modulators,
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modeled after the potent drug A-007. All targets containing the barbiturate moiety were
successfully synthesized. While not all tested compounds proved active, valuable
research was performed surrounding the synthesis of these analogs, enabling future
scientists to find other potential uses for either the compounds designed or the reactions
performed.
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EXPERIMENTALS
All solvents and starting materials in this synthesis were obtained from Aldrich and used
without further purification. Thin-layer chromatography was performed using plasticbased 0.25 mm thick silica gel 60 F-254 plates (E. Merc, Inc.). All 1H and 13C NMR are
recorded in DMSO-d6 on a Gemini 2000 Varian instrument with the chemical shift of the
solvent at 2.49 and 36.0 ppm as referenced in hydrogen and carbon NMR spectra. All
DMSO-d6 samples were clear solutions. The CF3COOH samples contained a few drops
of DMSO-d6 as an internal reference and part of barbituric acid was not in the solution.
All electro-spray mass spectral analyses were performed on a Micromass Quattro 2 Triple
Quadropole Masspectrometer. Melting points were determined on Electrothermal 9100
melting point apparatus and they are not corrected. The ES-MS parameters (i.e.,
pressure, temperature, and voltage on the needle, etc.) were kept constant in each series
of solutions. A flow rate of 10 µL/min was applied using 100 µL of sample solution.
Elemental analyses were performed by Atlantic Microlab, Inc. X-ray structure
determination was performed on a Bruker SMART 1KCCD automated diffractometer.
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General Procedure A:
Synthesis of 5-(4-Dimethylamino-benzylidene)-pyrimidine-2,4,6-trione (A1)
A mixture of barbituric acid (12.8 g; 0.1 mol) and 4-(dimethylamino)benzaldehyde (14.9
g; 0.1 mol) in methanol (500 mL) were stirred at room temperature. After a few minutes
the solution became a suspension, and the color of solid went from yellow to dark purple.
The suspension was allowed to stir at room temperature overnight. The solid product
was separated by filtration and washed with cold methanol (3×50 mL). The isolated
yield was 35.4 g (98%). An analytical sample after drying in vacuum had m.p. 277º C
with decomposition; lit. m.p. 275º C with decomposition. IR (KBr) 3095-3080, 1700,
1640, 1500, cm-1. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.04 (s, 1H, NH),
10.91 (s, 1H, NH), 8.42 (d, J= 12.4 Hz, 2H, Ar), 8.13 (s, 1H, CH), 6.78 (d, J= 12.4 Hz,
2H, Ar), 3.11 (s, 6H, N(CH3)2).

13

C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 161.2,

159.2, 152.0, 150.7, 146.8, 135.6, 116.5, 107.7, 106.0, and 38.0 ppm. MS (CI+-NH3) 259
(5%, M+) 215 (100%), 172 (96%), 166 (11%), 144 (7%), 128 (18%), 101 (15%). Anal.
Calcd. For C13H13N3O3: C, 60.23: H, 5.05; N, 16.21. Found: C, 60.11; H, 5.13; N,
16.08.

Synthesis of 5-(3-Phenyl-allylidene)-pyrimidine-2,4,6-trione (A2)
A mixture of barbituric acid (1.28 g; 0.01 mol) and trans-cinnamaldehyde (1.32 g; 0.01
mol) in methanol (100 mL) were stirred at room temperature. After a few minutes the
solution became a suspension, and the color of solid went from white to yellow. The
suspension was allowed to stir at room temperature overnight. The solid product was
separated by filtration and washed with cold methanol (3×20 mL). The isolated yield
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was 2.30 g (95%). An analytical sample after drying in vacuum had m.p. 260º C with
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.27 (s, 1H, NH),
11.20 (s, 1H, NH), 8.42 (m, 1H, CH), 7.99 (d, J= 11.4, 1H, CH), 7.65 (m, 3H), 7.45 (m,
3H) ppm.

13

C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 159.6, 159.4, 150.1, 149.1,

146.8, 131.8, 127.6, 125.7, 125.0, 120.7, and 112.2 ppm. MS (ESI-) in methanol: 241
(50%, M-1), 273 (100%, M+MeOH).

Synthesis of 5-[3-(4-Dimethylamino-phenyl)-allylidene]-pyrimidine-2,4,6-trione (A3)
A mixture of barbituric acid (1.28 g; 0.01 mol) and 4-amino-trans-cinnamaldehyde (1.75
g; 0.01 mol) in methanol (100 mL) were stirred at room temperature. After a few
minutes the solution became a suspension, and the color of solid went from yellow to
dark purple. The suspension was allowed to stir at room temperature overnight. The
solid product was separated by filtration and washed with cold methanol (3×20 mL). The
isolated yield was 2.82 g (99%). An analytical sample after drying in vacuum had m.p.
250º C. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.01 (s, 1H, NH), 10.95 (s, 1H,
NH), 8.19 (m, 1H, CH), 7.94 (d, J= 16.8 Hz, 1H, CH), 7.59 (d, J= 19.6 Hz, 1H, CH),
7.51 (d, J= 11.6 Hz, 2H, Ar), 6.76 (d, J= 12.0, 2H, Ar), 3.02 (s, 6H, N(CH3)2).

13

C-NMR

(DMSO-d6 -400 MHz Varian Unity) δ 161.2, 159.7, 152.3, 150.9, 146.6, 131.1, 126.8,
125.5, 125.0, 119.9, and 112.1 ppm.
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Synthesis of 5-(4-Hydroxy-benzylidene)-pyrimidine-2,4,6-trione (A4)
A mixture of barbituric acid (1.28 g; 0.01 mol) and 4-hydroxybenzaldehyde (1.22 g; 0.01
mol) in methanol (100 mL) were stirred at room temperature. After a few minutes the
solution became a suspension, and the color of solid went from white to yellow. The
suspension was allowed to stir at room temperature overnight. The solid product was
separated by filtration and washed with cold methanol (3×20 mL). The isolated yield
was 2.20 g (95%). An analytical sample after drying in vacuum had m.p. 280º C with
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.24 (s, 1H, NH),
11.11 (s, 1H, NH), 10.81 (s, 1H, OH), 8.31 (d, J= 8.8 Hz, 2H, Ar), 8.19 (s, 1H, CH), 6.86
(d, J= 8.8 Hz, 2H, Ar).

13

C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 164.6, 163.4,

162.7, 155.9, 150.7, 138.7, 124.2, 115.9, and 114.6 ppm. MS (ESI-) in methanol: 231
(100%, M-1), 263 (45%, M+MeOH).

General Method B:
Synthesis of 5-Furan-2-ylmethylene-pyrimidine-2,4,6-trione (A5)
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2-furaldehyde (0.96 g; 0.01 mol) in
methanol (150 mL) was stirred at room temperature for 5 days. Methanol was
evaporated at room temperature under reduced pressure. The solid residue was slurred in
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by
filtration. The crystalline product was washed with cold water (3×50 mL) and then
slurred in ether After the second filtration, crystalline material was washed with ether
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product (1.67 g;
81%). An analytical sample after drying in vacuum had a m.p. 264º C with
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decomposition. The reported literature melting point is 260º C with decomposition. IR
(KBr) 3520-3480, 1730, 1690, 1645, 1615-1590, 1560-1530 cm-1. 1H-NMR (DMSO-d6 400 MHz Varian Unity) δ 11.35 (s, 1H, NH), 11.26 (s, 1H, NH), 8.45 (d, J= 3.6 Hz, 1H,
Ar), 8.24 (s, 1H, CH), 8.01 (s, 1H, Ar), 6.90 (d, J= 2.4 Hz, 1H, Ar) ppm.

13

C-NMR

(DMSO-d6 -400 MHz Varian Unity) δ 159.8, 158.6, 147.7, 133.4, 123.0, 111.8, and 109.3
ppm. Anal. Calcd. . For C9H6N2O4: C, 52.44; H, 2.93; N, 13.59. Found: C, 52.36; H,
3.07; N, 13.40.

Synthesis of 5-Benzylidene-pyrimidine-2,4,6-trione (A6)
A mixture of barbituric acid (1.28 g; 0.01 mol) and benzaldehyde (1.06 g; 0.01 mol) in
methanol (150 mL) was stirred at room temperature for 5 days. Methanol was
evaporated at room temperature under reduced pressure. The solid residue was slurred in
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by
filtration. The crystalline product was washed with cold water (3×50 mL) and then
slurred in ether After the second filtration, crystalline material was washed with ether
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product (1.84 g;
85%). An analytical sample after drying in vacuum had m.p. 250º C with decomposition.
The reported literature melting point is 250º C with decomposition. 1H-NMR (DMSO-d6
-400 MHz Varian Unity) δ 11.39 (s, 1H, NH), 11.23 (s, 1H, NH), 8.27 (s, 1H, CH), 8.06
(d, J= 6.6 Hz, 2H, Ar), 7.52 (t, J= 4.8 Hz, 1H, Ar), 7.45 (t, J= 8.2, 2H, Ar).

13

C-NMR

(DMSO-d6 -400 MHz Varian Unity) δ 159.9, 158.1, 151.2, 146.7, 129.6, 129.2, 124.6,
and 115.6 ppm. MS (ESI-) in methanol 172 (10%), 215 (75%, M-1), 247 (100%,
M+MeOH).
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Synthesis of 5-Naphthalen-2-ylmethylene-pyrimidine-2,4,6-trione (A7)
A mixture of barbituric acid (1.28 g; 0.01 mol) and naphthaldehyde (1.56 g; 0.01 mol) in
methanol (100 mL) were stirred at room temperature. After a few minutes the solution
became a suspension, and the color of solid went from white to yellow. The suspension
was allowed to stir at room temperature overnight. The solid product was separated by
filtration and washed with cold methanol (3×20 mL). The isolated yield was 2.20 g
(83%). An analytical sample after drying in vacuum had m.p. 250º C with
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.46 (s, 1H, NH),
11.17 (s, 1H, NH), 8.78 (s, 1H, CH), 8.01 (m, 2H, Ar), 7.84 (m, 2H, Ar), 7.56 (m, 3H,
Ar) ppm.

13

C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 163.4, 161.5, 152.1, 150.8,

133.1, 131.5, 131.1, 129.2, 128.8, 127.5, 126.8, 125.4, 124.8, and 122.4 ppm. MS (ESI-)
in methanol 265 (M-1), 297 (100%, M+MeOH)

Synthesis of 5-(2,4-Dihydroxy-benzylidene)-pyrimidine-2,4,6-trione (A8)
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2,4-dihydroxybenzaldehyde (1.38 g;
0.01 mol) in methanol (150 mL) was stirred at room temperature for 36 h. Methanol was
evaporated at room temperature under reduced pressure. The solid residue was slurred in
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by
filtration. The crystalline product was washed with cold water (3×50 mL) and then
slurred in ether After the second filtration, crystalline material was washed with ether
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product (2.11 g,
85%). An analytical sample after drying in vacuum had a m.p. 264º C with
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.10 (s, 1H, NH),
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10.96 (s, 1H, NH), 10.80 (broad s, 2H, OH), 8.75 (s, 1H, CH), 8.71 (d, J= 9.2 Hz, 1H,
Ar), 6.38 (d, J= 2.0 Hz, 1H, Ar), 6.30 (d, J= 11.6 Hz, 1H, Ar) ppm.

13

C-NMR (DMSO-

d6 -400 MHz Varian Unity) δ 162.1, 161.1, 159.8, 159.1, 146.8, 146.3, 132.7, 108.8,
107.9, 104.5, and 97.9 ppm. MS (ESI-) in methanol: 247 (M-1).

Synthesis of 5-(1H-Indol-2-ylmethylene)-pyrimidine-2,4,6-trione (A9)
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2-indolecarboxaldehyde (1.45 g; 0.01
mol) in methanol (150 mL) was stirred at room temperature for 36 h. Methanol was
evaporated at room temperature under reduced pressure. The solid residue was slurred in
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by
filtration. The crystalline product was washed with cold water (3×50 mL) and then
slurred in ether. After the second filtration, crystalline material was washed with ether
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product of 2.44 g,
(96%) yield. An analytical sample after drying in vacuum had a m.p. 260º C with
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 12.71 (s, 1H, NH), 11.10
(s, 1H, NH), 11.02 (s, 1H, NH), 9.48 (s, 1H, CH), 8.69 (s, 1H, Ar), 7.85 (d of d, J1= 4.0
Hz, J2= 8.0 Hz, 1H, Ar), 7.56 (d of d, J1= 4.0 Hz, J2= 8.0 Hz, 1H, Ar), 7.29 (d of d, J1=
8.4 Hz, J2= 2.4 Hz, 2H, Ar).

13

C-NMR (DMSO-d6 -400 MHz Varian Unity) δ 161.0,

159.7, 146.9, 140.2, 136.2, 132.9, 125.6, 120.1, 119.1, 114.1, 109.6, 107.9, and 105.1
ppm. MS (CI+) 256 (100%, M+), 145 (10%), 130 (40%), 118 (45%), 79 (5%).
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Synthesis of 5-(2-Hydroxy-benzylidene)-pyrimidine-2,4,6-trione (A10)
A mixture of barbituric acid (1.28 g; 0.01 mol) and 2-hydroxybenzaldehyde (1.22 g; 0.01
mol) in methanol (150 mL) was stirred at room temperature for 36 h. Methanol was
evaporated at room temperature under reduced pressure. The solid residue was slurred in
cold water (100 mL), stirred for 2 hours and then the solid residue was separated by
filtration. The crystalline product was washed with cold water (3×50 mL) and then
slurred in ether. After the second filtration, crystalline material was washed with ether
(3×20 mL) and dried in the air, resulting in a pure yellow crystalline product of 1.85 g,
(80%) yield. An analytical sample after drying in vacuum had a m.p. 230º C with
decomposition. 1H-NMR (DMSO-d6 -400 MHz Varian Unity) δ 11.29 (s, 1H, NH), 11.12
(s, 1H, NH), 10.61 (s, 1H, OH), 8.60 (s, 1H, CH), 8.14 (d, J= 10.4 Hz, 1H, Ar), 7.35 (t,
J= 10 Hz, 1H, Ar), 6.91 (d, J= 11.2 Hz, 1H, Ar), 6.80 (t, J= 10 Hz, 1H, Ar) ppm.

13

C-

NMR (DMSO-d6 -400 MHz Varian Unity) δ 160.2, 158.2, 155.4, 146.8, 131.1, 129.2,
116.3, 114.7, 113.6, and 111.9 ppm. MS (ESI-) in methanol: 231 (M-1).

General Procedure C:
1,3-Dimethyl-5-(2,4,6-trimethoxy-benzylidene)-pyrimidine-2,4,6-trione (A11)
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 2,4,6trimethyoxybenzaldehyde (1.98 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric
acid was stirred at room temperature for 12 h. Methanol was evaporated at room
temperature under reduced pressure. The solid residue was slurred in cold water (100
mL), stirred for 2 hours and then the solid residue was separated by filtration. The
crystalline product was washed with cold water (3×50 mL) and then slurred in ether (20
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mL). After the second filtration, crystalline material was washed with ether (3×10 mL)
and dried in the air, resulting in a pure crystalline product of 2.72 g (81%) yield. An
analytical sample after drying in vacuum had a m.p. 200º C with decomposition. 1HNMR (DMSO-d6 -500 MHz Varian Unity) δ 8.71 (s, 1H, CH), 8.45 (s, 1H, Ar), 6.65 (s,
1H, Ar), 3.90 (s, 6H, OCH3), 3.71 (s, 3H, OCH3), 3.16 (s, 3H, CH3), 3.14 (s, 3H, CH3)
ppm.

13

C-NMR (DMSO-d6 -500 MHz Varian Unity) δ 159.4, 157.4, 154.7, 152.9, 147.6,

146.0, 138.0, 112.3, 109.7, 109.2, 92.6, 53.2, 52.6, 52.3, 25.0, and 24.5 ppm.

Synthesis of 1,3-Dimethyl-5-(2,3,4-trimethoxy-benzylidene)-pyrimidine-2,4,6-trione
(A12)
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 2,3,4trimethyoxybenzaldehyde (1.98 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric
acid was stirred at room temperature for 12 h. Methanol was evaporated at room
temperature under reduced pressure. The solid residue was slurred in cold water (100
mL), stirred for 2 hours and then the solid residue was separated by filtration. The
crystalline product was washed with cold water (3×50 mL) and then slurred in ether (20
mL). After the second filtration, crystalline material was washed with ether (3×10 mL)
and dried in the air, resulting in a pure orange crystalline product of 2.65 g (79%) yield.
An analytical sample after drying in vacuum had m.p. 200º C with decomposition. 1HNMR (DMSO-d6 -500 MHz Varian Unity) δ 8.52 (s, 1H, CH), 8.22 (d, J= 8.5 Hz, 1H,
Ar), 6.89 (d, J= 9.5 Hz, 1H, Ar), 3.89 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.75 (s, 3H,
OCH3), 3.19 (s, 3H, CH3), 3.16 (s, 3H, CH3) ppm.

13

C-NMR (DMSO-d6 -500 MHz
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Varian Unity) δ 158.9, 156.9, 154.6, 151.5, 147.5, 146.7, 137.1, 125.6, 115.4, 112.6,
103.5, 58.4, 56.9, 52.7, 25.0, and 24.4 ppm.

Synthesis of 5-(4-Hydroxy-benzylidene)-1,3-dimethyl-pyrimidine-2,4,6-trione (A13)
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 4-hydroxybenzaldehyde
(1.22 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric acid was stirred at room
temperature for 12 h. Methanol was evaporated at room temperature under reduced
pressure. The solid residue was slurred in cold water (100 mL), stirred for 2 hours and
then the solid residue was separated by filtration. The crystalline product was washed
with cold water (3×50 mL) and then slurred in ether (20 mL). After the second filtration,
crystalline material was washed with ether (3×10 mL) and dried in the air, resulting in a
pure orange crystalline product of 2.08 g (80%) yield. An analytical sample after drying
in vacuum had m.p. 180º C with decomposition. 1H-NMR (DMSO-d6 -500 MHz Varian
Unity) δ 10.80 (s, 1H, OH), 8.26 (d, J= 8.5 Hz, 2H, Ar), 8.22 (s, 1H, CH), 6.85 (d, J= 10
Hz, 2H, Ar), 3.18 (s, 3H, CH3), 3.16 (s, 3H, CH3) ppm.

13

C-NMR (DMSO-d6 -500 MHz

Varian Unity) δ 163.8, 163.3, 161.4, 157.0, 151.7, 138.9, 124.4, 116.1, 114.4, 29.2, and
28.6 ppm. MS (ESI-) in methanol: 259 (M-1).

Synthesis of 5-(2,4-Dihydroxy-benzylidene)-1,3-dimethyl-pyrimidine-2,4,6-trione (A14)
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and 2,4dihydroxybenzaldehyde (1.38 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric
acid was stirred at room temperature for 12 h. Methanol was evaporated at room
temperature under reduced pressure. The solid residue was slurred in cold water (100
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mL), stirred for 2 hours and then the solid residue was separated by filtration. The
crystalline product was washed with cold water (3×50 mL) and then slurred in ether (20
mL). Material was washed with ether (3×10 mL) and dried in the air, resulting in a pure
orange crystalline product of 2.18 g (79%) yield. An analytical sample after drying in
vacuum had m.p. 220º C with decomposition. 1H-NMR (DMSO-d6 -500 MHz Varian
Unity) δ 10.80 (s, 1H, OH), 10.68 (s, 1H, OH), 8.78 (s, 1H, CH), 8.63 (d, J= 11 Hz, 1H,
Ar), 6.37 (s, 1H, Ar), 6.28 (d, J= 11.5 Hz, 1H, Ar), 3.14 (s, 3H, CH3), 3.11 (s, 3H, CH3)
ppm.

13

C-NMR (DMSO-d6 -500 MHz Varian Unity) δ 162.3, 160.1, 159.7, 157.5, 147.7,

147.3, 132.6, 109.0, 107.5, 104.5, 97.9, 25.0, and 24.4 ppm. MS (CI+-NH3) 277 (70%,
M+1), 261 (75%), 139 (30%), 96 (95%), 79 (100%).

Synthesis of 1,3-Dimethyl-5-(3-phenyl-allylidene)-pyrimidine-2,4,6-trione (A15)
A mixture of 1,3-dimethylbarbituric acid (1.56 g; 0.01 mol) and trans-cinnamaldehyde
(1.32 g; 0.01 mol) in methanol (150 mL) with 2 drops sulfuric acid was stirred at room
temperature for 12 h. Methanol was evaporated at room temperature under reduced
pressure. The solid residue was slurred in cold water (100 mL), stirred for 2 hours and
then the solid residue was separated by filtration. The crystalline product was washed
with cold water (3×50 mL) and then slurred in ether (20 mL). After the second filtration,
crystalline material was washed with ether (3×10 mL) and dried in the air, resulting in a
pure orange crystalline product of 2.20 g (81%) yield. An analytical sample after drying
in vacuum had m.p. 200º C with decomposition. 1H-NMR (DMSO-d6 -500 MHz Varian
Unity) δ 8.44 (m, 1H, CH), 8.06 (d, J= 15.6, 1H, CH), 7.73 (d, J= 20.8 Hz, 1H, CH),
7.66 (m, 2H, Ar), 7.46 (t, J= 3.8 Hz, 3H, Ar), 3.18 (s, 6H, CH3) ppm.
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C-NMR (DMSO-d6 -500 MHz Varian Unity) δ 158.1, 157.8, 150.8, 149.4, 147.5, 131.6,

127.6, 125.6, 125.0, 120.7, 111.8, 24.7, and 24.2 ppm.

General Procedure D: Preparation of mono C-alkylated barbituric acids with aliphatic
aldehydes and ketones
Synthesis of 5-isopropyl-1-phenylbarbituric acid (B1)
A suspension of 1-phenylbarbituric acid (2.04 g, 10.0 mmol) and 5% Pt-C with 50%
water (0.200 g) in acetone (30 mL) and acetic acid (100 mL) was hydrogenated under
hydrogen pressure of 50 psi for ~20 hours. The catalyst was separated by filtration, the
filtrate was evaporated to an oily residue and benzene (3×50 mL) was added successively
and evaporated to eliminate residue of acetic acid to give racemic 5-isopropyl-1phenylbarituric acid (2.35 g, 96%). Product decomposes at temperatures above 200º C.
1

H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 11.58 (1H, s, NH), 7.43 (3H, m) 7.22

(2H, d, J= 8.1 Hz), 3.41 (1H, d, J= 3.9 Hz) 2.48 (1H, m), 1.08 (6H, d, J= 5.7 Hz) ppm.
13

C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 165.6, 165.4, 147.3, 131.2, 125.2,

125.2, 125.1, 124.7, 124.6, 51.3, 28.8, 16.0, and 15.9 ppm. MS (EI): m/z 69 (40%,
CH3CH=CHCO+), 77 (5%, Ph) 83 (40%) 91, 119 (80%, PhN=C=O+), 176 (25%,
PhNHCOCH2CONH2+), 204 (100%, M-C(CH3)2+), 231 (20%, M-CH3+), 246 (20%, M+).
Anal. Calcd. for C13H14N2O3: C, 63.40; H, 5.73; N, 11.38. Found: C, 63.21; H, 5.92; N,
11.14.
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Synthesis of 5-Isopropyl-1,3-dimethyl-pyrimidine-2,4,6-trione (B2)
A suspension of 1,3-dimethylbarbituric acid(1.56 g, 10.0 mmol), 2 drops sulfuric acid
and 5% Pt-C with 50% water (0.2 g) in acetone (30 mL) and acetic acid (100 mL) was
hydrogenated under hydrogen pressure of 50 psi for ~20 hours. The catalyst was
separated by filtration, the filtrate was evaporated to an oily residue and benzene (3×50
mL) was added successively and evaporated to eliminate residue of acetic acid to give
1.92 g (97%) of racemic 5-isopropyl-1,3-dimethylbarituric acid. m.p. 157.2-159.1º C.
1

H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 3.42 (1H, d, J= 3.3 Hz), 3.144 (6H, s),

0.976 (6H, d, J= 6.9 Hz) ppm.

13

C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 164.9,

148.3, 51.1, 29.0, 24.2, and 15.8 ppm.

Synthesis of 5-Cyclohexyl-pyrimidine-2,4,6-trione (B3)
A suspension of barbituric acid (1.28 g, 10 mmol), cyclohexanone (1.55 mL, 1.47 g, 15
mmol) and 5% Pt-C with 50% water (0.2 g) in methanol (100 mL) was hydrogenated
under hydrogen pressure of 50 psi for ~20 hours. The catalyst was separated by
filtration, the filtrate volume was reduced to 1/10 the original volume, and diluted with
water (100 mL) to precipitate the product. The precipitate was separated by filtration and
dried on the air to afford 2.00 g (95%) 5-Cyclohexyl-pyrimidine-2,4,6-trione. Product
decomposes at temperatures above 150º C. 1H-NMR (DMSO-d6 -500 MHz Varian
Unity): δ 11.19(2H, s, NH), 3.11(1H, d, J= 3.6 Hz, CH), 2.11(1H, m), 1.67(6H, m),
1.23(4H, m) ppm.

13

C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 166.7, 147.6, 50.5,

50.4, 38.0, 25.9, 22.4, 21.9 ppm. MS (CI+-NH3) 129 (100%, ba +), 211 (55%, M+).
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Synthesis of 5-Heptyl-pyrimidine-2,4,6-trione (B4)
A suspension of barbituric acid (1.28 g, 10 mmol), heptaldehyde (2.10 mL, 1.71 g, 15
mmol) and 5% Pt-C with 50% water (0.2 g) in methanol (100 mL) was hydrogenated
under hydrogen pressure of 50 psi for ~20 hours. The catalyst was separated by
filtration, the filtrate volume was reduced to 1/10 the original volume, and diluted with
water (100 mL) to precipitate product. The precipitate was removed by filtration and
dried on the air to afford 2.19 g (97%) pure product. Product decomposes at
temperatures above 160º C. 1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 11.18 (2H,
s, NH), 3.49 (1H, t, J= 5.1 Hz, CH), 1.85 (2H, m), 1.20 (10H, m), 0.83 (3H. t. J= 6.8
Hz) ppm.

13

C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 167.0, 147.3, 44.3, 27.6,

25.3, 24.8, 24.4, 22.2, 18.5, and 10.4 ppm. MS (CI+-NH3) 129 (100%, ba), 227 (75%,
M+).

General Procedure E:
Preparation of C-5 monobenzylated barbituric acids with aromatic aldehydes:
Synthesis of 5-benzylbarbituric acid (B5)
Barbituric acid (1.28 g, 10 mmol), and benzaldehyde (1.06 g, 10 mmol) were refluxed in
methanol (100 mL) for 30 minutes. The reaction suspension was cooled to room
temperature and 5% Pd-C with 50% water (0.1 g) was added, together with benzene (50
mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated by filtration and
the solvent was evaporated to a solid residue. The solid residue was re-dissolved in
methanol (10 mL) and diluted with water (300 mL). The white precipitate was separated
by filtration and dried in the air to give 1.85 g (85%) pure product. m.p. > 200º C with
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decomp. 1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ 11.16 (2H, s, NH), 7.22 (5H,
broad m, Ar), 3.88 (2H, s, CH2).

13

C-NMR (DMSO-d6 -500 MHz Varian Unity): δ 170.6,

151.1, 137.9, 129.4, 128.9, 127.3, 49.9, and 39.3 ppm. MS (CI+-NH3) 91 (100%,
CH2C6H5+), 218 (70%, M).

Synthesis of 5-naphthalen-2-ylmethylbarbituric acid (B6)
Barbituric acid (1.28 g, 10 mmol), and 2-naphthaldehyde (1.56 g, 10 mmol) were
refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was cooled to
room temperature and 5% Pd-C with 50% water (0.1 g) was added, together with benzene
(50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated by filtration
and the solvent was evaporated to a solid residue. The solid residue was re-dissolved in
methanol (10 mL) and diluted with water (300 mL). The white precipitate was separated
by filtration and dried in the air to give 2.40 g (90%) 5-naphthalen-2-ylmethylbarbituric
acid. m.p. > 200º C with decomp. 1H-NMR (DMSO-d6 -500 MHz Varian Unity): δ
11.15 (2H, s, NH), 8.13 (1H, d, J= 6.6 Hz), 7.89 (1H, d, J= 6.6 Hz), 7.71 (1H, d, J= 8.7
Hz), 7.51 (2H, m), 7.41 (1H, t, J= 7.5 Hz), 7.25 (1H, d, J= 6.6 Hz), 3.95 (1H, t, J= 6.6
Hz), 3.66 (2H, d, J= 6.6 Hz) ppm.

13

C-NMR ((DMSO-d6 -500 MHz Varian Unity): δ

166.0, 146.6, 130.2, 129.2, 127.4, 124.4, 122.9, 122.5, 44.8, and 25.9 ppm. MS (CI+NH3) m/z 91 (C7H7+), 115 (12%, C8H9+), 128 (17%, ba+), 129 (16%, C10H9+), 141
(100%, C11H10+), 169 (7%, C11H10CO+), 268 (45%, M+), 269 (10%, M++1). Anal. Calcd.
for C16H12N2O3: C, 67.16; H, 4.51; N, 10.44. Found: C, 67.01; H, 4.82; N, 10.08.
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Synthesis of 5-(3-Phenyl-propyl)-pyrimidine-2,4,6-trione (B7)
Barbituric acid (1.28 g, 10 mmol), and trans-cinnamaldehyde (1.32 g, 10 mmol) were
refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was cooled to
room temperature and 5% Pd-C with 50% water (0.100 g) was added, together with
benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated by
filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The formed precipitate
was separated by filtration and dried in the air to give 2.26 g (92%). 1H-NMR (DMSO-d6
-300 MHz Varian Unity): δ 11.17 (2H, s, NH), 7.25 (2H, m), 7.16 (3H, m), 3.53 (1H, t,
J= 5.1 Hz), 2.53 (2H, m), 1.87 (2H, m), 1.54 (2H, m) ppm.

13

C-NMR (DMSO-d6 -300

MHz Varian Unity): δ 166.7, 147.2, 137.9, 124.6, 124.6, 122.1, 44.2, 36.8, 24.3, and 24.1
ppm.

5-[3-(4-Dimethylamino-phenyl)-propyl]-pyrimidine-2,4,6-trione (B8)
Barbituric acid (1.28 g, 10 mmol), and 4-dimethylaminocinnamaldehyde (1.75 g, 10
mmol) were refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together
with benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated
by filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The white precipitate
was separated by filtration and dried in the air to give 2.57 g (89%) pure product. 1HNMR (DMSO-d6 -300 MHz Varian Unity): δ 6.960 (2H, d, J= 7.8 Hz), 6.628 (2H, d, J=
8.7 Hz), 3.157 (2H, s), 2.816 (6H, s), 2.402 (2H, m), 1.484 (2H, m).

13

C-NMR (DMSO-
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d6 -300 MHz Varian Unity): δ 164.2, 147.7, 145.4, 125.6, 119.9, 108.0, 45.0, 36.1, 24.4,
and 21.3 ppm.

Synthesis of 5-(4-Dimethylamino-benzyl)-1,3-dimethyl-pyrimidine-2,4,6-trione (B10)
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and 4-dimethylaminobenzaldehyde (1.49
g, 10 mmol) were refluxed in methanol with 2 drops sulfuric acid (100 mL) for 30
minutes. The reaction suspension was cooled to room temperature and 5% Pd-C with
50% water (0.100 g) was added, together with benzene (50 mL) and hydrogenated at 30
psi for 4 hours. The catalyst was separated by filtration and the solvent was evaporated
to a solid residue. The solid residue was re-dissolved in methanol (10 mL) and diluted
with water (300 mL). The precipitate was separated by filtration and dried in the air to
give 2.80 g (97%) product. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 6.80 (2H, d,
J= 7.8 Hz), 6.56 (2H, d, J= 8.7 Hz), 3.86 (1H, broad t), 3.16 (2H, broad d), 2.99 (6H, s),
2.80 (6H, s).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 164.9, 147.6, 145.7,

125.5, 119.8, 108.5, 47.1, 36.8, 32.0, and 24.2 ppm.

Synthesis of 1,3-Dimethyl-5-(3-phenyl-propyl)-pyrimidine-2,4,6-trione (B11)
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and trans-cinnamaldehyde (1.32 g, 10
mmol) were refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together
with benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated
by filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The formed precipitate
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was separated by filtration and dried in the air to give 2.49 g (91%). 1H-NMR (DMSO-d6
-300 MHz Varian Unity): δ 7.24 (2H, t, J= 7.4 Hz), 7.16 (3H, m), 3.71 (1H, t, J= 5.4
Hz), 3.10 (6H, s), 2.54 (2H, m), 1.95 (2H, m), 1.57 (2H, m).

13

C-NMR (DMSO-d6 -300

MHz Varian Unity): δ 166.6, 164.6, 147.6, 137.4, 124.1, 121.6, 44.3, 30.8, 24.5, 24.0,
23.8 ppm. MS (CI+-NH3) 156 (45%, dmba), 170 (80%, C7H9+), 274 (20%, M+).

5-[3-(4-Dimethylamino-phenyl)-propyl]-1,3-dimethylpyrimidine-2,4,6-trione (B12)
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and 4-(dimethylamino)cinnamaldehyde
(1.75 g, 10 mmol) were refluxed in methanol with 2 drops sulfuric acid (100 mL) for 30
minutes. The reaction suspension was cooled to room temperature and 5% Pd-C with
50% water (0.100 g) was added, together with benzene (50 mL) and hydrogenated at 30
psi for 4 hours. The catalyst was separated by filtration and the solvent was evaporated
to a solid residue. The solid residue was re-dissolved in methanol (10 mL) and diluted
with water (300 mL). The white precipitate was separated by filtration and dried in the
air to give 2.99 g (94%) pure product. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ
6.960 (2H, d, J= 7.8 Hz), 6.628 (2H, d, J= 8.7 Hz), 3.157 (2H, s), 2.816 (6H, s), 2.787
(6H, s), 2.402 (2H, m), 1.484 (2H, m).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ

164.2, 147.7, 145.4, 125.6, 119.9, 108.0, 45.0, 36.1, 24.4, 24.1, and 21.3 ppm.

Synthesis of 5-(1H-Indol-3-ylmethyl)-1,3-dimethyl-pyrimidine-2,4,6-trione (B13)
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and indole-3-carboxaldehyde (1.45 g, 10
mmol) were refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together
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with benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated
by filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The formed precipitate
was separated by filtration and dried in the air to give 2.70 g (95%). 1H-NMR (DMSO-d6
-300 MHz Varian Unity): δ 10.87 (1H, s, NH), 7.32 (1H, t, J= 6.0 Hz), 7.28 (1H, s), 7.03
(1H, t, J= 5.6 Hz), 6.95 (2H, m), 3.89 (1H, t, J= 3.5 Hz), 3.43 (2H, d, J= 3.6 Hz), 2.87
(6H, s).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 165.5, 147.6, 132.2, 123.0,

120.0, 117.4, 114.7, 114.5, 107.8, 104.9, 46.8, 24.2, and 23.6 ppm.

Synthesis of 5-(4-Hydroxy-benzyl)-1,3-dimethylpyrimidine-2,4,6-trione (B14)
1,3-dimethylbarbituric acid (1.56 g, 10 mmol), and 4-hydroxybenzaldehyde (1.22 g, 10
mmol) were refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was
cooled to room temperature and 5% Pd-C with 50% water (0.100 g) was added, together
with benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated
by filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The formed precipitate
was separated by filtration and dried in the air to give 2.38 g (91%) product. 1H-NMR
(DMSO-d6 -300 MHz Varian Unity): δ 9.26 (1H, s, OH), 6.78 (2H, d, J= 8.4 Hz), 6.58
(2H, d, J= 8.4 Hz), 3.84 (2H, s), 2.97 (6H, s).

13

C-NMR (DMSO-d6 -300 MHz Varian

Unity): δ 165.0, 152.7, 147.6, 126.0, 122.6, 111.5, 47.1, 32.2, 24.2 ppm.
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Synthesis of 5-(4-Hydroxy-benzyl)-pyrimidine-2,4,6-trione (B15)
Barbituric acid (1.28 g, 10 mmol), and 4-hydroxybenzaldehyde (1.22 g, 10 mmol) were
refluxed in methanol (100 mL) for 30 minutes. The reaction suspension was cooled to
room temperature and 5% Pd-C with 50% water (0.100 g) was added, together with
benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated by
filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The formed precipitate
was separated by filtration and dried in the air to give 2.2 g (94%) product. 1H-NMR
(DMSO-d6 -300 MHz Varian Unity): δ 6.85 (2H, d, J= 8.1 Hz), 6.62 (2H, d, J= 8.1 Hz),
3.73 (1H, broad t), 3.15 (2H, d, J= 3.9 Hz).

13

C-NMR (CF3COOH- DMSO-d6 -300 MHz

Varian Unity): δ 169.6, (162.2, 161.7, 161.1, 160.5-belonging to TFA), 152.4, 134.7,
120.6, 116.8, 113.1, 109.3, and 38.2 ppm.

Synthesis of 5-(2-Hydroxy-benzyl)-pyrimidine-2,4,6-trione (B16)
Barbituric acid (1.28 g, 10 mmol), and 2-hydroxybenzaldehyde (1.22 g, 10 mmol) were
refluxed in methanol (100 mL) for 10 minutes. The reaction suspension was cooled to
room temperature and 5% Pd-C with 50% water (0.100 g) was added, together with
benzene (50 mL) and hydrogenated at 30 psi for 4 hours. The catalyst was separated by
filtration and the solvent was evaporated to a solid residue. The solid residue was redissolved in methanol (10 mL) and diluted with water (300 mL). The white precipitate
was separated by filtration and dried in the air to give 1.75 g (75%) of 5-(2-Hydroxybenzyl)-pyrimidine-2,4,6-trione. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.11
(2H, s, NH), 9.41 (1H, broad s, OH), 6.97 (1H, t, J= 7.4 Hz), 6.88 (1H, d, J= 7.5 Hz),
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6.71 (1H, d, J= 7.8 Hz), 6.64 (1H, t, J= 7.4 Hz), 3.78 (1H, t, J= 5.4 Hz), 3.14 (2H, d, J=
5.4 Hz).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 166.6, 151.7, 147.5, 126.5,

123.9, 120.1, 115.1, 111.2, 84.0, 44.3, 25.3 ppm.

General Procedure F: Preparation of C-5 dibenzylated barbituric acids:
Preparation of 5,5-di(benzyl)barbituric acid (B17)
A mixture of barbituric acid (0.64 g, 5.0 mmol) and benzaldehyde (1.59 g, 15 mmol) in
methanol (100 mL) was refluxed for 15 minutes. The reaction mixture changed from a
suspension (low solubility of barbituric acid) to a clear solution, and then again to a new
suspension. Into this suspension, 5% Pd-C with 50% water (0.150 g) was added and the
suspension was hydrogenated at 30 psi at room temperature overnight (14h). The catalyst
was separated by filtration and the methanol volume was evaporated to a reduced volume
(10 mL). Water was added (100 mL) and the resulting solid precipitate was separated by
filtration and washed with carbon tetrachloride (3×50 mL), and dried on the air to give
5,5-di(benzyl)barbituric acid (1.31 g, 86%). The product decomposed at temperatures
above 200º C. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.21 (2H, s, NH), 7.24
(6H, m), 7.03 (4H, d, J= 5.7 Hz), 3.27 (4H, s).

13

C-NMR (DMSO-d6 -300 MHz Varian

Unity): δ 167.9, 144.8, 131.0, 125.2, 124.4, 123.3, 54.9, 39.7 ppm. MS (CI+-NH3) m/z
309 (100%, M+1).

Preparation of 5,5-di(4-dimethyl-aminobenzyl)barbituric acid (B18)
A mixture of barbituric acid (0.64 g, 5.0 mmol) and 4-dimethylaminobenzaldehyde (2.44
g, 15 mmol) in methanol (100 mL) was refluxed for 15 minutes. The reaction mixture
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changed from a suspension (low solubility of barbituric acid) to a clear solution, and then
again to a new suspension. Into this suspension, 5% Pd-C with 50% water (0.150 g) was
added and the suspension was hydrogenated at 30 psi at room temperature overnight
(14h). The catalyst was separated by filtration and the methanol volume was evaporated
to a reduced volume (10 mL). Water was added (100 mL) and the resulting solid
precipitate was separated by filtration and washed with carbon tetrachloride (3 x 50 mL),
and dried on the air to give 5,5-di(4-dimethyl-aminobenzyl)barbituric acid (1.87 g, 95%).
The product decomposed at temperatures above 230º C. 1H-NMR (DMSO-d6 -300 MHz
Varian Unity): δ 11.09 (2H, s, NH), 6.84 (4H, d, J= 8.7 Hz), 6.57 (4H, d, J= 8.7 Hz),
3.10 (4H, s), 2.81 (12H, s,).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 169.1,

145.8, 145.7, 126.3, 118.7, 108.6, 56.1, 39.6, 36.5 ppm. MS (EI): m/z 134 (100%,
N(CH3)2C6H4CH2+), 261 (12%, M-(N(CH3)2C6H4CH2+), 394 (48%, M+). Anal. Calcd.
for C22H26N4O3: C, 66.99; H, 6.64; N, 14.20. Found: C, 66.55; H, 6.85; N, 13.97.

General Procedure G: Preparation of C-5-non-symmetric double alkylated barbituric
acids:
Synthesis of 5-(4-dimethylanimobenzyl)-5-(3-phenylpropyl)barbituric acid (B19). A
suspension of barbituric acid (0.64 g, 5.0 mmol) and cinnamaldehyde (0.66 g, 5.0 mmol)
in methanol (100 mL) was heated at 80º C for 2 hours. The reaction suspension was
cooled to room temperature and 4-dimethylaminobenzaldehyde (0.75 g, 5 mmol) and 5%
Pt-C (0.5 g) with 67% water content was added. The suspension was hydrogenated at 70
psi at room temperature for 4 hours. The catalyst was separated by filtration, and the
filtrate concentrated to a volume of 10 mL. The concentrated solution was diluted with
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water (200 mL), and the resulting white precipitate was separated by filtration and dried
on the air to afford 1.55 g (79%) of pure product. m.p.>250º C with decomp. 1H-NMR
(DMSO-d6 -300 MHz Varian Unity): δ 7.24 (2H, t, J= 5.7 Hz), 7.20 (1H, t, J= 5.4 Hz),
7.11 (2H, d, J= 5.7 Hz), 6.77 (2H, d, J= 5.7 Hz), 6.5 4(2H, d, J= 5.7 Hz), 2.98 (2H, s),
2.79 (6H, s), 2.51 (2H, t, J= 5.4 Hz), 1.91 (2H, m), 1.35(2H, m).

13

C-NMR (DMSO-d6 -

300 MHz Varian Unity): δ 169.6, 146.2, 146.2, 137.9, 126.5, 125.1, 125.0, 122.7, 118.8,
108.8, 54.0, 40.4, 34.3, 31.5, 23.2 ppm. Anal. Calcd. for C22H25N3O3: C, 66.64; H, 6.64;
N, 11.07. Found: C, 66.32; H, 6.88; N, 10.83.

General Procedure H:
Synthesis of 5-(cyclohexylmethyl)barbituric acid (C1). Into a methanol (100 mL)
suspension of barbituric acid (0.940 g, 7.35 mmol) and 4-methoxybenzaldehyde (1.00 g,
7.35 mmol), concentrated hydrochloric acid (100 mL) and 5% Pt-C with 50% water (1.30
g) were added. The resulting suspension was shaken under hydrogen pressure (70 psi)
for 5 hours. The catalyst was separated by filtration and the filtrate was concentrated to
50 mL and diluted with water (100 mL). The formed white precipitate was separated by
filtration and purified by crystallization from methanol, yielding 1.47 g (89%). Product
decomposes at temperatures above 170º C. 1H-NMR (DMSO-d6 -300 MHz Varian
Unity): δ 11.13 (2H, s, NH), 3.15 (1H, t, J= 8.7 Hz), 1.75 (2H, t, J= 6.0 Hz), 1.61 (4H,
m), 1.20 (1H, m), 1.10 (4H, m), 0.834 (2H, m).

13

C-NMR (DMSO-d6 -300 MHz Varian

Unity): δ 167.2, 147.3, 42.3, 31.6, 31.2, 28.9, 22.3, 22.1 ppm.
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Preparation of 5-(cyclohexylmethyl)-1-methylbarbituric acid (C2)
Into a methanol (100 mL) suspension of 1-methylbarbituric acid (1.16 g, 8.20 mmol) and
4-hydroxybenzaldehyde (1.00 g, 8.20 mmol), concentrated hydrochloric acid (100 mL)
and 5% Pt-C with 50% water (1.30 g) were added. The resulting suspension was shaken
under hydrogen pressure (70 psi) for 5 hours. The catalyst was separated by filtration and
the filtrate was concentrated to 50 mL and diluted with water (100 mL). The formed
white precipitate was separated by filtration and purified by crystallization from
methanol, yielding 1.64 g (84%) pure product. Product decomposes at temperatures
above 170º C. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.31 (1H, s, NH), 3.54
(1H, t, J= 6.0 Hz), 3.04 (3H, s), 1.76 (2H, t, J= 6.3 Hz), 1.60 (5H, m), 1.09 (2H, m), 0.83
(4H, m).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 168.4, 167.6, 146.7, 71.5,

43.1, 30.1, 28.8, 24.1, 22.2, 22.1 ppm.

Preparation of 5-(cyclohexylmethyl)-1-phenylbarbituric acid (C3). Into a methanol
(100 mL) suspension of 1-phenylbarbituric acid (1.50 g, 7.35 mmol) and 4methoxybenzaldehyde (1.00 g, 7.35 mmol), concentrated hydrochloric acid (100 mL) and
5% Pt-C with 50% water (1.00 g) were added. The resulting suspension was shaken
under hydrogen pressure (70 psi) for 5 hours. The catalyst was separated by filtration and
the filtrate was concentrated to 50 mL and diluted with water (100 mL). The formed
white precipitate was separated by filtration and purified by crystallization from
methanol, yielding 2.05 g (93%). Product decomposes at temperatures above 200º C. 1HNMR (DMSO-d6 -300 MHz Varian Unity): δ 11.70 (1H, s, NH), 7.41 (3H, m), 7.19 (2H,
broad singlet), 3.73 (1H, t, J= 6.7 Hz), 1.85 (2H, t, J= 6.7 Hz), 1.63 (5H, m), 1.12 (4H,
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m), 0.855 (2H, m).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 167.5, 167.0,

145.8, 130.7, 124.9, 124.7, 124.4, 71.5, 42.6, 29.6, 28.3, 26.6, 21.6 ppm.

Synthesis of 5-(cyclohexylmethyl)-1,3-dimethylbarbituric acid (C4). MW 252.31
Into a methanol (100 mL) suspension of 1,3-dimethylbarbituric acid (1.27 g, 8.20 mmol)
and 4-hydroxybenzaldehyde (1.00 g, 8.20 mmol), concentrated hydrochloric acid (100
mL) and 5% Pt-C with 50% water (1.30 g, 2 molar percent) were added. The resulting
suspension was shaken under hydrogen pressure (70 psi) for 5 hours. The catalyst was
separated by filtration and the filtrate was concentrated to 50 mL and diluted with water
(100 mL). The formed white precipitate was separated by filtration and purified by
crystallization from methanol, yielding 1.82 g (88%) pure product. Product decomposes
at temperatures above 150º C. 1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 3.66 (1H,
t, J= 6.0 Hz), 3.10 (6H, s), 1.79 (2H, t, J= 6.6 Hz), 1.63 (4H, m), 1.45 (1H, m), 1.12 (4H,
m), 0.83 (2H, m).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 165.4, 148.1, 42.8,

32.7, 31.1, 28.8, 24.5, 22.4, 22.0 ppm. MS (EI): m/z 83 (93%, C6H11+), 97 (30%,
C6H11CH3+), 157 (100%, dmba + 1), 169 (80%, M-C6H11+), 252 (15%, M+). Anal. Calcd.
for C13H20N2O3: C, 61.88; H, 7.99; N, 11.10. Found: C, 61.63; H, 5.11; N, 11.02.
Crystals were obtained by crystallization from methanol by allowing slow solvent
evaporation. Crystal data: Mr = 252.31, monoclinic space group P21, a = 24.369(3), b =
6.3025(8), c = 18.301(2) Å, β + 11.449(2)º, V = 2616.0(6) Å3, Z = 8, ρCalcd. 1.281 Mgm-3,
F000 = 1088, wavelength (λ) = 0.71073 Å, absorption coefficient (µ) = 0.091 mm-1.
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Method I: Preparation procedure for formylation of barbituric acid with chloroform.
The Reimer-Tiemann Reaction.
Preparation of 5-formyl-1,3-dimethylbarbituric acid (D1)
Into a 50% ethanol (400 mL) solution of potassium hydroxide (84.0 g, 1.50 mol), the
chloroform solution of 1,3-dimethylbarbituric acid (33.6 g, 0.20 mol) was added. The
rreaction is exothermic, and is controlled by an ice-water bath. A yellow precipitate
forms almost immediately. The reaction mixture was stirred at room temperature for an
additional 3 hours, then cooled in ice water (5º C). The solid was separated by filtration
and slurred in water (100 mL), and the pH was adjusted to ~3 by adding concentrated
hydrochloric acid. After cooling at 5º C for 1 hour, the solid was again separated by
filtration, washed with acetone (3×20 mL) and dried at 110º C for 0.5 hours, resulting in
isolation of pure product. If necessary, further purification can be performed using a
small amount of water-ethanol mixture. The yield of isolated product was 27.6 g (75%).
Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6-D2O; 5:1-500
MHz Varian Unity): δ 9.63 (1H, s), 3.04 (6H, s).

13

C-NMR (DMSO-d6- D2O; 5:1-500

MHz Varian Unity): δ 188.2, 148.5, 147.2, 97.0, 24.0 ppm. MS (EI): m/z 156 (39%, MCO)+, 169 (28%, M-CH3)+, 184 (20%, M+). Anal. Calcd. for C7H8N2O4 (MW 184.15):
C, 45.66; H, 4.38, N, 15.21. Found: C, 45.34; H, 4.65; N, 15.02.

Synthesis of 5-formylbarbituric acid (D2)
Into a 50% ethanol (400 mL) solution of potassium hydroxide (84.0 g, 1.50 mol), the
chloroform solution of barbituric acid (25.6 g, 0.20 mol) was added. The reaction is
exothermic, and is controlled by an ice-water bath. A yellow precipitate forms almost

171

immediately. The reaction mixture was stirred at room temperature for an additional 3
hours, then cooled in ice water (5º C). The solid was separated by filtration and slurred in
water (100 mL), and the pH was adjusted to ~3 by adding concentrated hydrochloric acid.
After cooling at 5º C for 1 hour, the solid was again separated by filtration, washed with
acetone (3×20 mL) and dried at 110º C for 0.5 hours, resulting in isolation of pure
product. If necessary, further purification can be performed using a small amount of
water-ethanol mixture. The yield of isolated product was 14.0 g (45%). Product
decomposes at temperatures above 250º C. 1H-NMR (D2O:DMSO-d6 (2:1) 500 MHz
Varian Unity): δ 9.78 (2H, s, NH), 8.59 (1H, s, HCO).

13

C-NMR (D2O:DMSO-d6 (2:1)

500 MHz Varian Unity): δ 185.3, 150.6, 145.3, and 95.6 ppm.

Synthesis of 5-formyl-1-phenylbarbituric acid (D3)
Into a 50% ethanol (400 mL) solution of potassium hydroxide (84.0 g, 1.50 mol), the
chloroform solution of barbituric acid (40.8 g, 0.20 mol) was added. The reaction is
exothermic, and is controlled by an ice-water bath. A yellow precipitate forms almost
immediately. The reaction mixture was stirred at room temperature for an additional 3
hours, then cooled in ice water (5º C). The solid was separated by filtration and slurred in
water (100 mL), and the pH was adjusted to ~3 by adding concentrated hydrochloric acid.
After cooling at 5º C for 1 hour, the solid was again separated by filtration, washed with
acetone (3×20 mL) and dried at 110º C for 0.5 hours, resulting in isolation of pure
product. If necessary, further purification can be performed using a small amount of
water-ethanol mixture. The yield of isolated product was 31.1 g (67%). Product
decomposes at temperatures above 200º C. 1H-NMR (D2O:DMSO-d6 (2:1) 500 MHz
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Varian Unity): δ 11.38 (1H, s, NH), 7.41 (5H, broad m, Ph), 3.70 (1H, s, CH).

13

C-NMR

(D2O:DMSO-d6 (2:1) 500 MHz Varian Unity): δ 163.3, 163.0, 148.2, 145.3, 131.2,
125.5, 125.4, 125.2, and 124.7 ppm.

Method J: Preparation for acetylbarbiturates.
Preparation of 5-acetylbarbituric acid (D4)
A mixture of barbituric acid (12.8 g, 0.10 mol) and acetic anhydride (300 mL) with a few
drops of concentrated sulfuric acid was refluxed for 1 hour. In the beginning the reaction
is a suspension, but quickly becomes solution. The reaction mixture was concentrated to
½ the original volume and cooled at 5º C, in an ice water bath. The formed solid was
separated by filtration, washed with hot water (3×25 mL), then acetone (3×25 mL), and
dried at 80º C for 30 minutes, yielding 16.1 g product (95%). Product decomposes at
temperatures above 250º C.1H-NMR (DMSO-d6 -300 MHz Varian Unity): δ 11.76 (1H, s,
NH), 11.03 (1H, s, NH), 2.56 (3H, s, H3C).

13

C-NMR (DMSO-d6 -300 MHz Varian

Unity): δ 191.3, 168.1, 158.7, 145.5, 91.9, and 20.3 ppm. MS (ESI+) in methanol with
0.1% acetic acid. 215.2 (M+2Na) and 251.1 (M+Na+HOAc).

Synthesis of 5-acetyl-1-phenylbarbituric acid (D5)
A mixture of 1-phenylbarbituric acid (20.4 g, 0.10 mol) and acetic anhydride (300 mL)
with a few drops of concentrated sulfuric acid was refluxed for 1 hour. In the beginning
the reaction is a suspension, but quickly becomes solution. The reaction mixture was
concentrated to ½ the original volume and cooled at 5º C in an ice water bath. The
formed solid was separated by filtration, washed with hot water (3×25 mL), then acetone
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(3×25 mL), and dried at 80º C for 30 minutes, yielding 16.0 g (65%) pure product.
Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6 -300 MHz
Varian Unity): δ 11.48 (1H, s, NH), 7.39 (5H, broad m, phenyl ring), 3.71 (1H, s, CH),
2.58 (3H, s, CH3).

13

C-NMR (DMSO-d6 -300 MHz Varian Unity): δ 163.1, 163.0, 147.9,

145.5, 131.4, 125.5, 125.3, 125.2, 124.7, 20.5 ppm.

Synthesis of 5-acetyl-1,3-dimethylbarbituric acid (D6)
A mixture of 1,3-dimethylbarbituric acid (15.6 g, 0.10 mol) and acetic anhydride (300
mL) with a few drops of concentrated sulfuric acid was refluxed for 1 hour. In the
beginning the reaction is a suspension, but quickly becomes solution. The reaction
mixture was concentrated to ½ the original volume and cooled at 5º C in an ice water
bath. The formed solid was separated by filtration, washed with hot water (3×25 mL),
then acetone (3×25 mL), and dried at 80º C for 30 minutes, yielding 18.2 g product
(92%). Product decomposes at temperatures above 190º C. 1H-NMR (DMSO-d6 -300
MHz Varian Unity): δ 3.13 (6H, s, dmba-CH3), 2.58 (3H, s, CH3).

13

C-NMR (DMSO-d6

-300 MHz Varian Unity): δ 191.0, 165.4, 146.3, 92.2, 24.0, 20.5 ppm.

Method K: Preparation for Schiff bases with ω-aminoalkanoic acids.
Preparation of 6-[1,3-dimethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylmethylene)amino]-hexanoic acid (D7)
A mixture of 5-formyl-1,3-dimethylbarbituric acid (0.92 g, 5.0 mmol) and 6aminohexanoic acid (0.655 g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours.
Methanol was evaporated to a solid residue and the solid residue was re-dissolved in a
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small amount of hot methanol (50 mL). The solution was left at room temperature to
slowly evaporate to 1/5 the original volume. The formed white needles were separated
by filtration, washed with cold methanol (3×5 mL), and dried at 60º C for 30 minutes to
afford 1.3 g (87%) product. 1H-NMR (DMSO-d6 - D2O (3:1) 500 MHz Varian Unity): δ
8.08 (1H, s). 3.41 (2H, d, J= 6.7 Hz), 3.08 (6H, d, J= 0.6 Hz), 2.18 (2H, t, J= 7.2 Hz),
1.48 (4H, m), 1.21 (2H, m).

13

C-NMR (DMSO-d6 - D2O (3:1) 500 MHz Varian Unity): δ

173.0, 161.3, 160.4, 156.6, 149.4, 86.7, 47.1, 30.9, 26.7, 25.0, 24.4, 22.5, 21.3. MS
(ESI+) in methanol with 0.1% acetic acid: 320.1 and 320.3 (M+Na), 617 and 618.1
(2M+Na).

Synthesis of 4-[(2,4,6-Trioxo-hexahydro-pyrimidin-5-ylmethylene)-amino]-butyric acid
(D8)
A mixture of 5-formylbarbituric acid (0.85 g, 5.0 mmol) and 4-aminobutanoic acid (0.515
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours. Methanol was evaporated
to a solid residue and the solid residue was re-dissolved in a small amount of hot
methanol (50 mL). The solution was left at room temperature to slowly evaporate to 1/5
the original volume. The formed white needles were separated by filtration, washed with
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.14 g (95%)
product. C=C isomer recorded. 1H-NMR (DMSO-d6:D2O (5:1) 500 MHz Varian
Unity): δ 8.83 (1H, s), 4.25 (2H, t, J= 5.3 Hz), 3.04 (2H, t, J= 5.5 Hz), 2.58 (2H, m).
13

C-NMR (DMSO-d6:D2O (5:1) 500 MHz Varian Unity): δ 171.0, 162.4, 160.5, 155.2,

147.5, 85.9, 45.7, 27.8, and 22.3 ppm.
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Synthesis of 6-[(2,4,6-Trioxo-hexahydro-pyrimidin-5-ylmethylene)-amino]-hexanoic
acid (D9)
A mixture of 5-formylbarbituric acid (0.85 g, 5.0 mmol) and 6-aminohexanoic acid
(0.655 g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours. Methanol was
evaporated to a solid residue and the solid residue was re-dissolved in a small amount of
hot methanol (50 mL). The solution was left at room temperature to slowly evaporate to
1/5 the original volume. The formed white needles were separated by filtration, washed
with cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.22 g (91%)
product. C=C isomer recorded. 1H-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian
Unity): δ 8.09 (1H, s), 3.43 (2H, t, J= 6.9 Hz), 2.10 (2H, t, J= 7.2 Hz), 1.51 (4H, m),
1.26 (2H, m) ppm.

13

C-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian Unity): δ 171.7,

162.4, 160.4, 155.1, 147.4, 85.7, 46.0, 31.1, 26.2, 22.0, 20.9 ppm.

Synthesis of 4-[(2,4,6-Trioxo-1-phenyl-hexahydro-pyrimidin-5-ylmethylene)-amino]butyric acid (D10)
A mixture of 5-formyl-1-phenylbarbituric acid (1.16 g, 5.0 mmol) and 4-aminobutanoic
acid (0.515 g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours. Methanol was
evaporated to a solid residue and the solid residue was re-dissolved in a small amount of
hot methanol (50 mL). The solution was left at room temperature to slowly evaporate to
1/5 the original volume. The formed yellow needles were separated by filtration, washed
with cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.27 g (80%)
product. C=C isomer recorded. 1H-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian
Unity): δ 8.10 (1H, d, J= 7.0 Hz), 7.38 (3H, m), 7.19 (2H, m), 3.48 (2H, m), 2.15 (2H,
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m), 1.742 (2H, m).

13

C-NMR (DMSO-d6:D2O (5:1) 300 MHz Varian Unity): δ 170.6,

161.2, 159.3, 155.4, 147.3, 131.6, 125.9, 125.0, 124.4, 86.1, 45.7, 27.4, 22.1 ppm.

Synthesis of 4-[1-(2,4,6-Trioxo-hexahydro-pyrimidin-5-yl)-ethylideneamino]-butyric
acid. (D11)
A mixture of 5-acetylbarbituric acid (0.85 g, 5.0 mmol) and 4-aminobutyric acid (0.515
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours. Methanol was evaporated
to a solid residue and the solid residue was re-dissolved in a small amount of hot
methanol (50 mL). The solution was left at room temperature to slowly evaporate to 1/5
the original volume. The formed white needles were separated by filtration, washed with
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.13 g (89%)
product. C=C isomer recorded. 1H-NMR (D2O:DMSO-d6 5:1-500 mHz): δ 3.06 (2H, t,
J= 7.5 Hz), 2.53 (3H, s, CH3), 2.51 (2H, t, J= 7.0 Hz), 1.98 (2H, m).

Synthesis of 6-[1-(2,4,6-Trioxo-hexahydro-pyrimidin-5-yl)-ethylideneamino]-hexanoic
acid (D12)
A mixture of 5-acetylbarbituric acid (0.85 g, 5.0 mmol) and 6-aminohexanoic acid (0.65
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours. Methanol was evaporated
to a solid residue and the solid residue was re-dissolved in a small amount of hot
methanol (50 mL). The solution was left at room temperature to slowly evaporate to 1/5
the original volume. The formed white needles were separated by filtration, washed with
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.23 g (87%)
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product. 13C-NMR (TFA:DMSO-d6 5:1 500 mHz): δ 200.7, 181.4, 163.3, (161.3, 160.8,
160.2, 159.6 for TFA), 150.8, 94.5, 40.9, 32.5, 26.1, 24.5, 23.3, 22.9 ppm.

Synthesis of 3-[1-(2,4,6-Trioxo-hexahydro-pyrimidin-5-yl)-ethylideneamino]-propanoic
acid. (D13)
A mixture of 5-acetylbarbituric acid (0.85 g, 5.0 mmol) and 3-aminopropanoic acid (0.44
g, 5.0 mmol) in methanol (200 mL) was refluxed for 5 hours. Methanol was evaporated
to a solid residue and the solid residue was re-dissolved in a small amount of hot
methanol (50 mL). The solution was left at room temperature to slowly evaporate to 1/5
the original volume. The formed white needles were separated by filtration, washed with
cold methanol (3×5 mL), and dried at 60º C for 30 minutes to afford 1.17 g (90%)
product. C=C isomer recorded. 1H-NMR (D2O:DMSO-d6 5:1 500 mHz): δ 2.98 (2H, t,
J= 7.5 Hz), 2.65 (2H, t, J= 7.5 Hz), 2.30 (3H. s).

Method L: Preparation procedure for nitrophenylhydrazones of formylated barbituric
acids.
Synthesis of 5-[(4-nitrophenyl)hydrazonomethyl]-pyrimidine-2,4,6-trione (D14)
A methanol (200 mL) suspension of 5-formylbarituric acid (1.56 g, 10 mmol) and 4nitrophenylhydrazine (1.53 g, 10 mmol) was refluxed overnight. After cooling to room
temperature, the solid was separated by filtration, slurred in hot water, washed with
methanol and recrystallized from acetic acid (500 mL) to give 2.3 g (80%) of pure
compound. 1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 11.22 (1H, broad singlet),
10.84 (1H, s), 10.74 (1H, s), 9.85 (1H, s), 8.12 (2H, d, J= 9.0 Hz), 7.98 (1H, s), 6.81 (2H,
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d, J= 9.0 Hz).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity): δ 155.4, 150.0, 147.1,

136.0, 122.1, 108.227, 108.227, 87.0 ppm. Anal. Calcd. for C11H9N5O5 (MW 291.2): C,
45.37; H, 3.11; N, 24.05. Found: C, 45.04; H, 3.38; N, 23.88.

Synthesis of 5-[(2,4-Dinitro-phenyl)-hydrazonomethyl]-pyrimidine-2,4,6-trione (D15)
A methanol (200 mL) suspension of 5-formylbarituric acid (1.56 g, 10 mmol) and 2,4dinitrophenylhydrazine (1.98 g, 10 mmol) was refluxed overnight. After cooling to room
temperature, the solid was separated by filtration, slurred in hot water, washed with
methanol and recrystallized from acetic acid (500 mL) to give 2.96 g (88%) of pure
compound. C=N isomer recorded. 1H-NMR (TFA:DMSO-d6 (5:1)-300 MHz VarianUnity): δ 10.92 (1H, s, NH), 10.87 (2H, s, NH), 8.88 (1H, d, J= 2.7 Hz), 8.40 (1H, d of d,
J1=9.3 Hz, J2=2.7 Hz), 8.11 (1H, s), 7.24 (1H, d, J= 9.6 Hz) ppm.

13

C-NMR

(TFA:DMSO-d6 (5:1)-300 MHz Varian-Unity): δ 160.8, 155.6, 147.2, 143.8, 134.1,
126.7, 126.4, 119.1, 112.6, 87.8 ppm.

Synthesis of 5-[(4-Nitro-phenyl)-hydrazonomethyl]-1-phenyl-pyrimidine-2,4,6-trione
(D16)
A methanol (200 mL) suspension of 5-formyl-1-phenylbarituric acid (2.32 g, 10 mmol)
and 4-nitrophenylhydrazine (1.53 g, 10 mmol) was refluxed overnight. After cooling to
room temperature, the solid was separated by filtration, slurred in hot water, washed with
methanol and recrystallized from acetic acid (500 mL) to give 3.37 g (92%) of pure
compound. C=C isomer recorded. 1H-NMR (DMSO-d6 -300 MHz Varian-Unity): δ
11.24 (2H, broad singlet, NH), 11.13 (1H, s, NH), 9.93 (1H, s), 8.13 (2H, d, J= 8.4 Hz),
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7.42 (3H, m), 7.24 (2H, m), 6.82 (2H, d, J= 7.5 Hz) ppm.

13

C-NMR (DMSO-d6 -300

MHz Varian-Unity): δ 161.1, 159.8, 155.5, 147.9, 147.1, 136.5, 132.2, 125.7, 125.4,
124.0, 122.2, 108.0, 86.6 ppm.

Synthesis of 4-[N'-(2,4,6-Trioxo-1-phenyl-hexahydro-pyrimidin-5-ylmethylene)hydrazino]-benzoic acid (D17)
A methanol (200 mL) suspension of 5-formyl-1-phenylbarituric acid (2.32 g, 10 mmol)
and 4-hydrazinobenzoic acid (1.52 g, 10 mmol) was refluxed overnight. After cooling to
room temperature, the solid was separated by filtration, slurred in hot water, washed with
methanol and recrystallized from acetic acid (500 mL) to give 3.40 g (93%) of pure
compound. C=C isomer recorded. 1H-NMR (DMSO-d6 -300 MHz Varian-Unity): δ
11.40 (2H, broad s, NH), 11.09 (1H, s, NH), 9.37 (1H, s), 8.07 (2H, m), 7.80 (2H, d, J=
8.7 Hz), 7.41 (3H, m), 6.78 (2H, d, J= 8.1 Hz) ppm.

13

C-NMR (DMSO-d6 -300 MHz

Varian-Unity): δ 164.5, 162.0, 159.9, 155.3, 147.7, 147.2, 132.1, 127.8, 125.5, 125.4,
124.8, 118.0, 108.9, and 86.1 ppm.

Synthesis of 1,3-Dimethyl-5-[(4-nitro-phenyl)-hydrazonomethyl]-pyrimidine-2,4,6trione (D18)
A methanol (200 mL) suspension of 5-formyl-1,3-dimethylbarituric acid (1.84 g, 10
mmol) and 4-nitrophenylhydrazine (1.53 g, 10 mmol) was refluxed overnight. After
cooling to room temperature, the solid was separated by filtration, slurred in hot water,
washed with methanol and recrystallized from acetic acid (500 mL) to give 3.03 g (95%)
of pure compound. C=C isomer recorded. 1H-NMR (DMSO-d6 -300 MHz Varian-
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Unity): δ 11.40 (1H, s, NH), 11.30 (1H, s, NH), 9.95 (1H, s), 8.13 (2H, d, J= 7.8 Hz),
6.82 (2H, d, J= 7.2 Hz), 3.18 (3H, s), 3.153 (3H, s) ppm.

13

C-NMR (DMSO-d6 -300

MHz Varian-Unity): δ 159.4, 158.1, 156.0, 149.8, 147.8, 136.1, 122.0, 108.1, 87.0, 23.8,
23.2 ppm.

Synthesis of 4-[N'-(1,3-Dimethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylmethylene)hydrazino]-benzoic acid (D19)
A methanol (200 mL) suspension of 5-formyl-1,3-dimethylbarituric acid (1.84 g, 10
mmol) and 4-hydrazinobenzoic acid (1.52 g, 10 mmol) was refluxed overnight. After
cooling to room temperature, the solid was separated by filtration, slurred in hot water,
washed with methanol and recrystallized from acetic acid (500 mL) to give 2.89 g (91%)
of pure compound. C=C isomer recorded. 1H-NMR (DMSO-d6 -300 MHz VarianUnity): δ 11.27 (1H, s, NH), 11.24 (1H, s, NH), 9.36 (1H, s), 7.79 (2H, d, J= 8.4 Hz),
6.74 (2H, d, J= 8.7 Hz), 3.14 (3H, s), 3.11 (3H, s) ppm.

13

C-NMR (DMSO-d6 -300 MHz

Varian-Unity): δ 163.6, 159.6, 158.4, 156.5, 148.1, 148.0, 127.5, 118.6, 108.4, 86.6, 24.0,
23.4 ppm.

Synthesis of 5-{1-[(4-Nitro-phenyl)-hydrazono]-ethyl}-pyrimidine-2,4,6-trione (D20)
A methanol (200 mL) suspension of 5-acetylbarbituric acid (1.70 g, 10.0 mmol) and 4nitrophenylhydrazine (1.53 g, 10.0 mmol) was refluxed overnight. After cooling to room
temperature, the solid was separated by filtration, slurred in hot water (~15 mL) and
washed with methanol (3×20 mL), yielding 2.23 g (73%). (C=C isomer recorded). 1HNMR (DMSO-d6- 300 MHz Varian Unity): δ 13.22 (1H, s, NH), 10.73 (2H, s, NH), 9.66
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(1H, s, NH), 8.13 (2H, d, J= 9.0 Hz), 6.83 (2H, d, J= 9.0 Hz), 2.61 (3H, s, CH3).

13

C-

NMR (DMSO-d6- 300 MHz Varian Unity): δ 171.5, 162.0, 148.8, 146.0, 136.0, 122.4,
107.7, 85.6, 12.1.

Synthesis of 5-{1-[(2,4-dinitrophenyl)-hydrazono]-ethyl}-pyrimidine-2,4,6-trione (D21)
A methanol (200 mL) suspension of 5-acetylbarbituric acid (1.70 g, 10.0 mmol) and 2,4dinitrophenylhydrazine (1.98 g, 10.0 mmol) was refluxed overnight. After cooling to
room temperature, the solid was separated by filtration, slurred in hot water (~15 mL) and
washed with methanol (3×20 mL) to give 3.01 g (86%) of pure compound. (C=C isomer
recorded). 1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.18 (1H, s, NH), 10.92
(1H, s, NH), 10.64 (1H, s, NH), 10.546 (1H, s, NH), 8.86 (1H, d, J= 2.4 Hz), 8.34 (1H, d
of d, J1=9.4 Hz, J2=2.4 Hz), 7.17 (1H, d, J= 9.6 Hz), 2.59 (3H, s, CH3).

Synthesis of 5-{1-[(4-Nitro-phenyl)-hydrazono]-ethyl}-1-phenyl-pyrimidine-2,4,6-trione
(D22)
A methanol (200 mL) suspension of 5-acetyl-1-phenylbarbituric acid (2.46 g, 10.0 mmol)
and 4-nitrophenylhydrazine (1.53 g, 10.0 mmol) was refluxed overnight. After cooling to
room temperature, the solid was separated by filtration, slurred in hot water (~15 mL) and
washed with methanol (3×25 mL), yielding 3.20 g, (84%) pure product. (C=C isomer
recorded). 1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.19 (1H, s, NH), 11.13
(1H, s, NH), 9.72 (1H, s, NH), 8.14 (2H, d, J= 9.3 Hz), 7.41 (3H, m), 7.24 (2H, d, J= 7.2
Hz), 6.84 (2H, d, J= 9.3 Hz), 2.62 (3H, s, CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian
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Unity): δ 171.8, 148.7, 146.0, 136.0, 125.7, 125.3, 125.1, 125.0, 124.6, 124.2, 122.4,
107.8, 85.9, and 12.5 ppm.

Synthesis of 5-{1-[(2,4-Dinitro-phenyl)-hydrazono]-ethyl}-1-phenyl-pyrimidine-2,4,6trione (D23)
A methanol (200 mL) suspension of 5-acetyl-1-phenylbarbituric acid (2.46 g, 10.0 mmol)
and 2,4-dinitrophenylhydrazine (1.98 g, 10.0 mmol) was refluxed overnight. After
cooling to room temperature, the solid was separated by filtration, slurred in hot water
(~15 mL) and washed with methanol (3×20 mL), yielding 3.45 g, (81%) pure product.
(C=C isomer recorded). 1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.10 (1H, s,
NH), 11.12 (1H, s, NH), 10.60 (1H, s, NH), 8.87 (1H, d, J= 2.7 Hz), 8.37 (1H, d of d, J1=
9.3 Hz, J2= 2.4 Hz), 7.42 (3H, m), 7.24 (3H, m), 2.61 (3H, s CH3).

Synthesis of 1,3-Dimethyl-5-{1-[(4-nitro-phenyl)-hydrazono]-ethyl}-pyrimidine-2,4,6trione. (D24)
A methanol (200 mL) suspension of 5-acetyl-1,3-dimethylbarbituric acid (1.98 g, 10.0
mmol) and 4-nitrophenylhydrazine (1.53 g, 10.0 mmol) was refluxed overnight. After
cooling to room temperature, the solid was separated by filtration, slurred in hot water (5
mL) and washed with methanol (3×20 mL), yielding 2.08 g (63%) pure product. (C=C
isomer recorded).

1

H-NMR (DMSO-d6- 300 MHz Varian Unity): δ 13.25 (1H, s, NH),

9.73 (1H, s, NH), 8.12 (2H, d, J= 9.3 Hz), 6.82 (2H, d, J= 9.3 Hz), 3.15 (6H, s, dmbaCH3), 2.63 (3H, s, CH3).
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Synthesis of 5-{1-[(2,4-Dinitro-phenyl)-hydrazono]-ethyl}-1,3-dimethyl-pyrimidine2,4,6-trione (D25)
A methanol (200 mL) suspension of 5-acetyl-1,3-dimethylbarbituric acid (1.98 g, 10.0
mmol) and 2,4-dinitrophenylhydrazine (1.98 g, 10.0 mmol) was refluxed overnight.
After cooling to room temperature, the solid was separated by filtration, slurred in hot
water (~15 mL) and washed with methanol (3×20 mL), yielding 3.17 g (84%) pure
product. (C=C isomer recorded). 1H-NMR (DMSO-d6- 300 MHz Varian Unity): δ
13.23 (1H, s, NH), 10.62 (1H, s, NH), 8.86 (1H, d, J= 2.7 Hz), 8.36 (1H, d of d, J1= 9.6
Hz, J2= 2.4 Hz), 7.16 (1H, d, J= 9.3 Hz), 3.16 (6H, s, dmba-CH3), 2.63 (3H, s, CH3).
13

C-NMR (DMSO-d6- 300 MHz Varian Unity): δ 172.4, 161.6, 146.9, 143.3, 134.2,

127.2, 126.7, 119.2, 111.7, 86.7, 24.1, 13.1 ppm.

General Procedure M;
Preparation of 5,5’-(4-dimethylaminobenzylidene)dibarbituric acid (E1)
Into a clear trifluoroacetic acid solution (30 mL) of barbituric acid (0.270 mg; 0.0021
mol), 4-dimethylaminobenzaldehyde (0.149g 0.001mol) was added. Clear reaction
mixture was left at room temperature and the solvent was slowly evaporated at room
temperature almost to dryness (eight days). Formed white crystalline product was
separated by filtration and washed with trifluoroacetic acid. The yield of the product is
0.37 g (95%). This compound is very sensitive to elevated temperature and other
solvents that are not strong acids, such as alcohol. It immediately decomposes to
barbituric acid and the benzylidene product. It is stable in crystalline form and in strong
acid at room temperature. The trifluoromethanesulfonic acid solution was stable for
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several months at 0º C. The NMR spectra were recorded in CF3SO3H with three drops of
DMSO-d6 as an internal standard and source of the deuterium lock signal. Product
decomposition occurs at temperatures above 285º C. 1H-NMR(CF3SO3H-DMSO-d6, 300
MHz) δ 7.57 (1H, broad singlet), 6.94 (2H, d, J= 8.7 Hz), 6.87 (2H, d, J= 8.4 Hz), 5.48
(1H, s), and 2.71 (6H, d, J= 5.1 Hz); 13C-NMR(CF3SO3H-DMSO-d6, 300 MHz) δ 167.6,
and 152.8 (two carbonyl carbons), 143.9, 138.0, 131.7, and 122.7 (four aromatic
carbons), 95.5 (benzyl carbon), 49.8 (two dimethylamino carbons), and 34.2 ppm
(barbituric acid C-5 carbon).

Preparation of 5,5’-(4-nitrobenzylidene)dibarbituric acid (E2)
Into a clear trifluoroacetic acid solution (30 mL) of barbituric acid (0.270 mg;
0.0021mol), p-nitrobenzaldehyde (151 mg; 1 mmol) was added. The clear reaction
mixture was left at room temperature for solvent to slowly evaporate. A hard white
precipitate was formed. Solid was separated by fitration, washed with cold trifluoroacetic
acid (3×3 mL), with methanol (3×10 mL), and dried in vacuum at 60º C for three hours to
afford pure white product in 87% yield (340 mg). Compound decomposes in neutral
solvents such as DMSO. In this solvent an equilibrium is established between
dibarbiturate and its decomposition products, free barbituric acid and 5-(4nitrobenzylidene)pyrimidine-2,4,6-trione. The amount of 5-(4nitrobenzylidene)pyrimidine-2,4,6-trione can be diminished if the concentration of
barbituric acid is increased in the solution. On the other hand, the acetic acid solution is
sufficiently stable that 1H-NMR spectra can be recorded. Product decomposes at
temperatures above 200º C. 1H-NMR (CF3SO3H-DMSO-d6, 300 MHz) δ 7.66 (2H, d, J=
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7.5Hz, 3H-benzene hydrogens), 6.88 (2H, d, J= 7.5 Hz, benzene 2H hydrogens), and
5.49 ppm (1H, benzyl hydrogen).

13

C-NMR (CF3SO3H-DMSO-d6, 300 MHz) δ 167.7

and 152.5 (two different barbituric acid carbonyls), 148.6, 144.8, 130.6, and 127.1 (four
aromatic carbons), 127.0, 122.8, 118.6, 114.5 (quartet from solvent – CF3SO3H), 94.9
(benzyl carbon, and 34.8 ppm (barbituric C-5 carbon).

Preparation of 5,5’-(4-nitrobenzylidene)di(1,3-dimethylbarbituric acid) (E2a)
A trifluoroacetic acid solution (30 mL) of 1,3-dimethylbarbituric acid (328 mg; 2.1
mmol) and 4-nitrobenzaldehyde (151 mg; 1 mmol) was left at room temperature for
solvent to slowly evaporate for four days. In this period the volume of the solvent was
reduced to approximately 10 mL and a hard white solid was formed. Solid was separated
by filtration, washed with ice-cold trifluoroacetic acid (3× 2mL), ice-cold methanol (3×3
mL) and dried on open air to afford 365 mg (82%) pure product. This compound has
very low solubility in DMSO, and it is temperature sensitive. The NMR sample was
prepared in ice-cold trifluoromethanesulfonic acid by keeping a suspension of 70 mg/0.7
mL of CF3SO3H at room temperature for approximately one hour. Two drops of DMSOd6 were added as both internal reference signal as well as solvent for the NMR signal
lock. Product melting point is 179.2-181.1º C. 1H-NMR (CF3SO3H-DMSO-d6, 300
MHz), δ 7.67 (2H, d, J= 8.4 Hz, 3H aromatic hydrogens), 6.85 (2H, d, J= 8.4Hz, 2H
aromatic hydrogens), 5.50 (1H, s, benzyl hydrogen), 3.05 ppm (12H, s, methyl
hydrogens).

13

C-NMR (CF3SO3H-DMSO-d6, 300 MHz) δ 166.2, 153.8 (two different

carbonyls), 148.8, 144.0, 130.5, 127.4 (four aromatic carbons), 127.0, 122.8, 118.6, and
144.4 (quartet from CF3SO3H), 96.2 (benzyl carbon), 37.3 (barbituric C-5 carbon), and
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34.0 ppm (methyl carbons). Anal. Calcd. for C19H19N5O8: C, 51.24; H, 4.30; N, 15.72
Found: C, 51.15; H, 4.43; N, 15.61.

Preparation of 5,5’-(4-quinolidinylmethylene)dibarbituric acid (E3). 4Quinolinecarboxaldehyde (0.160 g; 0.001 mol) was added into refluxing methanol (400
mL) solution of barbituric acid (0.256 g; 0.002 mol). Reaction mixture was refluxed for
three hours and the volume was reduced to 1/5 by evaporation of methanol at
atmospheric pressure. Solid product was separated by filtration, washed with ice-cold
methanol (3×30 mL) and dried at 110º C for three hours to give 0.36 g (91%) product.
Product decomposes at temperatures e×ceeding 280º C. 1H-NMR(DMSO-d6, 300 MHz)
δ 10.32 (4H, s, NH), 9.09 (1H, d, J= 0.020, quinoline 2-H), 8.48 (1H, d, J= 0.030,
quinoline 8-H), 8.15 (1H, d, J= 0.029, quinoline 5-H), 8.03 (1H, t, J= 0.024, quinoline 7H), 8.40 (1H, t, J= 0.021, quinoline 6-H), 7.83 (1H, d, J= 0.019, quinoline 3-H), and 6.76
ppm (1H, s, benzyl H);

13

C-NMR (DMSO-d6, 300 MHz) δ 161.1 and 161.0 (two

different carbonyl carbons), 146.8, 139.9, 133.8, 130.0, 125.4, 123.6, 121.9, 117.9, 117.6
(nine quinoline carbons), 86.4 (benzyl carbon), and 27.4 ppm (barbituric C-5). Anal.
Calcd. for C22H21N5O6: C, 58.53; H, 4.69; N, 15.51 Found: C, 58.35; H, 4.81; N, 15.42.

Preparation of 2,2’-di[4,4’-di(2,4,6-trioxa-3,5-diazacyclohexyl)methyl]pyridine (E4).
Into a clear trifluoroacetic acid solution (30 mL) of barbituric acid (0.320 g; 0.0025 mol)
the trifluoroacetic acid solution (5 mL) of 2,2’-bipyridine-4,4’-carboxaldehyde (0.106
mg; 0.0005 mol) was kept at room temperature for three days. Formed white precipitate
was separated by filtration, washed with trifluoroacetic acid (3×1 mL), methanol
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(3×5mL) and dried in vacuum at 90º C for one hour to afford 0.330 g (97%) of pure
product. Product decomposition occurs at temperatures exceeding 290º C. 1H-NMR
(DMSO-d6, 300 MHz) δ 10.32 (8H, s, NH), 8.60 (2H, d, J= 5.4Hz, 6H of pyridine ring),
8.03 (2H, s, 3H of pyridine ring) 7.47 (2H, d, J= 5.4Hz, 5H of pyridine ring), and 6.06
(2H, s, benzyl hydrogen). 13C-NMR (DMSO-d6, 300 MHz) δ 161.4 and 158.6 (two
barbituric acid carbonyls), 147.3, 144.4, 142.4, 121.8, and 118.4 (five pyridine
carbonyls), 84.5 and 29.1 ppm (two aliphatic carbons). MS-ES+ (CH3COOH) m/z 115
(100%), 277 (50%), 387 (45%), 483 (83%), 505 (43%), and 689 (M+1, 70%). Anal.
Calcd. for C28H20N10O12: C, 48.84; H, 2.93; N, 20.34 Found: C, 48.74; H, 2.98; N, 20.22.

Preparation of 2,2’-di[4,4’-di(2,4,6-trioxa-3,5-diaza-3,5dimethylcyclohexyl)methyl]pyridine (E5)
A trifluoroacetic acid (50 mL) solution of 2,2’-bipyridine-4,4’-carboxaldehyde (0.106 g;
0.0005 mmol) and 1,3-dimethylbarbituric acid (0.343 g; 0.0022 mol) was kept at room
temperature for three days. Solvent was evaporated to dryness. Solid material was
crystallized from large amount of methanol to produce pure product in 92% (0.370 mg)
yield. If necessary, further purification can be obtained by crystallization from a small
amount of acetic acid. Product decomposition occurs at temperatures exceeding 167º C.
1

H-NMR (DMSO-d6, 300 MHz) δ 8.60 (2H, d, J= 5.4Hz, 6H of pyridine ring), 8.02 (2H,

s, 3H of pyridine ring) 7.56 (2H, d, J= 5.4Hz, 5H of pyridine ring), 6.37 (2H, s, benzyl
hydrogen), and 3.14 ppm (24H, s, methyl hydrogens). 13C-NMR (DMSO-d6, 300 MHz) δ
159.2 and 159.0 (two different carbonyls of the barbituric acid moiety), 147.8, 143.5,
141.9, 122.0, 118.3 (five carbons of the pyridine moiety), 85.1 (benzyl carbon), 31.7 (C-5
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of the barbituric acid moiety), and 24.5 ppm (methyl carbon). MS-ES+ (CH3COOH) m/z
143 (35%), 277 (50%), 415 (44%), 539 (83%), 661 (33%), 677 (22%), 801 (M+1, 42%).
Anal. Calcd. for C36H36N10O12: C, 54.00; H, 4.53; N, 17.49 Found: C, 53.88; H, 4.61; N,
17.36.

Procedure M.
Preparation of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E7)
Into a hot (110º C) acetic acid (200 mL) solution of barbituric acid (1.28 g; 10 mmol) 3pyridinecarbaldehyde (0.55 g; 0.005 mol) was added. After a few minutes a pink
precipitate starts to form. Resulting suspension was heated at 110°C for 30 minutes and
the formed precipitate was separated by filtration, washed with acetic acid (3×20 mL),
acetone (3×20 mL) and dried at 80˚ C under reduced pressure for several hours. Product
decomposition at temperatures above 250º C. MS-ES+ (in acetic acid) 140 (38%), 209
(43%), 223 (100%), 251 (84%), 283 (26%), and 346 (M+1, 10%). 1H-NMR(DMSO-d6300 MHz Varian Unity) δ 10.21 (4H, s, NH), 8.64 (1H,d, J= 5.7 Hz, pyridine 6-H), 8.43
(1H, s, pyridine 2-H), 8.20 (1H, d, J= 5.7 Hz, pyridine 4-H), 7.89 (1H, d+d, J1= 5.7 Hz,
J2= 5.7 Hz, pyridine 5-H), and 6.13 (1H, s, pyrilidene H).

13

C-NMR (DMSO-d6- 300

MHz Varian Unity) δ 160.9, 147.0 (two different carbonyls), 141.9, 140.8, 136.4, 135.2,
122.7 (five pyridine carbons), 85.5 and 25.9 ppm (two aliphatic carbons). Yield 97%.
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Preparation of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E8)
After 1,3-dimethylbarbituric acid (0.78 g; 5.0 mmol) was dissolved in refluxing methanol
(100 mL) 3-pyridinecarboxaldehyde (0.27 g; 2.5 mmol) was added. After a few minutes
a white precipitate starts to form. The resulting methanol suspension was refluxed for an
additional twenty minutes and the reaction suspension was reduced to a volume of about
30 mL by evaporating methanol at atmospheric pressure. Suspension was cooled to room
temperature. Solid product was separated by filtration, washed with methanol (3×20
mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=92%. 1H-NMR
(DMSO-d6- 300 MHz Varian Unity) δ 8.64 (1H, d, J= 6 Hz, pyridine 6-H), 8.56 (1H, s,
pyridine 2-H), 8.29 (1H, d, J= 6 Hz, pyridine 4-H), 7.88 (1H, d, J1= 7.8 Hz, J2= 8.1 Hz,
pyridine 5-H), 6.337 (1H, s, benzyl H), and 3.13 ppm (12H, s, CH3);

13

C-NMR (DMSO-

d6- 300 MHz Varian Unity) δ 159.0, 147.8 (carbonyl carbons), 141.4, 141.1, 136.6,
135.0, 122.7 (aromatic carbons), 84.6, 29.0 and 24.4 ppm (aliphatic carbons).

Preparation of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E9)
After 1-methylbarbituric acid (0.71 g; 0.005 mol) was dissolved in refluxing methanol
(100 mL) 3-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added. After a few
minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
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methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=97%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.55 (2H, s, NH), 8.65 (1H, d, J= 5.7

Hz, pyridine 6-H), 8.49 (1H, s, pyridine 2-H), 8.24 (1H, d, J= 7.8 Hz, pyridine 4-H), 7.90
(1H,d+d, J1= 8.4 Hz, J2= 8.4 Hz, pyridine 5-H), 6.25 (1H, s, benzyl), and 3.08 (6H, s,
CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.8, 158.7, 147.3 (carbonyls

carbons), 141.7, 141.1, 136.3, 135.0, 122.8 (aromatic carbons), 85.5, 25.7, 23.4 ppm
(aliphatic carbon).

Preparation of 1-butyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E10)
Acetic acid solution (300 mL) of 1-butylbarbituric acid (920 mg; 5 mmol) and 3pyridinecarbaldehyde (255 mg; 2.5 mmol) was refluxed for four hours. Almost
immediately, a dark solution was formed. Solvent was evaporated to gummy residue.
This residue was dissolved in refluxing methanol (200 mL). The methanol solution was
left at room temperature in a paraffin foil covered beaker with a small opening for solvent
evaporation. After seven days at room temperature, the volume of the mixture was
reduced to 50 mL and an orange precipitate was formed. From the ice-cooled suspension
the solid was separated by filtration, washed with cold methanol (3×30 mL) and dried at
80º C under reduced pressure for five hours. Yield=81%. 1H-NMR (DMSO-d6- 300 MHz
Varian Unity) δ 10.48 (2H, s, NH), 8.46 (1H, d, J= 4.2 Hz, pyridine 6-H), 8.33 (1H, s,
pyridine 2-H), 7.79 (1H, d, J= 7.5 Hz), 7.56 (1H, t, J= 5.1 Hz), 6.164 (1H, s, CH), 3.70
(4H, J= 6.6 Hz, NCH2), 1.46 (4H, m, NCH2CH2), 1.24 (4H, m, CH2CH3), and 0.86 ppm
(6H, t, J= 6.6 Hz, CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.9, 158.9,
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147.2 (carbonyl carbons), 140.5, 139.7, 138.5, 135.8, 120.9 (aromatic carbons) 86.0,
27.3, 26.5, 16.1, and 10.1 ppm (aliphatic carbons).

Preparation of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E11)
After 1-phenylbarbituric acid (1.02 g; 0.005 mol) was dissolved in refluxing methanol
(100 mL) 3-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added. After a few
minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=93%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.74 (2H, s, NH), 8.66 (1H, d, J= 6.3

Hz, pyridine 6-H), 8.63 (1H, s, pyridine 2-H), 8.40 (1H, d, J= 8.7 Hz, pyridine 4-H), 7.93
(1H, d+d, J1=7.8 Hz, J2=7.2 Hz, pyridine 5-H), 7.392 (4H, t, J= 0.023, phenyl m-H);
7.319 (2H, t, J= 6.9 Hz, phenyl p-H), 7.19 (4H, d, J= 6.9 Hz, o-H), and 6.23 (1H, s, CH).
13

C-NMR (DMSO-d6- 300 MHz Varian Unity δ 160.8, 159.4, 147.1 (carbonyl carbons),

141.6, 141.3, 136.5, 135.1, 133.2, 125.8, 124.8, 123.8, 121.8 (aromatic carbons), 85.1,
and 27.7 ppm (aliphatic carbons).
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Preparation of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E12)
Into a hot (110º C) acetic acid (200 mL) solution of barbituric acid (1.28 g; 10 mmol) 4pyridinecarbaldehyde (0.55 g; 0.005 mol) was added. After a few minutes a pink
precipitate starts to form. Resulting suspension was heated at 110° C for 30 minutes and
the formed precipitate was separated by filtration, washed with acetic acid (3×20 mL),
acetone (3×20 mL) and dried at 80˚ C under reduced pressure for several hours. Product
decomposition at temperatures above 250º C. Yield=97%. 1H-NMR (DMSO-d6- 300
MHz Varian Unity) δ 10.24 (4H, s, NH), 8.63 (2H, d, J= 6.4Hz, pyridine 2-H), 7.63 (2H,
d, J= 6.9Hz, pyridine 3-H), and 6.18 ppm (1H, s, CH). 13C-NMR (DMSO-d6- 300 MHz
Varian Unity) δ 163.5, 162.3 (carbonyl carbons), 145.5, 121.5, 113.3 (aromatic carbons),
87.3, and 33.5 ppm (aliphatic carbons).

Preparation of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E13)
After 1-methylbarbituric acid (0.71 g; 0.005 mol) was dissolved in refluxing methanol
(100 mL) 4-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added. After a few
minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=98%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.60 (2H, s, NH), 8.64 (2H, d, J= 6.6
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Hz, pyridine 2-H), 7.69 (2H, d, J= 5.7 Hz, pyridine 3H), 6.32 (1H, s, CH), and 3.09 ppm
(6H, s, CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 164.0, 160.9, 158.8

(carbonyl carbons), 147.3, 137.0, 121.6 (aromatic carbons), 85.6, 30.9, 23.5 ppm
(aliphatic carbon).

Preparation of 1-butyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E14)
Acetic acid solution (300 mL) of 1-butylbarbituric acid (920 mg; 5 mmol) and 4pyridinecarbaldehyde (255 mg; 2.5 mmol) was refluxed for four hours. Almost
immediately, a dark solution was formed. Solvent was evaporated to gummy residue.
This residue was dissolved in refluxing methanol (200 mL). The methanol solution was
left at room temperature in a paraffin foil covered beaker with a small opening for solvent
evaporation. After seven days at room temperature, the volume of the mixture was
reduced to 50 mL and an orange precipitate was formed. From the ice-cooled suspension
the solid was separated by filtration, washed with cold methanol (3×30 mL) and dried at
80º C under reduced pressure for five hours. Yield=92%. 1H-NMR (DMSO-d6- 300
MHz Varian Unity) δ 10.54 (2H, s, NH), 8.64 (2H, d, J= 6.9 Hz, pyridine 4-H), 7.63 (2H,
d, J= 6.3 Hz, pyridine 3-H), 6.32 (1H, s), 3.70 (4H, t, J= 6.6 Hz), 1.46 (4H, m), 1.28 (4H,
m), and 0.87 ppm (6H, t, J= 6.6 Hz, CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian

Unity) δ 164.2, 160.7, 158.9 (carbonyl carbons), 147.1, 137.1, 121.5 (aromatic carbons)
85.5, 30.8, 26.5, 16.1, 10.1 ppm (aliphatic carbons).
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Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E15)
After 1-phenylbarbituric acid (g; 0.005 mol) was dissolved in refluxing methanol (100
mL) 4-pyridinecarboxaldehyde (0.27 g; 0.0025 mol) was added. After a few minutes a
white precipitate starts to form. The resulting methanol suspension was refluxed for an
additional twenty minutes and the reaction suspension was reduced to a volume of about
30 mL by evaporating methanol at atmospheric pressure. Suspension was cooled to room
temperature. Solid product was separated by filtration, washed with methanol (3×20
mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=92%. 1H-NMR
(DMSO-d6- 300 MHz Varian Unity) δ 10.74 (2H, s, NH), 8.67 (2H, d, J= 6.9 Hz,
pyridine 2-H), 7.84 (2H, d, J= 6.9 Hz, pyridine 3-H), 7.40 (4H, t, J= 6.9 Hz, phenyl mH), 7.32 (2H, t, J= 6.9 Hz, phenyl p-H), 7.19 (4H, d, J= 6.9 Hz, o-H), 6.27 ppm (1H, s,
CH).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 163.7, 160.7, 159.4 (carbonyl

carbon), 147.0, 137.1, 133.2, 125.9, 124.8, 123.8, 121.7 (aromatic carbon), 85.5, 30.8
ppm.

Synthesis of 3,dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E16)
After 1,3-dimethylbarbituric acid (0.78 g; 0.005 mol) was dissolved in refluxing
methanol (100 mL) 3-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added. After a
few minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
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was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=86%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 9.02 (1H, s, quinoline 2-H), 8.80 (1H,

s,q-2-H), 8.30 (2H, d, J= 8.1 Hz, q-8-H), 8.19 (1H, d, J= 6.0 Hz, q-5-H), 8.02 (1H, t. J=
8.1 Hz, q-7-H), 7.86 (1H, t, J= 7.2 Hz, q-6-H), 6.43 (1H, s, CH)), and 3.15 ppm (12H, s,
CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 159.1, 147.9, 142.4, 138.7,

135.7, 132.8, 129.3, 125.6, 125.2, 124.7, 123.9, 117.3 (two carbonyl and nine aromatic
carbons), 84.5, 29.4, and 24.5 ppm (aliphatic carbon).

Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E17)
After 1-phenylbarbituric acid (1.02 g; 0.005 mol) was dissolved in refluxing methanol
(100 mL) 3-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added. After a few
minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=93%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.78 (2H, s, NH), 9.05 (1H, s, q-2-H),

8.93 (1H, s, q-4-H), 8.36 (1H, d, J= 6.3 Hz, q-8-H), 8.20 (1H, d, J= 6.3 Hz, q-5-H), 8.00
(1H, t, J= 5.4 Hz, q-7-H), 7.88 (1H, t, J= 5.7 Hz, q-6-H), 7.39 (4H, t, J= 5.7, phenyl mH), 7.31 (2H, t, J= 5.7 Hz, phenyl p-H), 7.24 (4H, d, J= 5.7 Hz, phenyl o-H), and 6.34
ppm (1H, s, CH).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.0, 160.9, 159.6
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(carbonyl carbons), 147.2, 142.1, 139.1, 135.8, 133.2, 132.6, 129.6, 125.9, 125.3, 124.8,
124.7, 123.9 117.2 (aromatic carbons), 84.8, and 28.3 ppm (aliphatic carbons).

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E18)
After 1,3-dimethylbarbituric acid (0.78 g; 0.005 mol) was dissolved in refluxing
methanol (100 mL) 4-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added. After a
few minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=84%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 9.07, d, J= 5.7 Hz, q-2-H), 8.39 (1H, d,

J= 8.7 Hz, q-8-H), 8.16 (1H, d, J= 7.8 Hz, q-5-H), 8.03 (1H, t, J= 6.3 Hz, q-C-7), 7.92
(1H, d, J= 5.7 Hz, q-3-H), 7.84 (1H, t, J= 7.8 Hz, q-6-H), 6.97 (1H, s, CH), 3.69 (1H, s,
CH), and 3.13 ppm (12H, s, CH3).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity)

δ 160.5, 159.2 (carbonyl carbons), 147.6, 139.9, 133.8, 130.0, 125.6, 123.6, 121.7, 117.9
(aromatic carbons), 85.9, 30.3, and 24.5 ppm (aliphatic carbons).

Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E19)
After 1-methylbarbituric acid (0.71 g; 0.005 mol) was dissolved in refluxing methanol
(100 mL) 4-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added. After a few

197

minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=78%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.63 (2H, s, NH), 9.06 (1H, d, J= 5.4

Hz, q-2-H), 8.42 (1H, d, J= 6.0 Hz, q-8-H), 8.14 (1H, d, J= 8.7 Hz, q-5-H), 8.00 (1H, t,
J= 8.1 Hz, q-7-H), 7.83 (1H, d, J= 5.7 Hz, q-3-H), 7.83 (1H, t, J= 8.7 Hz, q-6-H), 6.87
(1H, s, CH), and 3.061 ppm (6H, s, CH3). 13C-NMR (DMSO-d6- 300 MHz Varian
Unity) δ 160.7, 160.2, 159.2 (carbonyl carbons), 147.141, 140.171, 134.257, 129.778,
125.343, 123.616, 121.788, 118.263, 117.7 (aromatic carbons), 86.5, 29.1, and 23.5 ppm
(aliphatic carbon).

Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione (E20)
After 1-phenylbarbituric acid (1.03 g; 0.005 mol) was dissolved in refluxing methanol
(100 mL) 4-quinolinecarboxaldehyde (0.378 g; 0.0025 mol) was added. After a few
minutes a white precipitate starts to form. The resulting methanol suspension was
refluxed for an additional twenty minutes and the reaction suspension was reduced to a
volume of about 30 mL by evaporating methanol at atmospheric pressure. Suspension
was cooled to room temperature. Solid product was separated by filtration, washed with
methanol (3×20 mL), ether (3×50 mL) and dried at 110º C for 30 minutes. Yield=95%.
1

H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.83 (2H, s, NH), 912 (1H, d, J= 5.7
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Hz, q-2-H), 8.49 (1H, d, J= 8.7 Hz, q-8-H), 8.17 (1H, d, J= 8.1 Hz, q-5-H), 8.05 (1H, t,
J= 7.2 Hz, q-7-H), 7.98 (1H, d, J= 5.7 Hz, q-3-H), 7.90 (1H, t, J= 8.4 Hz, q-6-H), 7.39
(4H, t, J= 7.5 Hz, phenyl m-H), 7.32 (2H, t, J= 6.0 Hz, phenyl p-H), 7.14 (4H, d, J= 7.5
Hz, phenyl o-H), and 6.87 ppm (1H,s CH).

13

C-NMR (DMSO-d6- 300 MHz Varian

Unity) δ 160.8, 160.5, 159.9 (carbonyl carbons), 146.9, 140.0, 133.9, 133.0, 130.2, 125.7,
125.6, 124.9, 123.9, 123.7, 121.8, 118.0, 117.8 (aromatic carbons), 86.2, and 29.2 ppm.

Preparation of Pyridinium-barbiturate Zwitterion (F1). A methanol solution (100 mL)
of 1,3-dimethylbarbituric acid (1.56 g; 10 mmol) and 2-pyridinecarbaldehyde (1.1 g; 10
mmol) was refluxed for 45 min. The solution was then transferred to an open 300 mL
beaker and left to stand at room temperature until the solvent evaporated to
approximately 1/10 of its original volume. The product slowly crystallized from the
methanol solution during the course of evaporation. Crystals were separated by filtration,
washed with cold methanol (3×20 mL) and then ether (3×20 mL), and dried at room
temperature to give 2.1 g (80%) of product. If necessary, further purification should be
repeated by dissolving the product in a larger amount of methanol (~100 mL) and by
leaving it at room temperature in open air to crystallize from the reduced volume (1/10)
of the solvent. Rf = 0.505 in 1:1 CH3OH-CH3COOH. 1H NMR (DMSO-d6- 300 MHz
Varian Unity) 9.00 (1H, d, J = 6.6 Hz, pyridinium 6-H), 8.41 (1H, t, J =7.8 Hz,
pyridinium 5-H), 8.34 (1H, d, J = 5.1 Hz, pyridine 6-H), 7.90 (1H, t, J = 6.3 Hz,
pyridinium, 4-H), 7.85 (1H, t, J = 7.8 Hz, pyridine 5-H), 7.71 (1H, d, J = 6.9 Hz,
pyridinium 3-H), 7.61 (1H, d, J = 8.4 Hz, pyridine 3-H), 7.36 (1H, d + d, J1 = 7.2 Hz, J2 =
7.8 Hz, pyridine 4-H), 6.94 (1H, s, pyridinium), 5.82 (1H, s, pyridinebenzyl), 2.99 (6H,
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1H, CH3), 2.90 (3H, s, CH3), and 2.83 (3H, s, CH3);

13

C NMR (DMSO-d6- 300 MHz

Varian Unity) 162.9, 161.2, 158.5, 154.3, 150.2, 148.9, 147.5, 145.0, 141.8, 141.2,
135.9, 132.9, 122.0, 121.8, 121.1, 120.1 (six signals for carbonyl carbons and 10 signals
for two pyridine rings), 70.8, 59.0, and 51.1 (signals for carbons from a five-membered
ring), 25.4, 25.1, and 23.3 (three different CH3 carbons); MS-ES (CH3OH-CH3COOHNaCl), 491 (M + 1), 492 (M + 2), and (M + 22). Anal. Calcd. For C24H22N6O6: C, 58.77;
H, 4.52; N, 17.13. Found: C, 58.71; H, 4.63; N 17.03.
Preparation of 5,5'-(2-Pyrimidine)bis(1,3-dimethyl-barbituric acid) (F3). A carbon
tetrachloride solution (500 mL) of 1,3-dimethylbarbituric acid (780 mg; 5 mM) and 2pyridinecarbaldehyde (270 mg; 2.5 mM) was stirred at room temperature for 7 days. The
yellow precipitate was separated by filtration, washed with carbon tetrachloride (3×50
mL) and then ether (3×50 mL), and dried in air to afford 650 mg (65%) of product: Rf =
0.640 in 1:1 CH3COOH-CH3OH. 1H NMR (DMSO-d6- 300 MHz Varian Unity) 8.58
(1H, d, J = 6.0 Hz, pyridine 6-H), 8.40 (1H, t, J = 6.6 Hz, pyridine 5-H), 7.87 (1H, d, J
=8.1 Hz, pyridine 3-H), 7.81 (1H, t, J =6.6 Hz, pyridine 4-H), 6.33 (1H, s, benzyl
hydrogen), and 3.13 (12H, s, four methyl group hydrogens);

13

C NMR (DMSO-d6- 300

MHz Varian Unity) 159.3 and 156.0 (two different barbituric acid carbonyls), 147.8,
142.3, 137.6, 122.3, and 120.5 (five carbons from the pyridine ring), 80.5 (benzylic
carbon), 32.0 (barbituric acid 5-carbon), 24.5 (barbituric methyl carbon). ES-MS
(CH3OH + NaCl) 424 (M + Na). Anal. Calcd. For C18H19N5O6: C, 53.86; H, 4.77; N,
17.45. Found: C, 53.68; H, 4.85; N 17.32.
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Preparation of Amide F6. Sodium hydroxide (80 mg; 2 mM) in water (1 mL) and
compound F1 (245 mg; 0.5 mmol) was kept at room temperature for 4 h with occasional
stirring. In the beginning, the reaction mixture was a suspension that became a clear
solution after ~10 min. Progress of the reaction was followed by TLC chromatography
and 1H NMR spectroscopy (D2O as a solvent). After approximately 2 h, zwitterion F1
was fully converted into amide F6. The Rf of the soluble product in ethanol is 0.295 in
1:1 CH3COOH-CH3OH. Into the water solution was added ethanol (200 mL), and the
solution was dried over anhydrous calcium chloride. The solid was separated by
filtration, and ethanol was evaporated in vacuo at room temperature. The oily residue
was slurried in anhydrous 1:1 alcohol-benzene, and the solvent was again evaporated.
This procedure was repeated several times. The solid residue left after evaporation of the
solvent was slurried in dry ether, filtered, and dried in a vacuum to give 198 mg (85%) of
amide. 1H NMR (D2O-KOH -300 MHz Varian Unity) 8.45 (1H, d-d, J = 6.0 Hz, J2 =
0.1.2 Hz), 8.21 (1H, t, J = 7.2 Hz), 7.84 (1H, t-d, J1 = 7.2 Hz, J2 = 1.2 Hz), 7.64 (1H, t, J
= 6.6 Hz), 7.60 (1H, d-d, J1 = 7.2 Hz, J2 = 1.2 Hz), 7.53 (1H, d-d, J1 = 7.2 Hz, J2 = 1.2
Hz), 7.49 (1H, t, J = 7.8 Hz), 7.38 (1H, d-d-d, J1 = 7.2 Hz, J2 = 6.0 Hz, J3 = 1.2 Hz), 3.04
(6H, s), and 2.46 (6H, s). 13C NMR (D2O-KOH -300 MHz Varian Unity) 171.7, 170.4,
163.8, 157.4, 120.8, 120.7, 120, 0, 118.6, 85.7, 53.1, 43.6, 23.2, and 21.9; MS-ES
(CH3OH-H2O-KOH), 502 (M + 38).
X-ray Single-Crystal Structure Determination of Compound F1 at 155(2) K. Crystal
Data: C24H22N6O6, Mr = 490.48, monoclinic, space group P21/n, a = 11.6777(6) Å, b =
13.4416(7) Å, c = 15.0367(8) Å, = 90 , = 111.630(1) , = 90 , V = 2194.1(2) Å3, Z =
4,

Calcd.

1.485 Mg/m3, F000 = 1024, wavelength ( ) = 0.71073 Å, absorption coefficient
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( ) = 0.110 mm-1. Data Collection and Reduction: crystal size = 0.4×0.5×0.6 mm; theta
range, 2.10-30.00 ; index ranges, -16 h 16, -18 k 18, -21 l 20; reflections
collected, 30679; independent reflections, 6390 [Rint = 0.0284]; refinement method, fullmatrix least-squares on F2; data/restraints/parameters, 6390/0/413; final R indices [I > 2
(I)]: R1 = 0.0370, wR2 = 0.1041, GOF on F2 = 1.035. R indices (all data) R1 = 0.0486,
wR2 = 0.1067; largest difference peak and hole: 0.388 and -0.241 eÅ-3. Measurement,
Computing, and Graphics: SMART 1K CDD (Bruker, 2000); cell refinement, SMART;
data reduction, SAINT-Plus (Bruker, 2000); programs(s) used to solve structure,
SHELXS97 (Sheldrick, 1997); program(s) used to refine structure, SHELX97 (Sheldrick,
1997); molecular graphics, SHELXTL97 (Sheldrick, 1997); software used to prepare
material for publication, SHELXTL97.
General Procedure N: Preparation of bis-barbiturate ammonium salts
Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3-yl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione piperidinium salt (G1)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) barbituric acid (0.256 g, 2.00
mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol (100 mL) was
refluxed for approximately 12 h. The reaction mixture was cooled to room temperature
and the volume of methanol reduced to ¼ its original volume, and diluted with anhydrous
ethyl ether (100 mL). The resulting solid precipitate was filtered, washed with ether (3 x
15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.400 g (93%) pure product.
Product decomposes at temperatures above 250º C. 1H-NMR (DMSO-d6- 300 MHz
Varian Unity) δ 10.09 (s, 4H), 8.21 (d, 1H, J= 4.8 Hz), 8.17 (d, 1H, J= 2.1 Hz), 7.34 (d,
1H, J= 7.5 Hz), 7.15 (m, 1H), 5.98 (s, 1H), 2.98 (t, 4H, J= 5.4 Hz), 1.60 (m, 4H), 1.51
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(m, 2H). 13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.9, 147.0, 144.7, 142.0,
136.4, 130.6, 119.1, 86.7, 40.3, 25.1, 18.7, 18.1 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione morpholinium salt (G2)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) barbituric acid (0.256 g,
2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol (100 mL)
was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.420 g (97%)
pure product. Product decomposes at temperatures above 250º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.11 (s, 4H), 8.29 (d, 2H, J= 5.1 Hz), 6.98 (d, 2H, J= 5.1
Hz), 5.93 (s, 1H), 3.72 (t, 4H, J= 4.7 Hz), 3.07 (t, 4H, J= 5.1 Hz).

13

C-NMR (DMSO-d6-

300 MHz Varian Unity) δ 161.3, 150.9, 147.1, 145.0, 118.8, 86.4, 59.8, 39.5, 27.0.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione ethanolaminium salt (G3)
A suspension of ethanolamine (0.090 mL, 0.092 g, 1.50 mmol) barbituric acid (0.256 g,
2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol (100 mL)
was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
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with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.420 g (92%)
pure product. Product decomposes at temperatures above 250º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.08 (s, 4H), 8.66 (d, 1H, J= 4.8 Hz), 8.14 (d, 1H, J= 7.8
Hz), 7.91 (d, 1H, J= 8.1 Hz), 7.60 (t, 1H, J= 8.1 Hz), 7.42 (t, 1H, J= 7.2 Hz), 7.28 (d,
1H, J= 4.5 Hz), 6.48 (s, 1H), 3.54 (t, 2H, J= 5.0 Hz), 2.83 (t, 2H, J= 5.3 Hz).

13

C-NMR

(DMSO-d6- 300 MHz Varian Unity) δ 161.1, 147.7, 146.9, 145.7, 144.1, 125.6, 124.6,
123.8, 121.9, 121.3, 117.0, 87.2, 53.8, 37.6, 25.6.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G4)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) barbituric acid (0.256 g,
2.00 mmol), and 3-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol (100 mL)
was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.396 g (82%)
pure product. Product decomposes at temperatures above 250º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.09 (s, 4H), 8.52 (d, 1H, J= 2.1 Hz), 7.88 (d of d, 2H), 7.78
(s, 1H), 7.60 (t, 1H, J= 8.1 Hz), 7.48 (t, 1H, J= 8.1 Hz), 6.17 (s, 1H), 3.73 (t, 4H, J= 5.1
Hz), 3.09 (t, 4H, J= 5.1 Hz).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.1,

148.1, 147.7, 147.1, 142.1, 134.0, 128.1, 124.7, 124.4, 124.0, 122.6, 86.7, 59.8, 39.5,
25.6.
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Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2nitrobenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G5)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) barbituric acid (0.256 g,
2.00 mmol), and 2-nitrobenzaldehyde (0.151 g, 1.00 mmol) in methanol (100 mL) was
refluxed for approximately 12 h. The reaction mixture was cooled to room temperature
and the volume of methanol reduced to ¼ its original volume, and diluted with anhydrous
ethyl ether (100 mL). The resulting solid precipitate was filtered, washed with ether
(3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.439 g (92%) pure product.
Product decomposes at temperatures above 250º C. 1H-NMR (DMSO-d6- 300 MHz
Varian Unity) δ 10.00 (s. 4H), 7.43 (t, 2H, J= 8.3 Hz), 7.24 (m, 2H), 6.08 (s, 1H), 3.75
(t, 4H, J= 4.8 Hz), 3.09 (t, 4H, J= 4.8 Hz). 13C-NMR (DMSO-d6- 300 MHz Varian
Unity) δ 160.7, 147.1, 146.4, 134.1, 126.9, 126.0, 122.3, 119.6, 86.5, 59.8, 39.4, 25.2
ppm.

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G6)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1,3-dimethylbarbituric acid
(0.312 g, 2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.520 g (97%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6-
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300 MHz Varian Unity) δ 8.65 (d, 1H, J= 4.5 Hz), 8.21 (s, 2H), 8.03 (d, 1H, J= 7.5 Hz),
7.90 (d, 1H, J= 7.5 Hz), 7.59 (t, 1H, J= 8.3 Hz), 7.42 (t, 1H, J= 8.3 Hz), 7.32 (d, 1H, J=
3.9 Hz), 6.73 (s, 1H), 3.11 (s, 12H), 2.98 (t, 4H, J= 5.7 Hz), 1.61 (m, 4H), 1.53 (m, 2H).
13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 159.0, 147.6, 146.8, 145.9, 144.3,

125.8, 124.5, 123.7, 122.0, 121.0, 117.2, 87.0, 40.2, 28.4, 24.0, 18.6, 18.0

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G7)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1,3-dimethylbarbituric acid
(0.312 g, 2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.454 g (93%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 8.34 (d, 2H, J= 6.0 Hz), 7.14 (d, 2H, J= 6.0 Hz), 3.73 (t, 4H,
J= 4.5 Hz), 3.12 (s, 12H), 3.08 (t, 4H, J= 4.5 Hz).

13

C-NMR (DMSO-d6- 300 MHz

Varian Unity) δ 158.9, 153.4, 147.7, 143.2, 119.4, 86.2, 59.7, 39.4, 30.2, 24.4 ppm.
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Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G8)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1,3-dimethylbarbituric acid
(0.312 g, 2.00 mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.462 g (95%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 8.25 (s, 2H), 8.22 (d, 1H, J= 4.8 Hz), 8.19 (d, 1H, J= 2.1 Hz),
7.37 (d, 1H, J= 7.8 Hz), 7.14 (m, 1H), 3.13 (s, 12H), 3.00 (t, 4H, J= 5.7 Hz), 1.62(m,
4H), 1.53 (m, 2H). 13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 159.0, 147.7, 144.8,
142.0, 135.7, 130.7, 119.1, 86.5, 40.3, 28.0, 24.4, 18.6, 18.0 ppm.

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G9)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1,3-dimethylbarbituric acid
(0.312 g, 2.00 mmol), and 3-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.440 g (82%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6-
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300 MHz Varian Unity) δ 8.54 (d, 1H, J= 2.1 Hz), 8.21 (s, 2H), 7.87 (t, 3H, J= 9.3 Hz),
7.60 (t, 1H, J= 6.9 Hz), 7.48 (t, 1H, J= 6.9 Hz), 6.40 (s, 1H), 3.15 (s, 12H), 3.00 (t, 4H,
J= 5.7 Hz), 1.62 (m, 4H), 1.54 (m, 2H).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity)

δ 159.2, 148.0, 147.9, 142.3, 133.8, 128.4, 124.8, 124.5, 124.3, 122.7, 86.7, 40.4, 28.6,
24.6, 18.8, and 18.2 ppm.

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3nitrobenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G10)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1,3-dimethylbarbituric acid
(0.312 g, 2.00 mmol), and 3-nitrobenzaldehyde (0.151 g, 1.00 mmol) in methanol (100
mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.447 g (84%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 8.67 (s, 2H), 7.94 (d, 1H, J= 7.8 Hz), 7.82 (s, 1H), 7.48 (m,
2H), 6.32 (s, 1H), 3.77 (t, 4H, J= 5.1 Hz), 3.12 (t, 4H, J= 5.1 Hz).

13

C-NMR (DMSO-d6,

300 MHz) δ 159.1, 147.8, 144.1, 123.6, 130.3, 125.4, 117.5, 116.3, 86.5, 59.7, 39.4,
30.1, and 24.4 ppm

208

Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione ethanolaminium salt (G11)
A suspension of ethanolamine (0.090 mL, 0.092 g, 1.50 mmol) 1-methylbarbituric acid
(0.284 g, 2.00 mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.378 g (87%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.40 (s, 2H), 8.22 (d, 1H, J= 4.5 Hz), 8.19 (s, 1H), 7.37 (d,
1H, J= 8.1 Hz), 7.16 (m, 1H), 6.10 (s, 1H), 3.56 (t, 2H, J= 5.4 Hz), 3.08 (s, 6H), 2.80 (t,
2H, J= 5.4 Hz). 13C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.9, 158.0, 147.3,
144.7, 142.0, 136.2, 130.6, 119.0, 86.6, 54.5, 37.9, 26.8, and 23.3 ppm.

Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G12)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-methylbarbituric acid
(0.284 g, 2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.399 g (87%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6-
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300 MHz Varian Unity) δ 10.30 (s, 2H), 8.27 (d, 2H, J= 6.0 Hz), 6.96 (d, 2H, J= 6.0
Hz), 6.07 (s, 1H), 3.06 (s, 6H), 2.99 (t, 4H, J= 5.7 Hz), 1.61 (m, 4H), 1.54 (m, 2H). 13CNMR (DMSO-d6- 300 MHz Varian Unity) δ 160.4, 159.0, 150.1, 146.8, 144.6, 118.2,
85.9, 39.8, 28.3, 22.9, 18.2, and 17.6 ppm.

Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G13) A suspension of
piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-methylbarbituric acid (0.284 g, 2.00 mmol),
and 3-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol (100 mL) was refluxed
for approximately 12 h. The reaction mixture was cooled to room temperature and the
volume of methanol reduced to ¼ its original volume, and diluted with anhydrous ethyl
ether (100 mL). The resulting solid precipitate was filtered, washed with ether (3×15
mL), and oven dried at 110º C for 2-3 hours, yielding 0.351 g (69%) pure product.
Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6- 300 MHz
Varian Unity) δ 10.41 (s, 2H), 8.53 (d, 1H, J= 2.1 Hz), 8.40 (s, 2H), 7.87 (m, 3H), 7.99
(s, 1H), 7.59 (t, 1H, J= 6.9 Hz), 7.47 (t, 1H, J= 6.9 Hz), 6.28 (s, 1H), 3.09 (s, 6H), 2.98
(t, 4H, J= 5.1), 1.59 (m, 4H), 1.52 (m, 2H). 13C-NMR (DMSO-d6- 300 MHz Varian
Unity) δ 161.0, 158.8, 158.3, 147.7, 147.3, 142.0, 133.9, 128.0, 124.6, 124.3, 124.0,
122.5, 86.6, 40.3, 27.3, 23.4, 18.7, and 18.1 ppm.

210

Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G14)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1-methylbarbituric acid
(0.284 g, 2.00 mmol), and 4-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.410 g (89%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.40 (s, 2H), 8.31 (d, 2H, J= 6.0 Hz), 7.04 (d, 2H, J= 6.0
Hz), 6.10 (s, 1H), 3.74 (t, 4H, J= 5.7 Hz), 3.10 (t, 4H, J= 5.7 Hz), 3.07 (s, 6H). 13C-NMR
(DMSO-d6- 300 MHz Varian Unity) δ 160.9, 151.9, 147.3, 144.3, 119.0, 86.3, 59.7, 39.4,
28.9, 23.3 ppm.

Synthesis of 1-methyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G15)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-methylbarbituric acid
(0.284 g, 2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.478 g (94%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6-
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300 MHz Varian Unity) δ 8.67 (d, 1H, J= 3.3 Hz), 8.10 (d, 1H, J= 6.0 Hz), 7.92 (d, 1H,
J= 6.0 Hz), 7.60 (t, 1H, J= 5.7 Hz), 7.43 (t, 1H, J= 5.7 Hz), 7.30 (d, 1H, J= 3.3 Hz), 6.62
(s, 1H), 2.98 (t, 4H, J= 3.3 Hz), 1.60 (m, 4H), 1.51(m, 2H). 13C-NMR (DMSO-d6- 300
MHz Varian Unity) δ 160.9, 159.2, 147.3, 146.0, 144.4, 125.9, 124.7, 123.9, 122.0,
121.3, 117.2, 87.4, 40.3, 27.3, 23.4, 18.7, 18.1 ppm.

Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione piperidinium salt (G16)
A suspension of piperidine (0.148 mL, 0.128 g, 1.50 mmol) 1-phenylbarbituric acid
(0.408 g, 2.00 mmol), and 4-quinolinecarboxaldehyde (0.159 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.601 g (95%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.56 (s, 2H), 8.71 (d, 1H, J= 4.8 Hz), 8.20 (s, 2H), 8.14 (d,
1H, J= 8.4 Hz), 7.93 (d, 1H, J= 8.4 Hz), 7.62 (t, 1H, J= 7.5 Hz), 7.48 (t, 1H, J= 7.5 Hz),
7.40 (t, 4H, J= 5.1 Hz), 7.29 (m, 3H), 7.11 (d, 4H, J= 7.5 Hz), 6.59 (s, 1H), 2.95 (t, 4H,
J= 5.1 Hz), 1.58 (m, 4H), 1.51 (m, 2H).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity)

δ 160.6, 159.6, 147.0, 146.8, 145.9, 144.3, 133.2, 125.8, 125.7, 124.7, 124.6, 123.8,
123.6, 121.9, 121.1, 117.1, 87.1, 40.2, 27.2, 18.6, 18.0 ppm.
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Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-3yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G17)
A suspension of morpholine (0.130 mL, 0.130 g, 1.50 mmol) 1-phenylbarbituric acid
(0.408 g, 2.00 mmol), and 3-pyridinecarboxaldehyde (0.107 g, 1.00 mmol) in methanol
(100 mL) was refluxed for approximately 12 h. The reaction mixture was cooled to room
temperature and the volume of methanol reduced to ¼ its original volume, and diluted
with anhydrous ethyl ether (100 mL). The resulting solid precipitate was filtered, washed
with ether (3×15 mL), and oven dried at 110º C for 2-3 hours, yielding 0.520 g (89%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.60 (s, 2H), 8.36 (s, 1H), 8.30 (d, 1H, J= 3.3 Hz), 7.59 (d,
1H, J= 5.7 Hz), 7.39 (t, 4H, J= 5.7 Hz), 7.29 (m, 3H), 7.18 (d, 4H, J= 5.7 Hz), 6.10 (s,
1H), 3.68 (t, 4H, J= 3.6 Hz), 3.02 (t, 4H, J= 3.6 Hz).

13

C-NMR (DMSO-d6- 300 MHz

Varian Unity) δ 160.9, 159.0, 147.0, 144.3, 141.7, 136.4, 133.4, 131.6, 125.8, 124.7,
123.7, 119.5, 87.7, 59.7, 39.4, 27.0 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4methylbenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G18)
Into 50 mL of methanol, 4-tolualdehyde (0.121 g; 1.00 mmol), barbituric acid (0.256 g;
2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and stirred. The
resulting reaction suspension was refluxed overnight. The reaction mixture was cooled to
room temperature and the volume reduced to ¼ the original volume, resulting in the
formation of a precipitate. The precipitate was removed by filtration and washed with
ether (3×20 mL). Solid was oven dried at 105º C for 3 hours, to afford 0.424 g (95%)
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pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.22 (s, 4H), 6.89 (m, 4H), 5.89 (s, 1H), 3.71 (t, 4H, J= 4.8
Hz), 3.04 (t, 4H, J= 4.8 Hz), 2.19 (s, 3H).

13

C-NMR (DMSO-d6- 300 MHz Varian

Unity) δ 161.9, 147.2, 137.7, 129.6, 124.5, 123.0, 87.7, 59.9, 39.6, 26.6, 16.9 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3methylbenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G19)
Into 50 mL of methanol, 3-tolualdehyde (0.121 g; 1.00 mmol), barbituric acid (0.256 g;
2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and stirred. The
resulting reaction suspension was refluxed overnight. The reaction mixture was cooled to
room temperature and the volume reduced to ¼ the original volume, resulting in the
formation of a precipitate. The precipitate was removed by filtration and washed with
ether (3×20 mL). Solid was oven dried at 105º C for 3 hours, to afford 0.401 g (90%)
pure product. Product decomposes at temperatures above 200º C. 1H-NMR (DMSO-d6300 MHz Varian Unity) δ 10.12 (s, 4H), 7.02 (t, 1H, J= 7.8 Hz), 6.83 (m, 3H), 5.89 (s,
1H), 3.72 (t, 4H, J= 4.8 Hz), 3.06 (t, 4H, J= 4.8 Hz), 2.19 (s, 3H).

13

C-NMR (DMSO-d6-

300 MHz Varian Unity) δ 162.9, 147.2, 141.0, 132.6, 123.8, 123.7, 121.7, 120.3, 87.6,
60.0, 39.7, 26.8, 17.8 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3methoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G2)
Into 50 mL of methanol, 3-methoxybenzaldehyde (0.136 g; 1.00 mmol), barbituric acid
(0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and
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stirred. The resulting reaction suspension was refluxed overnight. The reaction mixture
was cooled to room temperature and the volume reduced to ¼ the original volume,
resulting in the formation of a precipitate. The precipitate was removed by filtration and
washed with ether (3×20 mL). Solid was oven dried at 105º C for 3 hours, to afford
0.439 g (95%) pure product. Product decomposes at temperatures above 200º C. 1HNMR (DMSO-d6- 300 MHz Varian Unity) δ 10.12 (s, 4H), 7.06 (t, 1H, J= 7.8 Hz), 6.59
(m, 3H), 5.92 (s, 1H), 3.73 (t, 4H, J= 4.9 Hz), 3.65 (s, 3H), 3.10 (t, 4H, J= 5.1 Hz).

13

C-

NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.7, 155.4, 147.1, 143.0, 124.8, 115.8,
109.7, 105.5, 87.4, 59.8, 51.2, 39.5, 27.0 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4(dimethylamino)benzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt
(G21)
Into 50 mL of methanol, 4-(dimethylamino)benzaldehyde (0.149 g; 1.00 mmol),
barbituric acid (0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol)
were added and stirred. The resulting reaction suspension was refluxed overnight. The
reaction mixture was cooled to room temperature and the volume reduced to ¼ the
original volume, resulting in the formation of a precipitate. The precipitate was removed
by filtration and washed with ether (3×20 mL). Solid was oven dried at 105º C for 3
hours, to afford 0.456 g (96%) pure product. Product decomposes at temperatures above
200º C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 6.86 (d, 2H, J= 8.4 Hz), 6.56
(d, 2H, J= 8.7 Hz), 5.84 (s, 1H), 3.73 (t, 4H, J= 4.8 Hz), 3.09 (t, 4H, J= 4.8 Hz), 2.79 (s,
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6H).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 160.0, 147.3, 144.6, 128.6, 123.6,

108.9, 87.9, 59.9, 39.6, 37.1, 26.0 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(naphthyl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione morpholinium salt (G22)
Into 50 mL of methanol, 2-naphthaldehyde (0.158 g; 1.00 mmol), barbituric acid (0.256
g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and stirred.
The resulting reaction suspension was refluxed overnight. The reaction mixture was
cooled to room temperature and the volume reduced to ¼ the original volume, resulting
in the formation of a precipitate. The precipitate was removed by filtration and washed
with ether (3×20 mL). Solid was oven dried at 105º C for 3 hours, to afford 0.458 g
(95%) pure product. Product decomposes at temperatures above 200º C. 1H-NMR
(DMSO-d6- 300 MHz Varian Unity) δ 10.04 (s, 4H), 8.13 (d, 1H, J= 8.1 Hz), 7.78 (d,
1H, J= 8.1 Hz), 7.60 (d, 1H, J= 8.1 Hz), 7.33 (m, 4H), 6.45 (s, 1H), 3.73 (t, 4H, J= 4.8
Hz), 3.08 (t, 4H, J= 4.8 Hz).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.2,

147.0, 137.5, 130.0, 128.4, 124.7, 121.9, 121.8, 121.4, 121.3, 121.2, 121.1, 88.3, 59.8,
39.5, 25.7 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2hydroxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G23)
Into 50 mL of methanol, 2-hydroxybenzaldehyde (0.122 g; 1.00 mmol), barbituric acid
(0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and
stirred. The resulting reaction suspension was refluxed overnight. The reaction mixture
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was cooled to room temperature and the volume reduced to ¼ the original volume,
resulting in the formation of a precipitate. The precipitate was removed by filtration and
washed with ether (3×20 mL). Solid was oven dried at 105º C for 3 hours, to afford
0.403 g (90%) pure product. Product decomposes at temperatures above 200º C. 1HNMR (DMSO-d6- 300 MHz Varian Unity) δ 10.16 (s, 4H), 7.19 (d, 1H, J= 7.8 Hz), 6.88
(t, 1H, J= 7.7 Hz), 6.59 (m, 2H), 5.94 (s, 1H), 3.75 (t, 4H, J= 4.8 Hz), 3.10 (t, 4H, J= 4.8
Hz).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.8, 151.5, 146.9, 126.9, 125.2,

122.3, 114.2, 111.4, 87.1, 59.8, 45.0, 39.6 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4hydroxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G24)
Into 50 mL of methanol, 4-hydroxybenzaldehyde (0.122 g; 1.00 mmol), barbituric acid
(0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added and
stirred. The resulting reaction suspension was refluxed overnight. The reaction mixture
was cooled to room temperature and the volume reduced to ¼ the original volume,
resulting in the formation of a precipitate. The precipitate was removed by filtration and
washed with ether (3×20 mL). Solid was oven dried at 105º C for 3 hours, to afford
0.358 g (80%) pure product. Product decomposes at temperatures above 200º C. 1HNMR (DMSO-d6- 300 MHz Varian Unity) δ 10.02 (s, 4H), 6.79 (d, 2H, J= 8.4 Hz), 6.53
(d, 2H, J= 8.4 Hz), 5.82 (s, 1H), 3.72 (t, 4H, J= 4.8 Hz), 3.06 (t, 4H, J= 4.8 Hz).

13

C-

NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.1, 150.7, 147.1, 131.1, 123.9, 110.7,
87.7, 60.0, 39.7, 26.0 ppm.
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Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2,3,4trimethoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G25)
Into 50 mL of methanol, 2,3,4-trimethoxybenzaldehyde (0.198 g; 1.00 mmol), barbituric
acid (0.256 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5 mmol) were added
and stirred. The resulting reaction suspension was refluxed overnight. The reaction
mixture was cooled to room temperature and the volume reduced to ¼ the original
volume, resulting in the formation of a precipitate. The precipitate was removed by
filtration and washed with ether (3×20 mL). Solid was oven dried at 105º C for 3 hours,
to afford 0.501 g (96%) pure product. Product decomposes at temperatures above 200º
C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.00 (s, 4H), 6.78 (d, 1H, J= 9.0
Hz), 6.55 (d, 1H, J= 9.0 Hz), 5.86 (s, 1H), 3.72 (t, 4H, J= 4.8 Hz), 3.69 (s, 3H), 3.65 (s,
3H), 3.52 (s, 3H), 3.08 (t, 4H, J= 4.8 Hz).

13

C-NMR (DMSO-d6- 300 MHz Varian

Unity) δ 160.9, 147.6, 147.3, 147.1, 138.2, 127.1, 119.4, 102.7, 87.5, 59.9, 56.3, 56.2,
52.1, 39.5, 23.3 ppm.

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(2methoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G26)
Into 50 mL of methanol, 2-methoxybenzaldehyde (0.136 g; 1.00 mmol), 1,3dimethylbarbituric acid (0.312 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5
mmol) were added and stirred. The resulting reaction suspension was refluxed overnight.
The reaction mixture was cooled to room temperature and the volume reduced to ¼ the
original volume, resulting in the formation of a precipitate. The precipitate was removed
by filtration and washed with ether (3×20 mL). Solid was oven dried at 105º C for 3
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hours, to afford 0.481 g (93%) pure product. Product decomposes at temperatures above
200º C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 7.15 (d, 1H, J= 7.8 Hz), 7.03 (t,
1H, J= 7.7 Hz), 6.74 (m, 2H), 6.01 (s, 1H), 3.77 (t, 4H, J= 4.7 Hz), 3.57 (s, 3H), 3.16 (t,
4H), 3.12 (s, 12H).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 159.4, 153.6,

148.0, 128.9, 125.6, 122.6, 115.9, 107.3, 86.7, 59.8, 52.0, 39.6, 27.6, 24.3 ppm.

Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(3,4,5trimethoxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione ethanolaminium salt
(G27) Into 50 mL of methanol, 3,4,5-trimethoxybenzaldehyde (0.198 g; 1.00 mmol), 1,3dimethylbarbituric acid (0.312 g; 2.00 mmol), and ethanolamine (0.090 mL; 0.092 g; 1.5
mmol) were added and stirred. The resulting reaction suspension was refluxed overnight.
The reaction mixture was cooled to room temperature and the volume reduced to ¼ the
original volume, resulting in the formation of a precipitate. The precipitate was removed
by filtration and washed with ether (3×20 mL). Solid was oven dried at 105º C for 3
hours, to afford ).513 g (93%) pure product. Product decomposes at temperatures above
200º C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 6.34 (s, 2H), 6.12 (s, 1H), 3.61
(s, 6H), 3.60 (s, 3H), 3.57 (t, 2H, J= 5.5 Hz), 3.15 (s, 12H), 2.87 (t, 2H, J= 5.3 Hz).

13

NMR (DMSO-d6- 300 MHz Varian Unity) δ 158.6, 148.6, 147.9, 136.5, 131.6, 101.1,
87.4, 56.4, 54.0, 52.4, 37.8, 24.5, 23.3 ppm.

C-
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Synthesis of 1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(4hydroxybenzyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G28)
Into 50 mL of methanol, 4-hydroxybenzaldehyde (0.122 g; 1.00 mmol), 1,3dimethylbarbituric acid (0.312 g; 2.00 mmol), and morpholine (0.130 mL; 0.130 g; 1.5
mmol) were added and stirred. The resulting reaction suspension was refluxed overnight.
The reaction mixture was cooled to room temperature and the volume reduced to ¼ the
original volume, resulting in the formation of a precipitate. The precipitate was removed
by filtration and washed with ether (3×20 mL). Solid was oven dried at 105º C for 3
hours, to afford 0.463 g (92%) pure product. 1H-NMR (DMSO-d6- 300 MHz Varian
Unity) δ 6.81 (d, 2H, J= 8.1 Hz), 6.54 (d, 2H, J= 8.4 Hz), 6.08 (s, 1H), 3.74 (t, 4H), 3.15
(t, 4H), 3.11 (s, 12H).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 158.4, 150.9,

147.9, 130.4, 124.0, 111.7, 110.8, 59.9, 39.6, 29.1, 24.4 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(butyl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione morpholinium salt (G29) Into 100 mL methanol barbituric acid
(2.56 g; 0.02 mol), valeraldehyde (1.04 mL; 0.840 g; 0.01 mol), and morpholine (1.1 mL;
1.00 g, 0.011 mol) were mixed with stirring. The reaction suspension was refluxed
overnight. The volume of the mixture was reduced to 1/5 the original volume (~20 mL)
and was cooled to room temperature. The white solid precipitate was filtered and washed
with ether (3×25 mL). The solid was oven dried at 110 C for 3 hours, affording 3.8 g
(92%) pure product. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 9.86 (s, 4H), 4.46
(t, 1H, J= 8.5 Hz), 3.73 (t, 4H, J= 5.0 Hz), 3.06 (t, 4H, J= 5.0 Hz), 1.65 (m, 2H), 1.18
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(m, 2H), 1.02 (m, 2H).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.1, 147.0,

87.5, 60.2, 39.8, 27.0, 26.6, 22.3, 18.7, 10.6 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(hexyl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione morpholinium salt (G30) Into 100 mL methanol barbituric acid
(2.56 g; 0.02 mol), heptaldehyde (1.39 mL, 1.14 g; 0.01 mol), and morpholine (1.10 mL;
1.00 g, 0.011 mol) were mixed with stirring. The reaction suspension was refluxed
overnight. The volume of the mixture was reduced to 1/5 the original volume (~20 mL)
and cooled to room temperature. The solid precipitate was filtered and washed with ether
(3×25 mL). The solid was oven dried at 110º C for 3 hours, affording 3.30 g (75%) pure
product. Product decomposes at temperatures above 160º C. 1H-NMR (DMSO-d6- 300
MHz Varian Unity) δ 9.84 (s, 4H), 4.46 (t, 1H, J= 8.4 Hz), 3.75 (t, 4H, J= 4.8 Hz), 3.09
(t, 4H, J= 4.8 Hz), 1.64 (m, 2H), 1.22 (m, 2H), 1.17 (m, 4H), 1.03 (m, 2H), 0.82 (t, 3H,
J= 6.6 Hz).

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 151.4, 147.0, 87.6, 59.9,

39.6, 27.9, 27.4, 25.2, 24.2, 22.4, 18.5, 10.4 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(nonyl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione morpholinium salt (G31) Into 100 mL methanol barbituric acid
(2.56 g; 0.02 mol), decanal (1.88 mL, 1.56 g; 0.01 mol), and morpholine (1.10 mL; 1.00
g, 0.011 mol) were mixed with stirring. The reaction suspension was refluxed overnight.
The volume of the mixture was reduced to 1/5 the original volume (~20 mL) and cooled
to room temperature. The solid precipitate was filtered and washed with ether (3×25
mL). The solid was oven dried at 110º C for 3 hours, affording 4.53 g (94%) pure
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product. Product decomposes at temperatures above 160º C. 1H-NMR (DMSO-d6- 300
MHz Varian Unity) δ 9.90 (s, 4H), 4.44 (t, 1H, J= 8.1 Hz), 3.73 (t, 4H, J= 4.5 Hz), 3.07
(t, 4H, J= 4.5 Hz), 1.63 (m, 2H), 1.19 (m, 12H), 1.03 (m, 2H), 0.82 (t, 3H, J= 6.9 Hz)
ppm.

13

C-NMR (DMSO-d6- 300 MHz Varian Unity) δ 161.5, 147.2, 87.9, 60.2, 39.8,

27.9, 27.4, 25.8, 25.7, 25.6, 25.3, 24.4, 22.5, 18.7, 10.5 ppm.

Synthesis of 5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(heptyl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione piperidinium salt (G32) Into 100 mL methanol barbituric acid
(2.56 g; 0.02 mol), octanal (1.56 mL, 1.28 g; 0.01 mol), and piperidine (1.08 mL; 0.937
g, 0.011 mol) were mixed with stirring. The reaction suspension was refluxed overnight.
The volume of the mixture was reduced to 1/5 the original volume (~20 mL) and cooled
to room temperature. The solid precipitate was filtered and washed with ether (3×25
mL). The solid was oven dried at 110º C for 3 hours, affording 3.70 g (82%) pure
product. Product decomposes at temperatures above 160º C. 1H-NMR (DMSO-d6- 300
MHz Varian Unity) δ 9.85 (s, 4H), 4.46 (t, 1H, J= 8.1 Hz), 3.00 (t, 4H, J= 5.6 Hz), 1.64
(m, 4H), 1.55 (m, 2H), 1.17 (m, 10H), 1.03 (m, 2H), 0.83 (t, 3H, J= 6.8 Hz).

13

C-NMR

(DMSO-d6- 300 MHz Varian Unity) δ 161.7, 147.2, 87.9, 40.4, 27.8, 27.2, 25.6, 25.3,
24.4, 22.4, 18.7, 18.6, 18.2, 10.4 ppm.

Synthesis of 1-phenyl-5-[(2,4,6-trioxohexahydropyrimidin-5yl)(nonyl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt (G33) Into 50
mL methanol 1-phenylbarbituric acid (0.408 g; 0.002 mol), decanal (0.188 mL, 0.156 g;
0.001 mol), and morpholine (0.110 mL; 0.100 g, 0.0011 mol) were mixed with stirring.
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The reaction suspension was refluxed overnight. The volume of the mixture was reduced
to 1/5 the original volume (~10 mL) and cooled to room temperature. The solid
precipitate was filtered and washed with ether (3×25 mL). The solid was oven dried at
110º C for 3 hours, affording 0.462 g (73%) pure product. Product decomposes at
temperatures above 200º C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 10.36 (s,
2H), 7.37 (t, 4H, J= 7.4 Hz), 7.30 (t, 2H, J= 7.2 Hz), 7.10 (d, 4H, J= 7.2 Hz), 4.52 (t, 1H,
J= 8.1 Hz), 3.69 (t, 4H, J= 4.8 Hz), 3.02 (t, 4H, J= 4.8 Hz), 1.76 (m, 2H), 1.22 (m, 12H),
1.13 (m, 2H), 0.85 (t, 3H, J= 6.6 Hz) ppm.

13

C-NMR (DMSO-d6- 300 MHz Varian

Unity) δ 161.2, 159.2, 147.1, 133.6, 125.9, 124.8, 123.7, 88.2, 59.7, 39.4, 27.9, 27.3,
27.2, 27.0, 25.7, 25.6, 25.3, 24.4, 18.6, 10.5 ppm.

Synthesis of 5-[(2-thio-4,6-dioxohexahydropyrimidin-5-yl)(2nitrobenzyl)methyl]pyrimidine-2-thio-4,6-(1H,3H,5H)-dione piperidinium salt (G34)
Into 100 mL methanol, 4,6-dihydroxy-2-mercaptopyrimidine (2.88 g; 0.02 mol), 2nitrocarboxaldehyde (1.51g; 0.01 mol), and piperidine (1.1 mL; 1.00 g; 0.011 mol) were
mixed while stirring. The reaction suspension was refluxed overnight. The reaction
suspension was cooled to room temperature and the pale yellow solid was filtered and
washed with ether (3×20 mL). The solid was oven dried at 105 C for 3 hours to afford
5.10 g (90%) pure product. Product decomposes at temperatures above 200º C. 1H-NMR
(DMSO-d6- 300 MHz Varian Unity) δ 7.50 (d, 1H, J= 7.5 Hz), 7.43 (t, 1H, J= 7.4 Hz),
7.26 (m, 2H), 6.05 (s, 1H), 2.95 (t, 4H, J= 5.4 Hz), 1.60 (m, 4H), 1.50 (m, 2H).

13

C-

NMR (DMSO-d6- 300 MHz Varian Unity) δ 169.4, 159.2, 146.2, 133.1, 127.4, 126.1,
122.7, 119.8, 90.7, 40.4, 25.7, 18.7, 18.3 ppm.

223

Synthesis of 5-[(2-thio-4,6-dioxohexahydropyrimidin-5-yl)(2, 4, 5trimethoxybenzyl)methyl]pyrimidine-2-thio-4,6-(1H,3H,5H)-dione morpholinium salt
(G35) Into 100 mL methanol, 4,6-dihydroxy-2-mercaptopyrimidine (2.88 g; 0.02 mol),
2,4,5-trimethoxybenzaldehyde (1.98 g; 0.01 mol), and morpholine (1.10 mL; 1.00 g;
0.011 mol) were mixed while stirring. The reaction suspension was refluxed overnight.
The reaction suspension was cooled to room temperature and the pale yellow solid was
filtered and washed with ether (3×20 mL). The solid was oven dried at 105º C for 3
hours to afford 5.04 g (91%) pure product. Product decomposes at temperatures above
200º C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 6.71 (s, 1H), 6.51 (s, 1H), 5.87
(s, 1H), 3.74 (t, 4H), 3.71 (s, 3H), 3.58 (s, 3H), 3.57 (s, 3H), 3.09 (t, 4H).

13

C-NMR

(DMSO-d6- 300 MHz Varian Unity) δ 168.9, 159.2, 148.0, 144.1, 138.0, 120.0, 112.0,
95.6, 92.7, 60.1, 53.6, 52.9, 52.2, 39.7, 23.1 ppm.

Synthesis of 5-[(2-thio-4,6-dioxohexahydropyrimidin-5-yl)(4(dimethylamino)benzyl)methyl]pyrimidine-2-thio-4,6-(1H,3H,5H)-dione lysine salt
(G36) Into 100 mL methanol, 4,6-dihydroxy-2-mercaptopyrimidine (2.88 g; 0.02 mol),
4-dimethylaminobenzaldehyde (1.49 g; 0.01 mol), and lysine monohydrate (1.80 g. 0.011
mol) were mixed while stirring. The reaction suspension was refluxed overnight. The
reaction suspension was cooled to room temperature and the pale yellow solid was
filtered and washed with ether (3×20 mL). The solid was oven dried at 105º C for 3
hours to afford 3.77 g (90%) pure product. Product decomposes at temperatures above
200º C. 1H-NMR (DMSO-d6- 300 MHz Varian Unity) δ 6.79 (d, 2H, J= 8.4 Hz), 6.55
(d, 2H, J= 9.0 Hz), 5.85 (s, 1H), 3.35 (t, 1H, J= 5.9 Hz), 2.78 (s, 6H), 2.75 (t, 2H, J= 7.8
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Hz), 1.66 (m, 2H), 1.52 (m, 2H), 1.39 (m, 2H).

13

C-NMR (DMSO-d6- 300 MHz Varian

Unity) δ 169.1, 167.5, 160.1, 144.7, 127.3, 123.5, 108.9, 92.7, 49.9, 37.0, 36.8, 26.5,
25.9, 23.0, 18.2 ppm.

Preparation 5-Benzoyl-1-butylpyrimidine-2,4,6-trione (H5). Benzoyl chloride (14.1 g;
0.1 mol) was slowly added over 10 minutes into a stirring pyridine (60 mL) solution of 1butylbarbituric acid (18.4 g; 0.1 mol). The resulting reaction mixture was stirred at room
temperature for an additional two hours. The pyridine reaction mixture was then slowly
added over thirty minutes into a stirring solution of methanol (60 mL), water (50 mL) and
concentrated hydrochloric acid (150 mL). The resulting suspension was stirred at room
temperature for an additional half an hour and then at 0º C for an additional hour. Solid
precipitate was separated by filtration, washed (3×15 mL) with diluted hydrochloric acid
(one part of concentrated hydrochloric acid and nine parts of water). Solid product was
dried at 110º C for half an hour to afford pure 1e in 28.0 g (97%). m.p. 138.9-139.7 º C.
1

H-NMR (DMSO-d6, 500 MHz) δ 11.90 (1H, s), 7.55 (2H, d, J= 7 Hz), 7.53 (1H, t, J=

7.5 Hz), 7.43 (2H, t, J= 7.5 Hz), 3.71 (2H, t, J= 7.5 Hz), 1.47 (2H, m), 1.24 (2H, m), and
0.86 ppm (3H, t, J= 7 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 186.9, 164.0, 161.0,

146.0, 131.7, 127.9, 125.0, 124.0, 91.8, 36.0, 26.1, 16.1, and 10.2 ppm. MS-ES+
(CH3OH) m/z: 289 (M+1+), 311 (M+Na+), 343 (M+CH3OH+Na+). Anal. Calcd. for
C15H16N2O4 (288.30): C, 62.49; H, 5.59; N, 9.72; Found C, 62.23; H, 5.56; N, 9.88.
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Preparation 5-Benzoylpyrimidine-2,4,6-trione (H1). Benzoyl chloride (14.1 g; 0.1 mol)
was slowly added over 10 minutes into a stirring pyridine (60 mL) solution of barbituric
acid (12.8 g; 0.1 mol). The resulting reaction mixture was stirred at room temperature for
additional two hours. The pyridine reaction mixture was then slowly added over thirty
minutes into stirring solution of methanol (60 mL), water (50 mL) and concentrated
hydrochloric acid (150 mL). The resulting suspension was stirred at room temperature
for additional half an hour and at 0º C for an additional hour. The solid precipitate was
separated by filtration, washed (3×15 mL) with diluted hydrochloric acid (one part of
concentrated hydrochloric acid and nine parts of water). The solid product was dried at
110º C for half an hour to afford 20.9 g (90%) of pure product. 1H-NMR (DMSO-d6, 500
MHz) δ 11.48 (2H, s), 7.5 6(2H, d, J= 8.7 Hz), 7.53 (1H, t, J= 6.3 Hz), and 7.42 ppm
(2H, t, J= 7.5 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 186, 163, 145, 131, 128, 125, 123,

and 91 ppm. Anal. Calcd. for C11H8N2O4 (232.05): C, 56.90; H, 3.47; N, 12.06; Found
C, 56.81; H, 3.56; N, 11.91.

Preparation 5-Benzyl-1-phenylpyrimidine-2,4,6-trione (H2). Benzoyl chloride (14.1 g;
0.1 mol) was slowly added over 10 minutes into a stirring pyridine (60 mL) solution of 1phenylbarbituric acid (20.4 g; 0.1 mol). The resulting reaction mixture was stirred at
room temperature for additional two hours. The pyridine reaction mixture was then
slowly added over thirty minutes into stirring solution of methanol (60 mL), water (50
mL) and concentrated hydrochloric acid (150 mL). The resulting suspension was stirred
at room temperature for additional half an hour and at 0º C for an additional hour. The
solid precipitate was separated by filtration, washed (3×15 mL) with diluted hydrochloric
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acid (one part of concentrated hydrochloric acid and nine parts of water). Thesolid
product was dried at 110º C for half an hour to afford 25.5 g (83%) pure product. 1HNMR (DMSO-d6, 500 MHz) δ 12.09 (1H, s), 7.59 (2H, d, J= 7.2 Hz), 7.51 (d, 1H, J= 6.9
Hz), 7.42 (5H, m J= 7.8 Hz), and 7.29 ppm (2H, d, J= 9.3 Hz).

13

C-NMR (DMSO-d6) δ

186, 164, 161, 145, 131, 131, 127, 125, 125, 124, 124, 123, and 92 ppm. . Anal. Calcd.
for C17H12N2O4 (308.08): C, 66.23; H, 3.92; N, 9.09; Found C, 66.11; H, 3.98; N, 10.98.

Preparation of 5-benzoyl-1-methylpyrimidine-2,4,6-trione (H3). Benzoyl chloride (14.1
g; 0.1 mol) was slowly added over 10 minutes into stirring pyridine (60 mL) solution of
1-methylbarbituric acid (14.2 g; 0.1 mol). The resulting reaction mixture was stirred at
room temperature for additional two hours. The pyridine reaction mixture was then
slowly added over thirty minutes into stirring solution of methanol (60 mL), water (50
mL) and concentrated hydrochloric acid (150 mL). The resulting suspension was stirred
at room temperature for additional half an hour and at 0º C for an additional hour. The
solid precipitate was separated by filtration, washed (3×15 mL) with diluted hydrochloric
acid (one part of concentrated hydrochloric acid and nine parts of water). The solid
product was dried at 110º C for half an hour to afford 77%. 1H-NMR (DMSO-d6, 500
MHz) δ 11.91 (1H, s), 7.56 (2H, d, J= 8.1 Hz), 7.44 (3H, t+t), and 3.09 ppm (3H, s).
13

C-NMR (DMSO-d6) δ 186, 163, 159, 146, 131, 127, 124, 123, 91, and 23 ppm. Anal.

Calcd. for C12H10N2O4 (246.06): C, 58.54; H, 4.09; N, 11.38; Found C, 58.68; H, 4.01;
N, 11.22.
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Preparation of 5-(4-methoxybenzoyl)pyrimidine-2,4,6-trione (H6). 4-methoxybenzoyl
chloride (17.1 g; 0.1 mol) was slowly added over 10 minutes into stirring pyridine (60
mL) solution of barbituric acid (12.8 g; 0.1 mol). The resulting reaction mixture was
stirred at room temperature for additional two hours. The pyridine reaction mixture was
then slowly added over thirty minutes into stirring solution of methanol (60 mL), water
(50 mL) and concentrated hydrochloric acid (150 mL). The resulting suspension was
stirred at room temperature for additional half an hour and at 0º C for an additional hour.
The solid precipitate was separated by filtration, washed (3×15 mL) with diluted
hydrochloric acid (one part of concentrated hydrochloric acid and nine parts of water).
The solid product was dried at 110º C for half an hour to afford 22.8 g (87%) pure
product. 1H-NMR (DMSO-d6, 500 MHz) δ 11.41 (2H, s), 7.61 (2H, d, J= 8.7 Hz), 6.94
(2H, d, J= 8.7 Hz), and 3.80 ppm (3H, s).

13

C-NMR (DMSO-d6) δ 185,162, 159, 145,

128, 123, 109, 90, and 51 ppm. Anal. Calcd. for C12H10N2O5 (262.06): C, 54.97; H,
3.84; N, 10.68; Found C, 54.86; H, 3.92; N, 10.55.

Preparation 5-(4-methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (H7). 4Methoxybenzoyl chloride (17.1 g; 0.1 mol) was slowly added to stirring pyridine (60 mL)
solution of 1,3-dimethylbarbituric acid (15.6 g; 0.1 mol). The resulting reaction
suspension was stirred at room temperatures for four hours and then added into aqueous
hydrochloric acid made from water (50 mL) and concentrated hydrochloric acid (150
mL). The resulting suspension was stirred at room temperature for thirty minutes and
then at 70º C for 30 minutes. After heating, reaction suspension became clear water
solution. Water solution was extracted (4×100mL) with ethyl acetate. Combined ethyl
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acetate extracts were dried over anhydrous magnesium sulfate and evaporated to an oily
residue. Oily residue was dissolved in ethanol (10 mL) and kept at 0º C to form yellow
crystals that were separated by filtration, washed with ice cold ethanol (3×5 mL) and
dried on the air to give 26.1 g (90%). m.p. 143.8-145.1 º C. 1H-NMR (DMSO-d6, 500
MHz) δ 7.61 (2H, d, J= 8 Hz), 6.98 (2H, d, J= 8 Hz), 3.84 (3H, s), and 3.17 ppm (6H, s).
13

C-NMR (DMSO-d6, 500 MHz) δ 188.7, 162.5, 159.0, 150.1, 126.5, 112.8, 94.7, 55.4,

and 27.8 ppm. MS-ES+ (CH3OH) m/z: 291 (M+1+), 313 (M+Na+), 345
(M+CH3OH+Na+). Anal. Calcd. for C14H14N2O5 (290.27): C, 57.93; H, 4.86. Found: C,
57.83; H, 4.78.

Preparation of 5-benzoyl-1,3-dimethylpyrimidine-2,4,6-trione (H4). Benzoyl chloride
(14.1 g; 0.1 mol) was slowly added to stirring pyridine (60 mL) solution of 1,3dimethylbarbituric acid (15.6 g; 0.1 mol). The resulting reaction suspension was stirred
at room temperatures for four hours and then added into aqueous hydrochloric acid made
from water (50 mL) and concentrated hydrochloric acid (150 mL). The resulting
suspension was stirred at room temperature for thirty minutes and then at 70º C for 30
minutes. After heating, reaction suspension became clear water solution. Water solution
was extracted (4×100mL) with ethyl acetate. The combined ethyl acetate extracts were
dried over anhydrous magnesium sulfate and evaporated to an oily residue. Oily residue
was dissolved in ethanol (10 mL) and kept at 0º C to form yellow crystals that were
separated by filtration, washed with ice cold ethanol (3×5 mL) and dried on the air to
give 21.8 g (84%) pure product. 1H-NMR (DMSO-d6, 500 MHz) δ 7.53 (3H, d+t, J= 3.0
Hz), 7.44 (2H, t, J= 8.1 Hz), and 3.17 ppm (s, 6H).

13

C-NMR (DMSO-d6, 500 MHz) δ
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185, 163, 146, 131, 127, 124, 124, 92, and 24 ppm. Anal. Calcd. for C12H12N2O4
(260.25): C, 60.00; H, 4.65; N, 10.76. Found C, 59.91; H, 4.73; N, 10.65.

Preparation of 5-(4-nitrobenzyl)-1,3-dimethylbarbituric acid (H9). Into tetrahydrofuran
solution (200 mL) of 1,3-dimethylbarbituric acid (17.2 g; 0.11 mol) and 4-nitrobenzoyl
chloride (18.5 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 0.15 mol) was
added. Color of the reaction mixture immediately changes from yellow to deep red and
white precipitate (N-methylmorpholinium chloride) starts to form. Tetrahydrofuran was
distilled off under atmospheric pressure until volume of the reaction suspension was ~50
mL. This suspension was poured into ice cooled aqueous hydrochloric acid (800 mL
water and 200 mL concentrated hydrochloric acid). Yellow precipitate was separated by
filtration and washed with ice water (3×20 mL). Product contains ~3% 4-nitrobenzoic
acid. Crude product was added to aqueous sodium bicarbonate (3 g NaHCO3 in 200 mL
water) and resulting suspension was stirred at room temperature for one hour. Solid was
separated by filtration, washed with ice water and added to aqueous ammonium chloride
(4 g =NH4Cl in 100 mL water). Resulting suspension was refluxed for five minutes,
cooled in ice-water. White crystalline product was separated by filtration, washed with
ice water (3×15 mL) and dried at 110º C for half an hour to afford 27.8 g (91%) pure
product. Product decomposes at temperatures above 190º C. 1H-NMR (DMSO-d6, 500
MHz) δ 8.21 (2H, d, J= 8 Hz), 7.64 (2H, d, J= 8 Hz), and 3.12 ppm (6H, s).

13

C-NMR

(DMSO- d6, 500 MHz) δ 189.1, 163.9, 151.1, 147.7, 128.6, 122.8, 95.2, and 27.4 ppm.
MS-ESI+ (CH3OH) m/z: 360 (M+CH3OH+Na+), 382 (NaM+CH3OH+Na+). Anal. Calcd.
for C13H11N3O6 (305.24): C, 51.15; H, 3.63; N, 13.77; Found C, 51.08; H, 3.71; N, 13.72.
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Preparation of 5-(3-nitrobenzoyl)-pyrimidine-2,4,6-trione (H8). Into tetrahydrofuran
solution (200 mL) of barbituric acid (14.1 g; 0.11 mol) and 3-nitrobenzoyl chloride (18.5
g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 0.15 mol) was added. Color of
the reaction mixture immediately changes from yellow to deep red and white precipitate
(N-methylmorpholinium chloride) starts to form. Tetrahydrofuran was distilled off under
atmospheric pressure until volume of the reaction suspension was ~50 mL. This
suspension was poured into ice cooled aqueous hydrochloric acid (800 mL water and 200
mL concentrated hydrochloric acid). Yellow precipitate was separated by filtration and
washed with ice water (3×20 mL). Product contains ~3% 3-nitrobenzoic acid. Crude
product was added to aqueous sodium bicarbonate (3 g NaHCO3 in 200 mL water) and
resulting suspension was stirred at room temperature for one hour. Solid was separated
by filtration, washed with ice water and added to aqueous ammonium chloride (4 g
=NH4Cl in 100 mL water). Resulting suspension was refluxed for five minutes, cooled in
ice-water. White crystalline product was separated by filtration, washed with ice water
(3×15 mL) and dried at 110º C for half an hour to afford 25.7 g (93%) pure product. 1HNMR (DMSO-d6, 500 MHz) δ 8.61 (1H, s), 8.46 (1H, d, J= 11Hz), 8.34 (1H, d, J=
13Hz), and 7.81 (1H, t, J= 13 Hz) ppm (6H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ

188.2, 161.4, 154.0, 143.8, 131.3, 128.4, 126.5, 119.6, and 95.5 ppm.

Preparation of 1,3-dimethyl-5-(3-nitrobenzoyl)pyrimidine-2,4,6-trione (H11). Into
tetrahydrofuran solution (200 mL) of 1,3-dimethylbarbituric acid (17.2 g; 0.11 mol) and
3-nitrobenzoyl chloride (18.5 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g;
0.15 mol) was added. Color of the reaction mixture immediately changes from yellow to

231

deep red and white precipitate (N-methylmorpholinium chloride) starts to form.
Tetrahydrofuran was distilled off under atmospheric pressure until volume of the reaction
suspension was ~50 mL. This suspension was poured into ice cooled aqueous
hydrochloric acid (800 mL water and 200 mL concentrated hydrochloric acid). Yellow
precipitate was separated by filtration and washed with ice water (3×20 mL). Product
contains ~3% 3-nitrobenzoic acid. Crude product was added to aqueous sodium
bicarbonate (3 g NaHCO3 in 200 mL water) and resulting suspension was stirred at room
temperature for one hour. Solid was separated by filtration, washed with ice water and
added to aqueous ammonium chloride (4 g =NH4Cl in 100 mL water). Resulting
suspension was refluxed for five minutes, cooled in ice-water. White crystalline product
was separated by filtration, washed with ice water (3×15 mL) and dried at 110º C for half
an hour to afford 28.9 g (95%) pure product. 1H-NMR (DMSO-d6, 500 MHz) δ 8.34
(1H, d, J= 12Hz), 8.33 (1H, s), 7.95 (1H, d, J= 11Hz), 7.73 (1H, t, J= 13 Hz), and 3.15
ppm (6H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ 187.3, 164.8, 150.7, 147.3, 137.9,

134.8, 129.8, 125.7, 123.3, 96.2, and 28.0 ppm. Anal. Calcd. for C13H11N3O6 (305.24):
C, 51.15; H, 3.63; N, 13.77; Found C, 51.05; H, 3.76; N, 13.65.

Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione (H10). Into tetrahydrofuran
solution (200 mL) of barbituric acid (14.1 g; 0.11 mol) and 4-nitrobenzoyl chloride (18.5
g; 0.1 mol) with stirring N-methylmorpholine (15.15 g; 0.15 mol) was added. Color of
the reaction mixture immediately changes from yellow to deep red and white precipitate
(N-methylmorpholinium chloride) starts to form. Tetrahydrofuran was distilled off under
atmospheric pressure until volume of the reaction suspension was ~50 mL. This
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suspension was poured into ice cooled aqueous hydrochloric acid (800 mL water and 200
mL concentrated hydrochloric acid). The yellow precipitate was separated by filtration
and washed with ice water (3×20 mL). Product contains ~3% 4-nitrobenzoic acid. The
crude product was added to aqueous sodium bicarbonate (3 g NaHCO3 in 200 mL water)
and resulting suspension was stirred at room temperature for one hour. The solid was
separated by filtration, washed with ice water and added to aqueous ammonium chloride
(4 g =NH4Cl in 100 mL water). The resulting suspension was refluxed for five minutes,
cooled in ice-water. White crystalline product was separated by filtration, washed with
ice water (3×15 mL) and dried at 110º C for half an hour to afford 25.7 g (93%) pure
product. 1H-NMR (DMSO-d6, 500 MHz) δ 11.64 (2H, s, NH), 8.27 (2H, d, J= 9.0Hz),
and 7.79 ppm (2H, d, J= 9Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 188.2, 149.3, 148.6,

141.7, 129.6, 122.8, and 95.8 ppm.

Preparation of 5-(3,5-Dinitro-benzoyl)-pyrimidine-2,4,6-trione (H12). Into
tetrahydrofuran solution (200 mL) of barbituric acid (14.1 g; 0.11 mol) and 3,5dinitrobenzoyl chloride (23.0 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g;
0.15 mol) was added. Color of the reaction mixture immediately changes from yellow to
deep red and white precipitate (N-methylmorpholinium chloride) starts to form.
Tetrahydrofuran was distilled off under atmospheric pressure until volume of the reaction
suspension was ~50 mL. This suspension was poured into ice cooled aqueous
hydrochloric acid (800 mL water and 200 mL concentrated hydrochloric acid). The
yellow precipitate was separated by filtration and washed with ice water (3×20 mL). The
product contains ~3% 3,5-dinitrobenzoic acid. The crude product was added to aqueous
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sodium bicarbonate (3 g NaHCO3 in 200 mL water) and resulting suspension was stirred
at room temperature for one hour. Solid was separated by filtration, washed with ice
water and added to aqueous ammonium chloride (4 g =NH4Cl in 100 mL water). The
resulting suspension was refluxed for five minutes, cooled in ice-water. White crystalline
product was separated by filtration, washed with ice water (3×15 mL) and dried at 110º C
for half an hour to afford 29.0 g (90%) pure product. 1H-NMR (DMSO-d6, 500 MHz) δ
9.90 (2H, s), 8.79 (1H, s), and 8.42 ppm (2H,s).

13

C-NMR (DMSO-d6, 500 MHz) δ

186.3, 165.4, 151.2, 147.5, 147.2, 127.5, 118.1, and 93.3 ppm.

Preparation of 5-(3,5-dinitrobenzoyl)-1-methylpyrimidine-2,4,6-trione (H13).
Into tetrahydrofuran solution (200 mL) of 1-methylbarbituric acid (15.6 g; 0.11 mol) and
3,5-dinitrobenzoyl chloride (23.0 g; 0.1 mol) with stirring N-methylmorpholine (15.15 g;
0.15 mol) was added. The color of the reaction mixture immediately changes from
yellow to deep red and white precipitate (N-methylmorpholinium chloride) starts to form.
Tetrahydrofuran was distilled off under atmospheric pressure until volume of the reaction
suspension was ~50 mL. This suspension was poured into ice cooled aqueous
hydrochloric acid (800 mL water and 200 mL concentrated hydrochloric acid). The
yellow precipitate was separated by filtration and washed with ice water (3×20 mL).
Product contains ~3% 3,5-dinitrobenzoic acid. The crude product was added to aqueous
sodium bicarbonate (3 g NaHCO3 in 200 mL water) and resulting suspension was stirred
at room temperature for one hour. The solid was separated by filtration, washed with ice
water and added to aqueous ammonium chloride (4 g =NH4Cl in 100 mL water). The
resulting suspension was refluxed for five minutes, cooled in ice-water. White crystalline
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product was separated by filtration, washed with ice water (3×15 mL) and dried at 110º C
for half an hour to afford 31.2 g (93%) pure product. 1H-NMR (DMSO-d6, 500 MHz) δ
8.78 (1H, s), 8.41 (2H, s), and 3.05 ppm (6H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ

187.1, 163.2, 152.3, 148.2, 147.4, 127.3, 118.1, 93.4, and 27.1 ppm. Anal. Calcd. for
C12H8N3O8 (336.21): C, 42.87; H, 2.40; N, 16.66; Found C, 42.78; H, 2.51; N, 16.55.

Preparation of 5-(3-hydroxybenzoyl)barbituric acid (H14). Chloroform solution (150
mL) of 3-acetoxybenzoic acid (1.8 g; 0.01 mol) and oxalyl chloride (2.5 g 0.02 mol) was
stirred at room temperature for four hours. After evaporation of solvent the oily residue
was dissolved in carbon tetrachloride (70 mL) and solvent was again evaporated.
Chloroform (~30 mL) of this oily residue was slowly added into stirring pyridine (30 mL)
suspension of barbituric acid (1.28 g; 0.01 mol). The resulting dark red reaction mixture
was stirred at room temperature for additional hour and then added slowly over of 20
minutes into stirring aqueous hydrochloride (10 mL water, 20 mL concentrated
hydrochloric acid, and 5 mL methanol). The resulting suspension was stirred at room
temperature for additional half an hour and kept at 0º C for one hour. The solid material
was separated by filtration and it contains both 5-(3-acetyloxybenzoyl)barbituric acid and
5-(3-hydroxybenzoyl)barbituric acid. To complete the ester hydrolysis solid material was
mixed with aqueous sodium hydroxide (0.6 g; 0.015 mol of NaOH in 30 mL water) and
heated at 70º C for half an hour. The resulting reaction mixture was acidified to pH=2 at
ice-water bath temperature. The formed white solid precipitate was separated by
filtration, washed with ice-cooled water (3×5 mL) and dried at 110º C for 30 minutes.
Isolated yield of 5-(3-hydroxybenzoyl)barbituric acid is 91% (2.26 g). Product
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decomposes at temperatures above 270º C. 1H-NMR (DMSO-d6, 500 MHz) δ, 11.43
(2H, s), 9.65 (1H, s), 7.22 (1H, t, J= 8 Hz), 6.97 (1H, d, J= 8 Hz), 6.95 (1H, s), and 6.93
ppm (1H, d, J= 8 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 190.3, 156.6, 149.4, 136.4,

128.8, 119.3, 118.6, 115.3, and 95.1 ppm. MS-ES+ (CH3OH) m/z: 249 (M+1+), 271
(M+Na+), 313 (M+2CH3OH+1+), 519 (2M+Na+). Anal. Calcd. for C11H8N2O5 (248.19):
C, 53.23; H, 3.25; N, 11.29; Found C, 53.42; H, 3.34; N, 11.19.

Preparation of 1-butyl-5-(4-hydroxybenzoyl)pyrimidine-2,4,6-trione (H15). Chloroform
solution (150 mL) of 4-acetoxybenzoic acid (1.8 g; 0.01 mol) and oxalyl chloride (2.5 g
0.02 mol) was stirred at room temperature for four hours. After evaporation of solvent
the oily residue was dissolved in carbon tetrachloride (70 mL) and solvent was again
evaporated. Chloroform (~30 mL) of this oily residue was slowly added into stirring
pyridine (30 mL) suspension of 1-butylbarbituric acid (1.84 g; 0.01 mol). Resulting dark
red reaction mixture was stirred at room temperature for additional hour and then added
slowly over of 20 minutes into stirring aqueous hydrochloride (10 mL water, 20 mL
concentrated hydrochloric acid, and 5 mL methanol). Resulting suspension was stirred at
room temperature for additional half an hour and kept at 0º C for one hour. To complete
the ester hydrolysis solid material was mixed with aqueous sodium hydroxide (0.6 g;
0.015 mol of NaOH in 30 mL water) and heated at 70º C for half an hour. Resulting
reaction mixture was acidified to pH=2 at ice-water bath temperature. Formed white
solid precipitate was separated by filtration, washed with ice-cooled water (3×5 mL) and
dried at 110º C for 30 minutes to yield 2.34 g (77%) pure product. 1H-NMR (DMSO-d6,
500 MHz) δ, 11.67(1H, s), 7.51(2H, d, J= 8.5 Hz), 6.80(2H, d, J= 8.5 Hz), 3.70 (2H, t,
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J= 7.2 Hz), 1.47 (2H, m), 1.25 (2H, m), and 0.86 ppm (3H, t, J= 7.0 Hz).

13

C-NMR

(DMSO-d6, 500 MHz) δ 186, 163, 161, 158, 145, 128, 121, 110, 90, 36, 26, 16, 10 ppm.

Preparation of 5-(4-hydroxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (H16).
Chloroform solution (150 mL) of 4-acetoxybenzoic acid (18.0 g; 0.1 mol) and oxalyl
chloride (25.0 g 0.2 mol) was stirred at room temperature for four hours. After
evaporation of solvent the oily residue was dissolved in carbon tetrachloride (70 mL) and
solvent was again evaporated. Chloroform (~30 mL) of this oily residue was slowly
added into stirring pyridine (30 mL) suspension of 1,3-dimethylbarbituric acid (15.6 g;
0.1 mol). Resulting dark red reaction mixture was stirred at room temperature for
additional hour and then added slowly over of 20 minutes into stirring aqueous
hydrochloride (10 mL water, 20 mL concentrated hydrochloric acid, and 5 mL methanol).
Resulting suspension was stirred at room temperature for additional half an hour and kept
at 0º C for one hour. To complete the ester hydrolysis solid material was mixed with
aqueous sodium hydroxide (6.00 g; 0.15 mol of NaOH in 30 mL water) and heated at 70º
C for half an hour. Resulting reaction mixture was acidified to pH=2 at ice-water bath
temperature. Formed white solid precipitate was separated by filtration, washed with icecooled water (3×5 mL) and dried at 110º C for 30 minutes yielding 23.4 g (85%) pure
product. 1H-NMR (DMSO-d6, 500 MHz) δ 7.51(2H, d, J= 6.3 Hz), 6.80 (2H, d, J= 6.9
Hz), and 3.17 ppm (6H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ 185, 161, 158, 146, 128,

121, 110, 90, and 24 ppm. Anal. Calcd. for C13H12N2O5 (276.24): C, 56.52; H, 4.38; N,
10.14; Found C, 56.45; H, 4.42; N, 10.09.
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Preparation of 5-(4-hydroxybenzoyl)pyrimidine-2,4,6-trione (H17). Chloroform
solution (150 mL) of 4-acetoxybenzoic acid (18.0 g; 0.1 mol) and oxalyl chloride (25.0 g
0.2 mol) was stirred at room temperature for four hours. After evaporation of solvent the
oily residue was dissolved in benzene (70 mL) and solvent was again evaporated.
Chloroform (~30 mL) of this oily residue was slowly added into stirring pyridine (30 mL)
suspension of barbituric acid (12.8 g; 0.1 mol). Resulting dark red reaction mixture was
stirred at room temperature for additional hour and then added slowly over of 20 minutes
into stirring aqueous hydrochloride (10 mL water, 20 mL concentrated hydrochloric acid,
and 5 mL methanol). Resulting suspension was stirred at room temperature for additional
half an hour and kept at 0º C for one hour. To complete the ester hydrolysis solid
material was mixed with aqueous sodium hydroxide (6.00 g; 0.15 mol of NaOH in 30 mL
water) and heated at 70º C for half an hour. Resulting reaction mixture was acidified to
pH=2 at ice-water bath temperature. Formed white solid precipitate was separated by
filtration, washed with ice-cooled water (3×5 mL) and dried at 110º C for 30 minutes
yielding 19.8 g (80%) pure product. 1H-NMR (DMSO-d6, 500 MHz) δ 11.33 (2H, s),
7.52 (2H, d, J= 8.0 Hz), and 6.82 ppm (2H, d, J= 8.5 Hz).

13

C-NMR (DMSO-d6, 500

MHz) δ 186, 162, 158, 145, 128, 121, 110, 90 ppm.

Preparation of 5-(4-hydroxybenzoyl)-1-phenylpyrimidine-2,4,6-trione (H18).
Chloroform solution (150 mL) of 4-acetoxybenzoic acid (18.0 g; 0.1 mol) and oxalyl
chloride (25.0 g 0.2 mol) was stirred at room temperature for four hours. After
evaporation of solvent the oily residue was dissolved in benzene (70 mL) and solvent was
again evaporated. Chloroform (~30 mL) of this oily residue was slowly added into
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stirring pyridine (30 mL) suspension of 1-phenylbarbituric acid (20.4 g; 0.1 mol).
Resulting dark red reaction mixture was stirred at room temperature for additional hour
and then added slowly over of 20 minutes into stirring aqueous hydrochloride (10 mL
water, 20 mL concentrated hydrochloric acid, and 5 mL methanol). Resulting suspension
was stirred at room temperature for additional half an hour and kept at 0º C for one hour.
To complete the ester hydrolysis solid material was mixed with aqueous sodium
hydroxide (6.00 g; 0.15 mol of NaOH in 30 mL water) and heated at 70º C for half an
hour. Resulting reaction mixture was acidified to pH=2 at ice-water bath temperature.
Formed white solid precipitate was separated by filtration, washed with ice-cooled water
(3×5 mL) and dried at 110º C for 30 minutes yielding 27.0 g (83%) pure product. 1HNMR (DMSO-d6, 500 MHz) δ 11.91 (1H, s), 7.55 (2H, d, J= 8.5 Hz), 7.44 (2H, t, J= 7.5
Hz), 7.38 (1H, t, J= 7.0 Hz), 7.28 (2H, d, J= 8.0 Hz), and 6.78 ppm (2H, d, J= 8.5 Hz).
13

C-NMR (DMSO-d6, 500 MHz) δ 186, 164, 161, 158, 145, 131, 128, 125, 125, 124, 121,

and 110, 90 ppm.

Preparation of 5-[[2,4-dinitrophenyl)hydrozono]-(4-methoxyphenyl)methyl]-1,3dimethylpyrimidine-2,4,6-trione (H26). To a 1-propanol (20 mL) suspension of 5-(4methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (1.0 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield of pure
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product is 1.30 g (81%). m.p: 98-99.2º C. 1H-NMR(CF3CO2H- DMSO-d6, 500 MHz),
δ 9.51 (1H, s), 8.62 (1H, d, J= 2.5 Hz), 8.01 (1H, d, J= 9 Hz), 6.94 (1H, d, J= 9 Hz),
6.83 (2H, d, J= 7 Hz), 6.56 (2H, d, J= 7Hz), 3.44 (3H, s), 2.97(6H, s).

13

C-NMR

(CF3CO2H- DMSO-d6, 500 MHz), δ 176.2, 165.5, 163.2, 153.1, 146.5, 139.5, 131.2,
128.6, 123.8, 123.4, 114.9, 109.3, 92.1, 55.4, and 28.4 ppm. MS-ES+ (MeOH) m/z 413
(75%), 423 (55%), 493 (M + 23). Anal. Calcd. for C20H18N6O8 (470.39): C, 51.07; H,
3.86; N, 17.87; Found C, 51.01; H, 3.92; N, 17.82.

Preparation of 5-{[N'-(4-nitrophenyl)hydrazino]phenylmethylene}pyrimidine-2,4,6trione (H19). To a 1-propanol (20 mL) suspension of 5-(benzoyl)-pyrimidine-2,4,6trione (0.792 g; 3.4 mmol) and 4-nitrophenylhydrazine (0.520 g; 3.4 mmol) one drop of
sulfuric acid was added. The reaction mixture was stirred while refluxing and became a
clear solution after 30 minutes. The reaction mixture was refluxed for additional four
hours and left at 0º C for one hour. Resulting brown precipitate was separated by
filtration, washed with 1-propanol (3 x 5 mL), ether (3 x 10 mL) and dried at 50º C for
twenty minutes. The isolated yield of pure is 0.913 g (73%). 1H-NMR (CF3CO2HDMSO-d6, 500 MHz), δ 7.72 (2H, d, J= 8.5 Hz), 7.03 (1H, t, J= 7.8 Hz), 6.96 (2H, t, J=
7.0 Hz), 6.81 (2H, d, J= 8.0 Hz), and 6.38 ppm (2H, d, J= 9.5 Hz).

13

C-NMR

(CF3CO2H- DMSO-d6, 500 MHz), δ 177, 166, 152, 151, 141, 131, 129, 129, 126, 126,
112, and 89 ppm.
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Preparation of 4-{N’-[phenyl-(2,4,6-trioxo-1-phenylhexahydropyrimidin-5yl)methylene]-hydrazino}benzoic acid (H20). 1-Propanol (20 mL) mixture of 5-benzoyl1-phenylpyrimidine-2,4,6-trione (1.0 g; 3.25 mmol) and 4-hydrazino-benzoic acid (0.494
g; 3.25 mmol) were added. To the resulting reaction mixture 1 drop of sulfuric acid was
carefully added. The reaction was stirred while refluxing and became a clear solution
after 10 minutes. The reaction mixture was allowed to reflux for 4 hours. The resulting
reaction mixture was then cooled to room temperature, and a solid yellow precipitate
formed. The solid was removed by filtration and washed with ether (3 x 15 mL). The
resulting solid was oven dried at 110º C for 2 hours. Isolated yield of pure product is
1.10 g (79 %). Product decomposes at temperatures above 200º C. 1H-NMR(CF3CO2HDMSO-d6, 500 MHz), δ 7.57 (d, 2H, J= 4.5 Hz, Ar), 7.06 (d of t, 3H, J= 3.0 Hz, Ar),
7.01 (t, 1H, J= 7.0 Hz, Ar), 6.93 (t, 2H, J= 7.0 Hz, Ar), 6.86 (d of t, 4H, J= 3.5 Hz, Ar),
6.37 (d, 2H, J= 4.5 Hz, Ar).

13

C-NMR (CF3CO2H- DMSO-d6, 500 MHz), δ 176, 173,

166, (162, 161, 161, 160 quartet belonging to CF3CO2H), 152, 150, 132, 132, 131, 130,
130, 130, 129, 128, 126, 121, (120, 116, 113, 109 quartet belonging to CF3CO2H), 113,
90 ppm. MS-ES+ (MeOH) m/z 195(75%), 360(100%), 408(60%), 465 (M + 23).
MW=442.42 g/mol + 0.3 molecules H2O. Anal. Calcd. for C24H18N4O5: C, 64.36; H,
4.19; N, 12.51. Found C, 64.36; H, 4.21; N, 12.53.

Preparation of 5-{[N'-(2,4-dinitrophenyl)hydrazino]phenylmethylene}-1,3dimethylpyrimidine-2,4,6-trione (H21). To a 1-propanol (20 mL) suspension of 5(benzoyl)-1,3-dimethylpyrimidine-2,4,6-trione ( 0.887 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
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reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes to yield 1.24 g (83%) pure
product. Mp: 92.2-94.5º C. 1H-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 9.42 (1H, s),
8.55 (1H, s), 8.01 (1H, d, J= 9.5 Hz), 7.00 (1H, d, J= 6.5 Hz), 6.90 (3H, m), 6.86 (2H, t,
J= 8.0 Hz), and 2.96 ppm (6H, s).

13

C-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 175,

165, 152, 146, 139, 131, 130, 130, 130, 129, 125, 123, 116, 91, and 28 ppm.

Preparation of 5-{[N'-(2,4-dinitrophenyl)hydrazino]phenylmethylene}-1phenylpyrimidine-2,4,6-trione (H22). To a 1-propanol (20 mL) suspension of 5(benzoyl)-1-phenylpyrimidine-2,4,6-trione (1.05 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 1.46 g
(88%). 1H-NMR (DMSO-d6, 500 MHz) δ 11.51 (1H, s), 10.69 (1H, s), 8.88 (1H, d, J=
2.4 Hz), 8.37 (1H, d, J1=12.6 Hz, J2=2.7 Hz), 8.10 (1H, d, J= 9.6 Hz),7.83 (2H, d, J= 9.0
Hz), 7.39 (5H, m), 7.30 (1H, t, J= 7.2 Hz), and 7.21 ppm (2H, d, J= 7.8 Hz).

13

C-NMR

(DMSO-d6, 500 MHz) δ 157, 157, 150, 147, 140, 134, 133, 132, 126, 125, 125, 125, 124,
124, 124, 123, 119, 113, and 77 ppm. Anal. Calcd. for C23H16N6O7: C, 56.56; H, 3.30;
N, 17.21. Found C, 56.48; H, 3.41; N, 17.09.
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Preparation of 5-{[N'-(2,4-dinitrophenyl)hydrazino]phenylmethylene}-pyrimidine2,4,6-trione (H23). To a 1-propanol (20 mL) suspension of 5-(benzoyl)-pyrimidine2,4,6-trione ( 0.792 g; 3.4 mmol) and 2,4-dinitrophenylhydrazine (0.683 g; 3.4 mmol)
one drop of sulfuric acid was added. The reaction mixture was stirred while refluxing
and became a clear solution after 30 minutes. The reaction mixture was refluxed for
additional four hours and left at 0º C for one hour. Resulting orange precipitate was
separated by filtration, washed with 1-propanol (3×5 mL), ether (3×10 mL) and dried at
50º C for twenty minutes. The isolated yield is 1.17 g (84%). 1H-NMR (DMSO-d6, 500
MHz) δ 11.41 (1H, s), 10.74 (2H, s), 8.87 (1H, d, J= 2.7 Hz), 8.39 (1H, d, J1=12.3 Hz,
J2=2.4 Hz), 8.12 (1H, d, J= 9.9 Hz), 7.79 (2H, t, J= 9.9 Hz), and 7.39 (3H, J= 3.2 Hz).
13

C-NMR (DMSO-d6, 500 MHz) δ 158, 148, 147, 140, 133, 133, 126, 125, 125, 124, 123,

119, 113, and 78 ppm.

Preparation of 4-{N'-[(1,3-dimethyl-2,4,6-trioxotetrahydropyrimidin-5ylidene)phenylmethyl]hydrazino}-benzoic acid (H24). To a 1-propanol (20 mL)
suspension of 5-(benzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (0.887 g; 3.4 mmol) and
4-hydrazinobenzoic acid (0.520 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting brown precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 79%.
1

H-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 7.55 (2H, d, J= 8.5 Hz), 7.01 (1H, t, J= 7.5

Hz), 6.95 (2H, t, J= 7.5 Hz), 6.81 (2H, d, J= 7.5 Hz), 6.36 (2H, d, J= 8.5 Hz), and 2.95
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ppm (6H, s).

13

C-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 175, 173, 165, 153, 151,

132, 131, 130, 129, 126, 120, 112, 90, and 28 ppm.

Preparation of 5-{(4-Methoxyphenyl)-[N'-(4-nitrophenyl)hydrazino]methylene}-1,3dimethylpyrimidine-2,4,6-trione (H25). To a 1-propanol (20 mL) suspension of 5-(4methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (1.0 g; 3.4 mmol) and 4nitrophenylhydrazine (0.520 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting brown precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 82%.
1

H-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 9.51 (1H, s), 8.03 (2H, d, J= 9.0 Hz), 7.16

(2H, d, J= 9.0 Hz), 6.86 (2H, d, J= 9.0 Hz), 6.75 (2H, d, J= 9.0 Hz), 3.73 (3H, s), and
3.11 ppm (3H, s).

13

C-NMR (CF3CO2H- DMSO-d6, 500 MHz) δ 162.8, 158.0, 150.5,

151.6, 149.8, 137.3, 132.6, 128.3, 126.1, 113.1, 110.4, 81.2, 53.4, and 26.5 ppm. Anal.
Calcd. for C2oH19N5O6: C, 56.47; H, 4.50; N, 16.46. Found: C, 56.33; H, 4.58; N, 16.38.

Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-methoxyphenyl)methylene]-1methylpyrimidine-2,4,6-trione (H27). To a 1-propanol (20 mL) suspension of 5-(4methoxybenzoyl)-1-methylpyrimidine-2,4,6-trione (0.942 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
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Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 81%.
1

H-NMR (DMSO-d6, 500 MHz) δ 11.32 (1H, s), 11.01 (2H, s), 8.83 (1H, d, J= 2.7 Hz),

8.33 (1H, d, J= 6.0 Hz), 8.05 (1H, d, J= 9.6 Hz), 7.73 (2H, d, J= 8.7 Hz), 6.93 (2H, d, J=
9.0 Hz), and 3.76 ppm (3H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ 163, 158, 157, 147,

140, 133, 126, 125, 125, 119, 113, 110, 109, 78, and 51 ppm.

Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(3-hydroxyphenyl)methylene]-1methylpyrimidine-2,4,6-trione (H28). To a 1-propanol (20 mL) suspension of 5-(3hydroxybenzoyl)-1-methylpyrimidine-2,4,6-trione (0.894 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 1.30 g
(88%). 1H-NMR (DMSO-d6, 500 MHz) δ 11.37 (1H, s), 10.76 (2H, s), 8.87 (1H, d, J=
2.1 Hz), 8.41 (1H, d, J= 12.0 Hz), 8.06 (1H, d, J= 9.5 Hz), 7.24 (1H, t, J= 7.5 Hz), 7.17
(2H, d), and 6.79 ppm (1H, d, J= 10.0 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 158, 153,

148, 147, 140, 135, 133, 126, 125, 125, 119, 114, 113, 112, 110, and 78 ppm.
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Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1methylpyrimidine-2,4,6-trione (H29). To a 1-propanol (20 mL) suspension of 5-(4hydroxybenzoyl)-1-methylpyrimidine-2,4,6-trione (0.894 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 1.32 g
(88%). 1H-NMR (DMSO-d6, 500 MHz) δ 11.44 (1H, s), 10.34 (1H, s), 8.86 (1H, d, J=
1.5 Hz), 8.33 (1H, d, J= 6.0 Hz), 8.04 (1H, d, J= 4.5 Hz), 7.60 (2H, d, J= 4.0 Hz), 6.75
(2H, d, J= 4.5 Hz), and 3.03 ppm (3H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ 158, 157,

155, 153, 149, 140, 132, 126, 126, 125, 124, 120, 113, 111, 77, and 22 ppm.

Preparation of 1-butyl-5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]pyrimidine-2,4,6-trione (H30). To a 1-propanol (20 mL) suspension of 5-(4hydroxybenzoyl)-pyrimidine-2,4,6-trione ( 0.894 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 1.20 g
(80%). 1H-NMR (DMSO-d6, 500 MHz) δ 11.34 (1H, s), 10.98 (1H, s), 8.86 (1H, d, J=
2.5 Hz), 8.36 (1H, d, J= 12.0 Hz), 8.05 (1H, d, J= 9.5 Hz), 7.63 (2H, d, J= 8.5 Hz), 6.79
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(2H, d, J= 8.5 Hz), 3.72 (2H, t, J= 7.5 Hz), 1.50 (2H, m), 1.26 (2H, m), and 0.86 ppm
(3H, t, J= 7.5 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 157, 156, 155, 149, 147, 140, 133,

126, 125, 125, 124, 119, 113, 111, 78, 26, 26, 16, and 10 ppm.

Preparation of 5-[[N'-(2,4-dinitrophenyl)-hydrazino]-(4-hydroxyphenyl)methylene]pyrimidine-2,4,6-trione (H31). To a 1-propanol (20 mL) suspension of 5-(4hydroxybenzoyl)-pyrimidine-2,4,6-trione ( 0.846 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 1.32 g
(91%). 1H-NMR (DMSO-d6, 500 MHz) δ 11.36 (1H, s), 10.79 (2H, s), 8.85 (1H, d, J=
2.1 Hz), 8.36 (1H, d, J= 10.5 Hz), 8.04 (1H, d, J= 9.9 Hz), 7.63 (2H, d, J= 8.7 Hz), and
6.78 ppm (2H, d, J= 9.0 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 158, 156, 147, 147,

140, 133, 126, 126, 125, 123, 118, 113, 111, and 78 ppm. Anal. Calcd. for C17H12N6O8:
C, 47.67; H, 2.82; N, 19.62. Found: C, 47.55; H, 2.93; N, 19.54.

Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1phenylpyrimidine-2,4,6-trione (H32). To a 1-propanol (20 mL) suspension of 5-(4hydroxybenzoyl)-1-phenylpyrimidine-2,4,6-trione (1.10 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
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The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 1.42 g
(83%). 1H-NMR (DMSO-d6, 500 MHz) δ 11.52 (1H, s), 10.37 (1H, s), 8.87 (1H, d, J=
2.7 Hz), 8.33 (1H, d, J= 12.0 Hz), 8.03 (1H, d, J= 9.9 Hz), 7.67 (2H, d, J= 9.0 Hz), 7.38
(2H, t, J= 7.4 Hz), 7.28 (1H, t, J= 7.5 Hz), 7.19 (2H, d, J= 8.4 Hz), and 6.76 ppm (2H, d,
J= 8.4 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 158, 157, 156, 149, 147, 140, 133, 132,

126, 126, 125, 125, 125, 124, 124, 119, 113, 111, and 79 ppm.

Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1methylpyrimidine-2,4,6-trione (H33). To a 1-propanol (20 mL) suspension of 5-(4hydroxybenzoyl)-1-methylpyrimidine-2,4,6-trione ( 0.894 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 84%.
1

H-NMR (DMSO-d6, 500 MHz) δ 11.40 (1H, s), 10.34(1H, s), 8.85 (1H, d J= 3.0 Hz),

8.33 (1H, d, J1=12.5 Hz, J2=3.0 Hz), 7.99 (1H, d, J= 9.5 Hz), 7.61 (2H, d, J= 8.5 Hz),
and 6.75 ppm (2H, d, J= 8.5 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 158, 157, 155, 153,

149, 140, 132, 126, 126, 125, 124, 119, 112, 111, and 78, 24 ppm.

248

Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4-hydroxyphenyl)methylene]-1,3dimethylpyrimidine-2,4,6-trione (H34). To a 1-propanol (20 mL) suspension of 5-(4hydroxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione ( 0.941 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 91%.
1

H-NMR (DMSO-d6, 500 MHz) δ 11.40 (1H, s), 10.35 (1H, s), 8.34 (1H, d of d, J1=16

Hz, J2=4 Hz), 8.00 (1H, d, J= 16 Hz), 7.61(2H, d of d, J1=11 Hz, J2=4 Hz), and 6.70 ppm
(2H, d of d, J1=11 Hz, J2=3 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 157.1, 155.6, 153.7,

149.1, 140.4, 132.5, 126.3, 126.2, 125.2, 124.9, 120.0, 113.0, 111.4, 78.2, and 23.8 ppm.

Preparation of 5-[[(2,4-dinitrophenyl)hydrazono]-(4-nitrophenyl)methyl]pyrimidine2,4,6-trione (H35). To a 250 mL round bottom flask charged with 20 mL propanol, 5(4nitro-benzoyl)-pyrimidine-2,4,6-trione (0.277 g; 1.00 mmol), 2,4-dinitrophenylhydrazine
(0.198 g; 1.00 mmol), and drop of sulfuric acid was stirred with refluxing for six hours.
After cooling to room temperature orange solid product was separated by filtration,
washed with 1-propanol (1 x10 mL), ether (3×15 mL) and dried at 110º C for two hours.
The yield of pure product was 0.409 g (89%). Product decomposes at temperatures above
275º C. 1H-NMR (DMSO-d6, 500 MHz), δ 11.51 (1H, s, NH), 10.59 (2H, s, NH), 8.87
(1H, d, J= 1.0 Hz), 8.40 (1H, d, J= 5.5 Hz), 8.20 (2H, d, J= 4.5 Hz), 8.14 (1H, d, J= 5.0
Hz), 8.00 (2H, d, J= 4.5 Hz).

13

C-NMR (DMSO-d6, 500 MHz), δ 159, 147, 146, 143,
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140, 140, 133, 126, 126, 125, 119, 119, 113, and 78 ppm. MS-ES+ (MeOH) m/z 408
(100%). Anal. Calcd. for C17H11N7O9: C, 44.65; H, 2.42; N, 21.44. Found C, 44.65; H,
2.54; N, 21.20.

Preparation of 5-[[N'-(2,4-dinitrophenyl)hydrazino]-(4nitrophenyl)methylene]pyrimidine-2,4,6-trione (H36). To a 1-propanol (20 mL)
suspension of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione (0.945 g; 3.4 mmol) and 2,4dinitrophenylhydrazine (0.683 g; 3.4 mmol) one drop of sulfuric acid was added. The
reaction mixture was stirred while refluxing and became a clear solution after 30 minutes.
The reaction mixture was refluxed for additional four hours and left at 0º C for one hour.
Resulting orange precipitate was separated by filtration, washed with 1-propanol (3×5
mL), ether (3×10 mL) and dried at 50º C for twenty minutes. The isolated yield is 91%.
1

H-NMR (DMSO-d6, 500 MHz) δ 11.51 (1H, s), 10.59 (2H, s), 8.87 (1H, d, J= 2.5 Hz),

8.40 (1H, d, J= 11.5 Hz), 8.20 (2H, d, J= 8.5 Hz), 8.14 (1H, d, J= 10.0 Hz), and 8.00
ppm (2H, d, J= 9.0 Hz).

13

C-NMR (DMSO-d6, 500 MHz) δ 159, 147, 146, 143, 140,

140, 133, 126, 126, 125, 119, 119, 113, and 78 ppm.

Preparation of 5-(4-nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione morpholinium
salt (H47). Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-1,3dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and morpholine (191 mg; 2.2 mmol)
was stirred at room temperature for half an hour. Solvent was evaporated. Solid residue
was mixed with ether (100 mL), and resulting suspension was stirred at room temperature
for ten minutes. Solid product was separated by filtration, washed with ether (3×15 mL)
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and dried at 110º C for half an hour. The yield of product is 740 mg (94%). Product
decomposes at temperatures above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 8.12 (2H,
d, J= 8.5 Hz), 7.52 (2H, d, J= 8.5 Hz), 3.77 (4H, m) , 3.13 (4H, m), and 3.06 ppm (6H,
s).

13

C-NMR (DMSO-d6, 500 MHz) δ 191.0, 163.0, 152.2, 151.4, 146.9, 127.9, 122.6,

93.7, 63.4, 43.1, and 26.9 ppm. Anal. Calcd. for C17H20N4O7 (392.36) C, 52.04; H, 5.14;
N, 14.28; Found C, 51.96; H, 5.12; N, 14.15.

Preparation of 5-benzoylpyrimidine-2,4,6-trione piperidinium salt (H37).
Tetrahydrofuran (200 mL) solution of 5-benzoyl-1,3-dimethylpyrimidine-2,4,6-trione
(522 mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for
half an hour. Solvent was evaporated. Solid residue was mixed with ether (100 mL), and
resulting suspension was stirred at room temperature for ten minutes. Solid product was
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour.
The yield of product is 556 mg (80%). Product decomposes at temperatures above 220º
C. 1H-NMR (DMSO-d6, 500 MHz) δ 7.47 (2H, d, J= 7.0 Hz), 7.36 (1H, t, J= 7.5 Hz),
7.30 (2H, t, J= 7.5 Hz), 2.97 (4H, t, J= 5.5 Hz), 1.61 (4H, m), and 1.51 ppm (2H, m).
13

C-NMR (DMSO-d6, 500 MHz) δ 190, 162, 148, 139, 126, 125, 124, 90, 41, 19, and 18

ppm.

Preparation of 5-benzoyl-1-methylpyrimidine-2,4,6-trione piperidinium salt (H38).
Tetrahydrofuran (200 mL) solution of 5-benzoyl-1-methylpyrimidine-2,4,6-trione (494
mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for half
an hour. Solvent was evaporated. Solid residue was mixed with ether (100 mL), and
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resulting suspension was stirred at room temperature for ten minutes. Solid product was
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour.
The yield of product is 317 mg (95%). Product decomposes at temperatures above 220º
C. 1H-NMR (DMSO-d6, 500 MHz) δ 9.69(1H, s), 8.52(2H, s), 7.45 (2H, d, J= 9.9 Hz),
7.28(3H, m) 3.01 (4H, t, J= 6.0 Hz), 2.99 (3H, s), 1.64 (4H m), and 1.54 ppm (2H, m).
13

C-NMR (DMSO-d6, 500 MHz) δ 189, 160, 159, 148, 140, 125, 124, 123, 89, 40, 22, 18,

and 18 ppm.

Preparation of 5-(4-methoxybenzoyl)pyrimidine-2,4,6-trione piperidinium salt (H39).
Tetrahydrofuran (200 mL) solution of 5-(4-methoxybenzoyl)-pyrimidine-2,4,6-trione
(610 mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for
half an hour. Solvent was evaporated. Solid residue was mixed with ether (100 mL), and
resulting suspension was stirred at room temperature for ten minutes. Solid product was
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour.
The yield of product is 88%. Product decomposes at temperatures above 220º C. 1HNMR (DMSO-d6, 500 MHz) δ 9.70 (2H, s,), 8.58 (2H, s), 7.51 (2H, d, J= 8.7 Hz), 6.83
(2H, d, J= 8.7 Hz), 3.76 (3H, s), 2.98 (4H, t, J= 5.4 Hz), 1.61 (4H, m), and 1.51 ppm
(2H, m).

13

C-NMR (DMSO-d6, 500 MHz) δ 188, 161, 157, 147, 131, 127, 108, 89, 51,

40, 18, and 18 ppm.

Preparation of 5-(4-methoxybenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione piperidinium
salt (H40). Tetrahydrofuran (200 mL) solution of 5-(4-methoxybenzoyl)-1,3dimethylpyrimidine-2,4,6-trione (582 mg; 2 mmol) and piperidine (191 mg; 2.2 mmol)
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was stirred at room temperature for half an hour. Solvent was evaporated. Solid residue
was mixed with ether (100 mL), and resulting suspension was stirred at room temperature
for ten minutes. Solid product was separated by filtration, washed with ether (3×15 mL)
and dried at 110º C for half an hour. The yield of product is 93%. Product decomposes at
temperatures above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 8.40 (2H, s), 7.52 (2H, d
J= 8.7 Hz), 6.85 (2H, d, J= 8.7 Hz), 3.77 (3H, s), 3.07 (6H, s), 3.00 (4H, t, J= 5.4 Hz),
1.63 (4H, m), and 1.54 ppm (2H, m).

13

C-NMR (DMSO-d6, 500 MHz) δ 188, 159, 157,

148, 130, 127, 109, 89, 51, 40, 23, 18, and 18 ppm.

Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione piperidinium salt (H41).
Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione (558
mg; 2 mmol) and piperidine (191 mg; 2.2 mmol) was stirred at room temperature for half
an hour. Solvent was evaporated. Solid residue was mixed with ether (100 mL), and
resulting suspension was stirred at room temperature for ten minutes. Solid product was
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour.
The yield of product is 95%. Product decomposes at temperatures above 220º C. 1HNMR (DMSO-d6, 500 MHz) δ 9.65 (2H, s), 8.50 (2H, s), 8.12 (2H, d, J= 8 Hz), 7.51
(2H, d, J= 8 Hz), 3.00 (4H, m), 1.61 (4H, m), and 1.52 ppm (2H, m).

13

C-NMR (DMSO-

d6, 500 MHz) δ 190.5, 165.3, 151.5, 151.3, 147.1, 128.3, 122.8, 93.6, 44.1, 22.3, and 21.8
ppm.
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Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione morpholinium salt (H42).
Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)- pyrimidine-2,4,6-trione (558
mg; 2 mmol) and morpholine (191 mg; 2.2 mmol) was stirred at room temperature for
half an hour. Solvent was evaporated. Solid residue was mixed with ether (100 mL), and
resulting suspension was stirred at room temperature for ten minutes. Solid product was
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour.
The yield of product is 90%. Product decomposes at temperatures above 220º C. 1HNMR (DMSO-d6, 500 MHz) δ 9.75 (2H, s), 8.11 (2H, d, J= 8.0 Hz), 7.52 (d, 2H, J=
8.0), 3.74 (4H, m), and 3.09 ppm (4H, m).

13

C-NMR (DMSO-d6, 500 MHz) δ 190.9,

165.6, 151.5, 151.2, 147.2, 128.4, 122.9, 93.9, 63.5, and 43.3 ppm.

Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione N-methylmorpholinium salt
(H43). Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione
(558 mg; 2 mmol) and N-methylmorpholine (224 mg; 2.2 mmol) was stirred at room
temperature for half an hour. Solvent was evaporated. Solid residue was mixed with
ether (100 mL), and resulting suspension was stirred at room temperature for ten minutes.
Solid product was separated by filtration, washed with ether (3×15 mL) and dried at 110º
C for half an hour. The yield of product is 91%. Product decomposes at temperatures
above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 9.68 (2H, s), 8.12 (2H, d, J= 8 Hz),
7.52 (2H, d, J= 8 Hz), 3.80 (4H, m), 3.20 (4H, m), and 2.79 ppm (3H, s).

13

C-NMR

(DMSO-d6, 500 MHz) δ 190.5, 165.3, 151.4, 151.0, 147.2, 128.4, 122.8, 93.7, 63.6, 53.0,
and 40.0 ppm.
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Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione ethanolammonium salt
(H44). Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6-trione
(558 mg; 2 mmol) and ethanolamine ( 140 mg; 2.2 mmol) was stirred at room
temperature for half an hour. Solvent was evaporated. Solid residue was mixed with
ether (100 mL), and resulting suspension was stirred at room temperature for ten minutes.
Solid product was separated by filtration, washed with ether (3×15 mL) and dried at 110º
C for half an hour. The yield of product is 98%. Product decomposes at temperatures
above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 9.62 (2H, s), 8.12 (2H, d, J= 8 Hz),
7.79 (3H, s), 7.52 (2H, d, J= 8 Hz), 3.67 (2H, m), and 2.85 ppm (2H, m).

13

C-NMR

(DMSO-d6, 500 MHz) δ 190.3, 165.2, 151.5, 151.0, 147.2, 128.4, 122.8, 93.5, 57.6, and
41.5 ppm.

Preparation of 5-(4-nitrobenzoyl)pyrimidine-2,4,6-trione 4-dimethylaminopyridinium
salt (H45). Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-pyrimidine-2,4,6trione (558 mg; 2 mmol) and 4-(dimethylamino)benzaldehyde (328 mg; 2.2 mmol) was
stirred at room temperature for half an hour. Solvent was evaporated. Solid residue was
mixed with ether (100 mL), and resulting suspension was stirred at room temperature for
ten minutes. Solid product was separated by filtration, washed with ether (3×15 mL) and
dried at 110º C for half an hour. The yield of product is 97%. Product decomposes at
temperatures above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 9.50 (2H, s), 8.17 (2H, d,
J= 7 Hz), 8.11 (2H, d, J= 8 Hz), 7.51 (2H, d, J= 8 Hz), 6.95 (2H, d, J= 7Hz), and 3.16
ppm (6H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ 190.1, 165.0, 157.1, 151.5, 151.3,

147.1, 139.3, 128.4, 122.8, 107.1 93.3, and 39.8 ppm.
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Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione piperidinium salt
(H46). Tetrahydrofuran (200 mL) solution of 5-(4-nitrobenzoyl)-1,3dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and piperidine ( 187 mg; 2.2 mmol)
was stirred at room temperature for half an hour. Solvent was evaporated. Solid residue
was mixed with ether (100 mL), and resulting suspension was stirred at room temperature
for ten minutes. Solid product was separated by filtration, washed with ether (3×15 mL)
and dried at 110º C for half an hour. The yield of product is 92%. Product decomposes at
temperatures above 220º C. 1H-NMR (DMSO-d6, 500 MHz) δ 8.13 (2H, d, J= 8.5 Hz),
7.52 (2H, d, J= 8.5 Hz), 3.07 (6H, s), 3.03 (4H, m), 1.65 (4H, m), and 1.54 ppm (2H, m).
13

C-NMR (DMSO-d6, 500 MHz) δ 191.0, 163.0, 152.2, 151.5, 146.9, 127.9, 122.6, 93.7,

44.0, 26.3, 22.3, and 21.8 ppm.

Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione Nmethylmorpholinium salt (H48). Tetrahydrofuran (200 mL) solution of 5-(4nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and Nmethylmorpholine (224 mg; 2.2 mmol) was stirred at room temperature for half an hour.
Solvent was evaporated. Solid residue was mixed with ether (100 mL), and resulting
suspension was stirred at room temperature for ten minutes. Solid product was separated
by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour. The yield
of product is 89%. Product decomposes at temperatures above 220º C. 1H-NMR
(DMSO-d6, 500 MHz) δ 8.13 (2H, d, J= 8.5 Hz), 7.54 (2H, d, J= 8.5 Hz), 3.81 (4H, m),
3.22 (4H, m), 3.08 (6H, s), and 2.80 ppm (3H, s).

13

C-NMR (DMSO-d6, 500 MHz) δ

191.2, 163.1, 152.1, 151.4, 146.9, 127.9, 122.6, 93.8, 63.5, 52.9, 43.1, and 26.9 ppm.
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Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione Nethanolammonium salt (H49). Tetrahydrofuran (200 mL) solution of 5-(4nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and ethanolamine
(140 mg; 2.2 mmol) was stirred at room temperature for half an hour. Solvent was
evaporated. Solid residue was mixed with ether (100 mL), and resulting suspension was
stirred at room temperature for ten minutes. Solid product was separated by filtration,
washed with ether (3×15 mL) and dried at 110º C for half an hour. The yield of product
92%. Product decomposes at temperatures above 220º C. 1H-NMR (DMSO-d6, 500
MHz) δ 8.31 (2H, d, J= 8 Hz), 7.56 (2H, d, J= 8 Hz), 3.48 (2H, m), .3.06 (6H, s), and
2.98 ppm (2H, m).

13

C-NMR (DMSO-d6, 500 MHz) δ 170.1, 150.9, 147.4, 141.3, 128.0,

123.6, 89.3, 59.2, 47.3, and 27.3 ppm.

Preparation of 5-(4-nitrobenzoyl)1,3-dimethylpyrimidine-2,4,6-trione N-4diemethylaminopyridinium salt (H50). Tetrahydrofuran (200 mL) solution of 5-(4nitrobenzoyl)-1,3-dimethylpyrimidine-2,4,6-trione (610 mg; 2 mmol) and N-4dimethylaminopyridine (328 mg; 2.2 mmol) was stirred at room temperature for half an
hour. Solvent was evaporated. Solid residue was mixed with ether (100 mL), and
resulting suspension was stirred at room temperature for ten minutes. Solid product was
separated by filtration, washed with ether (3×15 mL) and dried at 110º C for half an hour.
The yield of product 93%. Product decomposes at temperatures above 220º C. 1H-NMR
(DMSO-d6, 500 MHz) δ 8.22 (2H, d, J= 8 Hz), 8.11 (2H, d, J= 8.5 Hz), 7.52 (2H, d, J=
8.5 Hz), 6.97 (2H, d, J= 8.0 Hz), 3.18 (6H, s), and 3.04 ppm (6H, s).

13

C-NMR (DMSO-
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d6, 500 MHz) δ 190.4, 162.5, 156.9, 152.4, 151.4, 146.9, 139.2, 128.1, 122.6, 106.9, 93.1,
and 26.8 ppm.

General Procedure O. Preparation of piperidinium salt of 5-[[2,4dinitrophenyl)hydrazono]-(4-hydroxyphenyl)methyl]-1,3-dimethyl-pyrimidine-2,4,6trione (H52). 1-Propanol (20 mL) suspension of 5-[[2,4-dinitrophenyl)hydrazono]-(4hydroxyphenyl)methyl]-1,3-dimethyl-pyrimidine-2,4,6-trione (0.50 g; 1.09 mmol) and
piperidine (1.3 mL; 0.111 g; 1.30 mmol) was stirred at room temperature for 2 hours.
Reaction suspension was diluted with ether (50 mL) and solid precipitate was separated
by filtration, washed with ether (3 x 15 m), and dried at 110º C for 2 hours to give 0.535
g (98%) of pure product. Product decomposes at temperatures above 250º C.

1

H-

NMR(DMSO-d6, 500 MHz), δ 11.48(1H, NH), 8.85(1H, d, J= 3.5 Hz), 8.31 (1H, d, J=
11.0 Hz), 8.03 (1H, d, J= 16 Hz), 7.56 (2H, d, J= 14 Hz), 6.72 (2H, d, J= 14 Hz), 3.10
(6H, s), 2.98 (4H, t, J= 9 Hz), 1.61 (4H, m), and 1.54 ppm (2H, m).

13

C-NMR (DMSO-

d6, 500 MHz), δ 157.1, 155.0, 153.8, 149.5, 140.4, 132.1, 126.3, 126.1, 125.9, 124.5,
120.0, 113.0, 111.2, 77.2, 40.3, 23.5, 18.7, and 18.1 ppm. MS-ES+ (CH3COOH) m/z 360
(100%). Anal. Calcd. for C24H27N7O8*0.3 H2O: C, 52.71; H, 5.09; N, 17.93; Found C,
52.82; H, 5.07; N, 17.97.

Preparation of piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(3hydroxyphenyl)methyl]pyrimidine-2,4,6-trione (H51). This compound was prepared in
93% isolated yield by following General Procedure O. 1H-NMR (DMSO-d6, 500 MHz)
δ 11.48(1H, s), 10.31 (2H, s), 8.87 (1H, d, J= 2.7 Hz), 8.37 (1H, d, J= 12.3 Hz), 8.05
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(1H, d, J= 9.6 Hz), 7.24 (1H, t, J= 7.8 Hz), 7.16 (2H, m. J= 7.8), 6.76 (1H, d, J= 10.2
Hz), 2.91 (4H, t, J= 5.1 Hz), 1.57 (4H, m), and 1.48 ppm (2H, m).

13

C-NMR (DMSO-d6,

500 MHz) δ 159.2, 153.7, 150.6, 148.2, 140.6, 135.9, 133.0, 126.5, 125.5, 125.2, 119.9,
115.0, 113.1, 112.9, 111.1, 78.0, 40.4, 18.7, and 18.2 ppm.

Preparation of piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(4hydroxyphenyl)methyl]-1-phenylpyrimidine-2,4,6-trione (H53). This compound was
prepared in 81% isolated yield by following General Procedure O. 1H-NMR (DMSOd6, 500 MHz) δ 8.89 (1H, d, J= 2.7 Hz), 8.31(1H, d, J= 12.3 Hz), 8.04 (1H, d, J= 10.2
Hz), 7.65 (2H, d, J= 8.7 Hz), 7.37 (2H, t, J= 7.5 Hz), 7.27 (1H, t, J= 7.5 Hz), 7.19 (2H,
d, J= 8.1 Hz), 6.75 (2H, d, J= 8.4 Hz), 2.91 (4H, t, J= 5.2 Hz), 1.56 (4H, m), and 1.50
ppm (2H, m).

13

C-NMR (DMSO-d6, 500 MHz) δ 158.4, 158.2, 155.1, 153.3, 148.6,

140.4, 133.8, 132.2, 126.3, 126.1, 126.0, 125.9, 124.6, 124.5, 123.3, 120.0, 113.1, 111.2,
77.1, 40.4, 18.8, and 18.2 ppm.

Synthesis of methyl L-lysine salt of 5-{(4-methoxyphenyl)[2-(4nitrophenyl)hydrazino]methylene}pyrimidine-2,4,6-trione (H54). Methanol (500 mL)
suspension of 5-{(4-methoxyphenyl)[2-(4-nitrophenyl)hydrazino]methylene}pyrimidine2,4,6-trione (0.397 g; 1.00 mmol) and L-lysine (0.146 g; 1.00 mmol) was stirred at 50º C
for ten minutes until reaction mixture becomes solution. Solvent was evaporated to solid
residue. Solid residue was mixed with ether (50 mL). Solid was separated by filtration
from resulting suspension, washed with ether (3×20 mL) and dried at 110º C for ten
minutes to give 0.525 g (97%). Product decomposes at temperatures above 200º C. 1H-
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NMR (DMSO-d6, 500 MHz) δ 10.09 (1H, s), 9.44 (2H, s), 8.06 (2H, d, J= 9.5 Hz), 7.56
(2H, d, J= 9 Hz), 7.14 (2H, d, J= 7.5 Hz), 6.84 (2H, d, J= 7.0 Hz), 3.76 (3H, s), 3.26
(1H, t, J= 6 Hz), 2.74 (2H, d, J= 7 Hz), 1.65 (2H, m), 1.51 (2H, m), and 1.37 ppm (2H
m). 13C-NMR (DMSO-d6, 500 MHz) δ 171.4, 163.6, 159.1, 152.4, 151.6, 149.6, 137.1,
132.6, 128.3, 126.0, 113.0, 111.5, 81.7, 55.1, 53.5, 38.5, 30.1, 26.6, and 21.7 ppm. MSES+ (CH3OH), m/z: 381 (M-H2O-Lysine, 100%), 632 (MNa3 +Na+), 654 (MNa4 + Na+),
676 (MNa5 + Na+), 708 (MNa5 + CH3OH + Na+), 984 (2MNa-Lysine). Anal. Calcd. for
C24H31N7O8 (545.22): C, 52.84; H, 5.73; N, 17.97; Found C, 52.82; H, 5.07; N, 17.97.

Synthesis of 5,5’-(2-pyrilidene)bis(1,3-dimethylbarbituric acid)(I-1) A methanol
solution (400 mL) of 2,2’-pyridil (0.212 g, 1.00 mmol) and 1,3-dimethylbarbituric acid
(0.468 g, 3.00 mmol) was refluxed for 5 h. The resulting dark reaction mixture was
concentrated to a 50 mL volume at atmospheric pressure and left at room temperature in
an open beaker overnight. The resulting crystalline product was slurred in ice-cold
methanol (3 x 10 mL), separated by filtration, washed with cold methanol (3 x 10 mL),
and dried at 90º C for 30 min to afford 0.350 g (87%) pure product. If necessary further
crystallization can be performed in acetic acid. 1H NMR (DMSO-d6) 8.58 (1H, d, J=
5.2 Hz), 8.41 (1H, t, J= 7.1 Hz), 7.88 (1H, d, J= 5.4 Hz), 7.81 (1H, t, J= 7.1 Hz), 6.33
(1H, s), 3.13 (12H, s) ppm.

13

C-NMR (DMSO-d6) 159.3, 155.9, 147.9, 142.4, 137.5,

122.3, 120.6, 81.1, 32.0, 24.5 ppm. MS-ESI+ in methanol 424 (M + Na)+. Anal. Calcd. .
For C18H19N5O6: C, 53.75; H, 4.83; N, 17.33. Found: C, 53.86; H, 4.77; N, 17.45.
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Synthesis of 5,5’-(2-pyrilidene)bis(1-phenylbarbituric acid)(I-2) A methanol solution
(400 mL) of 2,2’-pyridil (0.212 g, 1.00 mmol) and 1-phenylbarbituric acid (0.612 g, 3.00
mmol) was refluxed for 5 h. The resulting dark reaction mixture was concentrated to a
50 mL volume at atmospheric pressure and left at room temperature in an open beaker
overnight. The resulting crystalline product was slurred in ice-cold methanol (3 x 10
mL), separated by filtration, washed with cold methanol (3 x 10 mL), and dried at 90º C.
Yield=78%. 1H-NMR(DMSO-d6) δ 10.84 (2H, s, NH), 8.64 (2H, d, J= 6.9Hz, pyridine
6-H), 8.44 (1H, t, J= 6.9 Hz, pyridine 4-H), 7.98 (1H, d, J= 6.9Hz, pyridine 3-H), 7.83
(1H, t, J= 6.9Hz, pyridine 4-H), 7.40 (4H, t, J= 6.9 Hz, phenyl m-H), 7.32 (2H, t, J= 6.9
Hz, phenyl p-H), 7.20 (4H, d, J= 6.9 Hz, phenyl o-H), 6.23 (1H, benzyl). 13C-NMR
(DMSO-d6) δ 163.0, 159.9, 156.2 (three different carbonyls), 147.9, 147.2, 142.4, 137.6,
133.0, 125.7, 124.8, 123.9, 122.4 (nine aromatic carbons), 82.30, 30.84 ppm (two
aliphatic carbons).
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APPENDIX

X-ray Crystallographic Data, Positional Parameters, General Displacement, Parameter
Expressions, Bond Distances and Bond Angles
for
5-{(4-Methoxyphenyl)-[N'-(4-nitrophenyl)hydrazino]methylene}-1,3dimethylpyrimidine-2,4,6-trione (H25)

piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(4-hydroxyphenyl)methyl]-1,3dimethyl-pyrimidine-2,4,6-trione (H52)

Pyridinium-barbiturate Zwitterion (F1)

1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4-yl)methyl]pyrimidine2,4,6(1H,3H,5H)-trione morpholinium salt (G37)

and

5,5’-(2-pyrilidene)bis(1,3-dimethylbarbituric acid)(I-1)

262

X-ray crystallographic Data- Compound H25
(5-{(4-Methoxyphenyl)-[N'-(4-nitrophenyl)hydrazino]methylene}-1,3dimethylpyrimidine-2,4,6-trione)
Table 1: Crystal data and structure refinement for compound H25.
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space group
Unit cell dimensions
Volume
Z, Calculated density
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Limiting indices
Reflections collected / unique
Completeness to theta = 22.50
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I2sigma(I)]
R indices (all data)
Largest diff. peak and hole

C20.55 H21.98 N5 O7.07
452.20
150(2) K
0.71073 Å
Triclinic, P-1
a = 10.7707(11) Å
α = 92.675(2) deg.
b = 13.4704(14) Å
β = 90.176(3) deg.
c = 15.4021(16) Å
γ = 112.341(2) deg.
2064.1(4) Å 3
4, 1.455 Mg/m3
0.112 mm-1
947
0.15 x 0.15 x 0.4 mm
2.04 to 22.50 deg.
8<=h<=11, -14<=k<=13, -14<=l<=16
8652 / 5362 [R(int) = 0.0471]
99.1 %
Empirical
1.000000 and 0.779916
Full-matrix least-squares on F2
5362 / 1269 / 748
1.280
R1 = 0.0798, wR2 = 0.1643
R1 = 0.0918, wR2 = 0.1814
0.706 and -0.426 e. Å -3
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters
(Å 2 x 103) for H25
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
x
C(1)
N(2)
C(3)
N(4)
C(5)
C(6)
C(7)
N(8)
N(9)
C(10)
C(11)
C(12)
C(13)
C(14)
C(15)
O(16)
C(17)
O(18)
C(19)
O(20)
N(21)
O(22)
O(23)
C(24)
C(25)
C(26)
C(27)
C(28)
C(29)
O(30)
C(31)
C(51)
N(52)
C(53)
N(54)
C(55)
C(56)
C(57)

8448(10)
8350(7)
8172(9)
8085(7)
8110(8)
8352(8)
8615(7)
8645(6)
8935(6)
10242(6)
11341(6)
12595(6)
12790(6)
11691(6)
10442(6)
8582(10)
8457(11)
8072(8)
7915(11)
7912(6)
14101(6)
15063(6)
14241(6)
8846(8)
10175(9)
10384(10)
9349(10)
8032(9)
7831(9)
9499(7)
10836(12)
5840(7)
5049(6)
3688(7)
3040(6)
3701(7)
5112(7)
5809(7)

y

z

U(eq)

727(7)
-71(6)
-1090(7)
-1366(5)
-645(6)
435(6)
1233(6)
995(5)
1754(5)
2176(5)
2125(5)
2571(5)
3091(6)
3143(6)
2704(5)
1598(6)
212(8)
-1767(6)
-2467(7)
-1013(4)
3538(5)
3495(5)
3972(5)
2372(6)
3135(7)
4205(7)
4504(7)
3771(7)
2692(7)
5545(5)
6312(8)
1529(5)
1205(4)
690(5)
527(4)
847(6)
1411(5)
1898(6)

164(5)
-472(4)
-307(5)
555(4)
1237(5)
1068(5)
1734(4)
2559(3)
3246(3)
3619(4)
3180(4)
3551(4)
4367(4)
4810(4)
4436(4)
-71(4)
-1404(5)
-891(4)
762(6)
1976(3)
4757(4)
4338(4)
5498(4)
1583(5)
1560(5)
1425(5)
1290(5)
1330(5)
1464(5)
1140(4)
1040(7)
4741(4)
3985(3)
3948(5)
4728(4)
5534(4)
5540(4)
6334(4)

65(2)
55(2)
60(2)
58(2)
48(2)
48(2)
46(2)
45(2)
43(2)
42(2)
45(2)
47(2)
46(2)
45(2)
41(2)
112(3)
76(3)
91(2)
80(3)
57(2)
55(2)
67(2)
78(2)
50(2)
58(2)
62(2)
61(2)
64(2)
59(2)
79(2)
91(3)
36(2)
37(1)
37(2)
38(1)
38(2)
35(2)
42(2)
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N(58A)
5080(80)
1880(70)
7030(40)
52(3)
N(58)
5149(17)
1747(14)
7078(7)
51(3)
N(59)
5709(7)
2380(6)
7834(4)
53(2)
N(59A)
5430(40)
2190(20)
7935(11)
61(3)
C(60)
5616(6)
3401(6)
8032(5)
81(2)
C(60A)
5260(30)
3163(17)
7785(9)
75(3)
C(61)
5125(8)
3903(6)
7419(5)
84(2)
C(61A)
4000(30)
3219(18)
7751(16)
77(4)
C(62A)
3860(20)
4160(20)
7606(16)
84(3)
C(62)
5043(8)
4868(7)
7613(5)
87(2)
C(63)
5445(7)
5384(6)
8427(5)
92(3)
C(63A)
4990(30)
5090(17)
7491(10)
93(3)
C(64)
5932(9)
4889(7)
9038(5)
95(3)
C(64A)
6250(20)
5035(18)
7526(16)
90(3)
C(65A)
6380(20)
4090(20)
7669(16)
86(3)
C(65)
6016(8)
3921(7)
8845(5)
89(3)
O(66)
7067(5)
1868(4)
4668(3)
45(1)
C(67)
5722(8)
1428(7)
3138(4)
50(2)
O(68)
3073(5)
370(4)
3257(3)
47(1)
C(69)
1574(7)
-25(7)
4699(5)
55(2)
O(70)
3002(5)
615(4)
6191(3)
49(1)
N(71A)
4900(30)
6093(19)
7339(14)
112(4)
N(71)
5354(10)
6388(8)
8624(6)
108(3)
O(72A)
5970(30)
6870(20)
7240(20)
122(6)
O(72)
5493(13)
6736(9)
9395(6)
137(4)
O(73A)
3800(30)
6170(30)
7300(20)
129(7)
O(73)
5140(12)
6918(8)
8052(7)
124(3)
C(74)
7250(7)
2639(6)
6399(4)
39(2)
C(75)
8176(7)
2288(6)
6742(4)
41(2)
C(76)
9514(7)
2978(6)
6803(4)
43(2)
C(77)
9913(7)
4020(6)
6531(4)
41(2)
C(78)
8987(7)
4373(6)
6213(5)
45(2)
C(79)
7627(8)
3672(6)
6128(5)
45(2)
O(80)
11256(5)
4613(4)
6617(3)
48(1)
C(81)
11727(8)
5698(7)
6364(5)
60(2)
O(101)
5494(15)
1532(13)
8541(10)
58(3)
C(102)
5320(30)
1960(30)
9320(20)
50(4)
C(103)
5160(30)
1260(20)
10056(19)
45(3)
C(104)
5220(20)
187(18)
9949(19)
30(4)
O(105)
4978(11)
1389(11)
9526(9)
67(3)
O(106)
5252(10)
184(10)
8659(9)
76(3)
O(107)
4996(12)
447(11)
9399(11)
67(4)
________________________________________________________________
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C(1)-O(16)
C(1)-N(2)
C(1)-C(6)
N(2)-C(3)
N(2)-C(17)
C(3)-O(18)
C(3)-N(4)
N(4)-C(5)
N(4)-C(19)
C(5)-O(20)
C(5)-C(6)
C(6)-C(7)
C(7)-N(8)
C(7)-C(24)
N(8)-N(9)
N(9)-C(10)
C(10)-C(11)
C(10)-C(15)
C(11)-C(12)
C(12)-C(13)
C(13)-C(14)
C(13)-N(21)
C(14)-C(15)
N(21)-O(23)
N(21)-O(22)
C(24)-C(29)
C(24)-C(25)
C(25)-C(26)
C(26)-C(27)
C(27)-O(30)
C(27)-C(28)
C(28)-C(29)
O(30)-C(31)
C(51)-O(66)
C(51)-N(52)
C(51)-C(56)
N(52)-C(53)
N(52)-C(67)
C(53)-O(68)
C(53)-N(54)
N(54)-C(55)
N(54)-C(69)

1.200(10)
1.394(10)
1.457(11)
1.348(11)
1.497(10)
1.226(10)
1.389(11)
1.389(10)
1.474(11)
1.249(9)
1.415(11)
1.396(10)
1.328(7)
1.488(11)
1.384(7)
1.412(7)
1.388(6)
1.391(6)
1.363(7)
1.385(6)
1.391(6)
1.426(8)
1.360(7)
1.239(6)
1.241(6)
1.334(12)
1.411(11)
1.397(11)
1.340(12)
1.380(10)
1.390(12)
1.411(11)
1.432(12)
1.230(8)
1.391(9)
1.445(9)
1.362(9)
1.481(9)
1.222(8)
1.375(9)
1.394(9)
1.467(9)
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C(55)-O(70)
C(55)-C(56)
C(56)-C(57)
C(57)-N(58A)
C(57)-N(58)
C(57)-C(74)
N(58A)-N(59A)
N(58)-N(59)
N(59)-C(60)
N(59A)-O(101)
N(59A)-C(60A)
C(60)-C(65)
C(60)-C(61)
C(60A)-C(61A)
C(60A)-C(65A)
C(61)-C(62)
C(61A)-C(62A)
C(62A)-C(63A)
C(62)-C(63)
C(63)-C(64)
C(63)-N(71)
C(63A)-C(64A)
C(63A)-N(71A)
C(64)-C(65)
C(64A)-C(65A)
N(71A)-O(73A)
N(71A)-O(72A)
N(71)-O(73)
N(71)-O(72)
C(74)-C(75)
C(74)-C(79)
C(75)-C(76)
C(76)-C(77)
C(77)-C(78)
C(77)-O(80)
C(78)-C(79)
O(80)-C(81)
O(101)-C(102)
C(102)-C(103)
C(103)-C(104)
O(16)-C(1)-N(2)
O(16)-C(1)-C(6)
N(2)-C(1)-C(6)

1.243(8)
1.417(10)
1.426(10)
1.331(11)
1.333(8)
1.492(10)
1.44(8)
1.399(16)
1.435(8)
1.33(3)
1.425(10)
1.388(7)
1.399(7)
1.389(8)
1.393(8)
1.355(8)
1.362(9)
1.387(8)
1.389(7)
1.387(7)
1.412(10)
1.390(8)
1.419(11)
1.360(8)
1.357(9)
1.236(9)
1.243(9)
1.233(8)
1.243(8)
1.370(10)
1.379(10)
1.386(10)
1.389(10)
1.356(11)
1.364(9)
1.411(10)
1.426(9)
1.35(4)
1.47(3)
1.47(3)
117.8(7)
124.8(8)
117.4(8)

267

Table 3 (H25) cont.
C(3)-N(2)-C(1)
C(3)-N(2)-C(17)
C(1)-N(2)-C(17)
O(18)-C(3)-N(2)
O(18)-C(3)-N(4)
N(2)-C(3)-N(4)
C(3)-N(4)-C(5)
C(3)-N(4)-C(19)
C(5)-N(4)-C(19)
O(20)-C(5)-N(4)
O(20)-C(5)-C(6)
N(4)-C(5)-C(6)
C(7)-C(6)-C(5)
C(7)-C(6)-C(1)
C(5)-C(6)-C(1)
N(8)-C(7)-C(6)
N(8)-C(7)-C(24)
C(6)-C(7)-C(24)
C(7)-N(8)-N(9)
N(8)-N(9)-C(10)
C(11)-C(10)-C(15)
C(11)-C(10)-N(9)
C(15)-C(10)-N(9)
C(12)-C(11)-C(10)
C(11)-C(12)-C(13)
C(12)-C(13)-C(14)
C(12)-C(13)-N(21)
C(14)-C(13)-N(21)
C(15)-C(14)-C(13)
C(14)-C(15)-C(10)
O(23)-N(21)-O(22)
O(23)-N(21)-C(13)
O(22)-N(21)-C(13)
C(29)-C(24)-C(25)
C(29)-C(24)-C(7)
C(25)-C(24)-C(7)
C(26)-C(25)-C(24)
C(27)-C(26)-C(25)
C(26)-C(27)-O(30)
C(26)-C(27)-C(28)
O(30)-C(27)-C(28)
C(27)-C(28)-C(29)
C(24)-C(29)-C(28)
C(27)-O(30)-C(31)

124.5(7)
117.2(7)
118.4(7)
121.9(8)
120.0(9)
118.0(7)
122.2(7)
119.6(7)
118.2(7)
116.2(7)
124.0(7)
119.7(7)
122.1(7)
119.7(7)
117.9(7)
120.5(7)
115.9(7)
123.7(6)
123.2(6)
119.2(5)
119.1(5)
122.1(5)
118.8(5)
120.4(4)
120.4(4)
119.4(5)
120.0(5)
120.5(5)
120.1(4)
120.6(4)
122.4(7)
118.7(5)
118.9(5)
119.0(8)
121.8(7)
119.2(8)
118.9(9)
121.0(9)
123.4(9)
121.0(9)
115.6(9)
117.5(9)
122.5(8)
117.4(8)
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O(66)-C(51)-N(52)
O(66)-C(51)-C(56)
N(52)-C(51)-C(56)
C(53)-N(52)-C(51)
C(53)-N(52)-C(67)
C(51)-N(52)-C(67)
O(68)-C(53)-N(52)
O(68)-C(53)-N(54)
N(52)-C(53)-N(54)
C(53)-N(54)-C(55)
C(53)-N(54)-C(69)
C(55)-N(54)-C(69)
O(70)-C(55)-N(54)
O(70)-C(55)-C(56)
N(54)-C(55)-C(56)
C(55)-C(56)-C(57)
C(55)-C(56)-C(51)
C(57)-C(56)-C(51)
N(58A)-C(57)-C(56)
N(58)-C(57)-C(56)
N(58A)-C(57)-C(74)
N(58)-C(57)-C(74)
C(56)-C(57)-C(74)
C(57)-N(58A)-N(59A)
C(57)-N(58)-N(59)
N(58)-N(59)-C(60)
O(101)-N(59A)-C(60A)
O(101)-N(59A)-N(58A)
C(60A)-N(59A)-N(58A)
C(65)-C(60)-C(61)
C(65)-C(60)-N(59)
C(61)-C(60)-N(59)
C(61A)-C(60A)-C(65A)
C(61A)-C(60A)-N(59A)
C(65A)-C(60A)-N(59A)
C(62)-C(61)-C(60)
C(62A)-C(61A)-C(60A)
C(61A)-C(62A)-C(63A)
C(61)-C(62)-C(63)
C(64)-C(63)-C(62)
C(64)-C(63)-N(71)
C(62)-C(63)-N(71)
C(62A)-C(63A)-C(64A)

117.9(6)
126.7(6)
115.4(6)
125.7(6)
116.0(6)
118.3(6)
121.7(7)
121.5(6)
116.8(6)
123.6(6)
117.4(6)
119.0(6)
117.2(6)
125.1(6)
117.7(6)
119.9(6)
120.2(6)
119.8(6)
118(4)
119.8(10)
116(4)
115.6(10)
124.5(6)
133(7)
121.5(13)
123.1(10)
144.8(13)
125(4)
88(4)
118.0(6)
120.5(6)
121.5(6)
118.6(7)
122.0(10)
119.4(10)
121.0(5)
120.7(6)
120.6(6)
120.8(5)
118.5(6)
121.1(6)
120.4(6)
118.8(7)
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C(62A)-C(63A)-N(71A)
122.7(9)
C(64A)-C(63A)-N(71A)
118.5(9)
C(65)-C(64)-C(63)
120.9(5)
C(65A)-C(64A)-C(63A)
120.7(6)
C(64A)-C(65A)-C(60A)
120.6(6)
C(64)-C(65)-C(60)
120.9(5)
O(73A)-N(71A)-O(72A)
122.2(16)
O(73A)-N(71A)-C(63A)
120.4(12)
O(72A)-N(71A)-C(63A)
117.4(12)
O(73)-N(71)-O(72)
119.9(10)
O(73)-N(71)-C(63)
121.6(8)
O(72)-N(71)-C(63)
118.5(8)
N(71A)-O(72A)-C(12)#1
141.8(17)
C(75)-C(74)-C(79)
121.0(7)
C(75)-C(74)-C(57)
119.4(7)
C(79)-C(74)-C(57)
119.6(7)
C(74)-C(75)-C(76)
119.3(7)
C(75)-C(76)-C(77)
120.5(7)
C(78)-C(77)-O(80)
125.3(7)
C(78)-C(77)-C(76)
119.9(7)
O(80)-C(77)-C(76)
114.8(7)
C(77)-C(78)-C(79)
120.2(7)
C(74)-C(79)-C(78)
119.0(7)
C(77)-O(80)-C(81)
117.5(6)
N(59A)-O(101)-C(102)
108(2)
O(101)-C(102)-C(103)
115(3)
C(104)-C(103)-C(102)
122(3)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms:
#1 -x+2,-y+1,-z+1
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Table 4. Anisotropic displacement parameters (A2 x 103) for H25.
The anisotropic displacement factor exponent takes the form:
-2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11
U22
U33
U23
U13
U12
_______________________________________________________________________
C(1)
98(5) 52(4) 28(3)
-5(3)
2(4)
10(4)
N(2)
69(4) 63(3) 25(3)
-9(3)
0(3)
17(3)
C(3)
70(4) 63(4) 42(3)
-11(3)
6(4)
21(4)
N(4)
72(4) 49(3) 45(3)
-12(3)
5(3)
16(3)
C(5)
50(4) 43(3) 39(3)
-5(3)
0(3)
3(3)
C(6)
57(4) 45(3) 31(3)
0(3)
-1(3)
8(3)
C(7)
51(4) 46(3) 30(3)
2(3)
5(3)
7(3)
N(8)
58(4) 39(3) 29(3)
-4(2)
0(3)
9(3)
N(9)
52(3) 44(3) 28(3)
-10(2)
7(2)
13(3)
C(10)
53(3) 36(4) 32(3)
-2(3)
5(3)
12(3)
C(11)
53(3) 36(4) 39(4)
-5(3)
3(3)
11(3)
C(12)
55(4) 36(4) 48(4)
6(3)
7(3)
15(3)
C(13)
52(3) 39(4) 43(3)
6(3)
1(3)
13(3)
C(14)
55(3) 44(4) 34(4)
-2(3)
2(3)
15(3)
C(15)
49(3) 36(4) 32(3)
1(3)
5(3)
10(3)
O(16) 220(7) 60(4) 38(3)
1(3)
-3(4)
34(5)
C(17) 108(7) 87(6) 28(4)
-8(4)
-4(4)
33(5)
O(18) 124(5) 84(4) 63(4)
-24(3)
12(4)
39(4)
C(19) 116(7) 54(5) 69(6)
-13(4)
2(5)
32(5)
O(20)
75(4) 37(3) 47(3)
4(2)
9(3)
8(3)
N(21)
57(3) 53(4) 55(4)
1(3)
-2(3)
21(3)
O(22)
59(3) 68(4) 77(4)
-3(3)
-1(3)
32(3)
O(23)
69(4) 93(5) 61(4)
-8(3)
-12(3)
20(3)
C(24)
65(4) 45(3) 33(3)
5(3)
9(3)
11(3)
C(25)
66(4) 46(4) 52(4)
5(4)
4(4)
11(3)
C(26)
77(4) 46(4) 53(4)
4(4)
2(4)
12(3)
C(27)
90(4) 54(3) 37(4)
7(3)
9(4)
26(3)
C(28)
81(4) 65(4) 52(4)
10(4)
8(4)
32(4)
C(29)
68(4) 60(4) 43(4)
10(4)
10(4)
17(3)
O(30) 120(4) 57(3) 57(3)
13(3)
12(3)
32(3)
C(31) 132(7) 59(6) 65(6)
11(5)
9(6)
17(5)
C(51)
47(3) 22(3) 34(3)
1(3)
3(3)
9(3)
N(52)
48(3) 28(3) 33(3)
0(2)
2(2)
14(2)
C(53)
50(3) 26(3) 31(3)
-2(3)
-3(3)
11(3)
N(54)
42(3) 36(3) 32(3)
-1(2)
-2(2)
10(2)
C(55)
46(3) 32(3) 31(3)
-1(3)
-1(3)
9(3)
C(56)
45(3) 28(3) 28(3)
4(3)
3(2)
9(3)
C(57)
49(3) 39(3) 30(3)
5(3)
2(2)
8(3)
N(58A) 58(5) 57(6) 30(4)
5(5)
2(4)
8(5)
N(58)
58(4) 56(5) 27(3)
7(3)
0(3)
6(4)
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N(59)
63(4) 60(4) 26(3)
5(3)
-1(3)
13(3)
N(59A) 70(5) 66(5) 34(4)
0(4)
-1(4)
12(4)
C(60)
97(5) 77(4) 55(4)
-2(3)
-3(4)
17(4)
C(60A) 91(5) 73(5) 52(5)
2(4)
-1(5)
21(4)
C(61) 105(5) 76(4) 66(4)
5(4)
0(4)
28(4)
C(61A) 95(6) 78(6) 55(7)
2(7)
3(7)
29(5)
C(62A) 105(6) 81(6) 64(6)
3(6)
5(6)
32(5)
C(62) 110(5) 80(5) 65(4)
2(4)
10(5)
29(4)
C(63) 114(6) 87(5) 68(5)
-3(4)
13(5)
32(4)
C(63A) 113(5) 86(5) 72(5)
2(5)
8(5)
28(5)
C(64) 119(7) 88(6) 65(5)
-8(5)
5(5)
28(5)
C(64A) 110(6) 80(6) 70(6)
5(6)
3(6)
23(5)
C(65A) 102(6) 77(5) 65(6)
4(6)
1(6)
18(5)
C(65) 109(7) 87(6) 60(5)
-10(5)
1(5)
26(5)
O(66)
48(3) 42(3) 38(3)
-1(2)
2(2)
9(2)
C(67)
55(5) 62(5) 29(4)
9(4)
5(3)
18(4)
O(68)
57(3) 40(3) 34(3)
-6(2)
-5(2)
10(2)
C(69)
42(4) 56(5) 52(5)
5(4)
0(3)
3(4)
O(70)
49(3) 49(3) 33(3)
4(2)
7(2)
2(2)
N(71A) 132(7) 98(6) 106(8)
9(7)
10(8)
42(6)
N(71) 143(7) 103(6) 85(5)
-5(4)
22(6)
55(5)
O(72A) 138(8) 107(8) 116(9)
11(8)
14(8)
39(7)
O(72) 180(8) 134(7) 101(6)
-20(5)
14(6)
69(6)
O(73A) 135(9) 120(12) 134(13)
5(11)
4(11)
51(8)
O(73) 146(6) 123(6) 115(6)
11(5)
17(5)
63(5)
C(74)
50(3) 33(3) 27(3)
-3(3)
-3(3)
8(3)
C(75)
53(3) 30(3) 34(4)
1(3)
0(3)
9(3)
C(76)
53(3) 44(3) 30(4)
1(3)
-1(3)
16(3)
C(77)
48(3) 37(3) 29(3)
-4(3)
1(3)
8(3)
C(78)
55(4) 32(3) 41(4)
3(3)
3(3)
10(3)
C(79)
56(4) 38(3) 37(4)
6(3)
-2(3)
12(3)
O(80)
47(3) 42(3) 46(3)
-1(2)
3(2)
6(2)
C(81)
58(5) 49(4) 53(5)
3(4)
2(4)
-1(4)
O(101) 60(5)
68(5)
36(4)
0(4)
2(4)
13(4)
C(102) 52(7)
56(7)
36(5)
-2(5)
2(6)
14(6)
C(103) 49(6)
55(6)
32(5)
-8(6)
1(6)
24(5)
C(104) 30(8)
52(7)
7(6)
-14(6)
-10(6)
17(6)
O(105) 64(5)
73(5)
59(5)
-12(5)
-1(4)
23(4)
O(106) 64(6)
80(6)
80(6)
-63(5)
-1(5)
30(5)
O(107) 58(5)
70(6)
61(6)
-16(5)
-3(5)
12(4)
_______________________________________________________________________
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters
(A2 x 103) for H25.
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
H(8)
8472
322
2674
54
H(9)
8311
1970
3447
52
H(11)
11219
1778
2617
54
H(12)
13340
2524
3249
56
H(14)
11813
3484
5376
55
H(15)
9699
2759
4736
49
H(17A)
9227
99
-1660
113
H(17B)
8578
968
-1440
113
H(17C)
7634
-245
-1724
113
H(19A)
6956
-2910
797
121
H(19B)
8362
-2448
1321
121
H(19C)
8313
-2774
305
121
H(25)
10915
2925
1634
70
H(26)
11274
4729
1429
74
H(28)
7296
3988
1268
77
H(29)
6938
2174
1470
71
H(31A)
11342
6421
1589
136
H(31B)
10802
6995
876
136
H(31C)
11280
6043
584
136
H(58A)
4211
1620
6923
63
H(58)
4343
1238
7094
62
H(59)
6138
2141
8206
63
H(61)
4845
3563
6859
101
H(61A)
3218
2592
7828
93
H(62A)
2996
4190
7584
101
H(62)
4707
5195
7187
104
H(64)
6209
5230
9598
114
H(64A)
7026
5663
7448
108
H(65A)
7252
4069
7691
103
H(65)
6353
3596
9272
107
H(67A)
6044
857
2973
75
H(67B)
6484
2120
3188
75
H(67C)
5083
1454
2694
75
H(69A)
1212
134
4161
82
H(69B)
1193
224
5201
82
H(69C)
1337
-802
4714
82
H(75)
7904
1578
6936
49
H(76)
10163
2736
7033
51
H(78)
9255
5095
6048
53
H(79)
6980
3908
5886
54
H(81A)
11440
5712
5762
90
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H(81B)
12709
6015
6410
90
H(81C)
11353
6112
6746
90
H(10A)
4521
2147
9283
60
H(10B)
6108
2635
9453
60
H(10C)
5845
1669
10502
54
H(10D)
4274
1150
10309
54
H(10E)
4775
-167
9400
45
H(10F)
4772
-247
10433
45
H(10G)
6164
262
9943
45
H(101)
5580(150)
1920(120)
9300(150)
80
H(102)
5200(200)
1150(190)
9980(100)
80
H(103)
5810(190)
610(140)
8220(120)
91
H(104)
4500(80)
260(130)
8710(110)
91
H(105)
5700(300)
490(170)
8260(160)
80
H(106)
5360(190)
-50(120)
9190(120)
80
________________________________________________________________
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Table 6. Torsion angles [deg] for H25.
_______________________________________________________________
O(16)-C(1)-N(2)-C(3)
-178.7(10)
C(6)-C(1)-N(2)-C(3)
0.0(13)
O(16)-C(1)-N(2)-C(17)
1.8(14)
C(6)-C(1)-N(2)-C(17)
-179.5(8)
C(1)-N(2)-C(3)-O(18)
178.9(9)
C(17)-N(2)-C(3)-O(18)
-1.5(13)
C(1)-N(2)-C(3)-N(4)
-0.2(13)
C(17)-N(2)-C(3)-N(4)
179.4(8)
O(18)-C(3)-N(4)-C(5)
-176.0(8)
N(2)-C(3)-N(4)-C(5)
3.1(12)
O(18)-C(3)-N(4)-C(19)
2.0(13)
N(2)-C(3)-N(4)-C(19)
-178.9(8)
C(3)-N(4)-C(5)-O(20)
174.3(7)
C(19)-N(4)-C(5)-O(20)
-3.7(11)
C(3)-N(4)-C(5)-C(6)
-5.8(12)
C(19)-N(4)-C(5)-C(6)
176.2(8)
O(20)-C(5)-C(6)-C(7)
11.1(13)
N(4)-C(5)-C(6)-C(7)
-168.9(7)
O(20)-C(5)-C(6)-C(1)
-174.7(8)
N(4)-C(5)-C(6)-C(1)
5.4(12)
O(16)-C(1)-C(6)-C(7)
-9.6(15)
N(2)-C(1)-C(6)-C(7)
171.8(8)
O(16)-C(1)-C(6)-C(5)
176.0(10)
N(2)-C(1)-C(6)-C(5)
-2.6(12)
C(5)-C(6)-C(7)-N(8)
-0.1(12)
C(1)-C(6)-C(7)-N(8)
-174.2(8)
C(5)-C(6)-C(7)-C(24)
-178.7(8)
C(1)-C(6)-C(7)-C(24)
7.2(12)
C(6)-C(7)-N(8)-N(9)
178.3(7)
C(24)-C(7)-N(8)-N(9)
-3.0(10)
C(7)-N(8)-N(9)-C(10)
-99.5(8)
N(8)-N(9)-C(10)-C(11)
20.1(10)
N(8)-N(9)-C(10)-C(15)
-163.0(6)
C(15)-C(10)-C(11)-C(12)
1.1(11)
N(9)-C(10)-C(11)-C(12)
178.0(7)
C(10)-C(11)-C(12)-C(13)
-0.8(11)
C(10)-C(11)-C(12)-O(72A)#1
-148.2(11)
C(11)-C(12)-C(13)-C(14)
0.9(11)
O(72A)#1-C(12)-C(13)-C(14)
148.0(12)
C(11)-C(12)-C(13)-N(21)
178.8(7)
O(72A)#1-C(12)-C(13)-N(21)
-34.1(14)
C(12)-C(13)-C(14)-C(15)
-1.4(11)
N(21)-C(13)-C(14)-C(15)
-179.3(7)
C(13)-C(14)-C(15)-C(10)
1.8(11)
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C(11)-C(10)-C(15)-C(14)
N(9)-C(10)-C(15)-C(14)
C(12)-C(13)-N(21)-O(23)
C(14)-C(13)-N(21)-O(23)
C(12)-C(13)-N(21)-O(22)
C(14)-C(13)-N(21)-O(22)
N(8)-C(7)-C(24)-C(29)
C(6)-C(7)-C(24)-C(29)
N(8)-C(7)-C(24)-C(25)
C(6)-C(7)-C(24)-C(25)
C(29)-C(24)-C(25)-C(26)
C(7)-C(24)-C(25)-C(26)
C(24)-C(25)-C(26)-C(27)
C(25)-C(26)-C(27)-O(30)
C(25)-C(26)-C(27)-C(28)
C(26)-C(27)-C(28)-C(29)
O(30)-C(27)-C(28)-C(29)
C(25)-C(24)-C(29)-C(28)
C(7)-C(24)-C(29)-C(28)
C(27)-C(28)-C(29)-C(24)
C(26)-C(27)-O(30)-C(31)
C(28)-C(27)-O(30)-C(31)
O(66)-C(51)-N(52)-C(53)
C(56)-C(51)-N(52)-C(53)
O(66)-C(51)-N(52)-C(67)
C(56)-C(51)-N(52)-C(67)
C(51)-N(52)-C(53)-O(68)
C(67)-N(52)-C(53)-O(68)
C(51)-N(52)-C(53)-N(54)
C(67)-N(52)-C(53)-N(54)
O(68)-C(53)-N(54)-C(55)
N(52)-C(53)-N(54)-C(55)
O(68)-C(53)-N(54)-C(69)
N(52)-C(53)-N(54)-C(69)
C(53)-N(54)-C(55)-O(70)
C(69)-N(54)-C(55)-O(70)
C(53)-N(54)-C(55)-C(56)
C(69)-N(54)-C(55)-C(56)
O(70)-C(55)-C(56)-C(57)
N(54)-C(55)-C(56)-C(57)
O(70)-C(55)-C(56)-C(51)
N(54)-C(55)-C(56)-C(51)
O(66)-C(51)-C(56)-C(55)
N(52)-C(51)-C(56)-C(55)

-1.6(11)
-178.6(7)
-177.9(7)
-0.1(11)
3.3(11)
-178.8(7)
-96.8(9)
81.8(11)
83.6(9)
-97.8(9)
0.9(12)
-179.5(7)
-2.3(12)
-178.9(7)
3.8(13)
-3.7(13)
178.8(7)
-1.1(12)
179.3(7)
2.4(13)
6.5(12)
-176.1(8)
171.3(6)
-7.7(9)
-8.5(9)
172.5(6)
-175.2(6)
4.6(10)
3.5(10)
-176.7(6)
177.9(6)
-0.8(10)
-1.4(10)
179.9(6)
-177.3(6)
1.9(10)
2.9(10)
-177.8(6)
-9.3(11)
170.4(6)
172.9(7)
-7.3(10)
-169.5(7)
9.4(9)
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O(66)-C(51)-C(56)-C(57)
N(52)-C(51)-C(56)-C(57)
C(55)-C(56)-C(57)-N(58A)
C(51)-C(56)-C(57)-N(58A)
C(55)-C(56)-C(57)-N(58)
C(51)-C(56)-C(57)-N(58)
C(55)-C(56)-C(57)-C(74)
C(51)-C(56)-C(57)-C(74)
N(58)-C(57)-N(58A)-N(59A)
C(56)-C(57)-N(58A)-N(59A)
C(74)-C(57)-N(58A)-N(59A)
N(58A)-C(57)-N(58)-N(59)
C(56)-C(57)-N(58)-N(59)
C(74)-C(57)-N(58)-N(59)
C(57)-N(58)-N(59)-C(60)
C(57)-N(58A)-N(59A)-O(101)
C(57)-N(58A)-N(59A)-C(60A)
N(58)-N(59)-C(60)-C(65)
N(58)-N(59)-C(60)-C(61)
O(101)-N(59A)-C(60A)-C(61A)
N(58A)-N(59A)-C(60A)-C(61A)
O(101)-N(59A)-C(60A)-C(65A)
N(58A)-N(59A)-C(60A)-C(65A)
C(65)-C(60)-C(61)-C(62)
N(59)-C(60)-C(61)-C(62)
C(65A)-C(60A)-C(61A)-C(62A)
N(59A)-C(60A)-C(61A)-C(62A)
C(60A)-C(61A)-C(62A)-C(63A)
C(60)-C(61)-C(62)-C(63)
C(61)-C(62)-C(63)-C(64)
C(61)-C(62)-C(63)-N(71)
C(61A)-C(62A)-C(63A)-C(64A)
C(61A)-C(62A)-C(63A)-N(71A)
C(62)-C(63)-C(64)-C(65)
N(71)-C(63)-C(64)-C(65)
C(62A)-C(63A)-C(64A)-C(65A)
N(71A)-C(63A)-C(64A)-C(65A)
C(63A)-C(64A)-C(65A)-C(60A)
C(61A)-C(60A)-C(65A)-C(64A)
N(59A)-C(60A)-C(65A)-C(64A)
C(63)-C(64)-C(65)-C(60)
C(61)-C(60)-C(65)-C(64)
N(59)-C(60)-C(65)-C(64)

12.7(11)
-168.4(6)
-5(5)
172(5)
5.4(14)
-176.9(10)
-170.9(7)
6.9(11)
68(28)
173(7)
-20(11)
-86(28)
-166.2(11)
10.3(19)
85.3(16)
-94(10)
100(9)
170.6(8)
-9.4(8)
-82(4)
80(3)
98(4)
-100(3)
0.1(2)
-179.95(14)
0.0(2)
-179.99(14)
0.0(2)
0.0(2)
-0.1(2)
-179.87(17)
0.0(3)
180.00(17)
0.1(2)
179.92(18)
0.0(3)
180.00(17)
0.0(2)
0.0(2)
179.99(14)
-0.1(2)
0.0(2)
180.00(14)
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C(62A)-C(63A)-N(71A)-O(73A)
0.0(3)
C(64A)-C(63A)-N(71A)-O(73A)
-180.0(2)
C(62A)-C(63A)-N(71A)-O(72A)
-180.0(2)
C(64A)-C(63A)-N(71A)-O(72A)
0.0(3)
C(64)-C(63)-N(71)-O(73)
167.7(10)
C(62)-C(63)-N(71)-O(73)
-12.5(10)
C(64)-C(63)-N(71)-O(72)
-12.4(10)
C(62)-C(63)-N(71)-O(72)
167.4(9)
O(73A)-N(71A)-O(72A)-C(12)#1
-110(3)
C(63A)-N(71A)-O(72A)-C(12)#1
70(3)
N(58A)-C(57)-C(74)-C(75)
86(5)
N(58)-C(57)-C(74)-C(75)
75.6(12)
C(56)-C(57)-C(74)-C(75)
-108.0(9)
N(58A)-C(57)-C(74)-C(79)
-93(5)
N(58)-C(57)-C(74)-C(79)
-103.3(11)
C(56)-C(57)-C(74)-C(79)
73.1(10)
C(79)-C(74)-C(75)-C(76)
-1.0(11)
C(57)-C(74)-C(75)-C(76)
-180.0(6)
C(74)-C(75)-C(76)-C(77)
0.8(10)
C(75)-C(76)-C(77)-C(78)
0.9(10)
C(75)-C(76)-C(77)-O(80)
-179.4(6)
O(80)-C(77)-C(78)-C(79)
177.9(6)
C(76)-C(77)-C(78)-C(79)
-2.5(11)
C(75)-C(74)-C(79)-C(78)
-0.5(11)
C(57)-C(74)-C(79)-C(78)
178.4(6)
C(77)-C(78)-C(79)-C(74)
2.3(11)
C(78)-C(77)-O(80)-C(81)
0.9(10)
C(76)-C(77)-O(80)-C(81)
-178.8(6)
C(60A)-N(59A)-O(101)-C(102)
1(5)
N(58A)-N(59A)-O(101)-C(102)
-156(4)
N(59A)-O(101)-C(102)-C(103)
171(3)
O(101)-C(102)-C(103)-C(104)
2(5)
________________________________________________________________
Symmetry transformations used to generate equivalent atoms:
#1 -x+2,-y+1,-z+1
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X-ray crystallographic Data- Compound H52
(piperidinium salt of 5-[[2,4-dinitrophenyl)hydrazono]-(4-hydroxyphenyl)methyl]-1,3dimethyl-pyrimidine-2,4,6-trione)
Table 7. Crystal data and structure refinement for compound H52.
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space group
Unit cell dimensions
Volume
Z, Calculated density
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Limiting indices
Reflections collected / unique
Completeness to theta = 27.50
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^2
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole

C24 H27 N7 O8
541.53
150(2) K
0.71073 Å
Monoclinic, P2(1)/n
a = 8.5917(3) Å alpha = 90 deg.
b = 17.4016(5) Å beta = 101.8980(10) deg.
c = 16.8982(5) Å gamma = 90 deg.
2472.16(13) Å 3
4, 1.455 Mg/m3
0.112 mm-1
1136
0.3 x 0.4 x 0.5 mm
2.34 to 27.50 deg.
-11<=h<=11, -22<=k<=22, -21<=l<=21
34222 / 5677 [R(int) = 0.0348]
100.0 %
Empirical
1.000000 and 0.705996
Full-matrix least-squares on F2
5677 / 374 / 474
1.100
R1 = 0.0470, wR2 = 0.1526
R1 = 0.0568, wR2 = 0.1689
0.013(3)
0.683 and -0.548 e.A-3
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Table 8. Atomic coordinates ( x 104) and equivalent isotropic
displacement parameters (A2 x 103) for H52.
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
C(1)
11042(2)
701(1)
1889(1)
29(1)
N(3)
11211(2)
1472(1)
1651(1)
31(1)
C(3)
9975(2)
1983(1)
1480(1)
31(1)
N(5)
8530(2)
1746(1)
1615(1)
30(1)
C(5)
8258(2)
1016(1)
1928(1)
28(1)
C(6)
9562(2)
506(1)
2082(1)
27(1)
C(7)
9318(2)
-283(1)
2364(1)
27(1)
N(8)
8904(2)
-436(1)
3048(1)
30(1)
N(9)
8842(2)
188(1)
3538(1)
30(1)
C(10)
8267(2)
117(1)
4221(1)
28(1)
C(11)
8226(2)
740(1)
4761(1)
29(1)
C(12)
7569(2)
664(1)
5441(1)
32(1)
C(13)
6975(2)
-36(1)
5605(1)
34(1)
C(14)
7047(2)
-679(1)
5113(1)
36(1)
C(15)
7680(2)
-598(1)
4435(1)
32(1)
N(16)
8865(2)
1490(1)
4632(1)
36(1)
O(17)
9177(2)
1638(1)
3965(1)
49(1)
O(18)
9079(2)
1957(1)
5190(1)
48(1)
N(19)
6202(2)
-93(1)
6293(1)
47(1)
O(20)
5750(3)
-718(1)
6466(1)
76(1)
O(21)
6010(2)
497(1)
6654(1)
65(1)
O(22)
12173(1)
261(1)
1916(1)
39(1)
C(23)
12802(2)
1739(1)
1580(1)
41(1)
O(24)
10141(2)
2631(1)
1200(1)
39(1)
C(25)
7188(2)
2284(1)
1408(1)
39(1)
O(26)
6890(1)
868(1)
2022(1)
34(1)
C(27)
9445(2)
-945(1)
1839(1)
27(1)
C(28)
9645(2)
-1697(1)
2144(1)
30(1)
C(29)
9649(2)
-2321(1)
1640(1)
33(1)
C(30)
9495(2)
-2211(1)
810(1)
31(1)
C(31)
9325(2)
-1468(1)
495(1)
31(1)
C(32)
9294(2)
-847(1)
1008(1)
29(1)
O(33)
9551(2)
-2845(1)
347(1)
38(1)
N(34)
4978(2)
447(1)
8184(1)
30(1)
C(35)
5280(2)
353(1)
9083(1)
35(1)
C(36)
6642(2)
861(1)
9489(1)
38(1)
C(37)
6355(2)
1702(1)
9237(1)
40(1)
C(38)
6014(2)
1770(1)
8318(1)
40(1)
C(39)
4634(2)
1268(1)
7938(1)
35(1)
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Table 9. Bond lengths [A] and angles [deg] for H52.
_____________________________________________________________
C(1)-O(22)
1.231(2)
C(1)-N(3)
1.416(2)
C(1)-C(6)
1.417(2)
N(3)-C(3)
1.370(2)
N(3)-C(23)
1.472(2)
C(3)-O(24)
1.241(2)
C(3)-N(5)
1.372(2)
N(5)-C(5)
1.413(2)
N(5)-C(25)
1.469(2)
C(5)-O(26)
1.246(2)
C(5)-C(6)
1.411(2)
C(6)-C(7)
1.483(2)
C(7)-N(8)
1.303(2)
C(7)-C(27)
1.473(2)
N(8)-N(9)
1.3729(19)
N(9)-C(10)
1.352(2)
C(10)-C(15)
1.418(2)
C(10)-C(11)
1.422(2)
C(11)-C(12)
1.387(2)
C(11)-N(16)
1.449(2)
C(12)-C(13)
1.370(3)
C(13)-C(14)
1.403(3)
C(13)-N(19)
1.457(2)
C(14)-C(15)
1.373(2)
N(16)-O(18)
1.230(2)
N(16)-O(17)
1.237(2)
N(19)-O(20)
1.212(3)
N(19)-O(21)
1.223(3)
C(27)-C(32)
1.394(2)
C(27)-C(28)
1.403(2)
C(28)-C(29)
1.380(2)
C(29)-C(30)
1.395(2)
C(30)-O(33)
1.358(2)
C(30)-C(31)
1.395(2)
C(31)-C(32)
1.389(2)
N(34)-C(35)
1.497(2)
N(34)-C(39)
1.499(2)
C(35)-C(36)
1.514(3)
C(36)-C(37)
1.529(3)
C(37)-C(38)
1.524(3)
C(38)-C(39)
1.507(3)
O(22)-C(1)-N(3)
118.29(14)
O(22)-C(1)-C(6)
125.50(15)
N(3)-C(1)-C(6)
116.21(14)
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C(3)-N(3)-C(1)
C(3)-N(3)-C(23)
C(1)-N(3)-C(23)
O(24)-C(3)-N(3)
O(24)-C(3)-N(5)
N(3)-C(3)-N(5)
C(3)-N(5)-C(5)
C(3)-N(5)-C(25)
C(5)-N(5)-C(25)
O(26)-C(5)-C(6)
O(26)-C(5)-N(5)
C(6)-C(5)-N(5)
C(5)-C(6)-C(1)
C(5)-C(6)-C(7)
C(1)-C(6)-C(7)
N(8)-C(7)-C(27)
N(8)-C(7)-C(6)
C(27)-C(7)-C(6)
C(7)-N(8)-N(9)
C(10)-N(9)-N(8)
N(9)-C(10)-C(15)
N(9)-C(10)-C(11)
C(15)-C(10)-C(11)
C(12)-C(11)-C(10)
C(12)-C(11)-N(16)
C(10)-C(11)-N(16)
C(13)-C(12)-C(11)
C(12)-C(13)-C(14)
C(12)-C(13)-N(19)
C(14)-C(13)-N(19)
C(15)-C(14)-C(13)
C(14)-C(15)-C(10)
O(18)-N(16)-O(17)
O(18)-N(16)-C(11)
O(17)-N(16)-C(11)
O(20)-N(19)-O(21)
O(20)-N(19)-C(13)
O(21)-N(19)-C(13)
C(32)-C(27)-C(28)
C(32)-C(27)-C(7)
C(28)-C(27)-C(7)
C(29)-C(28)-C(27)
C(28)-C(29)-C(30)

123.68(14)
118.09(15)
118.24(15)
121.65(15)
121.04(16)
117.30(14)
123.89(14)
117.50(14)
118.60(14)
125.46(15)
117.87(14)
116.63(14)
121.51(14)
118.82(14)
119.30(14)
116.23(14)
123.84(14)
119.83(13)
115.11(14)
120.65(14)
120.64(15)
122.73(14)
116.62(14)
121.80(15)
116.28(15)
121.92(14)
118.96(16)
121.76(16)
118.12(16)
120.08(17)
119.02(16)
121.74(16)
122.29(15)
118.71(15)
119.01(14)
123.42(18)
118.37(18)
118.19(18)
117.62(14)
120.55(14)
121.76(14)
121.48(15)
120.09(15)
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Table 9 (H52) cont.
O(33)-C(30)-C(31)
123.15(15)
O(33)-C(30)-C(29)
117.43(15)
C(31)-C(30)-C(29)
119.41(15)
C(32)-C(31)-C(30)
119.82(15)
C(31)-C(32)-C(27)
121.57(15)
C(35)-N(34)-C(39)
111.66(13)
N(34)-C(35)-C(36)
110.58(15)
C(35)-C(36)-C(37)
111.51(15)
C(38)-C(37)-C(36)
110.19(15)
C(39)-C(38)-C(37)
110.95(15)
N(34)-C(39)-C(38)
109.97(14)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1
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Table 10. Anisotropic displacement parameters (A2 x 103) for H52.
The anisotropic displacement factor exponent takes the form:
-2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11
U22
U33
U23 U13
U12
____________________________________________________________________
C(1) 30(1) 33(1) 25(1) -2(1)
8(1) -1(1)
N(3) 32(1)
35(1)
28(1) -2(1)
9(1) -5(1)
C(3) 39(1) 29(1) 25(1) -3(1)
8(1) -5(1)
N(5) 36(1)
27(1)
28(1)
0(1)
9(1)
2(1)
C(5) 32(1) 29(1) 24(1)
-3(1)
7(1)
0(1)
C(6) 29(1) 30(1) 24(1)
0(1)
7(1)
0(1)
C(7) 26(1) 30(1) 26(1)
0(1)
7(1)
2(1)
N(8) 33(1)
29(1)
29(1) -2(1) 10(1)
1(1)
N(9) 36(1)
27(1)
27(1) -2(1)
11(1) -1(1)
C(10) 28(1)
30(1)
26(1)
0(1)
6(1)
2(1)
C(11) 31(1)
29(1)
28(1)
-2(1)
5(1)
0(1)
C(12) 31(1)
40(1)
25(1)
-4(1)
5(1)
4(1)
C(13) 32(1)
48(1)
24(1)
1(1)
8(1) -1(1)
C(14) 40(1)
40(1)
29(1)
2(1)
9(1) -6(1)
C(15) 36(1)
32(1)
28(1)
-1(1)
8(1) -2(1)
N(16) 39(1)
32(1)
39(1) -6(1)
10(1) -3(1)
O(17) 72(1)
35(1)
43(1) -1(1) 21(1) -10(1)
O(18) 54(1)
41(1)
50(1) -18(1) 15(1) -9(1)
N(19) 41(1)
71(1)
28(1)
2(1)
9(1) -2(1)
O(20) 102(2)
94(1)
41(1) -11(1)
34(1) -55(1)
O(21) 85(1)
79(1)
38(1)
7(1) 30(1) 35(1)
O(22) 29(1)
42(1)
47(1)
-2(1) 11(1)
4(1)
C(23) 34(1)
52(1)
37(1)
0(1)
9(1) -13(1)
O(24) 56(1)
29(1)
34(1) -1(1)
18(1) -6(1)
C(25) 43(1)
32(1)
43(1)
1(1) 10(1)
7(1)
O(26) 29(1)
33(1)
41(1)
1(1) 11(1)
2(1)
C(27) 25(1)
30(1)
26(1)
-1(1)
9(1)
2(1)
C(28) 34(1)
32(1)
27(1)
2(1) 10(1)
3(1)
C(29) 38(1)
29(1)
33(1)
3(1) 11(1)
3(1)
C(30) 32(1)
30(1)
32(1)
-3(1)
9(1)
1(1)
C(31) 36(1)
33(1)
25(1)
0(1)
7(1)
0(1)
C(32) 30(1)
28(1)
29(1)
1(1)
8(1)
1(1)
O(33) 54(1)
29(1)
32(1)
-4(1) 11(1)
0(1)
N(34) 28(1)
35(1)
30(1)
-1(1)
9(1)
0(1)
C(35) 35(1)
42(1)
30(1)
3(1) 11(1)
0(1)
C(36) 37(1)
44(1)
33(1)
-2(1)
4(1)
1(1)
C(37) 41(1)
41(1)
39(1) -8(1)
10(1) -2(1)
C(38) 44(1)
35(1)
43(1)
2(1) 17(1) -1(1)
C(39) 35(1)
38(1)
33(1)
3(1)
9(1)
8(1)
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Table 11. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2 x
103) for H52.
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
H(9)
9130(30)
660(14) 3415(13) 40(6)
H(12)
7600(30)
1072(13)
5805(15)
48(6)
H(14)
6550(30) -1127(14)
5249(15)
48(6)
H(15)
7670(30) -1044(13)
4050(15)
46(6)
H(23A)
12890(30)
2250(16)
1750(16)
55(7)
H(23B)
12920(40)
1710(16)
1023(19)
68(8)
H(23C)
13630(30)
1448(14)
1948(15)
48(6)
H(25A)
7030(40)
2403(18)
832(10)
46(12)
H(25B)
7480(40)
2745(13)
1738(15)
39(11)
H(25C)
6250(20)
2046(15)
1544(17)
27(9)
H(25F)
6330(40)
2000(20)
1050(30)
13(16)
H(25E)
7450(80)
2750(30)
1130(30)
60(30)
H(25D)
6840(80)
2430(40)
1900(30) 110(40)
H(28)
9800(20) -1787(10)
2728(12)
27(4)
H(29)
9810(30) -2830(13)
1850(14)
38(5)
H(31)
9180(30) -1388(13)
-95(14)
41(6)
H(32)
9190(20)
-328(12)
782(12) 30(5)
H(33)
9540(30) -2686(15)
-196(17)
55(7)
H(34A)
5870(30)
279(13)
8007(13)
39(5)
H(34B)
4150(30)
86(13)
8008(14)
45(6)
H(35A)
5510(30)
-197(13)
9194(14)
42(6)
H(35B)
4370(30)
467(12)
9236(12)
30(5)
H(36A)
6810(30)
795(12) 10060(15)
41(6)
H(36B)
7680(30)
693(13)
9332(13)
45(6)
H(37A)
7300(30)
2029(12)
9473(13)
37(5)
H(37B)
5410(30)
1918(13)
9434(15)
47(6)
H(38A)
6930(30)
1623(14)
8146(15)
50(6)
H(38B)
5760(30)
2317(15)
8138(15)
55(7)
H(39A)
4480(20)
1276(12)
7369(14)
36(5)
H(39B)
3610(30)
1393(12)
8104(13)
34(5)
________________________________________________________________
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Table 12. Torsion angles [deg] for H52.
________________________________________________________________
O(22)-C(1)-N(3)-C(3)
169.82(15)
C(6)-C(1)-N(3)-C(3)
-10.6(2)
O(22)-C(1)-N(3)-C(23)
-9.9(2)
C(6)-C(1)-N(3)-C(23)
169.69(15)
C(1)-N(3)-C(3)-O(24)
-173.12(14)
C(23)-N(3)-C(3)-O(24)
6.6(2)
C(1)-N(3)-C(3)-N(5)
5.7(2)
C(23)-N(3)-C(3)-N(5)
-174.57(14)
O(24)-C(3)-N(5)-C(5)
179.68(14)
N(3)-C(3)-N(5)-C(5)
0.9(2)
O(24)-C(3)-N(5)-C(25)
0.7(2)
N(3)-C(3)-N(5)-C(25)
-178.10(14)
C(3)-N(5)-C(5)-O(26)
-179.80(14)
C(25)-N(5)-C(5)-O(26)
-0.9(2)
C(3)-N(5)-C(5)-C(6)
-1.9(2)
C(25)-N(5)-C(5)-C(6)
177.07(14)
O(26)-C(5)-C(6)-C(1)
174.28(15)
N(5)-C(5)-C(6)-C(1)
-3.5(2)
O(26)-C(5)-C(6)-C(7)
1.3(2)
N(5)-C(5)-C(6)-C(7)
-176.45(13)
O(22)-C(1)-C(6)-C(5)
-171.20(16)
N(3)-C(1)-C(6)-C(5)
9.2(2)
O(22)-C(1)-C(6)-C(7)
1.7(2)
N(3)-C(1)-C(6)-C(7)
-177.83(13)
C(5)-C(6)-C(7)-N(8)
-63.2(2)
C(1)-C(6)-C(7)-N(8)
123.66(17)
C(5)-C(6)-C(7)-C(27)
112.97(16)
C(1)-C(6)-C(7)-C(27)
-60.2(2)
C(27)-C(7)-N(8)-N(9)
178.05(13)
C(6)-C(7)-N(8)-N(9)
-5.6(2)
C(7)-N(8)-N(9)-C(10)
172.95(15)
N(8)-N(9)-C(10)-C(15)
-1.6(2)
N(8)-N(9)-C(10)-C(11)
177.90(14)
N(9)-C(10)-C(11)-C(12)
177.13(16)
C(15)-C(10)-C(11)-C(12)
-3.3(2)
N(9)-C(10)-C(11)-N(16)
-2.7(2)
C(15)-C(10)-C(11)-N(16)
176.81(15)
C(10)-C(11)-C(12)-C(13)
1.5(2)
N(16)-C(11)-C(12)-C(13)
-178.65(15)
C(11)-C(12)-C(13)-C(14)
1.4(3)
C(11)-C(12)-C(13)-N(19)
-176.32(15)
C(12)-C(13)-C(14)-C(15)
-2.2(3)
N(19)-C(13)-C(14)-C(15)
175.42(16)
C(13)-C(14)-C(15)-C(10)
0.2(3)
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Table 12 (H52) cont.
N(9)-C(10)-C(15)-C(14)
-178.01(16)
C(11)-C(10)-C(15)-C(14)
2.5(2)
C(12)-C(11)-N(16)-O(18)
14.1(2)
C(10)-C(11)-N(16)-O(18)
-166.04(16)
C(12)-C(11)-N(16)-O(17)
-165.92(16)
C(10)-C(11)-N(16)-O(17)
13.9(2)
C(12)-C(13)-N(19)-O(20)
-176.18(19)
C(14)-C(13)-N(19)-O(20)
6.1(3)
C(12)-C(13)-N(19)-O(21)
5.5(3)
C(14)-C(13)-N(19)-O(21)
-172.21(17)
N(8)-C(7)-C(27)-C(32)
156.20(15)
C(6)-C(7)-C(27)-C(32)
-20.3(2)
N(8)-C(7)-C(27)-C(28)
-20.7(2)
C(6)-C(7)-C(27)-C(28)
162.85(15)
C(32)-C(27)-C(28)-C(29)
-1.7(2)
C(7)-C(27)-C(28)-C(29)
175.28(15)
C(27)-C(28)-C(29)-C(30)
1.7(3)
C(28)-C(29)-C(30)-O(33)
178.28(15)
C(28)-C(29)-C(30)-C(31)
-0.5(3)
O(33)-C(30)-C(31)-C(32)
-179.35(15)
C(29)-C(30)-C(31)-C(32)
-0.6(3)
C(30)-C(31)-C(32)-C(27)
0.6(2)
C(28)-C(27)-C(32)-C(31)
0.5(2)
C(7)-C(27)-C(32)-C(31)
-176.49(15)
C(39)-N(34)-C(35)-C(36)
-57.28(19)
N(34)-C(35)-C(36)-C(37)
54.9(2)
C(35)-C(36)-C(37)-C(38)
-54.3(2)
C(36)-C(37)-C(38)-C(39)
55.9(2)
C(35)-N(34)-C(39)-C(38)
58.86(19)
C(37)-C(38)-C(39)-N(34)
-58.0(2)
________________________________________________________________
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1
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X-ray crystallographic Data- Compound F1
(Pyridinium-barbiturate Zwitterion)
Table 13. Crystal data and structure refinement for compound F1
_________________________________________________________________
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space group
Unit cell dimensions
Volume
Z, calculated density
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Limiting indices
Reflections collected / unique
Completeness to theta = 30.00
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints/ parameters
Goodness of fit on F2
Final R indices [I>2sigma(I)]
Largest diff. peak and hole

C24 H22 N6 O6
490.48
150(2) K
0.71073 Å
Monoclinic, P2(1)/n
a=11.6777(6) Å, alpha = 90.00 deg.
b=13.4416(7) Å, beta = 111.6300(10) deg
c=15.0367(8) Å, gamma = 90.00 deg
2194.1(2) Å3
4, 1.485 Mg/m3
0.110 mm-1
1024
0.4 x 0.5 x 0.6 mm
2.10 to 30.00 deg.
-16<=h<=16, -18<=k<=18, -21<=l<=20
30679 / 6390 [R(int) = 0.0284]
100.0%
empirical
1.000000 and 0.811722
Full matrix least squares on F2
6390 / 0 / 413
1.035
R1=0.0486, wR2=0.1041
0.388 and -0.241 e.A3
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Table 14: Atomic coordinates and equivalent isotropic displacement parameters (A2) for
F1. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
___________________________________________________________________
x
y
z
U(eq)
___________________________________________________________________
C(1)
0.40154(9)
0.76110(7)
0.32067(7)
0.01620(19)
C(2)
0.37268(9)
0.66438(7)
0.35879(7)
0.0173(2)
C(3)
0.37981(10) 0.56702(8)
0.33032(8)
0.0217(2)
C(4)
0.34872(10) 0.49033(8)
0.37943(9)
0.0247(2)
C(5)
0.31165(10) 0.51147(8)
0.45610(9)
0.0246(2)
C(6)
0.30312(10) 0.60879(8)
0.48059(8)
0.0215(2)
N(7)
0.33290(8)
0.68190(6)
0.43083(6)
0.01767(18)
C(8)
0.32301(9)
0.79020(7)
0.44947(8)
0.0177(2)
C(9)
0.42018(9)
0.83200(7)
0.41155(7)
0.01618(19)
C(10)
0.40282(9)
0.93899(8)
0.37796(7)
0.0179(2)
N(11)
0.50556(8)
0.97972(6)
0.36542(7)
0.01981(19)
C(12)
0.62265(10) 0.93615(8)
0.40039(8)
0.0203(2)
N(13)
0.64245(8)
0.86229(7)
0.46952(7)
0.01974(18)
C(14)
0.54844(9)
0.81456(7)
0.48722(7)
0.0178(2)
C(15)
0.49643(9)
0.75965(7)
0.27610(7)
0.0169(2)
C(16)
0.60439(9)
0.70148(7)
0.31489(7)
0.0175(2)
N(17)
0.68541(8)
0.70188(7)
0.26378(7)
0.02065(19)
C(18)
0.66641(10) 0.75685(8)
0.18230(8)
0.0203(2)
N(19)
0.56146(8)
0.81420(7)
0.14951(6)
0.02109(19)
C(20)
0.47389(9)
0.81994(8)
0.19443(7)
0.0176(2)
O(21)
0.30749(7)
0.98487(6)
0.35799(6)
0.02502(18)
C(22)
0.48702(11) 1.06806(8)
0.30363(9)
0.0247(2)
O(23)
0.70576(7)
0.96754(6)
0.37764(6)
0.02848(19)
C(24)
0.77081(10) 0.83330(10) 0.52487(10) 0.0264(2)
O(25)
0.56654(7)
0.76029(6)
0.55579(6)
0.02343(17)
O(26)
0.63307(7)
0.65141(6)
0.38941(6)
0.02345(17)
C(27)
0.79630(12) 0.63983(10) 0.29909(10) 0.0295(3)
O(28)
0.74013(7)
0.75544(7)
0.14071(6)
0.02804(19)
C(29)
0.54155(13) 0.87453(11) 0.06397(10) 0.0331(3)
O(30)
0.38443(7)
0.87667(6)
0.15982(6)
0.02363(17)
C(31)
0.18991(9)
0.82394(8)
0.39900(8)
0.0195(2)
N(32)
0.13528(8)
0.79654(7)
0.30716(7)
0.0230(2)
C(33)
0.01985(11) 0.82892(9)
0.25990(9)
0.0277(2)
C(34)
-0.04474(11) 0.88746(10) 0.30170(10) 0.0317(3)
C(35)
0.01122(11) 0.91232(9)
0.39715(10) 0.0319(3)
C(36)
0.13147(11) 0.87981(9)
0.44767(9)
0.0254(2)
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Table 15: Bond lengths [Å] and angles [deg] for F1.
C1-C15
1.4915(13)
C1-C2
1.5083(14)
C1-C9
1.6136(14)
C2-N7
1.3475(13)
C2-C3
1.3889(14)
C3-C4
1.3918(15)
C4-C5
1.4018(17)
C5-C6
1.3725(16)
C6-N7
1.3559(13)
N7-C8
1.4948(13)
C8-C31
1.5257(15)
C8-C9
1.5510(13)
C9-C10
1.5128(14)
C9-C14
1.5286(14)
C10-O21
1.2097(13)
C10-N11
1.3934(13)
N11-C12
1.3996(14)
N11-C22
1.4738(14)
C12-O23
1.2173(13)
C12-N13
1.3938(14)
N13-C14
1.3794(13)
N13-C24
1.4737(14)
C14-O25
1.2163(13)
C15-C20
1.4128(14)
C15-C16
1.4138(14)
C16-O26
1.2425(12)
C16-N17
1.4220(13)
N17-C18
1.3769(14)
N17-C27
1.4654(14)
C18-O28
1.2367(13)
C18-N19
1.3763(14)
N19-C20
1.4202(13)
N19-C29
1.4648(14)
C20-O30
1.2421(12)
C31-N32
1.3418(14)
C31-C36
1.3905(15)
N32-C33
1.3435(15)
C33-C34
1.3902(17)
C34-C35
1.3810(19)
C35-C36
1.3976(17)
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1
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Table 16: Anisotropic displacement parameters (A2 ) for F1. The anisotropic
displacement factor exponent takes the form: -2 pi2 [h2 a*2U11 + … + h k a*b* U12]
U11
U22
U33
U23
U13
U12
______________________________________________________________________
C1 0.0174(4) 0.0158(4)
0.0172(5)
0.0002(4)
0.0085(4)
-0.0001(4)
C2 0.0160(4) 0.0188(5)
0.0182(5)
0.0005(4)
0.0076(4)
-0.0017(4)
C3 0.0215(5) 0.0197(5)
0.0248(6)
-0.0030(4)
0.0097(4)
-0.0032(4)
C4 0.0234(5) 0.0171(5)
0.0328(6)
-0.0007(4)
0.0092(5)
-0.0035(4)
C5 0.0226(5) 0.0226(5)
0.0271(6)
0.0056(4)
0.0073(4)
-0.0048(4)
C6 0.0209(5) 0.0248(5)
0.0201(5)
0.0040(4)
0.0091(4)
-0.0044(4)
N7 0.0183(4) 0.0175(4)
0.0190(4)
0.0013(3)
0.0090(3)
-0.0019(3)
C8 0.0200(5) 0.0178(5)
0.0186(5)
-0.0019(4)
0.0110(4)
-0.0021(4)
C9 0.0173(4) 0.0159(4)
0.0175(5)
-0.0001(4)
0.0090(4)
-0.0012(4)
C10 0.0197(5) 0.0172(4)
0.0185(5)
-0.0013(4)
0.0091(4)
-0.0012(4)
N11 0.0201(4) 0.0165(4)
0.0250(5)
0.0033(3)
0.0108(4)
-0.0007(3)
C12 0.0199(5) 0.0188(5) 0.0228(5)
-0.0012(4)
0.0085(4)
-0.0029(4)
N13 0.0165(4) 0.0198(4) 0.0225(5)
0.0011(3)
0.0068(4)
-0.0014(3)
C14 0.0201(5) 0.0171(4) 0.0176(5)
-0.0021(4)
0.0085(4)
-0.0008(4)
C15 0.0184(5) 0.0173(4)
0.0177(5)
0.0002(4)
0.0096(4)
-0.0001(4)
C16 0.0193(5) 0.0167(4) 0.0183(5)
-0.0011(4)
0.0091(4)
-0.0003(4)
N17 0.0199(4) 0.0235(4) 0.0221(5)
0.0031(3)
0.0120(4)
0.0051(3)
C18 0.0202(5) 0.0237(5) 0.0192(5)
-0.0016(4)
0.0100(4)
-0.0006(4)
N19 0.0214(4) 0.0267(5) 0.0184(4)
0.0052(4)
0.0111(4)
0.0026(4)
C20 0.0183(4) 0.0188(5) 0.0173(5)
-0.0014(4)
0.0085(4)
-0.0014(4)
O21 0.0233(4) 0.0207(4) 0.0343(5)
0.0031(3)
0.0145(3)
0.0035(3)
C22 0.0291(6) 0.0185(5)
0.0281(6)
0.0050(4)
0.0125(5)
-0.0012(4)
O23 0.0222(4) 0.0298(4) 0.0370(5)
0.0050(4)
0.0150(4)
-0.0039(3)
C24 0.0166(5) 0.0272(6)
0.0317(7)
0.0031(5)
0.0044(5)
0.0012(4)
O25 0.0258(4) 0.0250(4) 0.0199(4)
0.0044(3)
0.0089(3)
0.0005(3)
O26 0.0254(4) 0.0237(4) 0.0232(4)
0.0072(3)
0.0112(3)
0.0037(3)
C27 0.0261(6) 0.0335(6)
0.0326(7)
0.0078(5)
0.0152(5)
0.0120(5)
O28 0.0253(4) 0.0393(5) 0.0254(4)
0.0007(4)
0.0162(3)
0.0012(3)
C29 0.0326(6) 0.0459(7)
0.0260(6)
0.0165(6)
0.0168(5)
0.0078(6)
O30 0.0228(4) 0.0253(4) 0.0230(4)
0.0060(3)
0.0086(3)
0.0059(3)
C31 0.0197(5) 0.0190(5) 0.0236(5)
-0.0007(4)
0.0124(4)
-0.0026(4)
N32 0.0200(4) 0.0256(5) 0.0246(5)
-0.0034(4)
0.0096(4)
-0.0014(4)
C33 0.0226(5) 0.0303(6) 0.0291(6)
-0.0034(5)
0.0082(5)
-0.0019(5)
C34 0.0204(5) 0.0319(6)
0.0407(8)
-0.0041(5)
0.0086(5)
0.0019(5)
C35 0.0267(6) 0.0306(6)
0.0433(8)
-0.0085(5)
0.0185(6)
0.0020(5)
C36 0.0255(5) 0.0276(6)
0.0274(6)
-0.0058(5)
0.0147(5)
-0.0022(4)
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Table 17: Hydrogen coordinates and isotropic displacement parameters (A2) for F1.
x
y
z
U(eq)
_____________________________________________________________________
H1
0.3248(12)
0.7836(9)
0.2719(9)
0.021(3)
H3
0.4067(12)
0.5553(10)
0.2770(10)
0.023(3)
H4
0.3552(13)
0.4244(11)
0.3629(10)
0.033(4)
H5 H
0.2909(12)
0.4636(10)
0.4937(10)
0.028(3)
H6 H
0.2770(12)
0.6285(10)
0.5332(10)
0.026(3)
H8 H
0.3469(10)
0.7980(8)
0.5170(9)
0.010(3)
H22A H
0.5598(15)
1.1079(11)
0.3231(11)
0.041(4)
H22B H
0.4693(14)
1.0485(12)
0.2381(12)
0.039(4)
H22C H
0.4188(15)
1.1054(12)
0.3092(11)
0.041(4)
H24A H
0.8090(16)
0.8214(13)
0.4832(13)
0.054(5)
H24B H
0.8121(17)
0.8808(14)
0.5627(14)
0.057(5)
H24C H
0.7714(18)
0.7710(15)
0.5532(14)
0.065(6)
H27A H
0.7900(16)
0.5899(14)
0.2491(13)
0.054(5)
H27B H
0.7910(17)
0.6029(14)
0.3546(14)
0.059(5)
H27C H
0.8673(15)
0.6790(11)
0.3107(11)
0.038(4)
H29A H
0.6067(17)
0.9293(14)
0.0757(13)
0.059(5)
H29B H
0.5521(16)
0.8305(13)
0.0117(13)
0.051(5)
H29C H
0.4543(16)
0.9002(12)
0.0413(12)
0.050(5)
H33 H
-0.0176(14) 0.8088(11)
0.1926(11)
0.038(4)
H34 H
-0.1253(14) 0.9100(11)
0.2628(10)
0.035(4)
H35 H
-0.0328(14) 0.9549(12)
0.4260(11)
0.037(4)
H36 H
0.1752(13)
0.8971(11)
0.5157(11)
0.033(4)
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Table 18: Torsion angles [deg] for F1.
____________________________________________________________
C15 C1 C2
C15 C1 C9
C2 C1 C9
N7 C2 C3
N7 C2 C1
C3 C2 C1
C2 C3 C4
C3 C4 C5
C6 C5 C4
N7 C6 C5
C2 N7 C6
C2 N7 C8
C6 N7 C8
N7 C8 C31
N7 C8 C9
C31 C8 C9
C10 C9 C14
C10 C9 C8
C14 C9 C8
C10 C9 C1
C14 C9 C1
C8 C9 C1
O21 C10 N11
O21 C10 C9
N11 C10 C9
C10 N11 C12
C10 N11 C22
C12 N11 C22
O23 C12 N13
O23 C12 N11
N13 C12 N11
C14 N13 C12
C14 N13 C24
C12 N13 C24
O25 C14 N13
O25 C14 C9
N13 C14 C9
C20 C15 C16
C20 C15 C1
C16 C15 C1
O26 C16 C15
O26 C16 N17
C15 C16 N17

117.82(8)
119.83(8)
99.58(8)
119.35(9)
110.27(8)
130.37(9)
118.51(10)
120.41(10)
119.27(10)
118.94(10)
123.47(9)
113.22(8)
123.31(9)
109.34(8)
99.58(7)
117.31(9)
111.61(8)
116.16(8)
108.64(8)
108.61(8)
109.21(8)
102.05(7)
121.71(9)
124.43(9)
113.74(8)
123.74(9)
117.91(9)
118.04(9)
121.75(10)
121.27(10)
116.66(9)
123.38(9)
118.96(9)
117.65(9)
122.72(10)
122.65(9)
114.59(9)
121.87(9)
116.86(9)
121.27(9)
125.07(9)
118.52(9)
116.40(9)
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Table 18 (F1) cont.

C18 N17 C16
C18 N17 C27
C16 N17 C27
O28 C18 N19
O28 C18 N17
N19 C18 N17
C18 N19 C20
C18 N19 C29
C20 N19 C29
O30 C20 C15
O30 C20 N19
C15 C20 N19
N32 C31 C36
N32 C31 C8
C36 C31 C8
C31 N32 C33
N32 C33 C34
C35 C34 C33
C34 C35 C36
C31 C36 C35
C15 C1 C2 N7
C9 C1 C2 N7
C15 C1 C2 C3
C9 C1 C2 C3
N7 C2 C3 C4
C1 C2 C3 C4
C2 C3 C4 C5
C3 C4 C5 C6
C4 C5 C6 N7
C3 C2 N7 C6
C1 C2 N7 C6
C3 C2 N7 C8
C1 C2 N7 C8
C5 C6 N7 C2
C5 C6 N7 C8
C2 N7 C8 C31
C6 N7 C8 C31
C2 N7 C8 C9
C6 N7 C8 C9
N7 C8 C9 C10
C31 C8 C9 C10
N7 C8 C9 C14

124.19(9)
117.31(9)
118.50(9)
121.43(10)
121.86(10)
116.71(9)
124.21(9)
117.18(9)
118.59(9)
125.08(9)
118.42(9)
116.50(9)
123.40(10)
116.17(9)
120.43(10)
117.33(10)
123.37(12)
118.62(11)
119.01(11)
118.19(11)
152.38(9)
21.12(10)
-28.54(16)
-159.80(11)
-1.82(16)
179.16(10)
-0.28(17)
1.76(17)
-1.12(16)
2.57(16)
-178.24(9)
-176.54(9)
2.66(12)
-1.06(16)
177.96(10)
97.38(10)
-81.72(12)
-26.14(11)
154.75(9)
154.65(9)
36.94(13)
-78.56(9)
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Table 18 (F1) cont.
C31 C8 C9 C14
N7 C8 C9 C1
C31 C8 C9 C1
C15 C1 C9 C10
C2 C1 C9 C10
C15 C1 C9 C14
C2 C1 C9 C14
C15 C1 C9 C8
C2 C1 C9 C8
C14 C9 C10 O21
C8 C9 C10 O21
C1 C9 C10 O21
C14 C9 C10 N11
C8 C9 C10 N11
C1 C9 C10 N11
O21 C10 N11 C12
C9 C10 N11 C12
O21 C10 N11 C22
C9 C10 N11 C22
C10 N11 C12 O23
C22 N11 C12 O23
C10 N11 C12 N13
C22 N11 C12 N13
O23 C12 N13 C14
N11 C12 N13 C14
O23 C12 N13 C24
N11 C12 N13 C24
C12 N13 C14 O25
C24 N13 C14 O25
C12 N13 C14 C9
C24 N13 C14 C9
C10 C9 C14 O25
C8 C9 C14 O25
C1 C9 C14 O25
C10 C9 C14 N13
C8 C9 C14 N13
C1 C9 C14 N13
C2 C1 C15 C20
C9 C1 C15 C20
C2 C1 C15 C16
C9 C1 C15 C16
C20 C15 C16 O26
C1 C15 C16 O26

163.72(9)
36.72(9)
-80.99(10)
71.12(11)
-158.91(8)
-50.81(11)
79.16(9)
-165.67(9)
-35.70(9)
-143.23(10)
-17.94(15)
96.32(12)
40.87(12)
166.16(9)
-79.59(10)
170.06(10)
-13.91(14)
-16.38(15)
159.65(9)
170.68(10)
-2.88(16)
-15.62(15)
170.82(9)
-170.11(10)
16.22(15)
8.85(16)
-164.83(10)
-169.75(10)
11.32(16)
12.61(14)
-166.33(10)
141.71(10)
12.35(13)
-98.19(11)
-40.64(12)
-170.00(8)
79.46(10)
141.54(10)
-97.15(11)
-39.24(14)
82.06(12)
175.71(10)
-3.46(16)
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Table 18 (F1) cont.
C20 C15 C16 N17
C1 C15 C16 N17
O26 C16 N17 C18
C15 C16 N17 C18
O26 C16 N17 C27
C15 C16 N17 C27
C16 N17 C18 O28
C27 N17 C18 O28
C16 N17 C18 N19
C27 N17 C18 N19
O28 C18 N19 C20
N17 C18 N19 C20
O28 C18 N19 C29
N17 C18 N19 C29
C16 C15 C20 O30
C1 C15 C20 O30
C16 C15 C20 N19
C1 C15 C20 N19
C18 N19 C20 O30
C29 N19 C20 O30
C18 N19 C20 C15
C29 N19 C20 C15
N7 C8 C31 N32
C9 C8 C31 N32
N7 C8 C31 C36
C9 C8 C31 C36
C36 C31 N32 C33
C8 C31 N32 C33
C31 N32 C33 C34
N32 C33 C34 C35
C33 C34 C35 C36
N32 C31 C36 C35
C8 C31 C36 C35
C34 C35 C36 C31

-3.90(15)
176.92(9)
-177.66(10)
1.98(15)
2.61(15)
-177.75(10)
179.37(10)
-0.89(16)
-0.22(15)
179.52(10)
-179.32(10)
0.27(15)
-0.78(16)
178.81(10)
-175.99(10)
3.22(15)
3.95(15)
-176.84(9)
177.86(10)
-0.66(15)
-2.09(15)
179.39(10)
-48.07(12)
64.24(12)
131.94(10)
-115.76(11)
2.79(16)
-177.21(9)
-0.83(17)
-1.26(19)
1.45(19)
-2.57(17)
177.43(10)
0.33(18)
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X-ray crystallographic Data- Compound G37
(1,3-dimethyl-5-[(2,4,6-trioxohexahydropyrimidin-5-yl)(quinolin-4yl)methyl]pyrimidine-2,4,6(1H,3H,5H)-trione morpholinium salt)
Table 19. Crystal data and structure refinement for compound
_________________________________________________________________
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space group
Unit cell dimensions
Volume
Z, calculated density
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Limiting indices
Reflections collected / unique
Completeness to theta = 29.00
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints/ parameters
Goodness of fit on F2
Final R indices [I>2sigma(I)]
Largest diff. peak and hole

C26 H34 N6 O9 S2
638.71
150(2) K
0.71073 Å
Monoclinic, P2(1)
a=8.5679(2) Å, alpha = 90.00 deg.
b=15.5485(4) Å, beta = 93.1700(10) deg
c=11.1461(3) Å, gamma = 90.00 deg
1482.59(7) Å3
2, 1.431 Mg/m3
0.242 mm-1
672
0.20 x 0.35 x 0.45 mm
2.250 to 29.00 deg.
-12<=h<=12, -22<=k<=22, -15<=l<=15
24322 / 7431 [R(int) = 0.0453]
100.0%
empirical
30.55 and 1.83
Full matrix least squares on F2
7431 / 262 / 465
0.691
R1=0.0773, wR2=0.0534
0.408 and -0.437 e.A3
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Table 20: Atomic coordinates and equivalent isotropic displacement parameters (A2) for
G37. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
_________________________________________________________________
x
y
z
U(eq)
__________________________________________________________________
C1
0.9958(2)
1.07946(11) 0.80317(15) 0.0160(4)
C2
0.8605(2)
1.04557(12) 0.84230(18) 0.0231(5)
C3
0.8608(2)
0.99872(14) 0.94918(19) 0.0295(5)
N4
0.98553(19) 0.98252(10) 1.01896(14) 0.0266(4)
C5
1.1243(2)
1.01517(12) 0.98316(17) 0.0220(4)
C6
1.2597(2)
0.99875(13) 1.05799(18) 0.0275(5)
C7
1.4027(3)
1.02771(13) 1.02718(19) 0.0286(5)
C8
1.4157(2)
1.07103(13) 0.91878(18) 0.0258(5)
C9
1.2872(2)
1.08913(12) 0.84473(17) 0.0189(4)
C10
1.1361(2)
1.06270(11) 0.87514(15) 0.0169(4)
C11
1.0012(2)
1.13043(11) 0.68623(16) 0.0144(4)
C12
1.0658(2)
1.22049(11) 0.70650(15) 0.0150(4)
C13
.1992(2)
1.24491(11) 0.64306(16) 0.0169(4)
N14
1.26397(18) 1.32472(10) 0.66855(13) 0.0179(3)
C15
1.2160(2)
1.38107(12) 0.75321(15) 0.0179(4)
N16
1.08894(17) 1.35404(10) .81203(13)
0.0174(4)
C17
1.0126(2)
1.27742(12) 0.79067(16) 0.0176(4)
O18
1.26202(13) 1.19902(8)
0.56667(11) 0.0196(3)
O19
1.28122(14) 1.45014(8)
0.77497(10) 0.0211(3)
O20
0.89068(14) 1.26498(8)
0.85227(10) 0.0203(3)
C21
0.85373(19) 1.12358(11) .60455(15)
0.0144(4)
C22
0.7153(2)
1.16403(12) 0.62423(16) 0.0185(4)
N23
0.59001(18) 1.15600(11) 0.54215(14) 0.0190(4)
C24
0.5919(2)
1.11117(12) 0.43690(16) 0.0182(4)
N25
0.72723(18) 1.06670(11) 0.42348(15) 0.0197(4)
C26
0.8576(2)
1.06604(11) 0.50437(16) 0.0185(4)
O27
0.68251(14) 1.21154(8)
0.71602(12) 0.0228(3)
O28
0.48105(14) 1.11032(8)
0.36287(11) 0.0261(3)
O29
0.96645(14) 1.01698(8)
0.48339(11) 0.0271(3)
N30
0.7226(4)
0.7629(2)
0.6817(4)
0.0251(8)
N30B
0.7549(11)
0.7482(6)
0.6678(11)
0.023(3)
Uiso 0.266(3)
C31
0.8188(4)
0.8414(2)
0.6758(3)
0.0372(9)
Uani 0.734(3)
C31B
0.8653(11)
0.8194(6)
0.6439(7)
0.025(2)
Uiso 0.266(3)
C32
0.9803(4)
0.8175(3)
0.6437(3)
0.0568(11)
0.734(3)
C32B
0.9564(10)
0.8435(5)
0.7584(7)
0.046(2)
Uiso 0.266(3)
O33
1.0515(2)
0.75667(16) 0.7250(3)
0.0516(7)
Uani 0.734(3)
O33B
1.0363(7)
0.7721(4)
0.8089(7)
0.0484(19)
Uiso 0.266(3)
C34
0.9604(4)
0.6810(2)
0.7239(3)
0.0512(10)
0.734(3)
C34B
0.9244(10)
0.7082(6)
0.8368(8)
0.053(3)
Uiso 0.266(3)
C35
0.7997(3)
0.6977(2)
0.7639(3)
0.0313(8)
0.734(3)
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Table 20 (G37) cont.
C35B
S36
O36
C37
C38
S39
O39
C40
C41

0.8398(13)
0.34706(6)
0.51865(14)
0.2812(2)
0.3353(2)
0.39083(7)
0.5092(2)
0.3435(3)
0.4979(2)

0.6744(6)
0.87188(3)
0.85421(9)
0.92138(13)
0.96397(12)
0.81411(4)
0.83465(11)
0.70381(14)
0.80405(15)

0.7255(8)
0.50932(4)
0.50005(11)
0.37130(17)
0.60254(17)
0.90142(5)
0.81213(14)
0.8803(2)
1.04116(16)

0.038(3)
0.02501(12)
0.0317(4)
0.0299(5)
0.0307(5)
0.04240(16)
0.0698(6)
0.0508(7)
0.0370(5)

Uiso 0.266(3)
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Table 21: Bond lengths [Å] and angles [deg] for G37
C1 C2
C1 C10
C1 C11
C2 C3
C3 N4
N4 C5
C5 C6
C5 C10
C6 C7
C7 C8
C8 C9
C9 C10
C11 C12
C11 C21
C12 C17
C12 C13
C13 O18
C13 N14
N14 C15
C15 O19
C15 N16
N16 C17
C17 O20
C21 C22
C21 C26
C22 O27
C22 N23
N23 C24
C24 O28
C24 N25
N25 C26
C26 O29
N30 C31
N30 C35
N30B C35B
N30B C31B
C31 C32
C31B C32B
C32 O33
C32B O33B
O33 C34
O33B C34B
C34 C35
C34B C35B

1.367(2)
1.432(2)
1.528(2)
1.396(3)
1.311(2)
1.372(2)
1.414(3)
1.421(2)
1.367(3)
1.393(3)
1.368(3)
1.417(2)
1.518(2)
1.520(2)
1.385(2)
1.428(2)
1.2548(19)
1.383(2)
1.367(2)
1.229(2)
1.367(2)
1.374(2)
1.296(2)
1.371(2)
1.433(2)
1.305(2)
1.377(2)
1.365(2)
1.223(2)
1.365(2)
1.396(2)
1.237(2)
1.477(3)
1.495(4)
1.486(7)
1.491(7)
1.496(4)
1.506(7)
1.423(3)
1.405(6)
1.412(4)
1.427(7)
1.494(4)
1.497(7)

300

Table 21 (G37) cont.
S36 O36
S36 C38
S36 C37
S39 O39
S39 C41
S39 C40

1.5048(13)
1.7752(19)
1.7836(18)
1.4940(17)
1.7703(18)
1.775(2)

__________________________________________________________________
Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1
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Table 22: Anisotropic displacement parameters (A2 ) for G37. The anisotropic
displacement factor exponent takes the form: -2 pi2 [h2 a*2U11 + … + h k a*b* U12]
U11
U22
U33
U23
U13
U12
______________________________________________________________________
C1
0.0180(10)
0.0140(10)
0.0158(9)
-0.0020(8) 0.0007(8) 0.0007(8)
C2
0.0135(10)
0.0273(12)
0.0288(12)
0.0055(9)
0.0024(9) 0.0008(9)
C3
0.0213(12)
0.0315(13)
0.0365(13)
0.0142(10) 0.0089(10) -0.0018(10)
N4
0.0284(10)
0.0278(10)
0.0242(9)
0.0080(8)
0.0072(8) 0.0027(8)
C5
0.0249(11)
0.0193(10)
0.0218(10)
0.0009(9)
0.0028(9) 0.0035(9)
C6
0.0361(13)
0.0273(12)
0.0187(11)
0.0034(10) -0.0034(10) 0.0040(1)
C7
0.0277(12)
0.0274(12)
0.0293(12)
0.0007(10) -0.0118(10) 0.0048(1)
C8
0.0206(11)
0.0260(12)
0.0304(12)
-0.0019(10) -0.0010(10) -0.0012(1)
C9
0.0222(11)
0.0163(11)
0.0180(10)
0.0010(9)
0.0007(9) 0.0017(8)
C10 0.0203(10)
0.0143(10)
0.0159(10)
-0.0032(8) -0.0003(8) 0.0028(8)
C11 0.0126(9)
0.0148(10)
0.0160(9)
0.0002(8)
0.0025(8) 0.0032(8)
C12 0.0144(9)
0.0163(9)
0.0143(9)
0.0012(8)
0.0017(7) -0.0004(8)
C13 0.0171(10)
0.0184(10)
0.0149(10)
0.0013(8)
-0.0012(8) 0.0011(8)
N14 0.0147(8)
0.0196(9)
0.0197(8)
0.0001(7)
0.0051(7) -0.0037(7)
C15 0.0179(10)
0.0187(10)
0.0163(9)
0.0014(9)
-0.0064(8) 0.0011(9)
N16 0.0182(9)
0.0174(9)
0.0170(9)
-0.0062(7)
0.0039(7) -0.0009(7)
C17 0.0160(10)
0.0200(10)
0.0167(10)
0.0018(8)
-0.0002(8) 0.0007(8)
O18 0.0169(7)
0.0192(7)
0.0234(7)
-0.0041(6) 0.0086(6) -0.0008(6)
O19 0.0236(7)
0.0182(7)
0.0215(7)
-0.0007(6) -0.0001(6) -0.0052(6)
O20 0.0178(7)
0.0248(7)
0.0190(7)
-0.0056(6) 0.0065(6) -0.0051(6)
C21 0.0132(9)
0.0143(9)
0.0158(9)
-0.0002(8) 0.0025(8) -0.0001(7)
C22 0.0222(11)
0.0152(10)
0.0182(10)
0.0016(8)
0.0021(8) -0.0010(8)
N23 0.0122(9)
0.0225(9)
0.0223(9)
-0.0034(7) 0.0005(7) 0.0059(7)
C24 0.0195(10)
0.0170(10)
0.0183(10)
0.0010(8)
0.0022(8) -0.0003(8)
N25 0.0186(9)
0.0232(9)
0.0172(9)
-0.0072(8) -0.0017(7) 0.0022(7)
C26 0.0180(10)
0.0161(10)
0.0213(10)
0.0028(9) -0.0009(8) -0.0004(9)
O27 0.0177(7)
0.0288(8)
0.0219(7)
-0.0105(6) 0.0016(6) 0.0024(6)
O28 0.0201(7)
0.0321(8)
0.0254(7)
-0.0039(7) -0.0060(6) 0.0044(6)
O29 0.0193(7)
0.0299(8)
0.0319(8)
-0.0125(7) -0.0015(6) 0.0094(6)
N30 0.0181(16)
0.0282(16)
0.0291(16)
-0.0044(14) 0.0013(14) 0.0003(1)
C31 0.038(2)
0.032(2)
0.040(2)
0.0045(16) -0.0071(17) -0.0094(15)
C32 0.0345(19)
0.082(3)
0.053(2)
0.025(2)
-0.0050(16) -0.0193(19)
O33 0.0170(12)
0.0768(17)
0.0601(19)
0.0120(15) -0.0049(11) -0.0056(11)
C34 0.0343(19)
0.053(2)
0.065(3)
-0.0040(19) -0.0082(17) 0.0174(17)
C35 0.0285(17)
0.0326(19)
0.0318(19)
0.0059(16) -0.0071(15) -0.0084(15)
S36 0.0245(3)
0.0231(3)
0.0284(3)
-0.0006(3) 0.0094(2) 0.0043(2)
O36 0.0244(8)
0.0459(10)
0.0253(7)
0.0005(7)
0.0076(6) 0.0157(7)
C37 0.0295(12)
0.0318(13)
0.0277(12)
-0.0024(10) -0.0060(10) 0.0045(10)
C38 0.0349(12)
0.0262(12)
0.0317(12)
-0.0004(10) 0.0087(10) 0.0052(10)
S39 0.0516(4)
0.0426(4)
0.0322(3)
-0.0017(3) -0.0043(3) 0.0172(3)
O39 0.1248(17)
0.0484(12)
0.0395(10)
0.0117(9) 0.0343(10) 0.0157(11)
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Table 22 (G37) cont.
C40
C41
_

0.0461(15)
0.0357(13)

0.0528(16)
0.0437(14)

.0516(16)
0.0315(12)

-0.0150(13) -0.0134(12) 0.0081(13)
0.0070(11) 0.0006(10) -0.0069(11)
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Table 23: Hydrogen coordinates and isotropic displacement parameters (A2) for G37
x
y
z
U(eq)
___________________________________________________________________
H2 H
0.765(2)
1.0508(10)
0.7986(14)
0.016(5) Uiso 1 1 d
H3 H
0.769(2)
0.9769(13)
0.9725(17)
0.037(6) Uiso 1 1 d
H6 H
1.2483(19)
0.9680(11)
1.1337(16)
0.022(5) Uiso 1 1 d
H7 H
1.4889(19)
1.0197(10)
1.0785(15)
0.012(5) Uiso 1 1 d
H8 H
1.509(2)
1.0946(12)
0.8922(15)
0.023(5) Uiso 1 1 d
H9 H
1.2946(17)
1.1154(10)
0.7728(13)
0.002(4) Uiso 1 1 d
H11 H
1.0720(17)
.0997(10)
0.6462(13)
0.004(4) Uiso 1 1 d .
H14 H
1.346(2)
1.3429(13)
0.6242(18)
0.053(7) Uiso 1 1 d
H16 H
1.048(2)
1.3894(13)
0.8624(17)
0.034(6) Uiso 1 1 d
H23 H
0.509(2)
1.1866(14)
0.5502(18)
0.047(7) Uiso 1 1 d
H25 H
0.724(2)
1.0347(12)
0.3643(17)
0.028(6) Uiso 1 1 d .
H27 H
0.772(3)
1.2330(16)
0.782(2)
0.083(9) Uiso 1 1 d
H30A H
0.7076
0.7397
0.6060
0.030 Uiso 0.734(3)
H30B H
0.6263
0.7768
0.7087
0.030 Uiso 0.734(3)
H30C H
0.6800
0.7675
0.7173
0.027 Uiso 0.266(3)
H30D H
0.7053
0.7305
0.5967
0.027 Uiso 0.266(3)
H31A H
0.8230
0.8711
0.7545
0.045 Uiso 0.734(3)
H31B H
0.7716
0.8812
0.6146
0.045 Uiso 0.734(3)
H31C H
0.8063
0.8700
0.6120
0.030 Uiso 0.266(3)
H31D H
0.9381
0.8009
0.5829
0.030 Uiso 0.266(3)
H32A H
0.9758
0.7930
0.5616
0.068 Uiso 0.734(3)
H32B H
1.0457
0.8699
0.6434
0.068 Uiso 0.734(3)
H32C H
1.0325
0.8892
0.7415
0.055 Uiso 0.266(3)
H32D H
0.8839
0.8665
0.8167
0.055 Uiso 0.266(3)
H34A H
1.0125
0.6378
0.7777
0.061 Uiso 0.734(3)
H34B H
0.9530
0.6569
0.6416
0.061 Uiso 0.734(3)
H34C H
0.8479
0.7333
0.8903
0.064 Uiso 0.266(3)
H34D H
0.9782
0.6602
0.8802
0.064 Uiso 0.266(3)
H35A H
0.8054
0.7196
0.8475
0.038 Uiso 0.734(3)
H35B H
0.7382
0.6437
0.7615
0.038 Uiso 0.734(3)
H35C H
0.9149
0.6499
0.6704
0.045 Uiso 0.266(3)
H35D H
0.7653
0.6287
0.7461
0.045 Uiso 0.266(3)
H37A H
0.3500
0.9697
0.3543
0.045 Uiso
H37B H
0.1742
0.9424
0.3777
0.045 Uiso 1 1 calc R . .
H37C H
0.2834
0.8792
0.3061
0.045 Uiso 1 1 calc R
H38A H
0.3726
0.9493
0.6847
0.046 Uiso 1 1 calc R . .
H38B H
0.2265
0.9834
0.6025
0.046 Uiso 1 1 calc R . .
H38C H
0.4003
1.0100
0.5719
0.046 Uiso 1 1 calc R
H40A H
0.2901
0.6959
0.8010
0.076 Uiso 1 1 calc R . .
H40B H
0.2747
0.6852
0.9427
0.076 Uiso 1 1 calc R . .
H40C H
.4396
0.6695
0.8855
0.076 Uiso 1 1 calc R . .
H41A H
0.5816
0.7617
1.0340
0.056 Uiso 1 1 calc R . .
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Table 23 (G37) cont.
H41B H
H41C H

0.4279
0.5435

0.7850
0.8598

1.1025
1.0643

0.056 Uiso 1 1 calc R . .
0.056 Uiso 1 1 calc R .
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Table 24: Torsion angles [deg] for G37
C2 C1 C10
C2 C1 C11
C10 C1 C11
C1 C2 C3
N4 C3 C2
C3 N4 C5
N4 C5 C6
N4 C5 C10
C6 C5 C10
C7 C6 C5
C6 C7 C8
C9 C8 C7
C8 C9 C10
C9 C10 C5
C9 C10 C1
C5 C10 C1
C12 C11 C21
C12 C11 C1
C21 C11 C1
C17 C12 C13
C17 C12 C11
C13 C12 C11
O18 C13 N14
O18 C13 C12
N14 C13 C12
C15 N14 C13
O19 C15 N14
O19 C15 N16
N14 C15 N16
C15 N16 C17
O20 C17 N16
O20 C17 C12
N16 C17 C12
C22 C21 C26
C22 C21 C11
C26 C21 C11
O27 C22 C21
O27 C22 N23
C21 C22 N23
C24 N23 C22
O28 C24 N25
O28 C24 N23
N25 C24 N23
C24 N25 C26

116.85(17)
122.58(16)
120.54(15)
120.79(19)
124.7(2)
116.57(17)
117.22(18)
122.85(16)
119.92(18)
120.7(2)
119.5(2)
121.5(2)
120.75(18)
117.56(16)
124.25(16)
118.18(17)
115.98(15)
112.30(15)
114.27(14)
117.90(16)
124.00(16)
117.82(16)
117.87(16)
124.74(16)
117.39(16)
125.75(16)
123.05(17)
122.64(17)
114.31(17)
124.58(17)
115.33(16)
124.66(16)
119.99(17)
117.93(16)
124.76(16)
117.17(15)
127.64(17)
112.25(16)
120.11(17)
124.84(16)
123.58(17)
122.63(17)
113.78(16)
125.94(17)
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Table 24 (G37) cont.
O29 C26 N25
O29 C26 C21
N25 C26 C21
C31 N30 C35
C35B N30B C31B
N30 C31 C32
N30B C31B C32B
O33 C32 C31
O33B C32B C31B
C34 O33 C32
C32B O33B C34B
O33 C34 C35
O33B C34B C35B
C34 C35 N30
N30B C35B C34B
O36 S36 C38
O36 S36 C37
C38 S36 C37
O39 S39 C41
O39 S39 C40
C41 S39 C40
C10 C1 C2 C3
C11 C1 C2 C3
C1 C2 C3 N4
C2 C3 N4 C5
C3 N4 C5 C6
C3 N4 C5 C10
N4 C5 C6 C7
C10 C5 C6 C7
C5 C6 C7 C8
C6 C7 C8 C9
C7 C8 C9 C10
C8 C9 C10 C5
C8 C9 C10 C1
N4 C5 C10 C9
C6 C5 C10 C9
N4 C5 C10 C1
C6 C5 C10 C1
C2 C1 C10 C9
C11 C1 C10 C9
C2 C1 C10 C5
C11 C1 C10 C5
C2 C1 C11 C12

117.84(17)
125.61(16)
116.54(16)
111.1(3)
110.5(9)
109.3(3)
109.7(8)
112.5(2)
111.2(7)
109.3(3)
108.6(7)
111.8(3)
111.4(8)
108.5(3)
106.9(9)
105.94(9)
106.45(9)
97.55(9)
105.50(10)
106.05(11)
97.76(11)
1.5(3)
179.42(18)
-0.7(3)
0.6(3)
179.56(19)
-1.3(3)
178.72(19)
-0.4(3)
-2.4(3)
3.3(3)
-1.2(3)
-1.6(3)
179.61(18)
-176.72(17)
2.4(3)
2.2(3)
-178.73(17)
176.66(17)
-1.3(3)
-2.2(2)
179.84(16)
121.94(19)
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Table 24 (G37) cont.
C10 C1 C11 C12
C2 C1 C11 C21
C10 C1 C11 C21
C21 C11 C12 C17
C1 C11 C12 C17
C21 C11 C12 C13
C1 C11 C12 C13
C17 C12 C13 O18
C11 C12 C13 O18
C17 C12 C13 N14
C11 C12 C13 N14
O18 C13 N14 C15
C12 C13 N14 C15
C13 N14 C15 O19
C13 N14 C15 N16
O19 C15 N16 C17
N14 C15 N16 C17
C15 N16 C17 O20
C15 N16 C17 C12
C13 C12 C17 O20
C11 C12 C17 O20
C13 C12 C17 N16
C11 C12 C17 N16
C12 C11 C21 C22
C1 C11 C21 C22
C12 C11 C21 C26
C1 C11 C21 C26
C26 C21 C22 O27
C11 C21 C22 O27
C26 C21 C22 N23
C11 C21 C22 N23
O27 C22 N23 C24
C21 C22 N23 C24
C22 N23 C24 O28
C22 N23 C24 N25
O28 C24 N25 C26
N23 C24 N25 C26
C24 N25 C26 O29
C24 N25 C26 C21
C22 C21 C26 O29
C11 C21 C26 O29
C22 C21 C26 N25
C11 C21 C26 N25

-60.2(2)
-12.8(2)
165.04(15)
83.2(2)
-50.8(2)
-103.03(19)
123.02(17)
178.26(17)
4.1(3)
-1.3(2)
-175.46(15)
-176.46(16)
3.1(3)
177.50(16)
-2.4(2)
-179.96(16)
0.0(2)
-177.30(15)
1.6(3)
177.93(16)
-8.3(3)
-0.9(2)
172.91(16)
-58.6(2)
74.5(2)
125.83(18)
-101.11(18)
172.53(17)
-3.0(3)
-6.8(3)
177.64(16)
178.90(16)
-1.7(3)
-175.12(18)
5.9(3)
179.36(17)
-1.7(3)
174.43(17)
-6.2(3)
-170.47(18)
5.4(3)
10.3(2)
-173.82(15)
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Table 24 (G37) cont.
C35 N30 C31 C32
53.5(4)
C35B N30B C31B C32B
-54.5(11)
N30 C31 C32 O33
56.3(4) .
N30B C31B C32B O33B
56.8(11)
C31 C32 O33 C34
60.0(4)
C31B C32B O33B C34B
-61.2(10)
C32 O33 C34 C35 -61.5(4)
C32B O33B C34B C35B 65.0(10)
O33 C34 C35 N30 59.1(4)
C31 N30 C35 C34 -54.9(4)
C31B N30B C35B C34B 56.3(11)
O33B C34B C35B N30B -62.0(11)
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X-ray crystallographic Data- Compound I-1
(5,5’-(2-pyrilidene)bis(1,3-dimethylbarbituric acid))
Table 25. Crystal data and structure refinement for compound I-1
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space group
Unit cell dimensions
Volume
Z, calculated density
Absorption coefficient
F(000)
Crystal size
Theta range for data collection
Limiting indices
Reflections collected / unique
Completeness to theta =30.498
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints/ parameters
Goodness of fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Largest diff. peak and hole

C18 H21 N5 O7
419.40
150(2) K
0.71073 Å
Monoclinic, P2(1)/n
a=8.9107(19) Å, alpha = 90.00 deg.
b=10.457(2) Å, beta = 93.098(5) deg
c=20.387(4) Å, gamma = 90.00 deg
1896.9(7) Å3
4, 1.469 Mg/m3
0.115 mm-1
880
0.50 x 0.50 x 0.30 mm
2.1895 to 30.498 deg.
-12<=h<=12, -14<=k<=14, -29<=l<=29
34737 / 5827 [R(int) = 0.0384]
100.0%
empirical
1.000000 and 0.761887
Full matrix least squares on F2
5827 / 89 / 310
0.699
R1=0.0383, wR2=0.0987
R1=0.0763, wR2=0.1032
0.209 to -0.211 e.A3
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Table 26: Atomic coordinates and equivalent isotropic displacement parameters (A2) for
I-1. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
_________________________________________________________________
x
y
z
U(eq)
__________________________________________________________________
C1 C 0.00074(13)
0.35018(11) 0.10837(6)
0.0301(3)
N1 N -0.00765(12)
0.12161(10) 0.10799(5)
0.0405(3)
O1 O -0.16289(12)
0.01743(9)
0.03357(6)
0.0656(3)
N2 N -0.15615(12)
0.23353(10) 0.03006(5)
0.0405(3)
C2 C -0.10899(14)
0.35304(12) 0.05472(6)
0.0339(3)
O2 O -0.16226(11)
0.45059(9)
0.02920(5)
0.0470(2)
O3 O 0.14573(11)
0.22187(9)
0.18332(5)
0.0478(3)
N3 N -0.13634(12)
0.69623(10) 0.24788(5)
0.0400(3)
C3 C -0.11202(16)
0.11818(13) 0.05580(7)
0.0437(3)
C4 C 0.04728(14)
0.23553(11) 0.13428(6)
0.0345(3)
O4 O -0.12521(13)
0.69851(9)
0.13728(5)
0.0578(3)
N4 N -0.01165(12)
0.54020(10) 0.31164(5)
0.0415(3)
N5 N 0.30302(13)
0.41658(10) 0.08727(5)
0.0364(3)
O5 O -0.14185(13)
0.69880(10) 0.35886(5)
0.0636(3)
C5 C 0.0376(2)
-0.00107(13) 0.13818(9)
0.0655(5)
O6 O 0.12712(11)
0.38474(9)
0.26720(4)
0.0475(3)
C6 C -0.27107(19)
0.23070(15) -0.02365(8) 0.0616(4)
O7 O 0.23413(16)
0.24469(11) -0.01023(6) 0.0660(4)
C7 C 0.06328(13)
0.47835(11) 0.13205(6)
0.0300(3)
C8 C 0.00400(13)
0.53311(11) 0.19488(6)
0.0305(3)
C9 C -0.08711(14)
0.64418(12) 0.18923(6)
0.0364(3)
C10 C -0.09947(15)
0.64812(13) 0.30917(7)
0.0419(3)
C11 C 0.04209(14)
0.48342(12) 0.25590(6)
0.0349(3)
C12 C -0.23013(18)
0.81121(14) 0.24477(8)
0.0559(4)
C13 C 0.0225(2)
0.48613(16) 0.37711(7)
0.0682(5)
C14 C 0.23319(14)
0.48678(11) 0.13125(6)
0.0322(3)
C15 C 0.32013(16)
0.57057(14) 0.16933(7)
0.0452(3)
C16 C 0.47168(17)
0.58118(16) 0.16045(8)
0.0560(4)
C17 C 0.53801(17)
0.50885(15) 0.11395(8)
0.0538(4)
C18 C 0.45060(16)
0.42533(14) 0.07768(8)
0.0457(3)
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Table 27: Bond lengths [Å] and angles [deg] for I-1.
C1 C4
C1 C2
C1 C7
N1 C3
N1 C4
N1 C5
O1 C3
N2 C3
N2 C2
N2 C6
C2 O2
O3 C4
N3 C10
N3 C9
N3 C12
O4 C9
N4 C10
N4 C11
N4 C13
N5 C14
N5 C18
O5 C10
O6 C11
C7 C14
C7 C8
C8 C11
C8 C9
C14 C15
C15 C16
C16 C17
C17 C18

1.3656(17)
1.4275(17)
1.5201(16)
1.3752(17)
1.3848(16)
1.4698(18)
1.2242(15)
1.3648(17)
1.4030(16)
1.4585(18)
1.2288(15)
1.3018(15)
1.3704(17)
1.4055(16)
1.4637(17)
1.2332(15)
1.3727(17)
1.3900(16)
1.4662(18)
1.3381(15)
1.3431(17)
1.2211(16)
1.2935(15)
1.5175(17)
1.5236(17)
1.3736(17)
1.4182(17)
1.3804(18)
1.377(2)
1.372(2)
1.362(2)
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Table 28: Anisotropic displacement parameters (A2 ) for G37. The anisotropic
displacement factor exponent takes the form: -2 pi2 [h2 a*2U11 + … + h k a*b* U12]
U11
U22
U33
U23
U13
U12
______________________________________________________________________
C1 0.0324(7) 0.0285(6)
N1 0.0479(7) 0.0271(5)
O1 0.0743(8) 0.0415(6)
N2 0.0414(6) 0.0416(6)
C2 0.0328(7) 0.0358(7)
O2 0.0498(6) 0.0435(5)
O3 0.0596(6) 0.0364(5)
N3 0.0402(6) 0.0358(6)
C3 0.0454(8) 0.0386(8)
C4 0.0374(7) 0.0312(6)
O4 0.0889(8) 0.0414(5)
N4 0.0467(7) 0.0462(7)
N5 0.0401(7) 0.0342(6)
O5 0.0771(8) 0.0674(7)
C5 0.0878(13) 0.0295(8)
O6 0.0576(6) 0.0460(6)
C6 0.0632(11) 0.0663(10)
O7 0.1120(11) 0.0432(7)
C7 0.0332(7) 0.0278(6)
C8 0.0327(7) 0.0275(6)
C9 0.0395(7) 0.0302(6)
C10 0.0409(8) 0.0456(8)
C11 0.0336(7) 0.0366(7)
C12 0.0554(10) 0.0446(8)
C13 0.0896(13) 0.0839(12)
C14 0.0392(7) 0.0290(6)
C15 0.0412(8) 0.0481(8)
C16 0.0436(9) 0.0623(10)
C17 0.0334(8) 0.0639(10)
C18 0.0391(8) 0.0485(8)

0.0294(6)
0.0470(7)
0.0809(8)
0.0382(6)
0.0335(7)
0.0460(6)
0.0459(6)
0.0441(7)
0.0483(8)
0.0352(7)
0.0417(6)
0.0317(6)
0.0352(6)
0.0483(7)
0.0795(12)
0.0380(5)
0.0533(10)
0.0415(7)
0.0286(7)
0.0312(7)
0.0391(7)
0.0399(8)
0.0343(7)
0.0682(11)
0.0310(8)
0.0286(7)
0.0465(9)
0.0613(10)
0.0645(11)
0.0503(9)

-0.0034(5)
-0.0024(5)
-0.0224(6)
-0.0104(5)
-0.0055(6)
0.0008(4)
0.0014(4)
-0.0061(5)
-0.0128(6)
-0.0029(5)
0.0003(5)
-0.0005(5)
-0.0020(5)
-0.0127(5)
0.0036(7)
0.0006(4)
-0.0195(8)
-0.0061(5)
0.0005(5)
-0.0016(5)
-0.0028(6)
-0.0058(6)
-0.0029(6)
-0.0092(8)
0.0046(8)
0.0016(5)
-0.0138(7)
-0.0099(8)
0.0038(8)
0.0002(7)

0.0027(5)
0.0075(6)
0.0031(6)
-0.0010(5)
0.0060(6)
-0.0129(5)
-0.0096(5)
0.0042(5)
0.0122(7) 0.0044(6)
-0.0102(5)
0.0030(5)
0.0043(5)
0.0208(6)
0.0087(10)
-0.0053(5)
-0.0150(8)
-0.0079(7)
-0.0012(5)
0.0001(5)
-0.0015(6)
0.0089(6)
0.0009(6)
0.0066(8)
0.0030(8)
0.0030(5)
0.0032(7)
-0.0031(8)
0.0074(7)
0.0101(7)

-0.0020(5)
-0.0029(5)
-0.0161(5)
-0.0082(5)
-0.0042(6)
0.0028(4)
0.0071(5)
0.0061(5)
0.0084(6)
-0.0019(6)
0.0212(5)
0.0059(5)
-0.0001(5)
0.0127(6)
0.0040(8)
0.0181(5)
-0.0098(8)
-0.0067(7)
-0.0005(5)
-0.0003(5)
-0.0006(6)
-0.0012(6)
-0.0011(6)
0.0157(7)
0.0233(10)
-0.0023(5)
-0.0093(7)
-0.0146(8)
-0.0031(8)
0.0046(7)
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Table 29: Hydrogen coordinates and isotropic displacement parameters (A2) for I-1
x
y
z
U(eq)
___________________________________________________________________
H3 H
H5 H
H5A H
H5B H
H5C H
H6A H
H6B H
H6C H
H7B H
H7C H
H7 H
H12B H
H12A H
H12C H
H13B H
H13C H
H13A H
H15 H
H16 H
H17 H
H18 H

0.143(2)
0.2501(17)
0.0428
0.1364
-0.0363
-0.3107
-0.3529
-0.2269
0.204(2)
0.213(2)
0.0276(12)
-0.3183
-0.2629
-0.1720
-0.0691
0.0986
0.0609
0.2695(13)
0.5255(16)
0.6415(8)
0.4831(14)

0.3011(19)
0.3583(15)
0.0077
-0.0258
-0.0669
0.3172
0.1737
0.1994
0.2770(16)
0.1657(12)
0.5374(9)
0.7980
0.8286
0.8841
0.4844
0.5390
0.3989
0.6202(11)
0.6421(12)
0.5216(14)
0.3706(11)

0.2212(11)
0.0624(7)
0.1861
0.1235
0.1250
-0.0313
-0.0121
-0.0636
-0.0469(7)
-0.0135(10)
0.0994(4)
0.2707
0.1990
0.2626
0.4016
0.4007
0.3728
0.2003(5)
0.1871(6)
0.1071(8)
0.0441(5)

0.104(6)
0.060(5)
0.098
0.098
0.098
0.092
0.092
0.092
0.082(6)
0.100(7)
0.024(3)
0.084
0.084
0.084
0.102
0.102
0.102
0.046(4)
0.069(5)
0.070(5)
0.040(4)
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Table 30. Torsion angles [deg] for I-1.
C4 C1 C2
C4 C1 C7
C2 C1 C7
C3 N1 C4
C3 N1 C5
C4 N1 C5
C3 N2 C2
C3 N2 C6
C2 N2 C6
O2 C2 N2
O2 C2 C1
N2 C2 C1
C10 N3 C9
C10 N3 C12
C9 N3 C12
O1 C3 N2
O1 C3 N1
N2 C3 N1
O3 C4 C1
O3 C4 N1
C1 C4 N1
C10 N4 C11
C10 N4 C13
C11 N4 C13
C14 N5 C18
C14 C7 C1
C14 C7 C8
C1 C7 C8
C11 C8 C9
C11 C8 C7
C9 C8 C7
O4 C9 N3
O4 C9 C8
N3 C9 C8
O5 C10 N3
O5 C10 N4
N3 C10 N4
O6 C11 C8
O6 C11 N4
C8 C11 N4
N5 C14 C15
N5 C14 C7
C15 C14 C7
C16 C15 C14

119.73(11)
123.56(11)
116.68(10)
122.14(11)
117.38(12)
120.36(12)
125.10(11)
116.54(11)
118.14(12)
119.10(11)
125.08(11)
115.81(11)
124.27(11)
116.70(11)
119.01(11)
121.67(14)
122.02(13)
116.31(11)
124.84(11)
114.35(11)
120.79(11)
122.83(11)
116.12(11)
121.05(12)
123.68(12)
113.37(10)
112.25(10)
117.42(10)
119.73(11)
122.64(11)
117.54(11)
117.91(11)
125.24(12)
116.84(11)
121.84(13)
121.85(13)
116.32(11)
125.22(11)
114.80(11)
119.97(12)
117.26(12)
118.40(11)
124.11(11)
120.13(13)
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Table 30 (I-1) cont.
C17 C16 C15
C18 C17 C16
N5 C18 C17

120.59(14)
118.29(14)
120.04(14)
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